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ABSTRACT 
Stem cell therapy represents a potential β-cell replacement strategy in diabetes and a 
pancreatic cancer (PC) stem cell is an attractive therapeutic target in this dire disease.  
However, a normal stem cell remains unidentified and proposed malignant stem cell 
markers await verification. 
 
Using human PC cell lines as an in vitro tumour model and human archival tissue, 
and proposed stem cell markers identified in other normal tissues and tumours, we 
attempted to identify a PC stem cell.  These markers included high aldehyde 
dehydrogenase activity, the Side Population (SP) phenotype, and the cell surface 
markers CD44 and CD133.  These markers were evaluated by flow cytometry, 
immunohistochemistry (IHC) and reverse-transcriptase PCR.  Positive populations 
were isolated from cell lines using fluorescence activated cell sorting (FACS) and 
subjected to in vitro colony-forming assays to assess their relative proliferative 
capacities.  The presence of a differentiation hierarchy was investigated in one line to 
test the assumptions of the tumour model.  No single marker or combination thereof 
consistently identified a highly clonogenic fraction, though some differences in 
clonogenicity were seen.  Furthermore, the dye Hoechst 33342 was found to inhibit 
proliferation, potentially inducing artefactual differences in clonogenicity between SP 
and non-SP cells. 
 
Recently, expression of trefoil factor family peptide (TFF) 3, a gastrointestinal 
motogen, was reported in human islets of Langerhans.  Furthermore, this peptide was 
reported as a β-cell mitogen in vitro, and a potential agent of functional β-cell 
production.  We employed isotopic in situ hybridization and IHC to evaluate TFF 
expression in normal human pancreas, chronic pancreatitis and PC.  Expression of all 
three TFFs was increased in inflammation and cancer, and TFF3 mRNA was 
occasionally detected in islets.  The motogenic activity of TFF peptides was 
investigated using in vitro wound healing and invasion assays on human PC lines and 
primary stellate cell cultures.  TFF2 was seen to enhance migration in PC lines at 
high concentrations. 
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Pancreatic disease represents an enormous healthcare burden in the UK: pancreatic 
cancer is the fifth commonest cancer, with the lowest survival rate of all cancers, and 
the morbidity and mortality associated with diabetes mellitus continue to rise, with 
the number of cases in the UK predicted to reach 3 million by 2010 (Pancreatic 
Cancer Research Fund http://www.pcrf.org.uk/ and Diabetes UK 
http://www.diabetes.org.uk/ ).  Given recent advances in the fields of adult and cancer 
stem cell biology, a pancreatic stem cell would provide not only a logical subject for 
manipulation for the replacement of lost β-cells in diabetes but also an attractive 
therapeutic target in pancreatic cancer.   
 
Originally thought to be confined to the germ line, stem cells have since been shown 
to exist in almost all adult tissues, and manipulation of embryonic stem (ES) cells and 
the induction of pluripotency in adult somatic cells have presented novel therapeutic 
paradigms for regenerative medicine.  In addition, the cancer stem cell hypothesis, 
which proposes that tumours are maintained and disseminated by stem-like cells has 
gained prominence, and numerous strategies to target cancer stem cells are in 
development.  Stem cells are defined by their unique ability to produce new stem 
cells (self-renewal) in addition to a hierarchy of differentiating offspring appropriate 
to their location (multilineage potential)[1].  Additionally, they may be uniquely 
capable of asymmetric division, employ several specialized mechanisms to maintain 
genomic integrity and escape the action of cytotoxic compounds, and be dependent 
on a tightly-regulated cellular microenvironment (niche) for maintenance of their 
stem cell properties.  As summarized by a previous review [2], on which the first 
section of this introduction builds, stem cells (SCs) have varying potential: the 
fertilized oocyte and the progeny of the first 2 divisions are totipotent, i.e. able to 
generate the entire embryo and placental trophoblasts.  Subsequently these cells go on 
to form the blastocyst and the inner cell mass (ICM) which goes on to form the 
embryo.  ICM cells are pluripotent, i.e. able to differentiate into most lineages that 
arise from the three germ layers, with the exception of the placenta.  These 
pluripotent ICM cells are the source of ES cells, which can be manipulated in vitro to 
give rise to a wide spectrum of differentiated cells that form the basis of the emerging 
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field of personalized regenerative medicine.  Recent work indicates that pluripotency 
can also be reinstated in ordinary somatic cells via the introduction of ES genes such 
as Oct-3/4, Klf4, Sox2 and c-Myc : so-called induced pluripotent stem cells (iPS) [3, 
4].  
 
In contrast to the embryonic scenario, most adult tissues contain multipotential stem 
cells that produce a range of differentiated tissue-specific cell lineages.  Small 
intestinal stem cells produce the goblet, absorptive columnar, Paneth and 
enteroendocrine cells that make up the crypt/villus unit, whereas the most primitive 
stem cells of the haematopoietic system give rise to all types of blood cell, including 
lymphoid, myeloid, granulocyte, erythroid and macrophage/monocyte lineages and 
central nervous system (CNS) stem cells generate neurons and glial cells 
(oligodendrocytes and astrocytes).  Furthermore, unipotential stem cells that generate 
one specific cell type also exist, for example SCs in the basal layer of the 
interfollicular epidermis only give rise to differentiated keratinocytes and at least 
some mature hepatocytes participate in maintenance of the liver parenchyma, 
although this may depend on environmental cues rather than intrinsic lineage 
restriction [5, 6].  Further evidence that potentiality is dependent on the environment 
comes from elegant transplantation experiments in the murine cornea, where 
oligopotent stem cells scattered across the cornea give rise solely to squamous 
corneal keratinocytes unless they are exposed to a conjunctival milieu, whereupon 
they also demonstrate the capacity to give rise to goblet cells [7].  All tissues are now 
thought to possess stem cells in some form, including tissues traditionally thought 
incapable of repair and renewal such as cardiac muscle and the CNS [8, 9].   
 
1.1 Adult Stem Cell Properties 
Production of differentiation hierarchies 
The defining properties of stem cells were first recognized and formalized in the bone 
marrow, where Till and McCulloch originally defined multipotent, self-renewing 
haematopoietic stem cells experimentally by their abilities to give rise to multilineage 
haematopoietic colonies in the spleen [10].  In tissues where there is continual 
 32
replacement of senescent or exfoliated cells, a unidirectional flow of cells with 
relatively undifferentiated stem cells at the beginning of a hierarchy of more 
committed differentiating cells is typically seen.  In the colon and small intestine, 
undifferentiated stem cells are located at or towards crypt bases; a protected location 
that ensures that the stem cell population (and additionally, the long-lived Paneth 
cells of the small intestine [11]) is protected from mechanical and chemical trauma 
from the gut contents and not lost in the upward migration of differentiating cells 
toward the luminal surface [1, 12].  Adult stem cells are generally rare amongst a 
large population of more differentiated cells in a given tissue: in the bone marrow the 
multipotential haematopoietic stem cell (HSC) fraction represents 0.05% of bone 
marrow cells [13], whereas approximately 3% of the cells of each small intestinal 
crypt are stem cells [12].  
 
Although stem cells, by definition, produce numerous progeny in order to affect 
maintenance of tissue mass, it was initially widely accepted that stem cells divide 
relatively infrequently in vivo, and that generation of a large number of differentiated 
cells was instead accomplished by a committed, highly proliferative transit 
amplifying population of daughter cells.  This can be demonstrated in vitro, where 
stem cells exhibit extremely high clonogenicity, producing highly proliferative 
(transit amplifying) progeny that begin to differentiate (thus becoming committed 
precursors), eventually producing terminally differentiated, reproductively sterile 
cells [14](Figure 1.1).  Restriction of cell division is a beneficial strategy for a long-
lived stem cell as DNA synthesis can be prone to error, and in many tissues stem cells 
indeed divide less frequently than the transit amplifying cells (TACs) that form the 
next level of the differentiation hierarchy.  In vivo, the stem cells of the murine 
whisker follicle bulge region that give rise to hair and root sheath cells divide less 
frequently but are more clonogenic than the TACs of the hair bulb [15, 16].  In 
addition to exhibiting high clonogenicity in vitro, these, corneal and interfollicular 
epidermal stem cells preferentially give rise to morphologically distinct colonies 
composed of tightly packed, undifferentiated cells, designated holoclones, whereas 
transit amplifying and terminally differentiated cells give rise to meroclone and 
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paraclone colonies (Figure 1.2) with progressively limited proliferative potential and 
increasing terminal differentiation ([7, 15, 17] see also Chapter 2).  Relative 
quiescence of stem cells is not universal, however: in the murine small intestinal 
crypt, the supra-basal stem cell population is quiescent in comparison with the more 
luminal TACs [12], although a further stem cell population located at the crypt base 
(crypt base columnar cells; CBCs) is highly proliferative [18, 19].  A similar scenario 
is also seen in the murine haematopoietic system, where stem cells with long-term 
repopulating activity and their immediate transit amplifying progeny show the same 
degree of proliferative activity [20].   
 
 
Figure 1.1:  A simplified adult tissue-based stem cell hierarchy 
 
In continually renewing tissues a hierarchy of increasingly differentiated cells is seen.  
Rare self-renewing stem cells (p = probability of self-renewal) give rise to a limited 
number of committed progenitors, or transit amplifying cells (TACs).  TACs have 
limited proliferative potential and produce reproductively sterile, terminally 
differentiated cells.  In vitro, stem cells, early TACs and late TACs are thought to 
generate holoclones, meroclones and paraclones respectively. 
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Figure 1.2:  Holoclone, meroclone and paraclone colonies of human keratinocytes 
 
Keratinocytes with long-term proliferative potential (stem cells) frequently produce 
numerous large colonies (holoclones), whilst those with intermediate proliferative 
potential (TACs) produce smaller meroclones and cells nearing terminal 
differentiation produce small paraclones with low frequency.  Figure from Y 
Barrandon and H Green (1987) [17]. 
 
 
 
Selective DNA strand segregation and asymmetric division 
Cycling cells may be labelled via brief administration of a nucleotide analogue label 
such as tritiated thymidine (3H-T) or bromodeoxyuridine (BrdU), which is 
incorporated into DNA during DNA synthesis.  This label is diluted with subsequent 
cell divisions, hence any differential in proliferation will manifest as differences in 
how long the label may be detected.  Occasionally-dividing stem cells would thus be 
label retaining cells (LRCs) whereas rapidly cycling TACs would quickly lose the 
label, and numerous studies have attempted to identify stem cells by virtue of this 
proposed label retention.  Although this strategy may seem flawed given observations 
that not all stem cells may be slowly cycling, label retention has also been shown in 
stem cells as a consequence of a further strategy for maintaining genomic integrity 
that does not require replicative quiescence.  According to Cairns’ immortal strand 
hypothesis [21], nascent stem cells designate one of the two strands of DNA in each 
chromosome as a template strand, which is retained by the daughter cell destined to 
remain a stem cell, while both strands of DNA are copied during DNA synthesis.  In 
this manner, replication errors present in the copied strand are transmitted solely to 
TACs that are soon lost from the population and label retention can occur in rapidly 
cycling stem cells.  Label retention due to segregation of immortal DNA strands into 
stem-fated daughter cells has been demonstrated through multiple division cycles in 
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the small intestine, breast and muscle satellite cells using sequential pulse labeling 
with 3H-T followed by BrdU [22-26].  It should be noted, however, that an alternative 
epigenetic explanation for the asymmetric cell division unique to stem cells, termed 
the “silent sister hypothesis” [27], has been proposed to counter problems inherent 
the above model [28], although not all studies support this hypothesis [29].  Label 
retention is thus a feature of many stem cell populations, although not a defining 
property, as some known SCs such as long-term repopulating haematopoietic stem 
cells (HSCs) do not exhibit label retention at all [20], and long-lived terminally 
differentiating cells would also exhibit label retention. 
 
Self-renewal: the roles of asymmetric division and the stem cell niche 
By undergoing asymmetric cell division (Figure 1.3 A), stem cells may 
simultaneously accomplish both self-renewal and the production of proliferative, 
differentiating cells, and asymmetric divisions are seen in at least some stem cell 
populations including mammalian HSCs and interfollicular epidermis, and 
Drosophila sensoria and gonads [30-33].  However, stem cell numbers could also be 
maintained solely via symmetrical divisions, if each stem cell division gave rise to 
two daughter TACs or to two daughter stem cells with equal probabilities (Figure 1.3 
B), or via a mixture of symmetric and asymmetric cell divisions (Figure 1.3 C) [33].  
Symmetrical stem cell divisions provide a method for regenerative expansion of stem 
cells subsequent to stem cell loss, as demonstrated by the phenomenon of niche 
succession and crypt fission during growth and repair of the mammalian intestine 
(reviewed in [34]), but dysregulation of asymmetric division may also have 
pathological consequences: disruption of asymmetric neuroblast cell division in 
Drosophila engenders tumour-like lesions when these cells are transplanted into 
adults [35], whereas compromised Wnt signaling causes a failure of embryonic 
murine gut stem cells to expand during organogenesis, resulting in a gut composed 
entirely of terminally differentiated cells [36].   
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Figure 1.3: Mechanisms for maintaining stem cell numbers 
 
 
A: Asymmetric division of all stem cells.  B: Equal numbers of symmetric divisions 
producing either stem cells or TACs.  C: A combination of asymmetric and 
symmetric divisions.  D: Both intrinsic and extrinsic signals determine cell fate.  E 
(I), E (II): In the Drosophila testis, correct orientation to the hub niche cells is 
important for self-renewal; misoriented divisions can result in surplus stem cells or 
premature differentiation.  E (III): In stratified epithelia a plane of cleavage parallel 
to the basement membrane serves to maintain the correct number of stem cells in the 
basal layer. See text for details.  Stem cells, white; TACs, dark grey.  Figure adapted 
from MR Alison and S Islam (2009) [2], with permission. 
 
 
The most studied models of asymmetric stem cell division are the neuroblasts (CNS 
stem cells) and germ-line stem cells of the ovarioles and testes of Drosophila 
melanogaster, and mammalian skin [37].  Here the mechanisms governing 
asymmetric cell division have been demonstrated to broadly fall into two categories 
(Figure 1.3 D).  Intrinsic mechanisms involve asymmetric distribution of intracellular 
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cell-fate determinants between daughter cells during division, whereas extrinsic 
mechanisms determine asymmetry of daughter cell fate by determining their position 
and relative access to external cues from the stem cell microenvironment [33, 37-39].  
Cell fate determinants include inhibitors of self-renewal such as Brat, Prospero and 
Mei-P26, which are assigned to daughter cells destined to become TACs in the 
Drosophila CNS and ovaries respectively [40, 41], and Numb, an inhibitor of Notch 
signalling, that controls lineage specification in a variety of cell types in a conserved 
fashion [39, 42].  Numb has been shown to be portioned asymmetrically during stem 
cell divisions in the mammalian gut and CNS, as well as the Drosophila CNS and 
ovary [43-45].       
 
Extrinsic signals governing asymmetric cell division often arise from cells of the stem 
cell niche, a specialised microenvironment in which all adult SCs are thought to 
reside and which regulates SC behaviour via direct physical contact and paracrine 
signalling (reviewed in [46-50]).  Stem cells are anchored to and interact with niche 
cells via specific cell adhesion molecules such as cadherins and integrins (as 
discussed below), that are linked to internal cytoskeletal proteins able to determine 
the plane of the mitotic spindle and thus the spatial positioning of daughter cells and 
their access to niche signals (Figure 1.3 EI)[37].  In the Drosophila ovary, the stem 
cell niche is termed the germarium: here, germ-line stem cells are in close contact 
with niche cap cells that inhibit differentiation by means of direct ligand-receptor 
interactions, to which the more distal differentiating daughter cells do not have access 
[51].  In Drosophila gonads, disruption of cadherin/β-catenin/centrosome interactions 
can result in an excess of germ-line stem cells secondary to alterations in the 
orientation of the mitotic spindle and subsequent plane of division, that determine the 
placement of nascent cells relative to the niche [52, 53].  The spindle orientation and 
resulting plane of division of basal epithelial stem cells is also important for correct 
maintenance of the differentiation hierarchy of the stratified epidermis [33, 54] 
(Figure 1.3 EIII).  Intrinsic and extrinsic mechanisms of asymmetric division often 
co-operate to maintain the correct stem cell complement, as seen in the 
haematopoietic system [55], where cues from the niche as well as those from 
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oncogenes interact to ensure the correct balance between asymmetric and symmetric 
divisions.  In addition, the observation that when stem cells are removed from the cap 
cell niche of the Drosophila germarium, differentiated somatic cells can be recruited 
to fill the vacant space, where they take on germ stem cell properties under the 
influence of niche signals, at least for a limited time, indicates that non-stem cells 
may acquire stem cell properties under some conditions [56]; a similar phenomenon 
has been demonstrated for melanocyte stem cells in murine skin [57].  
     
As access to niche signals can be vital for suppression of differentiation and 
maintenance of stemness, stem cells often express high levels of adhesion molecules 
to facilitate strong adherence to their niches.  In the mammalian bone marrow, 
adhesion molecules such as cadherins and catenins and BMP signalling are involved 
in the maintenance of haematopoietic stem cell (HSC) number via interactions with 
osteoblasts [58](Figure 1.4), although a more recent study has questioned this model, 
suggesting that HSCs are more numerous in the vascular sinusoids and may not 
express the N-cadherin proposed to anchor them to spindle-shaped osteoblast niche 
cells [59].  Further proteins may also play a role in niche-HSC interactions; 
alterations in the structure of the trabecular bone/osteoblast niche in Nf2/merlin-
deficient mice causes a rise in HSC numbers, which detach from the niche and enter 
the circulation [60].  Other well characterised stem cell niches include the bulge 
region of the hair follicles, where highly clonogenic multipotential stem cells are 
located, capable of forming all the cell lineages of the hair follicle and sebaceous 
gland [61-64], and the base of small intestinal crypts, where Wnt signalling 
(interacting with other pathways) from intestinal sub-epithelial myofibroblasts helps 
regulate stem cell homeostasis (Figure 1.5). 
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Figure 1.4: Schematic diagram of the proposed HSC niche in the bone marrow 
 
The niche for mammalian HSCs may involve osteoblasts attached to trabecular bone 
and stem cell differentiation may be inhibited by bone morphogenetic protein (BMP) 
ligands.  Spindle-shaped osteoblasts (putative niche cells) shown in blue; HSCs in 
yellow.  Figure after Zhang, et al. (2003)[58] and MR Alison and S Islam [2], used 
with permission. 
 
 
 
Integrins, heterodimeric cell surface receptors for extracellular (ECM) components 
such as collagen IV and laminin found in basement membranes, are also highly 
expressed in stem cells.  Integrins facilitate physical linkage between the ECM and 
cytoskeletal proteins and help determine cell behaviour through various regulatory 
cues.  In stratified epithelia, cells sorted on the basis of high levels of either β-1 or α-6 
integrins have superior clonogenic ability [65, 66], although this does not seem to be 
true of bulge region follicular cells [67].  The transcription factor p63, that trans-
activates Perp, a protein involved in the assembly of desmosomes, is another factor 
maintaining the integrity of stratified epithelia [68-70], possibly with the α3-integrin 
subunit as a further target [71], and with the TAp63 and ∆Np63 isoforms appearing to 
be involved in maintaining cells of the epidermis and cornea in an immature state [72, 
73].  MicroRNAs (miRs) are small, non-coding RNAs that regulate gene expression 
post-transcriptionally, and p63 is also a target of miR-203, which acts to induce cell 
cycle exit and promote differentiation in the epidermis [74, 75]. 
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Figure 1.5: Schematic diagram of the proposed small intestinal stem cell niche 
 
 
 
In the small intestine, two distinct stem cell populations exist: crypt base columnar 
cells (CBCs) situated between Paneth cells (PC), and label retaining cells (LRCs) 
higher up the crypt.  Sub-epithelial myofibroblasts comprise the niche, secreting 
Wnts that regulate stem cell self-renewal.  Wnt signalling is inhibited by BMPs, in 
turn inhibited by Noggin produced by other peri-cryptal mesenchymal cells. Stem 
cells, yellow; TACs, blue.  Figure adapted from MR Alison and S Islam [2], with 
permission.   
 
 
Cytoprotective strategies 
Many putative stem cells demonstrate enhanced capabilities to withstand exposure to 
cytotoxic substances via either enzyme-based detoxification systems or by those that 
enable rapid export of potentially harmful xenobiotics.  The aldehyde 
dehydrogenase (ALDH) gene super-family encodes detoxifying enzymes for many 
pharmaceuticals and environmental pollutants ([76, 77], see also Chapter 3).  In 
conjunction with other markers, high levels of ALDH activity have been shown to 
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characterise highly clonogenic, undifferentiated multipotential stem/progenitor cells 
of the mouse CNS [78], prostate [79] and bone marrow [80, 81], human bone marrow 
[82] and cord blood[83-85]; and high expression of ALDH1 has been described for 
human mammary stem cells [86].  High expression of ALDH can also provide a route 
for tumours to resist chemotherapy [87-89]. 
 
ALDHs are not the only cytoprotective molecules present in adult stem cells:  A 
novel method for the isolation of HSCs based on the ability of HSCs to efflux the 
fluorescent dye Hoechst 33342 (Ho33342) was initially developed by Margaret 
Goodell and co-authors in the mid 1990s [90].  As cells that actively efflux Ho33342 
form a distinct population on the side of the scatter profile on FACS analysis they 
were designated the ‘side population’ (SP).  The SP phenotype of human and murine 
HSCs and other stem cell populations has been shown to be a direct result of high 
expression and activity of proteins of the ABC-transporter family, primarily ABCG2 
(ATP-binding cassette [ABC] G2, a.k.a. BCRP1 [breast cancer resistance protein]) 
[91-94].  ABC-transporters are characterized by an ATP-binding cassette region and 
are trans-membrane pumps that facilitate energy-dependent export of substrates 
across membranes, often against steep concentration gradients, and principally act to 
export xenobiotics and other potential toxins from the cytoplasm to the extracellular 
space [95].  ABC transporters may also directly regulate stem cell function, and act to 
maintain stemness via modulation of signal transduction pathways involving 
molecules that induce differentiation or apoptosis such as retinoic acid or ceramide 
[96].  Expression of ABC-transporter family members MDR1 (a.k.a P-glycoprotein), 
MRP1 and/or ABCG2 is further associated with multidrug resistance (MDR) in 
cancer cells [97], largely because high ABC-transporter activity facilitates effective 
efflux of chemotherapeutic compounds out of cells, thereby lowering exposure and 
increasing resistance [98, 99].   
 
The SP of many solid organs, including the breast, liver and kidney, often represents 
a population enriched for clonogenic activity and other stem cell traits [100-103], and 
consequently isolation of cells with the SP phenotype is now commonly employed as 
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a method for prospective identification of stem cells [104, 105].  High expression of 
ABC-transporters is not an exclusive property of stem cells however: cells of the 
kidney cortical tubules and placental syncitiotrophoblasts express high levels, as do 
hepatocytes that transport bile acids into the biliary canaliculi, where a similar 
cytoprotective function is envisaged [106].   
 
 
Other markers of adult stem cells 
CD133 (Prominin-1) was the first identified member of the prominin family of 
pentaspan membrane proteins (reviewed in [107, 108]).  The specific functions and 
ligands of this family of molecules remain unclear, but expression appears to be 
restricted to plasma membrane protrusions such as epithelial microvilli [108-112], 
and observations that expression correlates with polarity and is asymmetrically 
distributed in dividing HSCs may provide some clues [30].  In combination with 
other markers, CD133 has been used to isolate haematopoietic and endothelial stem 
cells as well as those from the central nervous system [110, 112, 113], but its most 
well-known use has been in the isolation of tumour-initiating cells from various 
human solid tumours, including those of the brain, prostate, liver and colon ([114-
119] also, see below and Chapter 3).  However, it is unlikely that CD133 represents a 
specific and universal stem cell marker: a recent study has found that most normal 
and malignant colonic epithelial cells express CD133, and moreover CD133-negative 
cells isolated from colorectal liver metastases were at least as tumorigenic as their 
corresponding CD133+ fraction [120].  CD133 is also expressed in a range of 
differentiated adult cells, where its presence may reflect a high degree of cellular 
polarization [121, 122]. 
 
There is abundant evidence that the Wnt signaling pathway is involved in stem cell 
renewal for HSCs and many other stem cells such as those of the small intestine 
(reviewed in [34, 123]).  This pathway is highly complex, comprising both canonical 
and non-canonical systems, and intersects with several other signaling pathways, 
making it of limited use for the identification of stem cells.  However, active Wnt 
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signaling, as indicated by the nuclear localization of β-catenin, has been demonstrated 
for murine colonic basal cells, the putative colonic stem cell [124], although nuclear 
β-catenin is also seen in small intestinal Paneth cells, where Wnt signals are required 
for maturation [125].  Expression of Wnt target genes can also identify stem cells: 
lineage tracing of Lgr5+ cells in the mouse small intestine has demonstrated their 
ability to give rise to long-lived clones containing all cell lineages both in vitro and in 
vivo, thereby confirming their stem cell status [18, 62, 126].   
 
Musashi-1 (Msi-1) is an mRNA binding protein that blocks the translation of m-
Numb mRNA, thus enhancing Notch signaling, another important pathway 
regulating stem cell self-renewal (Figure 1.6).  Msi-1, first shown to regulate 
asymmetric division in cells of the Drosophila sensorium [32], is also expressed by 
neural progenitors, where it acts to maintain stem cell status via suppression of Numb 
[123, 127, 128].  Msi-1 also presents a promising candidate stem cell marker in the 
gut: Msi-1+ cells of the rat stomach are located in the putative stem cell niche [129] 
and Msi-1 expression also delineates putative stem cells in the mouse intestine [130, 
131].  Interestingly, in the small intestine not only were the cells at cell positions 4-5 
Msi-1+, but also the crypt base columnar cells subsequently shown to express Lgr5 
and to be capable of multilineage differentiation [18].    
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Figure 1.6: The role of Msi-1 in Notch signaling 
 
 
Binding of Notch ligands Delta or Jagged releases an intracellular domain of the 
Notch receptor (icN), which translocates to the nucleus and initiates the transcription 
of Notch target genes such as Hes-1.  Notch signaling is inhibited by Numb, which in 
turn is inhibited by Musashi-1, thus maintaining the active Notch signaling state.  
Diagram adapted from MR Alison and S. Islam [2], used with permission. 
 
 
Bmi1 is a member of the Polycomb family of transcriptional repressors necessary for 
the self-renewal of HSCs [132-134], and participates in the Hedgehog (Hh) 
signaling pathway responsible for regulation of progenitor cells during development 
and in several adult tissues [123, 135].  Loss of Bmi1 leads to a depletion of murine 
neural stem cells, and is associated with up-regulation of p16Ink4a [136], and 
conversely, expression prevents premature senescence of murine neural stem cells via 
suppression of p16Ink4a and p19Arf transcription [137] (Figure 1.7).  In the mouse small 
intestine, Bmi1+ cells are co-locate with the LRC population at cell position 4-5 from 
the crypt base, above the Paneth cells, and lineage tracing of these cells suggests that 
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these cells can generate long-lived clones containing all the intestinal cell lineages.  
Furthermore, the progeny of Bmi1+ pancreatic acinar cells show long-term 
homeostasis, and in some cases label retention [138].    
 
 
Figure 1.7:  Schematic diagram detailing the involvement of Bmi1 in the Sonic 
hedgehog (Shh) signaling pathway and subsequent influence on cell cycle 
 
Bmi1 is able to maintain the proliferative potential of precursor cells by suppression 
of cell cycle arrest via p16Ink4a and cyclin D and via p14Arf and p53, and is itself 
regulated by sonic hedgehog (Shh).  Diagram after MR Alison and S. Islam, with 
permission [2]. 
 
 
 
The transcription factor Oct-4, important for the maintenance of pluripotency in ES 
cells as well as for the induction of pluripotency in adult somatic cells [3, 4, 139, 
140], has been claimed to be expressed in a variety of adult stem cells and hailed as a 
universal stem cell marker [141].  However, the identity of Oct-4+ cells in some 
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studies is unclear and the presence of Oct-4 expression in all stem cells remains 
subject to independent confirmation (see Chapter 3); furthermore its necessity for 
stem cell self-renewal has also been called into question [142].   
 
Organ specific stem cells: some well-characterised epithelial systems 
Intestine: a hierarchical, multipotential system 
Unsurprisingly, stem cells of the mammalian small and large intestines exhibit 
several similarities.  Small intestinal stem cells are located around the crypt base, 
whereas in the large intestine the stem cells occupy the bottom of the crypt.  Sub-
epithelial myofibroblasts and their secreted factors, in particular Wnts, which interact 
with components of the Notch pathway and basement membrane proteins, are 
believed to form the stem cell niche and regulate epithelial cell differentiation in both 
the small and large intestine [131, 143, 144].  The role of Wnt signalling in intestinal 
stem cell maintenance is evidenced by the presence of nuclear β-catenin in putative 
colonic stem cells [124], although this is also seen in small intestinal Paneth cells 
[125].  Self-renewal of intestinal stem cells is also regulated by the Notch pathway: 
Msi-1 positively regulates the transcriptional repressor molecule Hes-1 by negatively 
regulating expression of Numb, thereby allowing for continued Notch signalling 
[127](Figure 1.7), and in the mouse small intestine, Msi-1 and Hes-1 are co-
expressed in the location of LRCs just above the Paneth cell zone (though Hes-1 
expression additionally extends to proliferative cells higher up the crypt) [145].  Msi-
1 also co-localises with another putative stem cell marker, DCAMKL-1, at cell 
position 4 [146].  Msi-1 expression is seen not only at cell positions 4-5, where LRCs 
reside, but also in crypt base columnar cells (Figure 1.5) [130, 145].  As mentioned 
previously, CBCs appear to function as stem cells, although they are actively cycling: 
using a tamoxifen-inducible Cre recombinase knocked into the Lgr5 locus, Lgr5-
positive CBCs have been demonstrated to give rise to long-lived clones that contain 
all small intestinal lineages, with similar observations in the large intestine [18].  A 
similar strategy tracing the progeny of Bmi1-expressing cells also demonstrated the 
generation of multilineage clones, but from cells located at the position of LRCs 
further up the crypt [147].  Therefore, in the mouse small intestine at least, two 
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distinct stem cell populations appear to co-exist; rapidly cycling Lgr5+/Msi-1+ CBCs 
and slowly cycling Bmi1+/DCAMLK-1+/Msi-1+ LRCs at positions 4-5 (Figure 1.5), 
whilst in the large intestine there may be just one stem cell population at the very 
base of the crypt.   
 
Interfollicular epidermis: a hierarchical, unipotential system 
Until relatively recently, epidermal stem cell identity was inferred either by virtue of 
label retention or by their growth potential in vitro [17].  However, selection of basal 
keratinocytes with high expression of β1-integrin (integrinbright cells) has been shown 
to present a useful technique to enrich for cells with high clonogenicities.  In vivo, 
human epidermal integrinbright cells tend to be clustered over the tips of dermal 
papillae (with the exception of the plantar and palmar surfaces) and exhibit low 
turnover, and it was suggested that TACs migrated laterally away from these stem 
cell clusters [148-150].  In contrast, lineage tracing of genetically marked human 
epidermal cells has suggested that stem cells are scattered all along the basal layer, 
giving rise to differentiating progeny that migrate vertically, forming tessellating 
columns of cells [151].  In murine epidermis, where dermal papillae and rete ridges 
are not prominent at the dermo-epidermal interface, scattered individual stem cells 
are thought to give rise to a hierarchy of TACs and differentiated progeny within 
tessellating spatial units called ‘epidermal proliferative units’ (EPUs) that stretch 
from the basal layer to the surface.  A basal LRC resides at the centre of each EPU 
surrounded by several other basal cells, most of which are TACs [152].  Although 
rare α6-integrinbright/CD71dim/keratin 14+ basal cells of human epidermis have been 
shown to be highly clonogenic and able to regenerate full-thickness epidermis in 
organotypic culture [153], there is still debate as to whether mouse skin contains both 
a stem cell and a TAC compartment [154].   In a murine tail skin model, inducible 
genetic labeling of occasional basal cells and subsequent analysis of clone size 
showed that tail epidermis was maintained by a single population of progenitor cells, 
which may undergo an unlimited number of symmetric and asymmetric divisions, 
rather than by a rarely-dividing stem population and a separate transit amplifying 
populations that undergoes a limited number of divisions [155]. 
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1.2 Adult stem cells and the pancreas 
In vivo evidence 
At the beginning of this project, there was much debate as to the possible location and 
phenotype of human pancreatic stem cells, as well as to their potentialities.  The 
pancreas is essentially two different tissues: the exocrine pancreas, consisting of 
secretory exocrine acini that produce digestive enzymes such as amylase, a branching 
ductal system that transports acinar secretions to the duodenum, emptying via the 
main pancreatic duct at the ampulla of Vater, and the endocrine islets of Langerhans: 
composed of α, β, δ and PP cells that produce the hormones glucagon, insulin, 
somatostatin and pancreatic polypeptide respectively.  The renewal of β-cells is of 
paramount interest for stem cell biologists, since the present Edmonton protocol of 
cadaveric islet transplantation for the treatment of diabetes is inefficient, unwieldy 
and beset by challenges pertaining to lifelong immunosuppression of recipients 
(reviewed in [156, 157]).  However, although differentiated β-cells of both rodents 
and humans have been shown to divide throughout life (reviewed in [158, 159]), a 
definitive adult pancreatic stem cell remains elusive.   
 
The generation of islets from the ductal tree during pancreatic ontogeny and 
observations of regenerating pancreata [160, 161] suggested a possible derivation of 
islet cells from cells resident in the ducts via a process termed islet neogenesis 
(reviewed in [162]).  Initially, all embryonic pancreatic cell lineages of the foregut-
derived pancreatic anlage express the homeobox transcription factor pdx1 [163, 164].  
Pdx1 is essential for pancreatic development, and knockout mice display pancreatic 
agenesis [165], but a further gene, Ngn3, appears to be necessary for the further 
development of endocrine tissue from multipotential Pdx1+ pancreatic precursors.  
Ngn3 knockout mice display a normal exocrine architecture but an absence of islets 
[164, 166], whereas over-expression in adult mice induces islet hyperplasia [167].  
However, direct lineage tracing experiments have suggested that most murine 
pancreatic precursors are subject to lineage restriction before birth [164].  In support 
of in vivo observations of apparent neogenesis following pancreatic injury [160], a 
genetically labelled non-endocrine human pancreatic epithelial cell (NEPEC) 
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population that expressed the ductal differentiation marker cytokeratin (CK) 19 was 
shown to undergo endocrine differentiation when co-transplanted with foetal pancreas 
under the renal capsule of mice [168].  In this instance, foetal pancreas was deemed to 
supply paracrine factors necessary to induce differentiation of the NEPECs.  
However, the functionality of these induced endocrine cells was not shown, nor the 
nature of the supposed inductive signals supplied by the foetal pancreas.  The 
forkhead box transcription factor (FoxM1) has also been shown to be vital for 
proliferation of adult β-cells in mice, and directed knockdown of FoxM1 via 
inducible Cre recombination has been used as a way of suppressing β-cell division 
[169].  Knockdown of FoxM1 expression in mice following partial pancreatectomy 
has shown that new islets were formed from small clusters of immature endocrine 
cells, and possibly from Ngn3+/CK19+ cells that arose in ducts, whereas mature β-
cells of extant islets fail to proliferate, further validating the possibility of islet tissue 
arising from ductal epithelium [169]. 
 
While islet neogenesis from ducts presents an attractive paradigm of β-cell renewal, 
there is also much evidence to suggest that this may not be the case.  Using an 
inducible Cre recombinase-based lineage tracing system linked to the insulin 
promoter in neonatal mice, it was shown that β-cells did not arise from insulin-
negative stem cells during the doubling of β-cell mass seen during the first year of 
life; instead arising entirely from self-duplication both during post-natal pancreatic 
growth and during pancreatic regeneration following partial pancreatectomy [170].  
Similarly, Teta et al. [171] sequentially administered two different DNA labels, so 
that each label could be separately identified within any cell that had incorporated 
them during DNA synthesis.  An actively proliferating cell, having taken up the first 
label which would mark both daughter cells, would yield double-labelled cells if 
either daughter entered the cell cycle again during the second labelling period.  In this 
system double labelled cells were very rare, even after massive pancreatic damage, 
suggesting that β-cell mass is maintained by duplication of existing β-cells, recalling 
the duplication of mature hepatocytes seen in response to partial hepatectomy in 
mammals.  The same conclusion was reached by a study of healthy adult mice that 
 50
employed a histone labelling system to follow the division kinetics of islet cells: label 
was equally diluted throughout the islet over time, indicating that all β-cells 
contributed equally to islet mass [172].  Although these experiments suggest that β-
cell mass is maintained by recruitment of existing differentiated β-cells into the cell 
cycle, the existence of a quiescent ductal stem cell population that is only activated in 
certain conditions, such as exemplified by the oval cells of the liver that act as a 
reserve stem cell population when division of hepatocytes is curtailed, is not ruled out 
by these experiments [161, 173].  Indeed, the route of islet cell regeneration seems to 
vary between damage and developmental models and between different models of 
pancreatic regeneration. 
  
Recently, further evidence that murine β-cells may be derived from pancreatic ducts 
has emerged.  Murine studies employing an inducible Cre recombinase under the 
control of the duct cell-specific promoter carbonic anhydrase II (CAII)[174] reported 
that, during pancreatic regeneration subsequent to pancreatic duct ligation (PDL), a 
population of relatively undifferentiated ductal cells arose, that regained expression of 
Pdx1 and contributed to islets and acini [175, 176].  This builds upon a similar, earlier 
observation in the transgenic IFNγ islet damage model, which showed generation of 
ductal cells with an intermediate ductal/acinar (CAII+/amylase+) phenotype that 
appeared to transdifferentiate to form multi-hormone+ cells that migrated to nascent 
islet cell clusters [177].  Similarly, expression of Ngn3 was seen in rare ductal cells 
with an embryonic β-cell phenotype in the PDL damage model, and direct lineage 
tracing found these cells able to become insulin+ (β-cell-like) or CK19+ (duct-like) in 
vivo, and furthermore these cells could form fully functional islets in vitro [167], 
recalling the appearance of insulin+/CK19+ cells during rodent pancreatogenesis 
[178].  Moreover, the observation that insulin+ cells can be found scattered along the 
ductal tree suggests that Dor’s experiments need not rule out derivation of β-cells 
from cells resident within ducts.   
 
Somewhat controversial experiments performed by Zajicek et al. that employed 
tritiated thymidine pulse labeling to track a cohort of cells in the rat pancreas, led to 
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proposition of the “streaming hypothesis” whereby cells slowly stream from the 
ductal epithelium or acini to the islets, where they differentiate into islet cells [179]; 
however these results have yet to be independently confirmed.  A recently developed 
lineage tracing technique that enables establishment of clonal relationships in human 
tissues may yet prove to shed more light on this report.  The existence of non-
pathogenic, spontaneous mitochondrial mutations in vivo (that arise slowly and 
infrequently in human tissues, becoming apparent during the 4th decade of life)[180] 
has been exploited to trace the progeny of the cells in which they occurred in human 
liver, colon and pancreas [181, 182].  Cells with mutant, mitochondrially-encoded 
cytochrome c oxidase (COX) were seen to form continuous patches in the exocrine 
pancreas, which were always connected to COX-mutated patches of ductal 
epithelium; furthermore these cells were shown to be clonal by virtue of possession 
of identical COX mutations [182], although the directionality of spread remains to be 
shown. 
 
ABC transporters in the pancreas 
There have been several attempts to prospectively isolate multipotential pancreatic 
precursors using stem cell markers proposed for other tissues.  The ABC transporters 
responsible for the SP phenotype have been shown to be expressed in both normal 
and malignant pancreatic tissue ([106, 183, 184], also see Chapter 3).  In the 
pancreas, lineage-negative SP cells isolated from human foetal islets have been 
shown to exhibit high clonogenicity and proliferative potential, and could be induced 
to form lineages which produce glucagon or insulin, Glut2 and Pdx1 in vitro.  
However, insulin release in response to glucose was low in comparison to that of 
primary β-cells [185].  Epithelial cells with SP characteristics have also been 
identified in the adult human pancreas, where they occur with low frequency [186], 
and have been suggested to represent a sub-fraction of a putative intra-islet precursor 
population [187], although this remains to be verified.  As ABC transporters serve a 
cytoprotective function in a broad range of differentiated cell types, further 
correlation with other markers and stem cell functions must be shown before they 
may be used successfully to delineate potential pancreatic precursor cells.   
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Pancreatic LRCs 
A BrdU pulse/chase approach was employed to identify cycling cells in the islets of 
rat pancreata, and after a 4-week chase period, LRCs were identified within or around 
the islets [188].  Intra-islet LRCs were frequently insulin+, with extra-islet LRCs 
showing no insulin expression, whereas Pdx1 expression was detected in both LRC 
populations.  As some Pdx1+ LRCs did not express endocrine markers, it was 
suggested that they may represent undifferentiated progenitor cells.  Similar 
Pdx1+/hormone- LRCs detected in an in vitro system suggested to model endocrine 
development were also shown to differentiate into insulin+ cells, although true β-cell 
identity as evidenced by insulin secretion in response to glucose was not shown 
[188]. 
 
ALDH and pancreatic stem cells 
ALDH family members are known to be expressed in the adult pancreas [189], and in 
particular, retinaldehyde has been shown to be vital for pancreatic development, 
acting via metabolism of retinoic acid to produce compounds that regulate pancreatic 
differentiation [190, 191].  Remarkably, in a very recent study, rodent 
centroacinar/terminal duct cells were proposed as a pancreatic precursor population 
that can be identified by high activity of ALDH: these cells reportedly do not show 
lineage-specific markers, instead showing an embryonic pancreatic expression profile 
[192].  Furthermore, these cells were shown to be capable of multilineage 
differentiation in vitro, producing both exocrine cells and β-cells capable of secreting 
insulin in response to glucose, and to expand dramatically in regenerating tubular 
complexes of a caerulein-induced pancreatitis damage model.  
 
 
Other suggested markers of pancreatic precursors 
Nestin, originally proposed as a neural stem cell marker, has also been suggested to 
delineate pancreatic precursor populations, and at one time formed a strong candidate 
for a pancreatic stem cell marker.  Nestin-expressing, lineage-negative cells have 
been demonstrated in the ducts and islets of rat pancreas, and were shown to have 
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extensive proliferative potential in vitro, where they were additionally shown to be 
capable of differentiating into pancreatic ductal, endocrine and hepatic lineages [193].  
This population of cells was also shown to contain a sub-population of cells 
displaying the SP phenotype [187].  However, subsequently, primary cultures of rare 
nestin+ cells isolated from murine islets and ducts were seen to form colonies in vitro 
with equal frequency to those derived from nestin- cells, and furthermore, nestin 
expression was seen in colonies derived from both nestin+ and nestin- cells, 
suggesting that nestin expression does not define the most primitive of pancreatic 
progenitors [194].  Moreover, a study of cells isolated from human foetal pancreata 
on the basis of nestin expression reported that nestin+ pancreatic cells were unable to 
differentiate into endocrine cells in vitro or xenotransplant models, in contrast to 
nestin- cells [195].  Further observations suggesting that nestin+ cells contribute to 
pancreatic vasculature rather than islets in damage models and during development, 
and is expressed additionally in mesenchymal and vascular cells of the pancreas [195-
197], including activated pancreatic myofibroblasts (stellate cells) [198, 199], have 
lead to the current consensus that nestin does not specifically mark a pancreatic 
progenitor population [200].   It is possible that nestin may show some utility as a 
marker of pancreatic progenitors in combination with other markers however, as a 
subset of rare nestin+ cells located in rat ducts and islets has been shown to co-express 
the embryonic pancreatic transcription factor Pdx-1, and hence may represent a 
precursor population [196]. 
 
CD133 has also been used to try to prospectively identify pancreatic stem cells:  A 
report that isolated CD133+ cells from islet-depleted pancreatic tissue has suggested 
that CD133+ cells from the exocrine pancreas represent progenitor cells with a stem-
like Ngn3+/Oct4+/Nanog+/ABCG2+/hTERT+ phenotype able to form endocrine cells 
in vitro [201]; however, only Ngn3 was exclusively expressed in the CD133+ 
fraction, low levels of contamination of exocrine preparations with islet cells was 
detected and the methods employed did not indicate what proportion of CD133+ cells 
co-expressed these markers.  Moreover, recent studies (including data presented in 
this thesis) have shown that CD133 is commonly expressed by cells of the pancreatic 
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ductal epithelium [202, 203], further suggesting that CD133 is unlikely to present a 
specific marker of pancreatic progenitors, should they exist.  Analysis of neonatal 
murine CD133+ duct cells in vitro has further suggested that the hepatocyte growth 
factor receptor molecule c-met is expressed by a sub-set of these cells that are highly 
clonogenic and capable of multilineage differentiation, and is more likely to represent 
a progenitor marker [204].   
 
The chemokine receptor CXCR4, which has stromal-derived factor (SDF) 1 as its 
ligand, has also been shown to be vital for pancreatic ductal regeneration, exerting 
effects both on migration, maintenance of proliferation and suppression of apoptosis 
of ductal cells [205].  CXCR4+ cells isolated from the pancreas were subsequently 
shown to express stem cell and embryonic pancreatic markers, including Ngn3, 
nestin, Oct-4, Nanog, CD133, and ABCG2, and to have the capacity to differentiate 
into endocrine cells in vitro [206], although this study is subject to the same 
criticisms as a similar study of CD133+ cells discussed above [201].  CXCR4 
expression has also been shown in pancreatic cancer, where it correlates with a 
migratory phenotype (see below and [207, 208]).   
 
 
Strategies for β-cell production 
As the definitive in vivo scenario remains unresolved and definitive markers for a 
pancreatic stem cell have yet to emerge, several strategies for the production of islets 
in vitro have also been investigated:  ES and iPS cells have been induced to form 
insulin-secreting cells via three-dimensional culture and use of defined media in vitro 
[209-211], and have also been shown to give rise to insulin-secreting cells in vivo in 
response to pancreatic β-cell damage [212], and although this approach to β-cell 
replacement requires significant refinement it presents a valuable growth area in the 
field of personalized medicine (reviewed in [213]). 
 
Expansion of β-cells in vitro has also been attempted, but is fraught with difficulties, 
most saliently the loss of glucose-stimulated insulin secretion (GSIS) with induction 
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of proliferation.  However, adenovirally-mediated over-expression of the embryonic 
islet transcription factor Nkx6.1 in rodent and human β-cells [214] has shown 
promise as a method of expanding functional insulin-secreting cells, and trefoil factor 
(TFF) 3 has also been reported to induce β-cell replication in vitro with retention of 
GSIS [215], although this latter observation is disputed [216].  It has also been 
suggested that manipulation of the Notch signaling pathway responsible for 
maintenance of endocrine precursors during development might also represent a 
method of expanding these populations in vitro for subsequent transplantation [217]. 
 
Several in vitro studies have shown the potential for ductal-derived cells to take on an 
endocrine phenotype.  Pancreatic ductal cells isolated from pre-diabetic non-obese 
diabetic (NOD) mice can be induced to form functional islets in vitro, which can 
reverse diabetes when transplanted into the diabetic counterparts of the donor 
mice [218, 219].  More recent in vitro studies suggest that both clusterin and all-trans 
retinoic may induce the transdifferentiation of rat ductal cells to β-cells [220, 221], 
and a similar phenomenon is reported for pancreatic ductal adenocarcinoma cells 
[222].  Moreover, colony-forming cells isolated from adult mouse pancreatic islets 
and ductal populations, termed pancreas-derived multipotent precursors (PMPs), 
differentiated to form multiple pancreatic lineages in vitro, including β-like cells that 
displayed GSIS [194].  Ductal PMPs and islet PMPs showed indistinguishable 
properties, implying that both may act as or contain β-cell progenitors.  PMP-derived 
β-cells displayed considerable phenotypic similarity to normal β-cells and exhibited 
expression of insulin I, glucokinase, GLUT2, Pax-6, Beta2/NeuroD, HlxB9, Isl-1, 
Nkx2.2, Nkx6.1, Pdx1 and insulin II, but insulin secretion was relatively low.  PMPs 
exhibited limited self-renewing capacity when single cells from the clonal colonies 
were re-plated, arguing against a true stem-cell nature, but this may be dependent on 
the tissue culture milieu. 
 
Non-epithelial intra- and extra-pancreatic cells, including pancreatic myofibroblasts 
[223], bone marrow cells [224] and splenocytes [225] have also been suggested as 
potential candidates for production of functioning β-cells both in vivo and in vitro, 
 56
with varied efficacy, although on the whole successes have proved irreproducible 
(reviewed in [226]). 
 
 
Phenotypic plasticity of differentiated pancreatic cells 
Differentiated pancreatic cells show considerable phenotypic plasticity both in vitro 
and in various pathologies in vivo (reviewed in [227]).  Acinar cells spontaneously 
transdifferentiate in vitro to a ductal phenotype [228] and rat acinar cells have been 
induced to form functional β-cells in vitro that are capable of restoring 
normoglycaemia in diabetic mice [229].  Acinar-ductal transformations have also 
been demonstrated in vivo: an inducible Cre-recombinase system under the control of 
the acinar-specific elastase promoter has demonstrated that acinar cells contribute to a 
minority of the mucinous metaplastic ducts that frequently arise in pancreatic 
inflammation [230, 231].  Lineage tracing of acinar cells in vitro utilizing a similar 
inducible Cre recombinase system under the control of the acinar cell-specific 
amylase or elastase promoter has also demonstrated that acinar cells may give rise to 
cells with an endocrine phenotype [232].   
  
Mature pancreatic cells are also capable of more dramatic transformations: 
differentiated pancreatic cells form hepatocytes in vitro in response to treatment with 
dexamethasone [233, 234], and furthermore, this transformation represents a true 
transdifferentiation, with no intervening de-differentiation or proliferation [235, 236], 
raising the possibility that the same process of transdifferentiation may be responsible 
for the generation of hepatocytes that arise in the pancreata of copper-deficient rats 
following restoration of copper bioavailability [237-241].  Metaplasia of pancreatic 
ductal epithelium is also commonly seen in inflammatory conditions in vivo, where 
transformation to a more gastrointestinal phenotype is seen, probably reflecting the 
origin of the pancreas from the proximal duodenum (see [227, 242, 243] and Chapter 
4).  It has even been suggested that the mass of evidence for maintenance of the 
pancreas via division of remarkably plastic differentiated cells calls into question the 
need for a multipotent intra-pancreatic stem cell to exist at all. 
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1.3 Cancer Stem Cells 
In the last decade, the view that cancer is a disease of stem cells has come to 
prominence following a seminal review outlining the hypothesis and supporting 
evidence in 2001 [244].  Cancer stem cells were subsequently defined as cells able to 
self-renew and to give rise to tumours composed of a hierarchy of more differentiated 
non-stem cells [245], but further attributes such as chemoresistance and the ability to 
initiate metastases are also thought to be the provenance of these cells, giving rise to a 
plethora of terms such as “tumour initiating cells” and “tumour propagating cells”, 
depending on the range of behaviours exhibited (reviewed in [114]).  The term 
“tumour initiating cell” (TIC) implies that tumorigenesis in a given tissue is mediated 
by genetic alterations in this cell type, which then are transmitted to a hierarchy of 
offspring that form the bulk of the tumour; whereas “tumour propagating cell” (TPC) 
implies the ability of a cell to give rise to tumours in xenografts, at distant sites or 
even to maintain tumour size by virtue of its self-renewal properties, rather than to 
have a proven role as the cell of origin of the initial neoplastic lesion per se.  
Evidence for the latter is more abundant, but prone to criticism on the grounds that 
xenograft models may not allow for reliable identification of this fraction with a great 
deal of relevance to the original tumour [246].  Despite the increasing popularity of 
the cancer stem cell model, there are still many unanswered questions pertaining to 
the nature of TICs, how cancer stem cell characteristics may evolve during tumour 
progression and are regulated by the tumour microenvironment (reviewed in [247]).     
 
Mutated stem cells are the cell of origin for at least some tumours 
The relative longevity of stem cells and their self-renewal capacities make them 
prime candidates for the cells in which the sequential mutations necessary for cancer 
to arise occur.  The simplest form of the cancer stem cell hypothesis proposes that 
tumour maintenance, recurrence, and the heterogeneity seen in tumours can all be 
explained by assuming that a population of stem-like tumour cells (that may be 
mutated adult stem cells or cells that have acquired stem cell traits during 
carcinogenesis) give rise to an albeit somewhat dysregulated hierarchy of 
differentiating cells caricaturing the normal scenario, where senescence of terminally 
 58
differentiated cells may be at least partially retained (Figure 1.8).  Early evidence for 
this model came from leukaemia, where the cell responsible for tumour recurrence 
and initiation in xenografts exhibits a phenotype closely resembling the normal HSC 
[248], although earlier in vitro studies had already demonstrated that cancer cells 
varied in their proliferative capacities [249].   
 
There is increasing evidence that a similar situation to that seen within leukaemia 
exists within at least some solid tumours, where tumours also appear to arise from the 
various stem cells contained therein:  In the small intestine, disruption of Wnt 
signaling necessary for stem cell function via targeted deletion of Apc in Lrg5+ CBCs 
resulted in the appearance of rapidly growing adenomas, whereas deletion of Apc in 
the more luminal TAC compartment failed to induce adenoma growth [250], 
demonstrating that mutations in the stem cell compartment were uniquely responsible 
for tumorigenesis.  Activation of Wnt signaling in CD133+ cells, that show 
considerable co-location with the Lgr5+ putative stem cell has further demonstrated 
that neoplastic cells are derived from this compartment, and the frequency of CD133+ 
cells in resultant adenomas was the same as the frequency of Lgr5+ cells in the 
adenomas generated in the Lgr5-Apc deletion studies [251].  Intestinal tumours may 
also be initiated from the label-retaining SCs located at positions 4-5 of small 
intestinal crypts: Wip1, an enzyme that functions to suppress the DNA damage 
response is expressed in this compartment, and loss of Wip1 in a murine polyposis 
model severely reduces polyp burden via p53-dependent apoptosis of damaged stem 
cells [252].  Wip1 and p53-dependent apoptosis occur at cell positions 4-5, not in 
CBCs, suggesting that dysregulated LRCs may also be responsible for tumorigenesis 
in this case. 
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Figure 1.8: Schematic representation of the current cancer stem cell hypothesis 
 
The current model of cancer suggests that the cells responsible for maintaining 
tumour mass (cancer stem cells; CSCs) have self-renewal properties, and 
considerable evidence suggests that this is due to derivation from normal stem cells 
(S), although new data also suggest that CSCs may also result from reacquisition of 
stem cell properties by transit amplifying cells (TACs).  CSCs give rise to 
dysregulated TACs that are nevertheless able to undergo terminal differentiation 
(TD).  Further mutations or the influence of stromal factors on CSCs might also lead 
to the development of secondary CSCs with new traits (CSC2), and a subset of CSCs 
may be responsible for the formation of metastases by acquisition of migratory 
properties via epithelial-mesenchymal transition (EMT).  Diagram adapted from M. 
Alison and S. Islam (unpublished), with permission. 
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The stem cell compartment of origin may also be sufficient to determine the 
phenotype of the resulting tumour, depending on the organizational hierarchy present 
in the normal tissue:  Prostatic tumours have been shown to exhibit features 
suggestive of derivation from either androgen receptor negative (AR-) basal cells 
thought to represent the adult prostatic stem cell population [116, 253] or from AR+ 
luminal cells.  In favour of an AR- CSC, androgen inhibition did not reduce the 
clonogenicity of prostatic cancer cell lines but did reduce colony size, suggesting that 
proliferation of TACs was androgen-dependent whereas self-renewal of CSCs was 
androgen-independent [254]; the expansion of a chemoresistant AR- TPC population 
could also explain the evolution of androgen-independence in recurrent prostatic 
tumours [116].  Conversely, when expression of the prostatic CSC marker CD133+ 
[116, 255, 256] was used to prospectively isolate TPCs from other human prostate 
cancer cell lines, these putative stem cell populations were AR+,  suggesting an origin 
from luminal cells [257].  These data may indicate the existence of two distinct target 
cells for tumour initiation, which could also account for the wide variations in 
androgen sensitivity seen in prostatic tumours.  A similar scenario is also seen in 
breast cancer, where both oestrogen receptor positive (ER+) and ER- cells have been 
demonstrated to possess TPC activity [102, 258]. 
 
The TIC for leukaemia is likely to be a multipotential haematopoietic stem cell (HSC) 
since, in chronic myeloid leukaemia (CML) and some cases of acute lymphoblastic 
leukaemia (Ph1-ALL) the Philadelphia chromosome (the likely founder mutation) can 
also be found in blood cells exhibiting an otherwise normal differentiated appearance 
[259], and in acute myeloid leukaemia (AML), the TPC shares many features of 
primitive HSCs and is assumed to be the target of leukaemic transformation [248], 
although these TPCs exhibit subtle phenotypic differences between patients [85].  
However it has also been shown experimentally that leukaemias can develop from 
more committed progenitors such as granulocyte monocyte progenitors [260]. 
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Prospective isolation and identification of cancer stem cells 
A wide range of candidate markers of cancer stem cells have been proposed and used 
to prospectively isolate sub-populations of cells from primary tumours and cancer cell 
lines, which can then be subject to in vitro and in vivo assessment of their TPC 
activity.  The ability to form serially transplantable tumours (tumorigenicity) 
exhibiting heterogeneous differentiation is considered the gold standard for TPC 
identification, and the ability to form colonies in vitro (clonogenicity) is commonly 
employed as an assay of proliferative capacity and can also act as a surrogate 
tumorigenicity assay [249, 261], although not all cells capable of initiating colonies 
are tumorigenic [262].  It has been pointed out that tumorigenicity assays performed 
in xenotransplant models may be flawed:  incomplete immunosuppression of animal 
recipients may result in underestimation of stem cell number, as when a standard 
immunodeficient mouse xenotransplant tumorigenicity assay was employed, the 
frequency of TPCs in human melanoma was estimated at 1 in 106 [263], whereas in a 
tumorigenicity assay employing a more immunocompromised recipient 
(NOD/SCID/IL2R null mice) single human melanoma cells were shown to be 
tumorigenic, indicating that most, if not all melanoma cells were potential TPCs 
[264].  In addition, studies of murine lymphoma utilizing histocompatible mice and 
other syngeneic systems have suggested not only that TPCs may occur with much 
higher frequency than previously reported [265], but also may not exhibit the same 
phenotypes as those implied by xenograft studies [266].   
 
It is possible that TPC populations vary in phenotype within the same tumour: in 
human glioblastomas, the central and peripheral areas have been shown to contain 
cytogenetically and phenotypically diverse TPCs, with distinct tumorigenic potentials 
[267], which may explain the intra-tumor heterogeneity displayed by many 
neoplasms, where multiple karyotypically distinct clones co-exist within the same 
lesion [268].  Similarly, in vitro, genotypically and phenotypically distinct sub-
populations have been shown to represent multiple TPC fractions within cell lines 
[269].  In addition, acquisition of stem cell properties such as chemoresistance and 
metastatic potential can be induced by epithelial-mesenchymal transition (EMT) 
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during tumour progression (Figure 1.7).  This process is regulated by several 
molecules including Slug, Snail and Twist and enables previously sessile, polarized 
epithelial cells to become non-adherent, non-polarized and motile (a more 
mesenchymal in phenotype) both during normal development and in cancer 
(reviewed in [144, 270]).  Up-regulation of Twist and Snail in a breast cancer cell line 
resulted in the generation of mesenchymal-like cells with TPC traits such as enhanced 
clonogenicity and tumorigenicity, and furthermore these cells resembled those 
identified as mammary TPCs in primary tumour specimens [271].  The development 
of metastasis may involve the dissemination of CSCs, and particularly involve cells at 
the tumour margins that have undergone EMT [144], a process that may be aided by 
the expression of chemokine receptors such as CXCR4 by CSCs, as seen in 
pancreatic cancer [272].  
Many markers have been employed for the prospective isolation of TPCs from human 
neoplasms; many are common to adult stem cells and thought to serve similar 
functions in their CSC counterparts.  CD133, integrins, ALDH activity and SP 
phenotype have all been suggested as markers for TPCs of various kinds, along with 
markers pertaining to CSC-specific traits such as metastatic potential (CD44 and 
CXCR4), immortality (telomerase) and chemoresistance (SP and ALDH).  For 
example, markers for TPCs in gastro-intestinal carcinomas include CD44, CD133 and 
ALDH.  Two studies presented strong evidence to suggest that CD133 enriches for 
TPCs in colorectal cancer [115, 273].  However, a subsequent study showed that both 
CD133+ and CD133- cells were equally tumorigenic, and that CD133- cells produced 
more aggressive tumours in NOD/SCID mice [120].  In human colorectal carcinoma, 
the hyaluronan receptor CD44 (alone or in combination with other markers including 
CD133 and ALDH1) has also been used to isolate highly clonogenic and tumorigenic 
cells [274-276], whereas other studies report ALDH1 as a specific marker of 
colorectal CSCs, with only modest enrichment of TPCs when CD133 or CD44 was 
used as an additional marker [277].  In addition, cyclophosphamide treatment of 
human colonic xenografts enriches for CD44+/ALDH+ cells, which are more 
tumorigenic than cells selected by solely by expression of CD44 [278].  Furthermore, 
ALDH1+ cells of colitis form a candidate for neoplastic transformation, thus possibly 
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representing the TIC for colorectal carcinoma [279].  Potential markers of cancer 
stem cells are covered in more detail in Chapter 3.   
 
 
1.4 Cancer stem cells and the pancreas 
Evidence for pancreatic cancer stem cells 
There are several forms of pancreatic cancer, with different aetiologies and 
phenotypes.  The commonest type of pancreatic cancer, ductal adenocarcinoma 
(PDAC), shows a ductal phenotype and is thought to be the end result of a 
premalignant metaplasia-dysplasia sequence within the ductal compartment, referred 
to as pancreatic intraepithelial neoplasia (PanIN) [242, 280, 281].  These increasingly 
dysplastic changes in ductal epithelial cells are accompanied by characteristic genetic 
and epigenetic alterations including activation of K-ras, p16Ink4a methylation and 
aberrantly activated Notch signaling [280, 282-286], and tumour progression is 
further influenced by interactions with the tumour stroma (i.e. stellate cells) [287-
291], expression of chemokine receptors including CXCR4 [208, 292-297] and 
hypoxia [298-300].  Other, less common pancreatic tumour types include rare 
exocrine acinar cell tumours, intraductal papillary mucinous neoplasms (IPMNs), 
papillary and cystic tumours that also arise within the ducts, and endocrine tumours 
which may express various islet cell hormones (i.e. insulinoma, glucagonoma, 
VIPoma, somatostatinoma and PPoma).  Interestingly, tumours exhibiting a 
genuinely mixed ductal/endocrine phenotype are extremely rare [301], and in many 
cases may represent the presence of entrapped normal structures [302], although the 
presence of metastases exhibiting ductal and endocrine differentiation cannot be 
explained this way [303].  Squamous differentiation is also sometimes seen in PDAC 
[304].   
 
Several experiments have provided interesting data on the possible derivation of 
PanIN and subsequently PDAC:  experimental activation of K-ras signaling in 
differentiated elastase+/Mist-1+ acinar cells not only lead to PanIN formation in 
murine models, but cells with an intermediate acinar/ductal phenotype are seen in 
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early PanINs, highly suggestive of an important role for acinar-ductal 
transdifferentiation in the generation of PDAC ([231, 285, 305, 306], reviewed in 
[307]).  However, generation of PDAC proper was not seen in these experiments, and 
it is not universally accepted that all PanINs are able to progress to cancer [281, 283, 
308].  However, these data raise the possibility that the TIC for PDAC may be a 
mature acinar cell that has undergone conversion to a ductal phenotype, which is then 
passed on to its progeny, rather than a hypothetical intraductal progenitor cell.  
Conversely, evidence for the ductal origin of PDAC has very recently come to light:  
three dimensional reconstructions of human and murine large pancreatic ducts of both 
normal and chronically inflamed pancreata have identified normally inconspicuous 
but morphologically and phenotypically distinct out-pouchings of the ductal 
epithelium that expand during chronic pancreatitis to form PanIN-like lesions [309].  
These so-called pancreatic ductal glands (PDGs) demonstrated active Shh signaling, 
thought to be absent from normal pancreata but which is a conspicuous feature of 
PanIN and PDAC.  Furthermore, PDGs expressed gastric mucins and a strikingly 
embryonic pattern of gene expression, thus possibly representing an intraductal stem 
cell population [309].      
 
In vitro studies of hamster pancreatic endocrine tissue demonstrated that islet cells 
have the potential to form malignant ductal-type cells following extensive treatment 
with carcinogens, leading to tentative suggestions for an intra-islet origin for PDAC 
[310-313] (reviewed in [314]).  However, subsequent lineage tracing experiments in 
vivo demonstrated that β-cells did not contribute to pre-malignant ductal 
proliferations, indicating that in vitro insulo-ductal conversions probably do not 
accurately reflect PDAC tumorigenesis [315].  Conversely, the possibility that islet 
cell tumours may be derived from exocrine cells under some circumstances has been 
shown by a study of multiple endocrine neoplasia type 1 (MEN1) [316]. 
 
Mixed endocrine/exocrine tumours are extremely rare in the pancreas and are often 
composed of non-neoplastic cells entrapped within a purely ductal or endocrine 
malignancy [301, 302], however the existence of pancreatic tumours capable of 
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forming metastases with a mixed endocrine/exocrine phenotype perhaps suggests 
derivation from a multipotent precursor [303, 317].  Mixed pancreatic 
endocrine/exocrine tumours are also found in extra-pancreatic sites such as the gut, 
perhaps originating in ectopic pancreatic tissue but also perhaps deriving from 
primitive stem cells responsible for prenatal pancreatic development [318]. 
 
 
Prospective isolation and identification of pancreatic CSCs 
Several attempts to isolate pancreatic TPCs have been performed since the inception 
of this project, using a variety of markers (reviewed in [207]).  The two most 
compelling studies to date have isolated PDAC cells that are highly tumorigenic and 
able to give rise to more differentiated progeny by their expression of CD133/CXCR4 
and CD44/CD24/ESA respectively [272, 319].  Over-expression of CD44 has also 
been reported in PDAC cells capable of anchorage-independent growth and with high 
proliferative potential both in vitro and in vivo [320].  However, although CD133 
expression has been shown to positively correlate with metastatic and angiogenic 
capabilities of PDAC in vivo [321], the broad range of expression in normal and 
malignant pancreatic tissues indicates that it probably does not represent an exclusive 
trait of adult SCs nor CSCs ([202], see also data presented in Chapter 3). 
  
CXCR4 presents considerable promise as a further marker of PDAC TPCs:  PDAC 
cells doubly positive for CD133 and CXCR4 showed enhanced tumorigenicity and 
were additionally uniquely responsible for formation of metastases in a xenograft 
model [272], building on previous reports that the CXCR4/SDF-1 axis may be 
implicated in PDAC progression via induction of motility, invasion and proliferation 
[292-294].  Recent epidemiological studies have also reported that high CXCR4 
expression in PDAC is correlated with poor prognosis and increased risk of 
metastases in vivo [296].     
 
Cells with a SP phenotype have recently been isolated and shown to represent a 
chemoresistant subset of PDAC cells [184], and furthermore preferentially undergo 
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EMT and exhibit enhanced invasion in vitro [322], and exhibit high tumorigenicity in 
vivo [323], although further work is required to confirm that the SP fraction genuinely 
represents a TPC for PDAC.  Reports of ALDH with reference to pancreatic CSCs 
are few and far between, although a recent report of enlargement of an ALDH+ 
subpopulation in xenografted tumours following gemcitabine treatment, with 
subsequent expansion of a gemcitabine-sensitive ALDH- fraction proposes that TPCs 
responsible for tumour recurrence following treatment may be defined by high ALDH 
expression coupled with expression of CD24 [324].  The expression of ∆Np63 was 
also investigated in PDAC, but found to be absent except in areas of squamous 
differentiation [325].   
 
Several studies have highlighted the involvement of signaling pathways vital for 
pancreatogenesis in the development and maintenance of PDAC.  Notch signaling is 
responsible for directing pancreatic differentiation fates and vital for pancreatogenesis 
[217, 326], and activation occurs during pancreatic tumorigenesis, confirmed by the 
observation that PanIN developed in mice when ectopic activation was induced [286].  
Further evidence that Notch signals may maintain PDAC TPCs is provided by a study 
that demonstrated that down-regulation of Notch using the siRNA miR-34 reduced 
clonogenicity and invasion whilst increasing cell cycle arrest, apoptosis and 
radiosensitivity [327].  Hedgehog signaling has also been shown to regulate key 
stages of pancreatogenesis, and has been shown to be partly responsible for 
promoting EMT and metastasis of PDAC (reviewed in [328, 329]): experimental 
over-expression of Gli1 induced metastatic behaviour in a non-metastatic 
immortalized pancreatic ductal cell line, and invasion and tumour growth of PDAC 
was greatly reduced in vivo and in vitro when Hh activity was suppressed with 
cyclopamine [330], although a further study has reported that Hh does not act alone to 
maintain PDAC CSCs [331].  Paracrine Hh and Notch signaling may act via tumour 
stromal cells (i.e. PSCs) to modulate tumour progression; furthermore PSCs induce 
proliferation, reduce apoptosis and increase invasiveness of PDAC cells [287, 291, 
332, 333] thus acting as a potential CSC niche in this disease (reviewed in [334], and 
see [5, 335] for further discussions of the cancer stem cell niche concept). 
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In summary, the identity and biology of normal and malignant pancreatic stem cells 
remains to be clearly elucidated although significant progress has been made.  In 
particular, the potential utility of CD133, CD44, the SP phenotype and CXCR4 to 
prospectively isolate normal or malignant pancreatic SCs deserves further 
investigation.  
 
 
NB: Section 1.1 Adult Stem Cell Properties builds upon and updates a published 
review, with figures used by permission of the authors [2] and Section 1.2 Adult Stem 
Cells in the Pancreas builds upon a published review [226] co-authored by myself. 
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CHAPTER 2:  Are there likely to be CSCs in pancreatic cancer cell lines that 
may shed light on a PDAC CSC or even a normal adult pancreatic SC? 
 
 
2.1 INTRODUCTION 
2.2 MATERIALS AND METHODS 
2.2.1 Selection of cell lines 
2.2.2 Identification and characterization of cell lines: 
 Monolayer culture; immunophenotyping; evaluation of growth rate; 
 assessment of clonogenicity under adhesion-dependent, adhesion-free and 
 serum- free conditions. 
2.2.3 Evidence for differentiation hierarchies in hPDAC cell lines: 
 Assessment of colony heterogeneity; morphological classification and  
 immunophenotyping. 
2.2.4 Assessment of the properties of clonal Panc-1 colonies:  
 Assessment of the proliferative capacities of holoclones, meroclones and 
 paraclones.  
2.2.5 Assessment of the differentiation capabilities of hPDAC cell lines 
2.3 RESULTS 
2.3.1 Identification and characterization of cell lines 
2.3.2 Differentiation hierarchies in hPDAC cell lines 
2.3.3 Properties of clonal Panc-1 colonies: 
 Proliferative capacities of holoclones, meroclones and paraclones;  
 Growth and phenotypic characteristics of holoclones, meroclones and 
 paraclones. 
2.3.4 Differentiation capabilities of hPDAC cell lines 
2.4 DISCUSSION  
2.5 CONCLUSIONS 
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2.1 INTRODUCTION 
 
Given the poor accessibility and availability of fresh normal and neoplastic human 
tissues, and difficulties associated with primary cultures such as spontaneous 
differentiation, culture adaptation, genetic instability and senescence [228, 336-338], 
the possibility of using established human pancreatic ductal adenocarcinoma 
(hPDAC) cell lines as a platform for prospective pancreatic stem cell identification 
was raised.  There are several reasons why this arguably highly artificial monoculture 
system may present a useful paradigm for stem cell identification. 
 
Firstly, there is abundant evidence to support the persistence of CSCs in vitro.  Cells 
isolated from a range of human cancer cell lines exhibit the ability to initiate serially 
transplantable tumours with morphology, differentiation and behaviour recapitulating 
that of the parent tumour when xenografted at low density [339-343], a strong 
indicator of cancer stem cell status, fulfilling the criteria of tumour initiation [244] 
and the production of an expanding hierarchy of differentiating offspring [1], 
although this is not true of all cancer cell lines.  These sub-populations may also 
initiate metastases, produce offspring exhibiting multi-lineage differentiation or resist 
apoptosis induced by chemotherapeutic agents; further attributes of cancer stem cells 
[339, 344-346].   
 
Secondly, there is plentiful evidence to suggest that a differentiation hierarchy similar 
to that seen in tissues and tumours in vivo may be retained by cultures of both normal 
and malignant cells.  For instance, cells derived from outgrowths of small skin 
biopsies and passaged several times in vitro may be used to produce extensive 
epithelial sheets able to effect permanent therapeutic re-epithelialization of full-
thickness burns or other epithelial defects [337, 347, 348], confirming that cells with 
stem capabilities are not only able to persist but also to proliferate and recapitulate 
epidermal organization in culture [349].  In addition, the ability to form expanding 
colonies in vitro capable of giving rise to a large number of offspring (i.e. highly 
clonogenic) has long been known to be a property of stem cells in untransformed 
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primary cultures and of cells with tumour-initiating capabilities in transformed or 
tumour-derived cell cultures [1, 249, 261, 350, 351].  However, the colonies thus 
formed are not necessarily equal.   
 
Heterogeneity of colonies is seen even within cultures derived from tissues with no 
multi-lineage differentiation such as the interfollicular epidermis.  Human 
keratinocytes form clonal colonies with a spectrum of morphologies, each associated 
with derivation from cells of a particular rung of the epidermal differentiation 
hierarchy, reflected by their differing proliferative capacities [17, 352].  Cells of 
holoclones showed the greatest proliferative potential (up to 130 generations), 
initially giving rise to holoclones, but eventually meroclone and paraclone colonies, 
whilst those of paraclones had the lowest proliferative potential (with a maximum of 
around 15 generations) and only gave rise to paraclones.  Likewise, meroclones 
exhibited a proliferative potential intermediate between holo and paraclones (up to 38 
generations) and initially gave rise to meroclones and subsequently paraclones with 
increasing frequency.  Holoclones were defined as large, symmetrical, smooth-
bordered colonies composed primarily of small, undifferentiated cells, often clustered 
at the perimeter, whilst small, irregular colonies formed predominantly from large, 
flattened, terminally differentiated cells were designated paraclones [17](See Chapter 
1; Figure 1.2).  Intermediate colonies, composed of fewer cells than holoclones but 
more than paraclones, and composed of a heterogeneous mixture of smaller, less 
differentiated cells and larger cells nearing terminal differentiation were termed 
meroclones [17].    Holoclones were the only colonies able to give rise to the entire 
spectrum of colony morphologies, and occurred with lower frequency in cultures 
from aged patients, and thus shown likely to be derived from epidermal stem cells, 
with meroclones formed from the transit amplifying compartment and paraclones 
from cells nearing the end of the differentiation hierarchy [17, 353].  Similarly, 
epithelial cells isolated from the multipotential stem cell niche of the follicular bulge 
region form high numbers of holoclone-type colonies [15], and this spectrum of 
stereotypical colony types has also recently been shown to exist in cultures of murine 
keratinocytes, where holoclones show a predominance of cells exhibiting a 
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progenitor-type cytokeratin expression profile and paraclones a characteristically 
terminally differentiated one [349].  A similar progression has also been 
demonstrated for oligodendrocytes in vitro [354-356]. 
 
Colony heterogeneity is also seen in malignant cell lines: colonies formed in soft agar 
by tumour cells exhibit variable proliferative capacity, some able to give rise to 
passageable cell lines and others unable to sustain proliferation beyond a few 
divisions [357].  Likewise, clonal cell lines derived from transformed murine 3T3 
fibroblasts produced morphologically distinct sub-clones that could be isolated 
almost immediately following transformation: these clones exhibited varying colony 
morphologies, tumorigenicity and proliferative capacities, and phenotypic drift that 
occurred too quickly to be explained by genetic mechanisms [357, 358].  
Furthermore, epithelial cell lines derived from non-epidermal solid tumours may 
exhibit a range of colony morphologies in vitro that closely mirrors that exhibited by 
primary keratinocyte cultures [353, 359, 360].  Here these stereotypical colony 
morphologies are similarly associated with cellular differentiation status: for 
example, in head and neck squamous cell carcinoma (HNSCC), holoclones express 
membranous CD44 and β1-integrin, and nuclear β-catenin; markers associated with 
CSC status in this malignancy, whereas paraclones exhibit none of the above, and 
conversely show high levels of the maturation marker cytokeratin 16 [361].  Thus, 
these varied colony morphologies and those exhibited by transformed 3T3 fibroblasts 
may also be a function of differentiation and senescence of offspring of a less-
differentiated long-lived stem/precursor cell. 
 
Embryonic or adult stem cells may also be maintained as cell lines in vitro, although 
retention of stemness is often dependent on complex defined media, the presence of 
mesenchymal feeder layers or extracellular matrix components that may simulate the 
in vivo niche [362, 363].  Difficulties remain for the long-term culture of human adult 
stem cells: culturing human breast stem cells as mammospheres allows for short-term 
retention of stem cell properties, but this cannot be prolonged for more than four 
passages at present [336].  Culture adaptation and the subsequent development of 
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genetic aberrations (including severe chromosomal abnormalities) in long-term 
culture also continue to pose problems for ES and neural stem cell lines [364-366].  
Nonetheless, even under more routine monolayer culture conditions, cancer cell lines 
continue to exhibit sub-populations of cells possessing markers of stem cells of the 
tumours or normal tissues from which they are derived.  For example, high ALDH 
activity has been associated with stem cell status in murine prostatic epithelium [79, 
367] and in human prostatic cancer cell lines, this property is similarly associated 
with the ability to produce serially transplantable, histologically heterogeneous 
tumours in vivo, as well as indicating poor prognosis in human tumours in vivo [367, 
368].  More advanced culture methods such as non-adherent spheroid culture, serum-
free culture with defined factors, or culture in low oxygen tension may further 
enhance the stem cell properties seen in tumour cell lines:  hypoxia-inducible factors 
are responsible for maintenance of the tumorigenic fraction of cultured glioma cells 
[369-371], and whereas glioblastoma cell lines are prone to mutation and loss of stem 
cell properties in monolayer culture these changes can be circumvented by spheroid 
culture [346].  Additionally, the ability to proliferate in adhesion-free conditions is 
itself correlated with tumorigenicity and, teleologically, TPC status [249, 261, 372, 
373]. 
 
Finally, in several systems, CSCs have been shown to be derived from normal adult 
SCs, and therefore retain many hallmarks thereof.  For example, in acute myeloid 
leukaemia, the tumour-initiating cell shares many phenotypic markers with cells with 
the ability to repopulate the bone marrow of SCID mice, analogous to the human 
haematopoietic stem cell [248].  Furthermore, ALDH1 expression has shown to 
identify a stem cell population within the human colon, which is expanded in pre-
malignancy and drives colorectal carcinogenesis [277, 279].  Therefore, it seems 
logical that identification and characterization of CSCs may inform on the potential 
characteristics of an adult stem cell, where this cell remains unidentified.   
 
In order to determine whether human pancreatic cancer cell lines represent a suitable 
platform for CSC identification, several lines were selected from the literature that 
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displayed features associated with CSCs such as tumorigenicity and the ability to 
metastasize, and which exhibited a spectrum of protein expression and genetic 
alterations typical of those seen in human pancreatic ductal adenocarcinomas in vivo.  
These cell lines were further characterized to investigate whether a hierarchy of 
differentiating cells with differing replicative capacities could be detected.  It was 
hypothesized that if a range of colony morphologies resembling holoclones, 
meroclones and paraclones resulted from plating single cells at low density that this 
might indicate the presence of a functional differentiation hierarchy.  Furthermore, 
the congruency of these distinctive colonies with those indicative of hierarchy 
position in primary keratinocyte cultures could be evaluated by examining their 
proliferative capabilities and differentiation statuses.  To this end, several cell 
pancreatic cell lines were characterized and their abilities to form heterogeneous 
colonies examined.  Where morphologically distinct colonies were seen, their relative 
proliferative capacities were evaluated and the characteristics of their progeny 
followed through several passages to assess whether this variation might truly reflect 
retention of a differentiation hierarchy.   
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2.2 MATERIALS AND METHODS 
 
2.2.1 Selection of cell lines 
Four human PDAC cell lines were selected for study: Capan-2 (ATCC: HTB-80; 
DSMZ: ACC 245), COLO357, Panc-1 (ATCC: CRL-1469) and Psn1.  These lines 
were selected as they have been relatively well characterized using in vivo xenograft 
models and in vitro studies, are relatively stable in culture and broadly retain the 
genotype and/or phenotype of the parent tumours [374-381].  Based on these studies, 
Panc-1 is considered to exhibit poor differentiation in vivo and in vitro, Psn1 and 
COLO357 are moderately well differentiated, whereas Capan-2 is well differentiated 
[380, 381].  These lines show cytokeratin (CK) profiles associated with pancreatic 
ductal (CK7/19) or exocrine differentiation (CK8/18), with the degree of cytokeratin 
positivity and mucin production (as indicated by Muc-1 expression) generally 
increasing with differentiation, and expression of the mesenchymal intermediate 
filament vimentin decreasing.  By comparison, normal ductal cells of the pancreas 
express CK7, CK19, carbonic anhydrase II (CAII) and Muc-1, but not vimentin [382-
384].  These published profiles are summarized in Table 2.1.  All cell lines were 
obtained from the Cancer Research UK (CRUK) cell banks or kindly supplied by Dr 
W Otto, CRUK, and certified negative for mycoplasmas.  Isoenzyme analysis had 
previously been performed and agreed with published data. 
 
2.2.2 Identification and characterization of cell lines 
Basic characterization of each line was performed in order to establish baseline 
behaviour in culture and to validate cell line identity [385].  Cells were cultured 
according to American Type Culture Collection (ATCC) recommendations or 
published descriptions of initial culture following cell line establishment: Panc-1 cells 
and COLO357 in Dulbecco’s Modified Eagle’s Medium supplemented with 10% 
foetal calf serum (DMEM/10% FCS), Psn1 in DMEM/10% FCS supplemented with 
2mM L-glutamine and Capan-2 cells in Roswell Park Memorial Institute-1640 
formula medium (RPMI) supplemented with 15% FCS, in humidified incubators 
maintained at a temperature of 37ºC and supplied with 10% CO2 in air.   
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Table 2.1:  Published characteristics of hPDAC cell lines in vitro and in vivo 
 Panc-1 Psn1 COLO357 Capan-2 
Original 
tumour 
Invasive undifferentiated ductal 
carcinoma of head of pancreas 
Grade 3 
Lymph node spread 
Line isolated from primary 
tumour 
PDAC with lymph 
node spread 
Line isolated from 
xenograft of frozen 
tissue sample 
Ductal adenocarcinoma 
Grade 1-2 
Isolated from lymph 
node metastasis 
Invasive ductal-type 
adenocarcinoma of head of 
pancreas  
Grade 1 
Line isolated from primary 
tumour 
Xenograft 
tumours*  
Poorly differentiated: Grade 3 
Solid pattern, focally sarcomatoid 
No mucin production 
CK7/CK19: 20/11%+ 
CK8/18: 63/88%+ 
Vimentin+++ (73%) 
Chromogranin A 2%+ 
α1-chymotrypsin 7%+ 
Pdx-1-/β-catenin-, Shh 28%+ 
(See above) Moderately differentiated 
Focally adenosquamous 
Grade 2-3  
(Focally Grade 1) 
 
Well-differentiated ductal 
pattern 
High mucin production 
Grade 1 
 
Kinetics in 
vitro 
Doubling time 52h 
Soft-agar colony formation 13% 
  Plating efficiency 55% 
Doubling time 96h 
In vitro 
phenotype 
Ultrastructure: Grade 3 
Highly pleomorphic 
CK7-/ β-catenin- 
CK8/18/19+++  
Vimentin+++, Muc-1+ 
 Ultrastructure: Grade 2 
Moderately pleomorphic 
CK7/8/18/19+/+++ 
Vimentin+ 
Muc-1+++ 
Ultrastructure: Grade 1 
Low pleomorphism 
CK7/8/18/19+++ 
Vimentin- 
Muc-1+++  
Key mutations K-ras, p53, p16 K-ras, p53,c-myc K-ras, Smad4 
(WT p53, WT p16) 
K-ras, p16, (WT p53) 
* Subcutaneous in nude mice; WT = wild type. Data from references 373-380 in section 2.2.1 above.
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Media were prepared in-house at CRUK and carbonate buffered for 10% CO2 
incubators (formulations detailed in Table 2.2).  Routine cultures were maintained in 
75cm2 tissue culture flasks in duplicate and media changed every other day, and all 
tissue culture plastics were Falcon brand (BD Biosciences, Oxford, UK) unless 
otherwise stated. 
 
Table 2.2:  Media used for routine tissue culture.   
Cell Line Medium Medium Formulation 
Capan-2 RPMI 1640/15% 
foetal calf serum 
(FCS) 
RPMI 2% (20 litres): 
207.8g RPMI 1640 powder (Sigma R604 or Life 
Technologies 074-1800) 
40g      NaHCO3 
6g        L-glutamine (0.24M stock solution) 
1.2g     penicillin 
2g        streptomycin 
pH 7.0 
COLO357 DMEM/10% 
FCS 
DMEM (E4; 5 litres): 
32g      NaCl 
22.5g   D-glucose 
0.3g     penicillin 
0.5g     streptomycin 
0.6g     sodium pyruvate 
18.5g   NaHCO3 
2.9g     L-glutamine (0.24M stock) 
10ml    KCl (20%) 
5ml      CaCl2 (26.5%) 
5ml      MgSO4 (20%) 
5ml      NaH2PO4 (14%) 
5ml      Fe(NO3)3 (0.01%) 
5ml      anti-mycotic (0.02% n-butyl p-
hydroxybenzoate) 
7.5 ml  phenol red 
pH 7.0 
Panc-1 DMEM/10% 
FCS 
As above 
Psn-1 RPMI/10% FCS 
+ 2mM L-
glutamine 
As above 
 
DMEM = Dulbecco’s Modified Eagle’s Medium; RPMI = Roswell Park Memorial 
Institute formulation 
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Routine monolayer culture 
Cells were seeded at a density of 3×104 cells/ml into 24-well polystyrene tissue 
culture plates and cultured under routine conditions until confluent.  Cultures were 
examined and photographed during the logarithmic growth phase and at confluence 
using an Olympus IMT-2 inverted phase contrast microscope equipped with a 
calibrated stage-mounted plate reader and Optronics digital camera (SNBG6024254-
H).  Images were captured using MagnaFire 2.0 (Karl Storz Imaging) running on a 
Mac G4 PowerPC (OS X 10.2.8) and images stored as monochrome .tif files.  The 
observed morphologies were then compared to those published for each line.  
Passaging regimens were constructed according to Freshney [386] and DMSZ or 
ATCC recommendations where these were available, and split ratios established to 
allow cultures to be passaged approximately weekly just before confluence was 
reached.  Well-documented cultures were selected and used up to a maximum of the 
30th passage, and discarded if any changes in growth pattern were observed [385]. 
 
Phenotyping by indirect streptavidin/biotin/peroxidase immunocytochemistry 
Cells were seeded at a density of 3×104 cells/ml into glass or PermanoxTM chambered 
slides (LabTekTM chamber slide system, NuncTM/Thermo Fisher Scientific, Roskilde) 
in routine media and allowed to grow under routine conditions until just or almost 
confluent.  Alternatively, cells were seeded ~100 cells/well into 6 well plates and 
cultured for 14 days with one change of medium at 7 days, until macroscopically 
visible colonies were present.  Cultures were then fixed according to Protocol 2.1 and 
stored for no more than a week before immunostaining was carried out.  Markers of 
pancreatic ductal differentiation were selected to confirm pancreatic ductal origin and 
to assess the degree of differentiation in monolayer cultures to compare to that 
published for each line (shown in Table 2.1).  The markers selected are shown in 
Table 2.3 below.  Frozen sections of normal human pancreas were obtained from the 
CRUK tissue banks in accordance with HTA guidelines for use as positive control 
material.  Cultures were immunostained using a standard indirect 
streptavidin/biotin/peroxidase method visualized with a diaminobenzidine (DAB) 
chromogen as outlined in Protocol 2.2.  Antibodies were previously titrated using 
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positive control material at a range of dilutions bracketing that recommended by the 
manufacturer by 10 to 100-fold, and the dilution giving the strongest specific signal 
without significant non-specific staining was then employed on test cultures.  The 
final primary antibody dilutions used for immunophenotyping cell lines are shown in 
Table 2.4 and reagents other than primary antibodies shown in Table 2.5.  Primary, 
secondary and tertiary antibodies were added in standardized volumes sufficient to 
cover cultures adequately without evaporation for the duration of the incubation (e.g. 
200µl/chamber for 8-chambered slides), with other reagents added to excess (e.g. 
500µl/chamber for 8-chambered slides) and all incubations were carried out at room 
temperature unless otherwise stated.  For negative controls, primary antibody was 
replaced by an identical volume of PBS during the primary antibody incubation step.  
A negative control was included for each cell line for each secondary antibody used 
in each staining run.   
 
Following immunocytochemistry, mounted slides were examined by light 
microscopy using a Nikon Eclipse E600 microscope equipped with Nikon plan lenses 
and Q Imaging MicroPublisher 5.0 RTV digital camera.  Images were captured using 
QCapture Pro 6 software (QImaging) running under Mac OS X and processed to 
remove shadows using Photoshop (Adobe, CS3), utilizing the method described by 
Marty and co-authors [387]. 
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Table 2.3:  Markers selected for initial phenotyping of hPDAC cell lines 
Marker Rationale 
β1-
integrin 
Adhesion molecule necessary for differentiation in pancreatic cell lines 
[388] 
β-catenin Assessment of Wnt signaling status [389] 
CAII Pancreatic ductal differentiation marker [175, 390, 391] 
CK19 Pancreatic ductal differentiation marker [383] 
MIB-1 Assessment of proliferation [392] 
MUC-1 Pancreatic ductal differentiation marker [384] 
 
 
Protocol 2.1:  Fixation of cell cultures for immunocytochemistry 
1. Media were gently aspirated from the cultures. 
2. Cultures were rinsed briefly in 0.01M phosphate-buffered saline pH 7.4 
(PBS) to remove remaining media. 
3. An appropriate volume of 4% paraformaldehyde (PFA) w/v in distilled 
water (dH2O) was added to each chamber or well and cultures fixed for 20 
minutes at room temperature. 
4. PFA was gently aspirated and cultures rinsed in two changes of PBS over 
10 minutes. 
5. An appropriate volume of fresh PBS was added to each chamber or well, 
the lid replaced and sealed using waterproof film (Parafilm). 
6. Slides were stored at 4ºC for no more than 7 days before use. 
See Table 2.4 for details of reagent formulations. 
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Protocol 2.2:  Indirect streptavidin/biotin/peroxidase immunocytochemistry 
1. Cultures were rinsed in fresh PBS/Tween 20 for 5 minutes at room 
temperature. 
2. Endogenous peroxidases were blocked by incubating cultures in 0.3% 
hydrogen peroxide (H2O2) in PBS for 10 minutes. 
3. Cultures were rinsed in two changes of PBS/Tween 20 over 10 minutes. 
4. For intracellular epitopes, cultures were permeabilised in 0.1% Triton 
X100 in PBS for 15 minutes. 
5. Non-specific antibody interactions were blocked by incubating cultures in 
normal serum from the species that the secondary antibody was raised in.  
Incubations were carried out at room temperature for 15 minutes, and the 
serum drained from the slide. 
6. Primary antibody was applied at the appropriate dilution (in PBS) for 60 
minutes at room temperature. 
7. Cultures were rinsed in two changes of PBS/Tween over 10 minutes. 
8. Biotinylated secondary antibody specific to the primary antibody species 
was applied to cultures at room temperature for 30 minutes. 
9. Cultures were rinsed twice in PBS/Tween 20 over 10 minutes. 
10. Streptavidin/horseradish peroxidase (streptavidin/HRP) was applied for 30 
minutes at room temperature. 
11. Cultures were rinsed three times in PBS/Tween 20 over 15 minutes. 
12. DAB solution was activated by adding H2O2 (see Table 2.4) no more than 
10 minutes before use and added to the slide for up to 5 minutes.  Staining 
progress was assessed by light microscopy at 1 minute intervals and DAB 
removed as necessary. 
13. The chambers were then removed as directed by the manufacturer.  Slides 
were rinsed in PBS/Tween then counterstained with haematoxylin, 
dehydrated through graded alcohols and cleared in xylene using an 
automated histostaining machine (Shandon). 
14. Slides were mounted using DPX permanent mountant or Vectamount AQ 
aqueous mountant as appropriate. 
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Table 2.4:  Primary antibodies used for hPDAC cell line characterization and 
identification by indirect streptavidin/biotin/peroxidase ICC 
 
Protein of 
interest 
Specificity Source Dilution Positive 
control 
β1-integrin Mouse monoclonal 
anti-human beta-1 
integrin sub-unit 
CD29; clone 4B7 
AbCam 
ab35 
1:200 Internal 
β-catenin Mouse monoclonal 
anti-human beta 
catenin 
DAKO 
M3539/ 
Transduction 
Laboratories  
GC19220 
1:25/1:100 Colon 
CAII Polyclonal sheep anti-
human carbonic 
anhydrase II 
AbD Serotec 
AHP206 
1:100 Pancreatic 
ducts 
CK19 Mouse monoclonal 
anti-human 
cytokeratin 19 
Clone RCK108 
DAKO 
M0888 
1:100 Pancreatic 
ducts 
MIB-1 Mouse monoclonal 
anti-human Ki67 
Clone MIB-1 
DAKO 
M7240 
1:100 Internal 
MUC-1 Mouse monoclonal 
anti-human Muc-1 
carbohydrate epitope 
Novocastra 
NCL-MUC1 
1:50 Pancreatic 
ducts 
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Table 2.5:  Other reagents used in indirect streptavidin/biotin/peroxidase ICC 
 
Reagent Details Source 
PBS 0.01M phosphate-buffered 
0.9% NaCl pH 7.4 
Prepared in-house at 
CRUK 
PFA 4% PFA in dH2O adjusted to 
pH 7 with NaOH 
Sigma-Aldrich Co. Ltd, 
Poole, Dorset, UK 
PBS/Tween 20 0.05% Tween 20 in 0.01M 
phosphate-buffered 0.9% 
NaCl pH 7.4 
Prepared in-house at 
CRUK 
H2O2 30% w/v (216763) 
Used as 0.3% H2O2 in PBS 
Sigma-Aldrich 
Triton X100 H5142 Molecular Biology 
Grade 
Used as 0.1% in PBS 
Promega UK Ltd, 
Southampton, Hants., UK 
Normal rabbit serum X0902 
Used at a dilution of 1:25 in 
PBS 
DAKO UK Ltd, 
Ely, Cambs., UK 
Normal donkey serum 566460-5ML 
Diluted 1:25 in PBS for use 
Calbiochem Ltd, 
Nottingham, UK 
Rabbit anti-mouse 
secondary antibody 
E0354 
Biotinylated rabbit polyclonal 
anti-mouse immunoglobulins 
Diluted 1:500 in PBS for use 
DAKO 
Donkey anti-sheep 
secondary antibody 
B7390 
Biotinylated donkey 
polyclonal anti-sheep 
immunoglobulins 
Diluted 1:100 in PBS for use 
Sigma-Aldrich 
Streptavidin/HRP P0397 
Diluted 1:500 in PBS for use 
DAKO 
DAB D8001 
0.05g DAB/10ml PBS, frozen 
as 1ml aliquots (10X).   
Diluted 1:10 in PBS and 20µl 
H2O2 added just prior to use 
Sigma-Aldrich 
Haematoxylin 72804 
Modified Mayer’s 
haematoxylin 
Diluted 1:10 in dH2O 
Thermo Fisher Scientific, 
Loughborough, Leics., 
UK 
 
DPX 360294H 
BDH Prolabo 
BDH (VWR 
International) 
Poole, Dorset, UK 
VectaMountTM AQ H5501 Vector Laboratories, 
Peterborough, UK 
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Assessment of growth rates in monolayer culture 
Capan-2 and Panc-1 cells were seeded at 1×105, 3×104 and 1×104 cells/ml into 24-
well tissue culture plates in triplicate in 1ml of routine medium per well.  At each of 8 
time points (24 hours apart), media were aspirated from 3 wells per experiment and 
1ml of trypsin/EDTA (1.25mg/ml trypsin in 0.5mM EDTA in PBS (T/V), pre-
warmed to 37ºC) added.  Plates were replaced into incubators at 37ºC until most of 
the cells had detached from the plate base (approximately 2-5 minutes for Panc-1 and 
20 minutes for Capan-2), then gently tapped or triturated with a sterile Pasteur pipette 
to detach the remaining adherent cells.  Five 100µl aliquots from each well were then 
counted using a haemocytometer to estimate the number of cells present in 1ml of 
medium, and hence the number of cells per well.  The average numbers of cells per 
well were calculated and plotted on a logarithmic scale versus time and doubling time 
determined at mid-log phase according to Freshney [393].  Media were changed daily 
from 48 hours following seeding onwards.  
 
Assessment of colony forming abilities (CFA) 
Three colony-forming assays were developed, to ascertain the baseline colony-
forming capabilities of each of the four cell lines employed in this study:  the first to 
assess anchorage-dependent colony formation, and the second two to assess 
anchorage-independent colony formation.   
 
Anchorage-dependent colony formation assay 
The plating density necessary for development of clonal colonies was established by 
plating single cell suspensions of each line at a range of densities from 20 to 2×103 
cells/ml into 24 or 6 well plates, and culturing for 14 days in routine medium, with 
one change of medium at 7 days.  Single-cell suspensions were obtained by filtering 
trypsinized and triturated cell suspensions through sterile 40µm CellSafe meshes and 
specific cell densities were obtained by counting using a haemocytometer and 
subsequent dilution.  Resulting colonies were assessed via phase contrast microscopy 
for size, number and degree of overlap, and clonal density was defined as the 
minimum number of cells/ml required to produce typical, non-overlapping colonies 
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which represented the full range of morphologic colony types for the line.  The CFA 
of each line was calculated as the number of colonies formed per 100 cells plated, 
each colony comprising of ≥20cells at 14 days.  This CFA technique was also suitable 
for use with fluorescence activated cell sorting (FACS), and in subsequent 
experiments, specific numbers of cells were added to each well using a MoFlo 
(DAKO Cytomation) FACS machine as outlined in detail in Chapter 3.  Panc-1 cells 
from confluent (high density) or sub-confluent (low density) cultures were 
additionally seeded at the clonal density obtained from previous experiments in 
routine medium or routine medium mixed 1:1 with sterile-filtered conditioned 
medium taken from log-phase cultures and colony formation assessed as above. 
 
A simplified colony-counting methodology was developed for 6 well plates as 
follows: colonies were fixed after 14 days according to Protocol 2.1, and then stained 
for 1 minute with 0.1% toluidine blue (BDH, VWR International, Poole, Dorset, UK) 
in 70% alcohol.  Plates were rinsed in dH2O to remove excess stain and a further 1ml 
of dH2O added to each well, then scanned at 1600dpi using an Epson 1680 flat-bed 
scanner using the transparency setting.  Image files were imported directly into 
Adobe Photoshop CS3, brightness and contrast optimized to enable visualization of 
all colonies, and then saved as high-resolution .tif or .jpg files.  Image files were 
examined using the GNU Image Manipulation Program (GIMP v2.6.6 for Windows 
XP, open source software) and colonies counted directly on the magnified image.  
The numbers of colonies visible on these images was found to correlate well with the 
number of colonies composed of 20 cells or more when counted using the phase-
contrast method (data not shown). 
 
The percentage of cells forming colonies when plated one cell per well into 96-well 
plates was also calculated.  Single cell suspensions were prepared in serum-free 
medium and using a MoFlo fluorescence activated cell sorter, cell populations were 
gated to exclude debris, doublets and dead cells as described in detail in Chapter 3, 
then live single cells sorted 1 cell/well into 96-well plates containing routine medium.  
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Plates were examined 30 minutes after sorting to ensure that a cell was present in 
every well, and cultured for 14 days under routine conditions. 
 
Anchorage-independent colony formation assay: non-adherent plates 
For assessment of anchorage-independent CFA, 96 or 24-well tissue culture plates 
were coated with poly-2-hydroxyethyl methacrylate (poly-HEMA), a polymer that 
does not support cell adhesion.  The protocol of Fukazawa et al. [394], which has 
been shown to yield results comparable to those obtained using soft agar or methocel 
was used, with modifications.  Poly-HEMA (Sigma P3932) was dissolved 5mg/ml in 
95% ethanol at 37ºC on an orbital shaker overnight, and then centrifuged to remove 
any bubbles.  Fifty microlitres of the resulting solution was added to each well of 96-
well plates and 250µl added to each well of 24-well plates as required and gently 
swirled to coat evenly; plates were then covered and allowed to dry for 2 days at 
37ºC.  Panc-1, Psn1 and Capan-2 cells were grown until approximately 75% 
confluent then seeded 10, 100 and 1000 cells/well into coated 24-well plates or 10, 20 
and 100 cells/well into coated 96-well plates by dilution in an appropriate volume of 
routine medium, or using a MoFlo cell sorter as before.  Plates were cultured under 
routine conditions for up to 14 days and media topped up as required.  Plates were 
examined and photographed via phase contrast microscopy at 7, 14 and 21 days as 
previously described and the number of multicellular spheroids present counted and 
expressed as spheroids formed per 100 cells plated. 
 
Anchorage-independent colony formation assay: serum-free culture 
A small, highly proliferative sub-set of Panc-1 cells is known to form floating 
spheroids when cultured under defined serum-free conditions [272, 320] and a 
modification of this protocol was created to assess the anchorage-independent growth 
capabilities of Panc-1 and Psn1 cultures.  Serum-free DMEM/F12 media 
supplemented with fibroblastic growth factor-basic (bFGF), epidermal growth factor 
(EGF), transferrin, insulin, selenium and bovine serum albumin (BSA) was prepared 
according to Table 2.6 and sterile-filtered.  Single cell suspensions were prepared 
from sub-confluent cultures as before, then rinsed briefly twice in sterile PBS to 
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remove traces of serum.  Panc-1 cells were seeded at 1×102, 1×103 and 1×104 cells/ml 
and Psn1 at 1×103, 1×104, 5×104 and 1×105 cells/ml in the above serum-free medium 
into 6 well plates in triplicate and allowed to grow for 14 days.  Cultures were 
inspected daily and medium carefully part-aspirated and replaced after 7 days. 
 
 
Table 2.6:  Defined serum-free medium formulation for assessment of adhesion-free 
colony formation 
 
Component Final 
formulation 
Details 
Base medium DMEM 
F12 
Mixed 1:1 
Prepared in-house at CRUK (See Chapter 3) 
Gibco 31675 F12 Glutamax 
EGF 20ng/ml Sigma E4127 
EGF from murine submaxillary gland 
bFGF 10ng/ml Sigma F0291 
Human recombinant bFGF, cell culture 
tested 
Insulin 5µg/ml Sigma I6634 
Bovine insulin, cell culture tested 
Transferrin 100µg/ml Sigma T1147 
Human apo-transferrin, cell culture tested 
Selenium 2.75ng/ml Sigma S5261, sodium selenite 
BSA 0.4% w/v Sigma A9418, cell culture tested BSA 
powder 
 
   
 
2.2.3 Investigation of differentiation hierarchies in hPDAC cell lines 
 
Colony morphologies 
Cells of each line were seeded at clonal density into 6 well plates and grown for 14 
days with one media change at 7 days, as described above.  The resulting colonies 
were examined via phase-contrast microscopy and classed as holoclones, meroclones 
or paraclones, using the criteria used by Locke et al. [359].  The relative proportions 
of each colony type for each line was calculated by classifying ~130 consecutive 
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colonies per line (~10 per well) and expressing the final number as a percentage of 
the total. 
 
Immunophenotyping of holoclones, meroclones and paraclones 
Panc-1 and Capan-2 exhibited heterogeneous colony morphologies and were selected 
for further investigation of clonal colony properties.  Cells were seeded at clonal 
density in 6 well plates as per the adhesion-dependent colony forming assay 
described in section 2.2.2 above.  At 14 days, colonies were fixed according to 
Protocol 2.1 and immunophenotyped according to Protocol 2.2 using primary 
antibodies to CK19, CAII, MIB-1, β1-integrin, CD44 and MUC-1 shown in Tables 
2.3 and 2.4.  Mouse monoclonal anti-CD44 (NCL-CD44-2) was purchased from 
Novocastra Laboratories Ltd (Newcastle-Upon-Tyne, UK) and used at a dilution of 
1:80 in PBS.  Immunostaining was evaluated by light microscopy and photographed 
and recorded for each colony type. 
 
 
2.2.4 Assessment of the properties of clonal Panc-1 colonies 
 
Assessment of the proliferative capacities of clonal Panc-1 colonies 
Since Panc-1 exhibited the broadest range of easily classifiable colony morphologies, 
this line was selected for further behavioral characterization of these colony types.  
Cells were sorted one cell/well into 96-well plates using a MoFlow FACS machine as 
described above and detailed in Chapter 3.  Plates were cultured under routine 
conditions for 14 days and the resulting clonal colonies classified as holoclones, 
meroclones and paraclones as before.  Five typical holoclones, 4 meroclones and 4 
paraclones were selected for assessment of proliferative capacity.  Colonies were 
photographed using a phase contrast microscope, removed from the plate base with 
T/V, quenched in routine medium, centrifuged for 4 minutes at 200 × g and the 
supernatant carefully removed as before.  Cell pellets were then gently triturated and 
re-suspended in 250µl routine medium and added, along with a further 250µl of 
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routine medium used to rinse the remaining cells from centrifuge tubes, to 1.5ml of 
routine medium in one well of a pre-labelled 6-well tissue culture plate.   
 
Plates were then cultured under routine conditions for 14 days and colonies arising 
from disassociated clonal colonies examined, morphologies noted, photographed 
using phase contrast microscopy and the proportion of holoclones, meroclones and 
paraclones calculated for each.  These colonies were then allowed to grow until the 
well was sub-confluent, then removed from the plate with T/V as normal and seeded 
in their entirety into 25cm2 tissue culture flasks and cultured under routine conditions 
for 7 days (first passage).  At 7 days, sub-confluent/confluent flasks were 
photographed and passaged in duplicate according to the split ratio adopted for the 
parent line and the resulting cultures designated “passage 2” (p2).  Flasks that were 
not yet confluent were allowed to grow until confluence was reached.   Lines thus 
obtained were then kept in continuous routine culture in duplicate up to a maximum 
of eleven passages.  Confluent cultures were photographed at regular intervals for 
evaluation of any morphological changes that might occur with increasing passage. 
 
Assessment of the growth rates of clonal Panc-1-derived cell lines 
At the second passaging, single cell suspensions of cells of each line left over from 
sub-culturing were plated 1×104 cells/well into 24-well plates in triplicate for 
assessment of growth rates according to the methodology outlined in section 2.2.2 
above.  Growth curves were constructed for each clonal cell line and doubling times 
calculated as before. 
 
Assessment of the adhesion-dependent CFAs of clonal Panc-1-derived cell lines 
At the second passaging, single cell suspensions of cells of each clonal line were 
prepared and live single cells sorted at clonal density into 6-well plates in triplicate 
using a MoFlo FACS sorter as described in detail in Chapter 3.  Cells of the uncloned 
parent line were used as controls.  Colonies were allowed to grow for 14 days, 
counted and the numbers of holoclone, meroclone and paraclone colonies recorded 
and expressed as a percentage of the total colonies formed.  This experiment was 
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repeated at around the mid-point of the culture time (around p7 for holoclone-derived 
lines) and at the last passage performed (around p11 for holoclone-derived lines). 
 
Immunophenotyping of colonies of clonal Panc-1-derived cell lines 
At the third passage, cells of all clonal lines were sorted at clonal density into 6-well 
plates and cultured for 14 days as described above.  Colonies were fixed according to 
Protocol 2.2 and immunostained according to Protocol 2.3, using antibodies to CK19, 
CAII, MIB-1, CD44 and β1-integrin and photographed as described previously. 
 
 
2.2.5 Assessment of differentiation capabilities of hPDAC cell lines 
The differentiation capabilities of Panc-1 and Capan-2 cells were assessed by 
examination of their growth patterns on the basement membrane matrix, MatrigelTM.  
This gel matrix is composed of various extracellular matrix components, including 
laminin, fibronectin and [395].  Isolated pancreatic cells form ducts and differentiate 
on contact with MatrigelTM, specifically the laminin component [390, 396].  
MatrigelTM Basement Membrane Matrix was purchased from BD Biosciences 
(Catalogue number 354234).  The characteristics of Capan-2 and Panc-1 cells when 
grown on thin gel layers or when embedded within thick gels were assessed.   
 
Growth on a thin gel:  Four well tissue culture plates (2cm2/well) were coated with a 
thin layer (approximately 0.5mm) of Matrigel as follows: 100µl of Matrigel diluted 
50:50 in serum-free medium on ice was added to each well and swirled to coat the 
plate evenly.  Plates were then incubated at 37ºC for 30 minutes to solidify and 700µl 
of cell suspension (1×105 cells/ml) added to each well. 
 
Growth in a thick gel:  Four well tissue culture plates (as before) were coated with a 
thick layer (approximately 1mm) of Matrigel in which cells were suspended as 
follows:  Matrigel was diluted 50:50 with Panc-1 or Capan-2 cells suspended at a 
density of 1×105 cells/ml in serum-free medium on ice, then 400µl of this mixture 
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was added to each well and plates incubated at 37ºC for 30 minutes to solidify.  
Routine medium (600µl) was then added to each well. 
 
Cells grown in thick gel layers were cultured for up to 14 days and photographed at 
24 hours and 7 days post-plating using a phase contrast microscope and images 
captured using MagnaFire as before.  Cultures grown on thin gel layers were cultured 
for a maximum of 4 days and photographed at regular intervals.  Media were changed 
every other day.  
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2.3 RESULTS 
 
2.3.1 Identification and characterization of cell lines 
Morphologies of cell lines (phase contrast) 
Cells of Panc-1 cultures exhibited a polygonal epithelioid morphology, with marked 
heterogeneity of size and shape and pleomorphic nuclei.  Monolayers were 
moderately cohesive with irregular borders and scattered cells with a fibroblastoid 
migratory morphology were seen (Figure 2.1a).  In contrast, Capan-2 cells formed 
highly cohesive monolayers of polygonal epithelioid cells, with smooth edges and no 
scattered fibroblastoid cells.  Cells of this line showed a high nuclear:cytoplasmic 
ratio compared to Panc-1 and a lower degree of  cytological heterogeneity (Figure 
2.1a).  Occasional, large cells showing prominent cytoplasmic vacuoles were seen in 
this line.  COLO357 cells showed morphology intermediate between that of Capan-2 
and Panc-1 when grown as monolayers, with moderate pleomorphism and cohesion 
(Figure 2.1b).  Monolayer borders were continuous but irregular in outline and only 
occasional scattered cells were seen (Figure 2.1b).  Occasional multinucleate cells 
were seen in these three cell lines.  Psn1 monolayers showed very low cohesion and 
cell morphology ranged from polygonal epithelioid to fusiform but was largely 
fibroblastoid (Figure 2.1b) and monolayers consequently showed discontinuous, 
ragged borders with many scattered cells (Figure 2.1b).  
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Figure 2.1a:  Morphology of Panc-1 and Capan-2 cells grown as monolayers under 
routine culture conditions (phase contrast). 
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Figure 2.1b:  Morphology of Psn1 and COLO357 cells grown as monolayers under 
routine conditions (phase contrast). 
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Characterization of monolayers by IHC 
Panc-1 and Capan-2 monolayers showed cells positive for MIB-1, CK19, CAII and 
β1-integrin, whereas Psn1 monolayers did not show any cells showing unequivocal 
β1-integrin expression (Table 2.7, Figure 2.2).  Panc-1 and Psn1 monolayers showed 
the highest proliferative fractions, as revealed by MIB-1 immunostaining (89% and 
85% MIB-1+ cells respectively) and Capan-2 the lowest (37%).  Similar proportions 
of cells showed expression of CAII and CK19 in each cell line, with a distinctive 
radiating fibrous pattern of CK19 immunostaining seen in Panc-1 cells.  Expression 
of β1-integrin was heterogeneous for cells of both Capan-2 and Panc-1, with 
membranous and cytoplasmic expression seen in both lines. 
 
 
Table 2.7:  Immunophenotypes of hPDAC cell lines in monolayer culture 
 Staining pattern 
MIB-1 CK19 CAII β1-integrin 
Capan-2 37%+ 
(nuclear) 
84%+ 
(cytoplasmic) 
Almost ubiquitous 
(cytoplasmic/apical) 
Heterogeneous 
(mostly 
membranous) 
Psn1 89%+ 
(nuclear) 
90%+ 
(weak 
cytoplasmic) 
Almost ubiquitous 
(weak 
cytoplasmic/apical) 
Negative or 
equivocal 
Panc-1 85%+ 
(nuclear) 
86%+ 
(cytoplasmic 
fibrous) 
Almost ubiquitous 
(cytoplasmic/apical) 
Heterogeneous 
(membranous and 
cytoplasmic) 
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Figure 2.2:  Immunophenotyping of hPDAC monolayers 
 
 
 
 
Cells were cultured under routine conditions then subjected to indirect 
streptavidin/biotin/HRP immunocytochemistry: DAB, haematoxylin.  Original 
magnification 200×.   
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Growth rates in monolayer culture 
During logarithmic growth, Panc-1 cells showed an average doubling time of around 
50 hours (h) when seeded at 1×105 cells/well and 52 hours when seeded at 3×104 
cells/well.  Likewise, Capan-2 cells showed an average doubling time of around 60h 
when seeded at 1×105 cells/well and 80h when seeded at 3×104 cells/well.  Both lines 
exhibited somewhat flattened sigmoid growth curves when plotted on logarithmic 
scales (Figure 2.3).  Panc-1 cells entered the logarithmic growth phase at around 24h 
following plating while Capan-2 cells did not enter this phase for a further 24h. 
 
Figure 2.3:  Growth characteristics of Panc-1 and Capan-2 monolayers 
 
 
 
Cells were grown in 24-well plates then the contents of 4 wells removed by 
trypsinisation and density estimated by counting using a haemocytometer at daily 
intervals. 
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Colony forming capabilities of hPDAC cell lines in routine culture 
 
Adhesion-dependent colony formation 
Clonal density in 6-well plates was established as 100 cells/well (50 cells/ml) for 
COLO357, Panc-1 and Psn1, and 500 cells/well (250 cells/ml) for Capan-2.  At these 
seeding densities, expanding, discrete, macroscopically visible colonies were seen in 
all lines.  Using dilution and FACS methodologies and routine media, the average 
percentages of colony-forming cells in the hPDAC lines studied ranged from 
approximately 20% for Capan-2 to 37% for Panc-1 (Figure 2.4).  The number of 
macroscopically visible colonies that could be counted using the scanned plate 
methodology correlated well to that obtained by the plate-reader methodology (data 
not shown).  No significant differences in colony formation were seen between Panc-
1 cells obtained from confluent or sub-confluent cultures, or between those plated 
into normal medium or normal medium diluted 50:50 with sterile-filtered conditioned 
medium from log-phase cultures (Figure 2.5).  The percentages of cells forming 
colonies when plated singly into 96-well plates were not significantly different to 
those forming colonies when plated at clonal density in 6-well plates (data not 
shown). 
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Figure 2.4: Adhesion-dependent colony-formation of hPDAC cell lines. 
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Cells were seeded at clonal density into 6-well plates using a MoFlo cell sorter and 
allowed to form colonies in routine culture for 14 days.  Average values shown ±SD.  
Student’s two-tailed t test. 
 
 
Figure 2.5:  Colony-formation of Panc-1 cells obtained from cultures of different 
densities when plated in normal or conditioned medium 
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Cells were obtained from high-density confluent (HD) or low-density log-phase (LD) 
cultures and seeded at clonal density into normal medium (NM) or normal medium 
diluted 50:50 with conditioned medium obtained from log-phase cultures (CM).  
Average values shown ±SD, Student’s two tailed t test, (n=6). 
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Adhesion-independent colony formation 
 
PolyHEMA 
Capan-2 cells infrequently formed slow-growing multicellular spheroids when plated 
at higher densities (100 and 1000 cells/ml) into 24-well non-adherent plates and 
allowed to grow for 7 days, whereas Panc-1 cells formed fast-growing multicellular 
spheroids with high frequency at all densities and Psn1 cells with intermediate 
frequency.  At this point, most Capan-2 cells plated into non-adherent plates were 
granular, irregular and clearly non-viable, whereas significant numbers of dead cells 
were not seen in similar Panc-1 cultures.  Seven days following plating into 96-well 
plates, Capan-2 showed very little evidence of spheroid formation at any plating 
density whereas Panc-1 spheroids were seen in plates seeded at all densities.  At 14 
days there was no significant change in the number of spheroids present for either 
line (data not shown).  Overall, an average of 0.3% (0.1-0.5%) of Capan-2 cells, 5.8% 
(3.8-6.7%) of Psn-1 and 14.6% (12.6-18.4%) of Panc-1 cells were able to form 
floating spheroids in this assay by 14 days.  Typical appearances of Panc-1 and 
Capan-2 cells cultured in non-adherent plates for 14 days are shown in Figure 2.6.  
 
Serum-free conditions 
Panc-1 cells initially adhered to the plate base but rounded up and detached after 
approximately 24h.  By 7 days, lobulated free-floating spheroids were seen at all 
plating densities, with very few dead cells seen (Figure 2.7).  By the 14th day, 
spheroids had increased in size and coalesced into large free-floating masses at higher 
densities.  In contrast, Psn1 cells adhered to the plate base soon after plating and 
largely remained attached to the plate base at 7 days.  Free-floating Psn1 aggregates 
were seen at high plating densities: these were often composed of non-viable cells 
with conspicuous blebbing (Figure 2.7, inset), although some small viable spheroids 
were identified.  By the 14th day, macroscopically visible, slowly expanding 
spheroids had formed in wells seeded at higher densities, which were often weakly 
attached to the plate base (Figure 2.7).   
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Figure 2.6:  Capan-2 and Panc-1 cells plated under non-adherent conditions and 
cultured for 14 days 
 
 
 
 
Capan-2 cells and Panc-1 cells formed multi-cellular spheroids (arrowheads) when 
plated into poly-HEMA-coated plates.  Capan-2 cells plates at 1000 cells/ml and 
panc-1 cells plated at 100 cells/ml in routine media.  Conspicuous granular debris can 
be seen in the Capan-2 culture.
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Figure 2.7:  Panc-1 and Psn1 cells cultured in defined serum-free medium 
 
Panc-1 and Psn-1 were plated at a range of densities into serum-free medium (shown right, as cells/ml) and grown for 14 days.  
Resulting Psn-1 spheroids can be seen remaining weakly adherent to the plate base (main pictures) and blebbing prior to cell death 
(inset), whereas no blebbing or attachment is seen in Panc-1 cells.  Phase contrast, original magnification 100×. 
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2.3.2 Differentiation hierarchies in hPDAC cell lines 
 
Colony morphologies 
Clonal colonies formed a spectrum of morphologies in all lines.  Holoclones were 
defined as large, tightly-packed, symmetrical colonies of uniform, small cells and 
paraclones as loosely adherent or scattered clusters comprised of large, often 
squamous and highly pleomorphic cells, with meroclones of an intermediate 
appearance [17, 359].  These definitions were easily applied to the Panc-1 line 
(Figure 2.8a).  However, in the Capan-2 line, typical irregular paraclone colonies 
consisting of dispersed cells were never seen.  Rather, large, symmetrical colonies of 
small, morphologically homogeneous cells; large, irregular colonies of larger 
heterogeneous cells and small colonies of more squamoid cells were seen and 
arbitrarily designated holoclones, meroclones and paraclones respectively (Figure 
2.8b).  In contrast, colonies of Psn1 cells were rarely tightly-packed, with almost all 
colonies composed of more or less scattered fibroblastoid cells, reflecting the poorly-
adherent nature of the line (Figure 2.8c).  Nevertheless, differences in colony 
morphology were apparent, largely dependent on the number of cells comprising each 
colony at 14 days: holoclones were composed of large numbers of homogeneous cells 
and tended to exhibit piling up of cells in the central zone, whilst those colonies 
designated meroclones and paraclones tended to show more scattering of cells at the 
periphery and less piling up (Figure 2.8c).  COLO357 colonies exhibited a similar 
morphological spectrum to Panc-1, with distinct, large holoclones composed of very 
small, uniform and tightly packed cells arranged into circular, smooth-edged colonies 
and paraclones showing an irregular outline and consisting of larger, morphologically 
heterogeneous cells (Figure 2.8d).    However, colonies that did not neatly fit this 
spectrum were present in all lines, and it was difficult to classify all colonies with any 
degree of certainty.  For example, colonies of close-packed, small, homogeneous cells 
showed considerable variation in size, and irregular colonies of poorly cohesive, large 
cells were frequently composed of large numbers of cells.    
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The frequencies of holoclones, meroclones and paraclones in clonal density cultures 
of all cell lines were similar.  Holoclones comprised approximately 25%, meroclones 
50% and paraclones 25% of all colonies (Figure 2.9).  These percentages did not 
grossly alter when cells of Panc-1 were derived from high density or low density 
monolayers, or when plated into normal or 50% conditioned medium (Figure 2.10). 
 
 
Figure 2.8a: Colony morphologies exhibited by Panc-1 
 
 
 
Cells were seeded at clonal density into routine medium and cultured under routine 
conditions for 14 days.  Holoclone, meroclone and paraclone colonies were 
designated as described in the text.  Representative colonies shown, phase contrast, 
original magnification 100×. 
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Figure 2.8b:  Colony morphologies exhibited by Capan-2 
 
 
 
 
Cells were seeded at clonal density into 6-well tissue culture plates and grown under 
routine conditions for 14 days.  Representative large, symmetrical holoclone-type 
colonies composed of uniform, small cells, small, irregular paraclone-type colonies of 
pleomorphic, squamous cells and intermediate meroclone-type colonies are shown.  
Phase contrast, original magnification 100×. 
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Figure 2.8c:  Colony morphologies exhibited by Psn1 
 
 
 
 
Psn1 cells were seeded at clonal density and grown under routine conditions for 14 
days.  Large symmetrical colonies of homogeneous, small cells were designated 
holoclones and small, irregular colonies of fewer cells designated paraclones, with 
meroclones of intermediate morphology.  Phase contrast, original magnification 
100×. 
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Figure 2.8d:  Colony morphologies exhibited by COLO357 
 
 
 
 
Cells were plated at clonal density into 6-well tissue culture plates and grown under 
routine conditions for 14 days.   Holoclone-type colonies were defined as consisting 
of many closely apposed, small, uniform cells, and paraclones smaller, irregular 
colonies composed of larger, poorly adherent cells with meroclones of intermediate 
morphology.  Phase contrast, original magnification 100×. 
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Figure 2.9:  Frequencies of morphological colony types in hPDAC cell lines 
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Proportions of holoclone, meroclone and paraclone colonies formed when plated at 
clonal density and cultured under routine conditions in 6-well plates for 14 days.  
Average data shown, ±SD.  Each replicate consisted of ~130 consecutive classifiable 
colonies scored across 2 wells. 
 
 
Figure 2.10:  Effect of culture density and medium conditioning on proportions of 
morphological clonal colony types formed from Panc-1 cells  
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Relative frequency distribution of holoclone, meroclone and paraclone-type colonies  
derived from high density confluent (HD) or low density log-phase (LD) cultures  
when plated at clonal density in normal (NM) or 50% conditioned medium (CM) 
derived from log-phase cultures.  100 colonies scored across 5 wells (20 consecutive 
colonies/well). 
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Immunophenotyping of holoclones, meroclones and paraclones 
For both cell lines, CK19 expression was highest in large cells with a low 
nuclear:cytoplasm ratio.  Panc-1 holoclones showed scattered CK19+ cells amongst a 
majority of smaller CK19- cells, while Capan-2 holoclones were composed largely of 
CK19+ cells with occasional, very small CK19- cells (Figure 2.11).  CK19 expression 
appeared to associate more strongly with cell size than with colony morphology in 
both lines.  Muc-1 expression was not detected in Panc-1 colonies (Figure 2.12), but 
was observed in a minority of cells of Capan-2 holoclones and the majority of 
meroclone and paraclone cells (Figure 2.13).  No β-catenin expression was detected 
in Panc-1 colonies, but membranous expression was seen in most Capan-2 cells, 
where no association with cell size was seen.   CD44 expression was ubiquitous in 
Panc-1 colonies, with cytoplasmic and membranous localization.  CD44 expression 
was largely membranous in Capan-2 colonies and tended to increase towards colony 
peripheries, but no correlation with cell size was seen.  Membranous β1-integrin 
expression was seen ubiquitously in Panc-1 holoclones, declining in meroclones and 
largely absent from paraclones.  Conversely, β1-integrin staining was difficult to 
interpret for Capan-2 and showed no correlation with colony type or cell size (data 
not shown).  Proliferating (MIB-1+) Capan-2 cells were small and concentrated at 
colony peripheries, whereas quiescent cells were larger and more central.  Panc-1 
holoclones were composed almost entirely of proliferating (MIB-1+) cells, whereas 
these cells declined in frequency in meroclone and holoclone colonies.  Both large 
and small cells were seen to be actively cycling in this line, and those of paraclones 
showed aberrant mitoses, multiple nuclei and nuclear fragmentation (Figure 2.14). 
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Figure 2.11:  CK19 expression in clonal Panc-1 and Capan-2 colonies 
 
   
 
 
Cells were seeded at clonal density and grown under routine conditions for 14 days 
and resulting colonies stained with anti-CK19 monoclonal antibody using indirect 
streptavidin/biotin/peroxidase IHC: DAB chromogen, haematoxylin counterstain, 
original magnification 100×. 
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Figure 2.12:  Immunophenotypes of clonal Panc-1 colonies as shown by indirect immunohistochemistry 
 
 
Membranous staining with anti-β1-integrin was most intense in small cells of holoclone colonies (H), with staining declining in the 
larger cells of meroclones (M) and paraclones (P).  MIB-1 cells were less plentiful in meroclone and paraclone colonies.  Muc-1 and 
β-catenin were not detected, and no obvious differences in CD44 staining were seen between colony types.  DAB chromogen, 
haematoxylin counterstain, original magnification 100×. 
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Figure 2.13:  Immunophenotypes of clonal Capan-2 colonies 
 
A minority of holoclone cells and the majority of meroclone and paraclone cells were Muc-1+.  Membranous β-catenin was seen in a 
sub-set of cells of varied sizes.  MIB-1+ and CD44+ cells were concentrated at the periphery of colonies.  MIB-1+ cells tended to be 
small, but CD44 staining did not correlate with cell size.  DAB, haematoxylin, original magnification 100×. 
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Figure 2.14:  Cytological abnormalities in Panc-1 paraclones 
 
 
 
Multinucleate cells (M), bizarre, irregularly lobed nuclei (*) with multiple nucleoli, 
atypical mitoses and nuclear fragmentation were commonly seen in Panc-1 
paraclones.  Representative colonies immunostained for MIB-1 (brown); original 
magnification 200×. 
 
 
2.3.3 Properties of clonal Panc-1 colonies 
 
Proliferative capabilities of holoclones, meroclones and paraclones 
Thirteen colonies were selected for the assessment of their proliferative capacities and 
are shown in Figure 2.15.  Of these, 4 of 5 holoclones,  4 of 4 meroclones and 2 of 4 
paraclones were able to give rise to cell lines that could be passaged beyond the 6th 
sub-culture, whilst 2 of 4 paraclones and 1 of 5 holoclones could not be expanded to 
confluence and passaged.  In addition, one of the two long-lived paraclone-derived 
lines could not be passaged beyond the 7th sub-culture. 
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Figure 2.15:  Morphologies of parent colonies from which clonal Panc-1 cell lines were derived 
 
 
 
Colonies derived from single Panc-1 cells, grown for 14 days and then selected for expansion to form clonal cell lines.  Phase contrast, 
original magnification 40×.  
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Characteristics of cloned Panc-1 cell lines and their relationship to derivation 
When the parent colonies were re-plated, all of those that could be expanded to 
confluence gave rise to heterogeneous colonies, which were largely comprised of 
cells resembling those of the parent colony (Figures 2.16-2.18), whereas the lines that 
could not be expanded to confluence produced small, paraclone-like colonies that 
failed to proliferate.  Several clones showed pronounced morphological similarities to 
each other:  holo#1, holo#3 and mero#3 produced colonies composed of small, 
uniform polygonal cells with scanty cytoplasm and high cell:cell adhesion, whereas 
holo#2, mero#2 and para#3 colonies were composed of more rounded cells with more 
abundant cytoplasm and highly refractile borders (Figures 2.16-2.18). 
 
When expanded monolayers were re-plated at clonal density, the resulting colonies 
were also composed of cells that cytologically closely resembled those comprising 
the parent colonies.  All clonal cell lines contained a similar percentage of colony-
forming cells to that of the uncloned parent line (Figure 2.19).  However, colonies of 
holoclone-derived cell lines exhibited holoclone morphology with significantly 
increased frequency and paraclone morphology with a correspondingly decreased 
frequency when compared with meroclone and paraclone-derived lines and the 
uncloned parent line (Figure 2.20).   
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Figure 2.16:  Morphologies of holoclone-derived colonies and monolayers before first passage 
 
 
 
Cells of holoclones produced a range of predominantly holoclone-like colony types (original magnification 100×), that expanded to 
form monolayers of homogeneous, small cells that were then passaged (p1, original magnification 200×).  However, colonies of 
holo#5 were largely paraclone-like and this line failed to reach confluence. Holo#1 and holo#3 were morphologically similar, while 
holo#2 and holo#4 were more similar to each other. H holoclone; M meroclone; P paraclone. 
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Figure 2.17: Morphologies of meroclone-derived colonies and monolayers before first passage 
 
 
 
 
When cells of meroclones were re-plated, predominantly meroclone-like colony types were seen (original magnification 100×), that 
expanded to form monolayers of small-medium cells with moderate pleomorphism that were then passaged (p1, original magnification 
200×).  Mero#3 and mero#4 showed a similar morphology to holo#1 and holo#3, whilst mero#1 and mero#2 resembled holo#2 and 
holo#4 (See Figure 2.16). 
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Figure 2.18: Morphologies of paraclone-derived colonies and monolayers before first 
passage 
 
 
 
 
When cells of paraclones were plated, predominantly paraclone and meroclone-like 
colonies were seen at 7 and 14 days (original magnification 100×).  In two of four 
cases, these colonies could be expanded to form monolayers of heterogeneous, 
polygonal to squamous cells with abundant cytoplasm and often multiple nuclei (p1; 
original magnification 200×).  Para#3 bore a strong resemblance to holo#2, holo#4, 
mero#1 and mero#2.  Para#2 and para#4 did not give rise to expanding colonies when 
re-plated. 
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Figure 2.19:  Colony-forming abilities of clonal Panc-1-derived cell lines 
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First passage cells of cloned Panc-1 cell lines were plated at clonal density and grown 
for 14 days as before.  Data shown ±SD, Student’s two-tailed t test. Average CFA 
plot: holoclones (n=8), meroclones (n=8), paraclones (n=4). 
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Figure 2.20:  Averaged distribution of colony morphologies exhibited by holoclone, 
meroclone and paraclone Panc-1-derived cell lines before the second passage 
 
 
 
Before the second passage, holoclone-derived colonies gave rise to significantly more 
holoclones at 14 days than the uncloned parent line.  Holoclones (n=4), meroclones 
(n=4), paraclones (n=2); data shown +SD, Student’s two tailed t test; comparisons 
versus corresponding uncloned control frequencies (i.e. frequency of holoclones in 
holoclone-derived line vs. frequency of holoclones in uncloned control, etc.),  
** p<0.01, *** p<0.001. 
 
 
At the second passage, growth rates of the clonal cell lines were varied, with doubling 
times ranging from approximately 39h for mero#1 to 81h for para#1.  When plotted 
simultaneously, growth curves did not rank according to derivation, although the 
lines with the longest doubling times were meroclone and paraclone-derived (Figure 
2.21).  When the data from all lines of similar derivation were pooled and averaged, 
growth curves of holoclone-derived and meroclone-derived cell lines were very 
similar, whilst that for paraclone-derived lines showed a shallower slope (Figure 
2.22).  The average doubling time was 56h for holoclones, 58.5h for meroclones and 
70h for paraclones, in comparison to around 60h for the parent line (data not shown).
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Figure 2.21: Growth curves of Panc-1 clones 
 
Growth curves of clonal Panc-1-derived cell lines at second passage.  Holoclone-derived lines showed growth curves with similar 
slopes (B), whilst meroclone (C) and paraclone-derived lines (D) showed more divergent growth rates.  Holoclone-derived lines were 
not the fastest growing, with growth curves of meroclone and paraclone-derived lines showing equal if not steeper slopes (A).  Cells 
were seeded into 1ml of routine medium in 24-well plates and contents of 3 wells counted daily (n=3 for each line).
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Figure 2.22: Growth curves of clonal Panc-1-derived cell lines averaged by parent 
colony type  
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When growth curves of all cell lines of a particular derivation were averaged and 
plotted, paraclone-derived lines showed a shallower growth curve at first passage 
than holoclone and meroclone-derived lines, which were steeper and more similar to 
each other.  For holoclone and meroclone-derived lines (n=4), while (n=2) for 
paraclone-derived lines.  Cells seeded into 1ml of routine medium per well into 24-
well plates. 
 
 
 
The appearance of monolayer cultures of clonal cell lines altered over time.  At first 
confluence, monolayers of holoclone-derived cell lines were composed of uniform, 
small cells; an appearance which persisted until the third passage (Figure 2.23).  By 
the seventh passage, monolayers of holoclone-derived cell lines were composed of 
heterogeneous, highly pleomorphic cells, which generally appeared larger in size than 
at lower passages (Figure 2.24).  This trend was seen to a lesser extent in meroclone-
derived monolayers, but there were no obvious differences between p1 and p4-6 
monolayers of paraclone-derived lines (Figure 2.25).  Para#1 could not be expanded 
beyond the 7th passage. 
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After several passages (mid-term: p7 for holoclones, p6 for meroclones and p5 for 
paraclones), no significant differences were seen between the colony-forming 
abilities of any clonal line versus that of the parent line (Figure 2.26).   The spectrum 
of morphologies exhibited by holoclone-derived cell lines at this point no longer 
differed from that of the uncloned parent line, whereas the ability of meroclone and 
paraclone-derived cell lines to form holoclone-type colonies was attenuated in 
comparison to the uncloned parent line (Figure 2.27).  These trends persisted until the 
end of the experiment (late-term: p11 for holoclones, p10 for meroclones and p7 for 
paraclones) as shown in Figures 2.28 and 2.29.  
 
Over the course of the experiment, the percentage of colony-forming cells fell in 
holoclone and paraclone derived lines but this did not reach statistical significance 
(Figure 2.30).  Meanwhile, the percentage of colonies with holoclone morphology 
formed when plated at clonal density fell for all lines (Figure 2.31). 
 
 123
Figure 2.23: Monolayer morphology of clonal Panc-1 holoclone-derived cell lines from p3-p7 
 
 
 
 
 
In general, the degree of cytological heterogeneity increased with passage in monolayer cultures of holoclone-derived lines.  Larger, 
more squamous cells arose in all lines, whilst a population of smaller cells was retained.  Representative phase contrast pictures taken 
just as confluence was reached, original magnification 400×.
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Figure 2.24: Routine monolayer morphologies of clonal Panc-1 meroclone-derived cell lines from p2-p6 
 
 
 
 
 
In general, the degree of cytological heterogeneity increased with passage number in monolayer culture of meroclone-derived lines.  
Large, squamous and often multinucleate cells increased in frequency, whilst small cells were seen with reduced frequency.  
Representative phase contrast micrographs taken just as confluence was reached, original magnification 400×.
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Figure 2.25: Monolayer morphologies of clonal Panc-1 paraclone-derived cell lines 
from p2-p4 
 
 
 
 
When cultured as monolayers under routine conditions, paraclone-derived lines 
contained many large, squamous, multinucleate cells, which increased in prominence 
with increasing passage number.  Representative phase contrast micrographs shown, 
as before.  Original magnification 400×. 
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Figure 2.26: Colony-formation of clonal Panc-1-derived cell lines at mid-term 
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There were no significant differences between CFA at 14 days of any clonal cell line 
derivation type and the parent line at around passage 7.  Data shown ±SD, Student’s 
two tailed t test, (n=9).  Mid-term passage numbers were as follows: p7 for 
holoclones, p6 for meroclones and p5 for paraclones. 
 
Figure 2.27:  Distribution of colony morphologies of Panc-1-derived clonal cell lines 
at mid-term 
 
 
At mid-term (see figure legend above), the percentage of colonies exhibiting 
holoclone morphologies was significantly lower than that of the parent line for 
meroclone and paraclone-derived lines, but not for holoclone-derived lines.  Average 
data shown ±SD, Student’s two-tailed t test, *** p<0.001, ** p<0.01, * p<0.05. 
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Figure 2.28: Colony-forming abilities of clonal Panc-1-derived cell lines at late-term 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There were no significant differences between CFA at 14 days of any clonal cell line 
type and the parent line at the end of the culture period (see text).  Average data 
shown ±SD, Student’s two-tailed t test (n=9).  Late-term passage numbers were as 
follows: p11 for holoclones, p10 for meroclones and p7 for paraclones. 
 
Figure 2.29:  Distribution of colony morphologies of Panc-1-derived cell lines at late 
term 
 
 
Comparison of the relative frequencies of holoclones, meroclones and paraclones in 
clonal Panc-1 cell lines compared to frequencies exhibited by the uncloned parent 
line (holoclone-derived lines at p11, meroclone-derived at p10 and paraclone-derived 
at p7).  Average data shown ±SD, Student’s two-tailed t-test, *** p<0.001, * p<0.05. 
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Figure 2.30:  Colony-forming abilities of clonal Panc-1-derived cell lines with 
increasing passage 
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Cloned Panc-1 cell lines were maintained in routine monolayer culture for up to 11 
passages and CFA at 14 days evaluated using the adhesion-dependent colony forming 
assay (described above) at several passage numbers.  Average data shown ±SD, 
Student’s paired t test for means, comparisons versus uncloned parent line. 
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Figure 2.31:  Frequencies of holoclone colonies in clonal Panc-1-derived cell lines 
with increasing passage. 
 
 
 
Cloned Panc-1 cell lines were maintained in routine monolayer culture for up to 11 
passages and plated at clonal density at several passage numbers.  The percentage of 
colonies with holoclone morphology was calculated for each line and compared to 
that shown by the uncloned parent line.  Average data shown ±SD, Student’s paired t 
test for means. 
 
 
2.3.4 Differentiation capabilities of hPDAC cell lines 
Both Panc-1 and Capan-2 showed alterations of growth when plated on top of thin 
Matrigel layers.  Panc-1 cells underwent morphogenesis, producing branching 
structures that resembled ducts, whereas Capan-2 cells began to produce copious 
amounts of secretory product which was visible as floating globules and as sinuous 
secretion-filled channels overlying the cell monolayer (Figure 2.32).  This secretion 
was shown to be diastase/PAS positive and most likely mucinous in nature (data not 
shown).  Both cell lines produced spheroids when plated in thick Matrigel layers, 
although Capan-2 spheroids enlarged very slowly (data not shown). 
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Figure 2.32:  Growth patterns of Panc-1 and Capan-2 cells on thin Matrigel layers 
 
 
 
 
Panc-1 cells formed branching, duct-like structures within 48 hours of plating onto 
thin Matrigel layers, thereafter forming monolayer outgrowths characterized by thin 
filopodia-like structures (double arrows).  Capan-2 cells formed monolayers which 
secreted a mucinous substance manifest as lakes surrounding colonies at 48 hours and 
serpentine lakes overlying monolayers (single arrows) and floating globules 
(arrowheads) at 96 hours.  Phase contrast, original magnification 100×. 
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2.4 DISCUSSION 
 
Four hPDAC lines were selected on the basis of published reports indicating 
possession of CSC criteria (i.e. self-renewal and tumour initiation) including 
production of tumours phenotypically and genotypically similar to the primary 
tumour, metastatic capabilities and chemoresistance [294, 374-378, 380, 397].  
Characterization of these cell lines revealed immunophenotypes and growth kinetics 
consistent with those previously published, and supported the previous identification 
of Panc-1 as poorly differentiated, Psn1 and COLO357 as moderately and Capan-2 as 
well differentiated hPDAC cell lines [380]. 
 
A minority of cells of each line were clonogenic, under both adherent and non-
adherent conditions.  Panc-1 exhibited the shortest doubling times and the largest 
fraction of colony-forming cells, and Capan-2 the opposite, in keeping with their 
original tumour grades.  Anchorage-free colony formation was lower than colony 
formation on plastic for all lines: Panc-1 cells efficiently formed spheroids in non-
adherent plates and in serum-free medium, and Psn1 and Capan-2 cells formed slow-
growing spheroids with lower frequency.  Several potential issues with the colony-
forming assays were apparent:  firstly, colony-formation on plastic was subject to 
slight inaccuracies caused by the presence of motile cells able to form increasing 
numbers of daughter colonies over time.  Secondly, adhesion-free assays were subject 
to aggregation of plated cells simulating the generation of multicellular spheroids by 
proliferation from a single cell.  However, reproducible measurements of colony-
formation were possible for each assay.  Colony assessment via the more traditional 
method of seeding into semi-solid medium such as methyl cellulose or agar 
represents a more rigorous assay of non-adherent clone formation, but was avoided 
due to the difficulties presented for subsequent immunophenotyping.  Although these 
types of colony formation assays are known to frequently indicate the proliferative 
capacities of cell lines in vitro, and of tumorigenicity in vivo, there are inherent 
problems that need to be acknowledged.  Culture adaptation may artefactually 
increase CFA on plastic, which in turn may not correlate with adhesion-free CFA, 
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which generally reflects tumorigenicity, if not proliferative capabilities, more 
accurately.    
 
All cell lines formed heterogeneous clonal colonies, which broadly corresponded to 
the morphological types correlated with proliferative capacity by Barrandon and 
Green and subsequent authors [15, 17, 349, 359, 361, 398].  However, these 
morphological spectra were neither simple, nor completely linear, with many colonies 
that did not fit the typical holoclone, meroclone, paraclone categories on morphologic 
criteria.  Capan-2 cells formed both large and small symmetrical colonies composed 
of homogeneous small cells, as well as very large and intermediate-sized slightly 
asymmetric colonies composed of heterogeneous cells.  Capan-2 colonies showed 
low diversity of outline, whilst Panc-1 and COLO357 colonies presented a broad 
range of shapes.  In Psn1, Panc-1 and COLO357, the number of cells forming a 
colony did not always correlate with colony outline or cellular heterogeneity, and 
particularly in Psn1, colony outline was always somewhat irregular due to the non-
cohesive nature of the cell line.  None of the cell lines employed had been cloned, 
therefore the persistence of multiple, phenotypically distinct clones within each line 
might have confounded any hierarchy-based morphological spectrum.  Consequently, 
the propensity to prospectively misclassify colony types based on morphology was 
fairly high. 
 
The hierarchy model ascribes several properties to holoclones:  greater proliferative 
potential (more offspring over time, but not necessarily a higher proliferation rate at a 
given time), a high proportion of holoclone offspring and high clonogenicity.  
Conversely, paraclones have a low proliferative potential and quickly die out, have 
low clonogenicity and are unable to give rise to holoclones.  Holoclones give rise to 
meroclones and paraclones, whilst retaining the ability to produce holoclones, 
whereas meroclones and paraclones produce increasing proportions of paraclones.  
Holoclones also consist mainly of relatively undifferentiated cells, with paraclones 
expressing markers of senescence such as involucrin [17].  In the present study, 
holoclone, meroclone and paraclone colonies were produced in similar ratios for each 
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hPDAC line, which were in turn similar to those reported by Barrandon and Green’s 
original paper [17].  Immunophenotyping revealed no gross differences in the 
expression of pancreatic ductal differentiation markers CK19 and CAII between 
holoclones and paraclones, with high expression tending to correlate with large cell 
size rather than colony type per se.  The proportion of cells expressing Muc-1, which 
correlates well with differentiation in vitro [380], increased from holoclones, through 
meroclones to paraclones in Capan-2, however; strongly suggesting that paraclones 
were composed of more well-differentiated cells.  It is not clear if CK19 is a 
necessarily a useful maturation marker for pancreatic cell lines in vitro [380], nor 
whether normal pancreatic progenitors express CK19 or CAII in vivo [161, 175, 176] 
and differentiation markers may be difficult to assign for a tissue without an obvious 
differentiation hierarchy in vivo, unlike those such as the colon or skin that exhibit 
continuous directional renewal.  The observation that the proportions of CK19+ and 
CAII+ cells did not vary between lines with differing differentiation statuses would 
tend to suggest that these are not reliable markers for detection of a differentiation 
hierarchy, although the absence of expression in small cells may indicate that 
expression may partly correlate with differentiation of individual cells.  On the other 
hand, β1-integrin, which is often highly expressed in strongly adherent progenitor 
cells [116, 148, 399], and CD44, a putative cancer stem cell marker [116, 343, 400], 
were seen at higher levels in the small cells of holoclones.  Paraclones additionally 
showed a markedly smaller percentage of cycling MIB-1+ cells when compared to 
holoclones, as predicted by Barrandon and Green’s model.   
 
Paraclones of Panc-1 showed a decreased ability to form cell lines, and one of the two 
paraclone-derived cell lines could not be expanded for as many passages as 
meroclone and holoclone-derived lines, indicating that in general, paraclones of this 
line have a reduced proliferative capacity.  Paraclone-derived lines also exhibited a 
greater doubling time on average than that seen for those derived from holoclones and 
meroclones.  The morphologies of paraclone-derived cell lines were also typical of 
the enlarged, squamous, vacuolated and frequently multinucleate phenotype typical of 
effete or senescing cells, and did not change over time.  However, paraclones did not 
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show all of the properties that might be expected from the literature as, initially, cells 
of paraclones formed holoclones, meroclones and paraclones in the ratio seen in 
parent lines, although this ratio skewed in favour of paraclones and the ability to form 
holoclones declined with repeated passage.  Colony-formation of paraclone-derived 
lines was also comparable for that seen for holoclone and meroclone-derived lines.  
 
Conversely, almost all Panc-1 holoclones and all meroclones formed passageable cell 
lines that could be passaged many times, and holoclones initially formed a 
significantly higher proportion of holoclones and lower proportion of paraclones 
when compared to the parent line.  Over time, the proportions of meroclone and 
paraclone colonies increased for meroclone and holoclone-derived cell lines, with 
those of holoclone-derived lines approximating those of the parent line by the final 
passage of the study and those of meroclones skewing towards paraclones over the 
same period.  These data are consistent with the hypothesis that these colony 
morphologies are indicative of proliferative potential and reflect Barrandon and 
Green’s observations.  Holoclone-derived cell lines also showed a small range of 
doubling times, which clustered together towards the top end of the range exhibited 
for all lines, whilst those of meroclones were divergent, in keeping with the 
observation that transit amplifying cells may exhibit a faster turnover than quiescent 
stem or senescing populations and perhaps indicating the onset of conversion to 
paraclones in two of the lines.  Initially, holoclone-derived lines were 
morphologically distinct from meroclone and paraclone-derived lines, but the 
morphologies and cellular heterogeneity of holoclone and meroclone-derived lines 
converged with that of the parent line over the course of the experiment, in contrast 
with paraclone-derived lines which maintained a composition of exclusively large 
cells resembling a subset of the parent line throughout.  This again supports 
Barrandon and Green’s observation that holoclones give rise to the full spectrum of 
differentiating cells seen in the parent population whilst meroclones give rise to a 
dwindling subset of these cells and paraclones even fewer.  However, one holoclone 
failed to produce a passageable line, producing solely cells with a senescent 
morphology.   
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There are several possible reasons why the data does not support the hierarchy 
hypothesis in a clear-cut way.  Several clonal cell lines bore pronounced 
morphological similarities, and thus may reflect the uncloned nature of the parent cell 
line and indicate the persistence of a range of clonal populations therein.  A small 
sample size was also employed for each clone type, and the potential for 
misidentification of the original clones was also high, as mentioned above.  In 
addition, Barrandon and Green were working with an untransformed cell population 
with finite renewal, dictated by numerous mechanisms that regulate proliferative 
capacity in normal cells such as the telomere/telomerase system and the inability to 
proliferate ad infinitum in the absence of the stem cell niche.  However, in pancreatic 
cancer, a transformed and genetically grossly abnormal system where multiple 
pathways regulating proliferation such as those involving k-ras, p16INK-4a and p53 are 
aberrant [282, 284, 401], proliferation capacities are unknown but necessarily far 
greater, and true replicative senescence is unlikely.  Therefore, hPDAC meroclones 
and paraclones might be capable of generating numbers of offspring far in excess of 
those seen in keratinocyte cultures, rendering a drop in proliferative capabilities 
harder to detect using the small number of clones examined in this experiment.  The 
malignant nature of the culture does not preclude the detection of a hierarchy using 
this method, however, as validation in long-term cultures of malignant prostatic 
epithelial cells has recently been performed, where holoclones but not paraclones are 
serially passageable in vitro and form serially transplantable tumours in vivo [398, 
402].      
 
A further explanation for the heterogeneity of cell morphologies and colony types 
seen in Panc-1 may pertain to genetic instability.  Genetic instability and attendant 
karyotypic evolution was for decades the primary mechanism described for the 
generation of cancer cell heterogeneity in vitro and in vivo [403, 404], giving rise to 
the concept of an inherently unstable “mutator phenotype” crucial not only for the 
generation of phenotypic and genetic heterogeneity seen in tumours, but also for 
tumour initiation and maintenance [405].    Although the cancer stem cell hypothesis 
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is currently the prevailing model of cancer heterogeneity, this is likely to offer an 
additional rather than an alternative mechanism, and both genetic instability and self-
renewal are implicated in tumour progression and recurrence in certain malignancies 
such as breast cancer and germ cell neoplasms [406-409].  Cell lines may also suffer 
additional genetic drift when separated from cues from the in vivo microenvironment 
and cease to resemble the parent tumour or even the parent tissue [385], while other 
lines may retain the features of the parent tumour even after considerable karyotypic 
evolution [410].  Furthermore, culture on bare plastic surfaces exacerbates the 
formation of karyotypic abnormalities in some cell lines [411].  This karyotypic 
evolution may drive polyclonality in vitro and affect tumorigenicity in xenograft 
models [408, 412, 413], and has been proposed as a mechanism for the stabilization 
of populations during culture adaptation, allowing for maintenance of the cell line as 
a whole whilst entire sub-populations may go extinct [414, 415].  As a corollary, 
genetic instability may continually give rise to dissimilar clones in vitro that either 
persist or eventually become effete, such as seen in long-term cultures of colonic 
cancer cells [416].  Therefore, paraclones might perhaps represent colonies formed 
from highly unstable, aneuploid cells rather than senescent cells as understood from 
the Barrandon and Green model per se.  Indeed, the frank cytological dysplasia 
typical of aneuploid cells as evidenced by abnormal mitoses, bizarre nuclei and 
multinucleation was frequently seen in paraclones but very rarely, if at all, in 
holoclones.  Since Panc-1 is a poorly-differentiated tumour cell line derived from a 
tissue without a stereotypical directional maturation hierarchy, a well-defined 
differentiation-senescence progression might also be considered unlikely to play a 
part in loss of CFA or the distinctive colony morphologies seen.    
 
Furthermore, the ability of cultures to undergo many passages can be attributed partly 
to telomere length, which determines the replicative capacities of cells in vivo [417-
419]; a mechanism often disrupted by abnormal activation of telomerase in cancer 
[420].  Abnormal spontaneous and stochastic telomere shortening (amongst other 
mechanisms) can cause senescence and death of cancer cells by apoptosis in culture 
[421].  Barrandon and Green showed that colony morphology is affected by donor 
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age, with holoclones virtually absent and paraclones common in aged cell populations 
where telomere shortening is seen, suggesting that stochastic telomere shortening 
secondary to genetic instability also might present a mechanism whereby colony 
morphology of cancer cells varies in vitro [17, 337].   
 
Genetic instability and heterogeneity are extremely high in PDAC and pancreatic 
premalignancy [284, 422, 423], and telomeric abnormalities are seen early in 
pancreatic carcinogenesis and thought to be responsible for driving genetic instability 
associated with tumour progression [282, 424, 425].  It has been demonstrated that 
the requisite degree of genetic instability for pancreatic carcinogenesis may be 
produced without telomere alterations, however [426].  Furthermore, genetic 
instability in pancreatic cancer both in vitro and in vivo may cause continuous 
evolution of clones and individual cells with heterogeneous characteristics 
stochastically [412, 427, 428], and diverse cytogenetic abnormalities are frequently 
seen in pancreatic cell lines including Panc-1 [429, 430].  The influence of genetic 
instability on cell line behaviour cannot be ruled out in this system at present, as 
extensive spectral karyotyping deemed necessary to investigate karyotypic evolution 
with any useful degree of resolution was impractical due to financial and time 
constraints and therefore must remain speculative.    
 
Whatever the reasons underlying the differing morphologies and proliferative 
capacities of Panc-1 colonies, that observation that cells with a range of proliferative 
capacities are present in this line remains.  Teleologically, it is irrelevant whether the 
cancer stem cell is actually an altered stem cell which gives rise to a hierarchy of 
differentiating cells that caricature the normal tissue, or whether “stemness” is a 
function of stochastically acquired or retained relative proliferative capacity, invasion 
or self-renewal, and for this reason the terms “tumour initiating cell” and “tumour 
propagating cell” better reflect the differing roles and potential natures of CSCs, as 
previously noted (see Chapter 1).  Furthermore, reactivation of telomerase and 
dysregulation of cell cycle regulators such as p16 predispose any remaining 
differentiation hierarchy to be abnormal in cancer, with an elongated “transit 
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amplifying” compartment which is no longer subject to the normal mechanisms of 
senescence, and tumour growth may be limited by unsupportable genetic instability 
rather than loss of proliferative capabilities due to differentiation. 
 
 
2.5 CONCLUSIONS  
 
All hPDAC cell lines studied gave rise to morphologically heterogeneous clonal 
colonies recalling those correlated with proliferative capacities in primary 
keratinocyte cultures by Barrandon and Green.  Evidence supporting the hypothesis 
that these colony morphologies were similarly correlated with proliferative capacity 
in hPDAC cell lines was seen.  Firstly, holoclone, meroclone and paraclone-type 
colonies of Panc-1 could be expanded to form cell lines with decreasing frequency.  
Additionally, one paraclone-derived line exhibited a limited culture lifespan 
compared to holoclone and meroclone-derived lines.  Moreover, holoclones, 
meroclones and paraclones of this line initially gave rise in turn to characteristic 
ratios of these three colony morphologies; holoclone cells preferentially forming 
holoclone-type colonies.  Over time, the ratios of colony types formed by holoclone 
lines converged with that of the parent line, whilst those of meroclones and 
paraclones skewed towards a predominance of paraclones, again consistent with the 
hierarchy model.  The morphological characteristics of holoclone and meroclone-
derived cell lines, while initially divergent, also tended to recapitulate that of the 
parent line over time, whereas paraclone-derived cell lines showed a steady subset of 
the variation seen in cells of the parent line.  However, different colony types of 
hPDAC lines did not show characteristic immunophenotypes when stained for 
various differentiation markers, although larger cells tended to show higher 
expression of Muc-1 and CK19, and smaller cells higher expression of β1-catenin and 
CD44.  Additionally, one holoclone could not be expanded to confluence and 
colonies formed by the parent lines did not always form a neat spectrum of 
morphologies fitting the hierarchy model.  Therefore, holoclone, meroclone and 
paraclone-type colonies of Panc-1 broadly showed decreasing respective proliferative 
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potentials, in agreement with the hierarchy model.  Nevertheless, these hierarchy 
patterns were not always clear, and the high genetic instability particular to PDAC 
might present a mechanism for the generation of dissimilar clones in this line, rather 
than retention of an intrinsic differentiation hierarchy according to the stem cell 
model.   
  
 
 140
CHAPTER 3:  Do sub-populations of cells expressing stem cell markers and 
traits exist in human pancreatic cell lines and tissue? 
 
3.1 INTRODUCTION 
3.2 MATERIALS AND METHODS 
3.2.1 Cell lines and human pancreatic tissue 
3.2.2 CD133 in cell lines and human pancreatic tissue:   
Evaluation of expression by immunofluorescence, flow cytometry and RT-
PCR, and correlation with colony formation. 
3.2.3 CD44 in human pancreatic cell lines:  
Evaluation of expression by immunocytochemistry and flow cytometry, and 
correlation with colony formation and CD133 expression. 
3.2.4 ALDH activity in human pancreatic cell lines:  
 Evaluation by flow cytometry and correlation with colony formation and 
CD133 expression. 
3.2.5 ABC-transporter activity in human pancreatic cell lines: the Side 
Population (SP) phenotype: 
 Evaluation by flow cytometry, correlation with colony formation, and an 
investigation of the effects of Ho33342 on cell proliferation. 
3.2.6 Other stem cell markers in human pancreatic cell lines and tissue: 
 Evaluation by immunocytochemistry and in-situ hybridization. 
3.3 RESULTS 
3.3.1 CD133 in human pancreatic cell lines and tissues 
3.3.2 CD44 in human pancreatic cell lines 
3.3.3 ALDH activity in human pancreatic cell lines 
3.3.4 The SP phenotype in human pancreatic cell lines 
3.3.5 Other stem cell markers in human pancreatic cell lines and tissue 
3.4 DISCUSSION 
3.5 CONCLUSIONS 
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3.1 INTRODUCTION 
 
Several well-documented markers of stem cells, both normal and malignant, were 
selected from the literature, as candidates for markers to be used to attempt to 
prospectively isolate cancer stem cells from hPDAC cell lines.  As discussed in 
Chapter 2, high activity of the detoxifying enzyme aldehyde dehydrogenase (ALDH) 
and an enhanced ability to efflux cytotoxic substances via membranous ABC-
transporter proteins (the “SP phenotype”) were initially reported as stem cell 
attributes in the haematopoietic system [80, 81, 90, 431, 432].  Subsequently, high 
ALDH activity was confirmed as a feature of neural stem cells [78], and the SP 
phenotype proposed with varying degrees of success as a marker of many normal and 
malignant stem cell populations, most notably the breast [102, 187, 340, 433-435].  
ABC-transporters, notably ABCG2, had also been demonstrated in normal and 
malignant pancreas via northern blotting and immunohistochemistry [106, 436-438].  
Several promising immunophenotypic stem cell markers had also been proposed for 
normal adult tissues and solid tumours: in particular, CD44 and CD133 for prostate 
cancer, liver, brain and breast cancer [116, 118, 343, 439, 440], and normal prostate, 
haematopoietic, and neural tissues respectively [80, 84, 113, 255].   
 
Numerous other candidate markers were also considered: Musashi 1 (Msi1), 
responsible for regulating asymmetric cell division in the Drosophila sensorium [32], 
had also been suggested as a regulator of this process and stem cell marker in 
mammalian gut epithelium [130, 441], breast [31, 442] and in the central nervous 
system [443].  Several cell adhesion molecules, such as integrins, were also shown to 
be highly expressed in malignant and normal adult stem cells [399, 444-447].  Nestin 
had often been proposed as a marker of mammalian pancreatic mesenchymal, 
endocrine and epithelial precursors, as well as a potential neural stem cell marker, but 
was rejected, as no definitive consensus had yet been reached as to its utility as an 
adult stem cell marker [193, 194, 196, 200, 448, 449], despite a subsequent report 
indicating that nestin+ cells act as founder cells for PanIN [450].   More latterly, the 
expression of the transcription factor Oct-4,  polycomb gene product Bmi1 and 
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leucine-rich repeat-containing G protein receptor Lgr5 were proposed as potential 
stem cell markers [4, 18, 62, 132, 141, 451-454], as well as many other molecules 
implicated in the Wnt, Hh and Notch signaling pathways, now thought to be 
important for maintenance of the stem cell phenotype and the formation of cancer 
stem cells [42, 43, 144, 455-458].  
 
Of these markers, the cell-surface proteins CD133 and CD44 have continued to 
receive attention as potential candidate markers for the prospective isolation of stem 
cell populations.   
 
CD133 
CD133, also known as prominin-1 and AC133, is a pentaspan membrane protein 
which is typically localized on apical microvilli [109, 110, 459, 460].  CD133 is the 
human orthologue of murine prominin-1, with which it shares 60% homology, 
although tissue distributions vary between the species [108].  This protein is 
associated with lipid rafts [461], which are implicated in signaling, maintenance of 
polarity and endocytosis [462, 463], and whilst roles in the organization of cellular 
protrusions, migration, polarity and possibly signal transduction have been proposed, 
these are still not fully understood [110, 111, 461, 463].  A familial homozygous 
frameshift mutation in CD133 leads to an absence of expression associated with 
retinal degeneration in humans, possibly secondary to a role in maintenance of 
cellular protrusions, but no further pathological phenotypes have been associated with 
CD133 loss [111, 464], suggesting a functional overlap with other molecules.  Many 
epitopes of CD133 exist [107, 465], partly due to the presence of two extracellular 
loops containing 8 potential N-linked glycosylation sites [108, 460] and partly due to 
alternative splicing [108, 466], and these were assigned a multiplicity of names until 
a formal nomenclature was proposed in 2003 and revised in 2007 [465, 466].  Of 
these, the glycosylation-specific isoform CD133-1 (AC133 antigen) was originally 
proposed as a hallmark of human CD34+ haematopoietic progenitors [80, 459], as 
well as neural and prostatic stem cells [113, 255], and has subsequently been reported 
to putatively identify prospectively isolated stem cells from further human tissues and 
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murine pancreas [107, 204, 467], and cancer stem cell fractions from human 
melanoma, gastrointestinal, hepatocellular, neural, and prostatic malignancies [115-
119, 256, 273, 468, 469].  However, CD133 expression is not limited solely to stem 
cells in adult tissues:  murine prominin-1 is expressed on microvilli of adult 
neuroepithelium and kidney tubule epithelium, and CD133 expression is widespread 
in human embryonic tissues, however, the glycosylation-specific CD133-1/AC133 
antigen is thought to be largely restricted to stem cells [107, 108].  Additionally, a 
second member of the prominin family, CD133-2 has been discovered, with less 
pronounced homology to its murine orthologue [122, 470] but with a similar 
restriction to membrane protrusions, which is not associated with stem cell status. 
 
CD44 
CD44, formerly known as PGP-1, gp90Hermes, ECMRIII, Hermes antigen, Ly-24 and 
H-CAM, is a trans-membrane glycoprotein receptor whose principal ligand is 
hyaluronate extracellular matrix (ECM) protein [471, 472].  Expression levels of 
CD44 are heterogeneous between cells of a given tissue, and many splice variants 
exist, due to alternative splicing of several variant exons (v2-10) during gene 
transcription.  These variable regions are located alongside the hyaluronan-binding 
domain in the extracellular region of the protein, and are affected by glycosylation 
and polymerization at the cell surface, which in turn influences the adhesive 
functionality of the molecule [471].  The prototypical CD44 standard (CD44s) form 
is expressed in a wide range of tissues, whilst the longer variant isoforms (CD44v) 
have more restricted tissue distributions.  CD44s and its variant isoforms are also 
variously able to interact with collagen, matrix metalloproteinases, osteopontin, 
selectins, laminin and fibronectin, thus facilitating cell-cell or cell-ECM binding.  
These interactions are relatively weak compared to those mediated by other cell 
adhesion molecules (CAMs) such as integrins, and are implicated in cell aggregation, 
migration, ECM degradation and lymphocyte homing [471-476].   
 
Over-expression of CD44 is seen in several tumours [473, 477-479], possibly 
secondary to Ras mutation or activation [480].  Experimental over-expression of 
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several forms of CD44 has been shown to promote metastasis characterized by 
enhanced hyaluronate degradation [472, 474, 481-483], which may account for the 
poor prognosis associated with over-expression in several malignancies in vivo [473, 
477, 484, 485].  Conversely, disruption of hyaluronan-CD44 interactions via 
application of soluble hyaluronan binding proteins or antibodies leads to abrogation 
of metastasis, invasion in vitro and tumour progression in vivo [400, 482, 486].  
Interactions between CD44 and ECM may induce production of autocrine factors or 
activate signaling pathways conducive to tumour growth [471, 487].  Unsurprisingly, 
expression of CD44s and CD44v (sometimes in conjunction with CD133) has also 
been linked to cancer stem cell status in breast, pancreatic and other tumours [116, 
343, 439, 440], though is not reported as a specific feature of normal tissue-based 
stem cells.  However, correlations of CD44 expression, metastatic potential and 
tumour prognosis are confounded by the multiplicity of splice variants and their 
differing roles in specific tissues. 
 
ALDH 
The aldehyde dehydrogenases form a large family of cytoplasmic detoxifying 
enzymes, which comprises 18 members in humans (http://www.aldh.org)[488].  
Expressed in a broad range of human tissues, prominently in the liver and kidney, 
these enzymes act (with NAD(P)+ as co-factors) not only to break down potentially 
toxic substrates by oxidation of acetaldehyde into acetate (or, more broadly, 
aldehydes to their corresponding carboxylic acids), but also participate in vitamin A 
metabolism [488-490].  In fact, broadly speaking ALDH functions can be 
summarized as cytoprotection via inactivation of potentially damaging xenobiotics 
(metabolism of exogenous aldehydes) and the correct processing of molecules 
necessary for growth and differentiation (metabolism of endogenous aldehydes) [76, 
488].  These functions can have a sinister side, however, as in cancers high levels of 
ALDHs can correlate with enhanced resistance to chemotherapeutic agents such as 
cyclophosphamide [89, 491-493], and experimental over-expression can be used to 
induce drug-resistance in vitro [88, 494].  
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ALDH family members are known to be expressed in the human pancreas, where 
they are present in adult acinar, ductal, islet and stellate cells [189, 495] as well as in 
the developing pancreas [191].  Pancreatic ALDHs have been shown to be major 
players in alcohol metabolism, and animal studies suggest that gene polymorphisms 
may influence alcohol-related pathologies such as chronic pancreatitis, although this 
role is not thought to be implicated in pancreatic carcinogenesis [496, 497].  Studies 
of ALDH-deficient animal models have underscored the importance of the 
involvement of pancreatic ALDH in vitamin A metabolism, particularly with respect 
to retinoic acid, which is vital for embryonic pancreatic development and the 
generation of differentiated cells from precursors [190, 191, 498].   
 
High ALDH activity was initially reported as a specific feature of normal human and 
murine haematopoietic [80, 81, 431] and murine neural [78] stem cell populations, 
and also as a feature of leukaemic, neural and other CSC populations [85, 86, 499].  
The primary role of ALDH (in particular ALDH1) in stem cells is thought to be 
cytoprotective, and high activity is associated with enhanced drug resistance of CSCs 
and ability of HSCs to resist damage by alkylating agents [87, 492, 494, 500, 501].  
However, generation of retinoic acid from vitamin A by ALDH has also been shown 
to be vital for maintenance of the progenitor state of HSCs, and a role in regulation of 
differentiation also seems likely in stem cells [502-504]. 
 
Although cells expressing ALDH1 or other ALDH family members may be identified 
by immunohistochemistry using specific antibodies, functional activity of all ALDHs 
may be accurately assessed in living cells using the commercial reagent Aldefluor 
(Stem Cell Technologies Inc.).  The Aldefluor substrate, BODIPY® 
aminoacetaldehyde (BAAA) is taken up by live cells by passive diffusion, whereupon 
it is converted in the cytoplasm into a fluorescent molecule (the negatively charged 
BODIPY® aminoacetate; BAA) under the action of ALDH [431].  This fluorescent 
product accumulates in cells, partly due to the presence of ABC-transporter inhibitors 
in the assay buffer, which prevent active efflux, allowing cells with high ALDH 
activity to be identified by their bright green fluorescence and subsequently isolated 
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by flow cytometry.  ALDH can be inhibited by addition of diethylaminobenzaldehyde 
(DEAB), allowing differentiation of cells with high ALDH activity from those with 
low or no activity.  Pertinently, very recently, induction of defective ALDH1a1 
expression has been shown not to affect the stem cell status, nor the degree of 
Aldefluor fluorescence of murine haematopoietic or neural stem cells [505], 
indicating not only functional overlap between ALDH family members, but also that 
evaluation of pan-ALDH activity via Aldefluor fluorescence may correlate more 
accurately with ALDH-mediated regulation of SC phenotype. 
 
ABC transporters and the SP phenotype  
The “side population” (SP), is a small population of cells separable by flow 
cytometry due to their ability to exclude the stoichiometric DNA-intercalating supra-
vital dye Hoechst (Ho) 33342 [90].  Ho33342, its isomer Ho33258, and the similar 
drug diaminophenylindole (DAPI) are useful in studies of cell cycle profiling, 
evaluation of DNA content, and chromatin structure [506] though Ho33342 has 
usually been used for SP studies.  A key feature of the SP cell phenotype is the 
presence of membrane ABC transporters [104, 105].  These are ATP-binding cassette 
proteins which efflux xenobiotics across cell membranes against a concentration 
gradient, and pump into the extracellular space: an activity that can be inhibited by 
verapamil and reserpine [507]. One function attributed to this phenomenon is the 
ability to efflux signaling molecules that may induce differentiation of stem cells 
[96], and thus assist in maintaining the stem cell state in haematopoietic cells.  These 
drug efflux pumps can also contribute to the drug resistance of some cancer cells, 
especially MDR-1 and ABCG2, which are common determinants of the SP [91, 92, 
98, 508].  SP cells of normal and malignant tissues are often highly clonogenic or 
tumorigenic and exhibit other stem cell characteristics [93, 94, 100, 185, 187, 434, 
442, 447, 509-514], and as such are often considered to be analogous to CSCs or 
normal SC populations.  However, this assumed equivalence might not always hold 
true, as several reports outside of the SP literature indicate that Ho33342 may exert 
considerable effects on cell cycle kinetics and differentiation [515-517]. 
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The presence of cells expressing these four traits (CD133 expression, CD44 
expression, high ALDH activity and SP phenotype) in hPDAC cell lines and in 
normal and malignant human pancreatic tissues was assessed by flow cytometry, 
immunohistochemistry (IHC) and the reverse transcriptase polymerase chain reaction 
(RT-PCR) as appropriate.  Where present, sub-populations of cells expressing these 
markers were isolated from cell lines by fluorescence activated cell sorting (FACS) 
and assessed for their relative abilities to form expanding colonies (clonogenicity) 
when cultured on plastic or to form spheroids in serum-free culture, with the intention 
of further characterizing the behaviour and phenotypes of sub-populations that 
exhibited enhanced colony forming capabilities.  The effects of Ho33342 exposure on 
the growth characteristics and viability of non-SP cells were also investigated in 
vitro.  In addition, the presence of cells expressing Lgr-5 investigated in human 
pancreatic tissues using isotopic in-situ hybridization, and the expression of Msi1 and 
Oct-4 was evaluated in hPDAC cell lines using immunohistochemistry. 
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3.2 MATERIALS AND METHODS 
 
3.2.1 Cell lines and pancreatic tissue 
 
Four human pancreatic cancer cell lines, Panc-1 and Capan-2, COLO357 and Psn1, 
and the human colorectal carcinoma cell line CaCo-2 were obtained from the Cancer 
Research UK cell banks as detailed in Chapter 2.  Capan-2 cells are identified in the 
literature as well-differentiated in vitro, with COLO357 moderately-well 
differentiated and Panc-1 and Psn-1 poorly differentiated [374-378, 380].  All four 
lines are relatively stable in culture, possess typical mutations seen in hPDAC such as 
k-Ras activation and p16 methylation, and are tumorigenic in vivo, forming tumours 
in mice that are histologically, phenotypically and genetically identical to the parent 
tumours from which they were derived [378, 380, 381, 401, 518].  These cell lines 
were characterized and their identities confirmed by immunohistochemistry (see 
Chapter 2) and referring to in-house isoenzyme analysis records, and tested and found 
negative for mycoplasmas prior to use.  Routine monolayer culture regimens for these 
lines were established as described in detail in Chapter 2.   
 
For the experiments described in this chapter, cultures were discarded at or before 
passage 40 and replaced from stocks with lower passage numbers.  Cultures were also 
discarded if any changes in growth characteristics or morphology were observed.   
Clonal density and baseline colony-forming ability (CFA) were established for all 
four cell lines as described in Chapter 2: clonal density was defined as the number of 
cells per milliliter of medium required to produce discrete, symmetrical expanding 
colonies when cultured under routine conditions.  Colony-forming ability (CFA) was 
evaluated in 6-well or 24-well plates by counting the number of colonies formed per 
100 cells plated after 7 or 14 days or the number of wells per 100 containing colonies 
when plated at one cell per well into 96-well plates.  Cells were sorted directly into 
plates using a fluorescence activated cell sorter as described below. 
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Formalin-fixed paraffin-embedded (FFPE) human pancreatic tissues were obtained 
from the archives of Hammersmith Hospital with the kind assistance of Dr M El-
Bahrawy, under the conditions of COREC license number 06/Q0601/33 and with 
local ethics committee approval.  Five micron thick sections were cut onto SuperFrost 
coated slides (Thermo Shandon) in the CRUK histopathology laboratory in 
accordance with the Human Tissue Act under HTA license 12271.  Sections were cut 
from 5 normal pancreata and 6 cases of PDAC.  Normal pancreatic material was 
obtained from resections performed for extra-pancreatic malignancy and PDAC 
specimens consisted of 4 moderate-poorly differentiated tumours, one well-
differentiated invasive mucinous tumour and one poorly differentiated tumour. 
 
 
3.2.2 CD133 in pancreatic cell lines and human pancreatic tissue 
The expression of CD133 protein in all four hPDAC cell lines was evaluated by 
immunofluorescence (IF) and flow cytometry.  The colorectal carcinoma line CaCo-2 
is known to express CD133, detectable by antibodies raised against AC133/CD133-1 
[110, 121] and was used as a positive control.  Expression of CD133 in normal 
human pancreata and PDAC tissue was determined by IF, and expression of CD133 
mRNA was investigated by the reverse-transcriptase polymerase chain reaction (RT-
PCR) in all four hPDAC cell lines, again using CaCo-2 as a positive control. 
 
For indirect IF, cell lines were grown until sub-confluent in either glass LabTek 
chamber slides (BD Falcon) or 24-well tissue culture plates (Falcon brand), then fixed 
for immunocytochemistry according to Protocol 2.1.  Fixed cultures were rinsed 
twice with PBS, immersed in fresh PBS then sealed with ParaFilm M (Alcan, Inc.) 
and stored at 4ºC for no more than a week before immunostaining was performed.  
Cell blocks were prepared for IF by growing cells until sub-confluent in 6-well tissue 
culture plates and fixing as described above; cell monolayers were then removed 
from the plate base using a cell scraper, then centrifuged at 250× g for 5 minutes in 
Eppendorf tubes to form loose pellets.  The PBS supernatant was then aspirated and 
liquid agarose (2% Invitrogen UltraPure agarose powder w/v in dH2O, heated to 60ºC 
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to liquefy) admixed with the pellet and allowed to solidify.  The pellet was then 
immersed in 70% ethanol, processed to paraffin blocks and 5µm sections cut onto 
SuperFrost slides and allowed to dry overnight.   
 
Immunofluorescence 
Indirect single and double IF was performed on cell blocks and monolayer cultures in 
situ using polyclonal primary antibodies to CD133 (described by the manufacturer as 
anti- CD133 (stem cell antigen), and raised to a sequence derived from the C-
terminus region corresponding to an area of the AC133 epitope, and able to 
selectively identify stem cells from neural tissue), monoclonal antibodies to the 
pancreatic ductal differentiation marker cytokeratin 19 (CK19), and species-specific 
AlexaFluor (Alexa)-labelled secondary antibodies as outlined in Protocols 3.1, 3.2 
and Table 3.1 below.  Primary antibodies were initially tested at a range of 
concentrations using positive control material (Caco-2 monolayers) to establish 
optimal staining conditions (Protocol 3.1).  Mounted, stained slides were kept in the 
dark at 4ºC for no more than 2 days before examination.   
 
Slides were examined using an Olympus BX61 microscope fitted with a motorized 
reflected fluorescence system (Olympus BX-RFAA illuminator, U-LH 100HGAP0 
mercury lamp, and U-25 ND6, 25 and 50 filters), and equipped with Olympus UPlan 
Apo objectives (10×/0.40[NA] oil, 20×/0.80 oil, 40×/1.0 oil iris and 60×/1.42 oil).  
Images were captured using a digital CCD camera (Hamamatsu Orca-ER C4742-80) 
and SmartCapture 3 software (Version 3.0.3; Digital Scientific Ltd) running under 
Mac OS X on a PowerMac G5 computer (Apple Macintosh).  CD133-Alexa 488 
fluorescence was captured in the fluorescein isothiocyanate (FITC; green), CK19-
Alexa 555 fluorescence in the Cy3 (red), DAPI in the blue and non-specific 
fluorescence in the aqua channel.  Non-specific signals were examined to evaluate the 
authenticity of signals in the FITC and Cy3 channels.  
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Protocol 3.1:  Single immunofluorescence for CD133 (in situ monolayers) 
1. Cultures were rinsed in PBS/Tween 20 for 5 minutes   
  Antibody titration series only: 
  Cells were permeabilised with 0.1% Triton-X100/PBS for 15 minutes 
  or rinsed in PBS for a further 15 minutes 
2. Non-specific antibody binding was prevented by application of normal goat 
serum (diluted 1:25 in PBS) for 15 minutes 
3. Normal serum was drained from cell monolayers and rabbit anti-human 
CD133 antibody applied for 120 minutes 
  Antibody titration series using CaCo-2 cells:   
  Primary antibody diluted 1:50, 1:100, 1:500 and 1:1000 in PBS 
  Final experiments: 
  Primary antibody diluted 1:500 in PBS 
  Negative controls (one for each cell line): 
  PBS was substituted for primary antibody 
4. Cultures were rinsed twice in PBS/Tween 20 for 5 minutes 
5. Alexa 488-conjugated goat anti-rabbit secondary antibody was applied at a 
dilution of 1:200 in PBS for 30 minutes in the dark 
6. Cultures were then rinsed three times in PBS/Tween 20 for 5 minutes  
7. Wells were removed from LabTek slides* and cultures mounted in DAPI-
containing aqueous mounting medium and allowed to dry overnight 
*Where plates were employed, circular coverslips were mounted directly onto the 
plate base.  Sections from cell blocks were de-waxed using an automated histo-
staining machine and subjected to the same protocol.  All incubations were 
carried out at room temperature. 
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Protocol 3.2:  Double immunofluorescence for CD133 and CK19 
1. Cultures were rinsed in PBS/Tween 20 for 5 minutes* 
2. Non-specific antibody binding was prevented by incubation in normal goat 
serum diluted 1:25 in PBS for 15 minutes 
3. Normal serum was drained from slides and admixed primary antibodies 
applied:  1:500 polyclonal rabbit anti-CD133 was applied for 60 minutes, 
drained from the slide, then 1:100 monoclonal mouse anti-CK19 admixed in a 
ratio of 1:1 with 1:250 polyclonal rabbit anti-CD133 and applied for a further 
60 minutes (giving a final dilution of 1:500 for CD133 and 1:200 for CK19 
and 120 minutes incubation with CD133 and 60 minutes with CK19)   
4. Cultures were rinsed twice with PBS/Tween 20 for 5 minutes each 
5. Alexa 488-labelled goat anti-rabbit and Alexa 555-labelled goat anti-mouse 
immunoglobulins were both diluted to 1:200 each in PBS and applied for 30 
minutes 
6. Cultures were rinsed three times in PBS/Tween 20 for 5 minutes each, 
mounted in DAPI-containing aqueous mountant and allowed to dry overnight 
*FFPE sections were de-waxed on an automated histostaining machine (Jung) and 
boiled in 0.1M citrate buffer pH 7.6 for 10 minutes to affect antigenic retrieval 
prior to this step. 
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Table 3.1: Reagents employed for indirect immunofluorescence 
Reagent Details Source 
PBS/Tween 20 0.05% Tween 20 in 0.01M phosphate-
buffered 0.9% NaCl pH 7.4 
Prepared in-
house at CRUK 
PBS 0.01M phosphate-buffered 0.9% NaCl 
pH 7.4 
Prepared in-
house at CRUK 
Normal goat serum X0907 
Whole serum 
DAKO 
Polyclonal rabbit 
anti-CD133 
ab19898 
IgG 
Immunogen is synthetic peptide derived 
from within residues 800 to the C-
terminus of human CD133. 
Product is able to selectively identify 
stem cells in neural and other tissues 
and immunogen corresponds to a region 
within the AC133 epitope according to 
the manufacturer. 
AbCam 
Monoclonal mouse 
anti-CK19 
M0888 
IgG1 kappa 
Clone RKC108 
DAKO 
Goat anti-rabbit 
IgG Alexa 488 
A-11034 
2mg/ml 
Invitrogen 
Goat anti-mouse 
IgG1Alexa 555 
A-21127 
2mg/ml 
Invitrogen 
DAPI-containing 
aqueous mountant 
VectaShield Hard Set + DAPI Vector 
 
 
Flow cytometry 
Cells were grown until sub-confluent in 75cm2 tissue culture flasks then removed 
from the flask base via minimal exposure to 1.25mg/ml trypsin in 0.5mM EDTA in 
PBS (T/V) and gentle application of a sterile cell scraper.  Cell suspensions were then 
quenched in 10% serum-containing medium and centrifuged at 200× g for 4 minutes, 
then subjected to direct immunostaining with phycoerythrin (PE) or allophycocyanin 
(APC)-labelled monoclonal anti-CD133-1 antibody as per Protocol 3.3 and Table 3.2 
below.   
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Protocol 3.3:  CD133-1 immunostaining for flow cytometry 
1. The supernatant was aspirated from pellets and cells re-suspended in 5ml of 
cold MACS buffer in sterile polystyrene FACS tubes.   
2. 1ml of cell suspension was removed from each sample to a new FACS tube to 
form negative controls and all tubes labelled. 
3. All samples were counted using a haemocytometer to evaluate total cell 
numbers and to ensure no more than 1×107 cells present in each replicate. 
4. Samples were re-pelleted by spinning at 200× g for 4 minutes, the supernatant 
aspirated and the cells re-suspended in an appropriate volume of fresh cold 
MACS buffer (160µl for tests and 1ml for negative controls). 
5. 40µl of FcR block was added to each test sample, followed immediately by 
20µl of CD133-PE/CD133-APC per 1×106 cells. 
6. All samples were mixed well with sterile pipette tips and incubated in the dark 
at 4ºC for 10 minutes. 
7. All samples were then spin-washed twice at 200× g for 4 minutes in twice 2ml 
of fresh cold MACS buffer. 
8. All samples were then filtered through a 40µm CellSafe cell strainer into new, 
labelled FACS tubes and placed on ice until analysis. 
9. 50µl of 40µg/ml 7-aminoactinomycin D (7AAD) or 5µl of 200µg/ml 4’, 6-
diamidino-2-phenylindole (DAPI) DNA-binding counterstain was added to 
each tube immediately prior to analysis as appropriate. 
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Table 3.2: Reagents employed for CD133-1 FACS analysis 
Reagent Details Source 
MACS buffer 0.5% BSA 
2mM EDTA 
in sterile PBS at pH7.2 
sterile filtered and stored 
at 4ºC 
Prepared in-house at 
CRUK 
FcR block FcR blocking reagent 
(human) 
130-059-901 
Miltenyi Biotec GmbH 
Anti-CD133-1 CD133/1-AC133-PE 
130-080-801 
CD133/1-AC133-APC 
130-090-826 
Both mouse anti-human 
IgG1 
Miltenyi Biotec GmbH 
Isotype control antibody Mouse IgG1-APC 
130-092-214 
Miltenyi Biotec GmbH 
7AAD 40µg/ml in PBS  
Sterile filtered 
Sigma A9400 
DAPI 200µg/ml in dH2O 
Sterile filtered 
Sigma D9542 
 
 
Cell suspensions were analyzed using LSRII or FACS Calibur flow cytometers (both 
Becton Dickinson).  The BD LSRII was equipped with 4 lasers: UV 355nm, violet 
407nm, blue 488nm and red 635nm; and data was collected using Facs Diva software 
(v4.1) running under Win XP (Microsoft) on a Hewlett-Packard PC.  The BD FACS 
Calibur was equipped with a 15mW 488nm argon ion laser and a 635nm red diode 
laser; data was collected using Cell Quest software (v3.3) running on a PowerMac 
G4, System 9.2.  7AAD and PE were excited at 488nm (blue), APC at 635nm, and 
DAPI at 355nm (UV).  A single cell population was selected by gating on forward 
scatter height (FSC-H) vs. side scatter height (SSC-H) signals and dead cells were 
excluded from the analysis by gating out 7AAD+ or DAPIbright cells on 650/70 or 
440/40 UV-A vs. FSC signals respectively, as shown in Figure 3.1.  A CD133- (PE or 
APC-) population was defined using negative controls and this gate applied to test 
samples to identify CD133+ (PE or APC+) cells.  PE fluorescence was evaluated in 
the 575/26nm blue channel and auto-fluorescence assessed at 530/30nm, whilst APC 
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fluorescence was evaluated in the 660/20nm channel.  Each experiment was carried 
out in triplicate and repeated at least 3 times. 
 
Figure 3.1:  Application of gates to include only a single, live cell population in 
FACS analysis 
 
 
Data captured using BD FACS Calibur and CellQuest software with subsequent 
FlowJo analysis.  Capan-2 cells, representative data.  Figures inside pink gates 
indicate percentage of plotted population contained within. 
 
 
Correlation of CD133 expression with colony formation 
Cell suspensions were labelled with PE or APC-conjugated monoclonal antibody to 
CD133-1 as described above.  For negative control purposes, aliquots from each 
sample were removed prior to immunostaining and the immunostaining protocol 
amended to replace the primary antibody with either PE-labelled non-specific 
isotype-matched primary antibody or an appropriate volume of MACS buffer.  Cells 
were sorted at clonal density into routine medium in 6-well plates using a DAKO 
Cytomation MoFlo Fluorescence Activated Cell Sorter equipped with Innova 70C 
argon ion 488nm, multiline UV and Innova 90 krypton 568nm and 648nm lasers and 
fitted with a 100µm nozzle.  Data collection was performed using Summit 4.0 
software running under Win XP (Microsoft) on a Dell PC.   
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Cell dot plots were gated to include only a live, single cell population as outlined 
above and CD133+, CD133- and live cells from immunostained and unstained 
negative control samples sorted in triplicate into 6-well plates at clonal density as 
shown in Table 3.3 below.  Plates were agitated gently after addition of cells in order 
to ensure even distribution and placed immediately into incubators and cultured under 
routine conditions.  Media were changed once at 7 days and colonies fixed, stained, 
and counted after 14 days as described in Chapter 2.  CFA was calculated for each 
treatment and plotted ± standard deviation (SD) using Microsoft Excel.  Analyses of 
variance (ANOVAs) or the appropriate Student’s two-tailed t tests were employed to 
assess the significance of the findings. 
 
 
Table 3.3: Details of FACS experiments to correlate CFA to CD133 expression in 
hPDAC cell lines 
 
Expt. # Cell Line Sorting 
density 
(Cells/well) 
Details Replicates per 
fraction 
1 Panc-1 100 PE label 
Vehicle 
control 
3 
2 Panc-1 100 PE label 
Vehicle 
control 
9 
3 Panc-1 
Psn1 
100 PE label 
Vehicle 
control 
3 
4 Panc-1 
Psn1 
100 PE label 
Isotype control 
9 
5 Psn1 100 PE label 
Isotype control 
9 
6 COLO357 100 APC label 
Isotype control 
9 
 
Each group of 3 replicates represents one independent sample sorted in triplicate. 
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Behaviour of CD133+ versus CD133- COLO357 cells in monolayer culture 
COLO357 cells were maintained in routine culture, then grown to sub-confluence in 
75cm2 tissue culture flasks and stained with anti-CD133/1 for flow cytometry as 
described in Protocol 3.3.  CD133+, CD133- and all live cells were sorted at low 
density (500 cells/well) in triplicate into 6-well tissue culture plates.  Plates were 
maintained under routine culture conditions and colony formation was observed for 
30 days, with media changes at 7 and 14 days, and every 2-3 days thereafter.  After 
30 days in culture, cells were trypsinized, then seeded, in triplicate, at high density 
(3×105 cells/ml) into 25cm2 tissue culture flasks for expansion and re-analysis by 
flow cytometry and at clonal density (100 cells/well) into 6 well plates for clone 
analysis.  These cultures were maintained in routine culture and examined and 
photographed using a phase contrast microscope (as before) at 4, 12 and 18 days.   
 
The percentage of clonal colonies exhibiting holoclone, meroclone and paraclone 
morphologies for each group were estimated by scoring 90 colonies per group across 
3 replicates.  In order to determine the differentiation status of offspring of CD133± 
COLO357 cells plated at clonal density, after 18 days, colonies in 6 well plates were 
fixed using 4% PFA as described for previously, and stored at 4ºC for no more than 4 
days prior to immunostaining.  Immunocytochemistry for the ductal differentiation 
marker CK19 was performed according to the indirect avidin/biotin peroxidase 
protocol outlined in Chapter 2 (Protocol 2.2).  Monoclonal mouse-anti human CK19 
antibody was purchased from Novocastra (NCL-CK19), normal rabbit serum and 
rabbit anti-mouse immunoglobulins were purchased from DAKO, and all other 
reagents were as described in Chapter 2.  Cultures were then examined using bright-
field microscopy and photographed as before, and the percentage of cells staining 
positively for CK19 was estimated for each culture by scoring 100 consecutive cells 
per randomly selected high power field (HPF) in 3 HPF per well, then calculating the 
mean value for all 3 wells (n=9). 
 
In order to ascertain the CD133 status of offspring of CD133± COLO357 cells, cells 
seeded at high density (3×105 cells/ml) into 25cm2 tissue culture flasks for 18 days 
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were removed from the flask base and stained for CD133 for FACS analysis 
according to Protocol 3.3.  Samples were analyzed using a BD LSRII flow cytometer 
and ~100,000 events recorded using Facs Diva software as before.  The percentage of 
CD133+ live cells present in each culture was recorded and compared to that of the 
parent population. 
 
Correlation of CD133 expression and anchorage-independent growth 
An anchorage-independent colony-formation assay was devised as described in 
Chapter 2 and outlined in Section 2.2.2 therein.  Briefly, 96-well tissue-culture plates 
(flat base, Falcon brand) were coated with poly-HEMA using a protocol modified 
from that described by Fukazawa and co-authors [394].  Poly-HEMA (Sigma P3932) 
was dissolved 5mg/ml in 95% ethanol at 37ºC on an orbital shaker overnight, and 
then centrifuged to remove any bubbles and 96-well plates coated with the resulting 
solution as described in Chapter 2.  Panc-1 and Psn1 cells were sorted 10 cells/well 
on the basis of CD133 antibody labeling into 100µl of routine medium per well, 
following labeling as described in Protocol 3.3 above.  Cultures were allowed to grow 
under routine conditions for 14 days then the number of spheroids/well counted 
manually using a phase-contrast microscope.  Media were carefully part-aspirated and 
topped up after 7 days.  Experiments were carried out in triplicate. 
 
Evaluation of CD133 mRNA expression via RT-PCR 
The 3794bp mRNA sequence of human CD133-1 (a.k.a. AC133, CD133, PROM1; 
Protein ID NP006008, Ref Seq NM006017, Acc # AF027208) was acquired and 
cross-checked using NCBI Nucleotide 
(http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_006017.1) and OMIM.  
The complete AC133 antigen mRNA sequence 
(gi/2688948/gb/AF027208.1/AF027208) was obtained from NCBI Nucleotide in 
FASTA format, and complimentary primers designed using the open-access program 
Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3) in accordance with the 
recommendations of Innis and Gelfand’s PCR protocols [519].  Briefly, five primer 
pairs specific to CD133-1 mRNA of 20bp length, ~50% G+C composition, a Tm of 
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55-60ºC, spanning several introns of the CD133-1 gene and yielding products of 500-
600bp were selected as shown in Table 3.4 and purchased from Sigma 
(http://sigma.com/oligos).  Primer sequences were also checked to ensure specificity 
for CD133-1 using NCBI Primer BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi) and for absence of significant secondary structure and self-
complimentarity using Primer3 (as above).  Primers were diluted to 200µM in UV-
irradiated Milli-Q filtered water, aliquoted and stored at -20ºC for no more than 4 
weeks before use. 
 
 
Table 3.4: AC133 primers used in RT-PCR of hPDAC cell lines.   
Pair 
# 
Sequence Product 
size 
Start Tm 
(ºC) 
% 
GC 
Exons 
contained 
1 L GCCACCGCTCTAGATACTGC 529 2351 60.1 60 4  
(#23-26) R ACAGGAAGGGAGGGAGTCAT 2879 59.93 55 
2 L ACCCATTGGCATTCTCCTTTG 542 187 59.93 45 4 
(#1-4) R TCAGATCTGTGAACGCCTTG 728 59.98 50 
3 L TCAGGATTTTGCTGCTTGTG 549 1891 59.9 45 6 
(#18-23) R GCTTTTCCTATGCCAAACCA 2439 60.1 45 
4 L TCAGTGAGAAAGTGGCATCG 561 2319 59.9 50 4 
(#23-26) R ACAGGAAGGGAGGGAGTCAT 2879 59.9 55 
5 L GCTCTCTGCTGACCCTCATC 549 1362 60.1 60 3 
(#1-3) R CACAAGCAGCAAAATCCTGA 1910 59.9 45 
 
Tm = primer melting temperature; exon numbers are as per NCBI reference data.  
Data obtained from Primer3 output. 
 
 
Capan-2, COLO357, Psn1, Panc-1 and CaCo-2 cells (up to passage 40) were cultured 
in 6-well culture plates under routine conditions until sub-confluent; CaCo-2 cells 
acting as a positive control.  Cultures were lysed and total RNA extracted according 
to manufacturer’s instructions using the Qiagen RNEasy Kit (Qiagen #74104) as 
described in Protocol 3.4.  For all nucleic acid handling, UV-treated nitrile gloves 
were worn and all laboratory plastics and solutions (other than those containing 
nucleic acids) were exposed to UV light in an enclosed hood for 45 minutes prior to 
use to minimize contamination.  All nucleic acid-containing solutions were kept on 
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ice in a laminar flow cabinet during extraction and PCR set-up.  RNA yields were 
quantified by measuring absorbance at 260nm using a spectrophotometer (NanoDrop 
ND-1000 UV-Vis) and purity assessed by calculating the 260nm:280nm absorbance 
ratio.  Purified RNA was stored at -20ºC in sterile, RNAse-free Eppendorf tubes for 
up to two weeks before use. 
 
RT-PCR was performed on 3 samples from each cell line using the Qiagen One-Step 
PCR Kit (Qiagen #210210) in accordance with the manufacturer’s instructions as 
described in Protocol 3.5 below.  Filtered pipette tips were used to prepare solutions 
on ice in a sterile laminar flow cabinet to minimize contamination and RNA 
degradation.  Following the RT-PCR reaction, plates were removed from the thermal 
cycler and kept sealed at 4ºC overnight or at -20ºC for up to 7 days before analysis of 
PCR products via gel electrophoresis (see Protocol 3.6 below).  Experiments to 
determine primer suitability and correct template concentration were carried out on 
Caco-2 cultures and subsequent experiments to evaluate the presence of CD133-1 
mRNA in hPDAC lines performed as shown in Table 3.7. 
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Protocol 3.4:  RNA extraction from cell cultures using Qiagen RNEasy Mini Kit 
1. Cells were removed from plate bases using trypsin/versene, quenched, spun 
and re-suspended in routine medium as per routine tissue culture protocol.  
2. Cell density was measured using a haemocytometer, suspensions aliquoted 
appropriately and 3 replicates per line of up to 3×106 cells pelleted in RNAse-
free sterile Falcon tubes. 
3. All medium was aspirated and the pellets loosened by gently flicking the tube. 
4. Kit reagents were activated according to the manufacturer’s instructions 
(http://www1.qiagen.com/HB/RNeasyMini), and 10µl β-mercaptoethanol 
added per milliliter of RLT buffer. 
5. 350µl of guanidine thiocynate-containing RLT lysis buffer was added to each 
pellet, then the pellets vortexed to mix.   
6. Pellets were triturated using sterile, RNAse-free 20 gauge syringes, diluted 
1:1 with DEPC-treated 70% ethanol and triturated further. 
7. ≤ 700µl of each sample was added to a separate spin column situated in a 2ml 
collection tube, spun at 8000× g in a micro-centrifuge for 15 seconds, then the 
eluate discarded. 
8. 700µl of RWI buffer was added to each column, spun as before and the eluate 
discarded. 
9. 500µl of RPE buffer was added to each column, spun as before and the eluate 
discarded.  A further 500µl of RPE buffer was added to each column, spun at 
8000× g for 2 minutes and the eluate again discarded. 
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10. Columns were then placed into clean 1.5ml collection tubes, 50µl of RNAse-
free water added to each, then spun at 8000× g in a micro-centrifuge for 1 
minute to elute bound RNA from the column.  A further 50µl of RNAse-free 
water added to each column and the total 100µl of eluate collected for 
measurement of RNA content. 
11. Following measurement of RNA content, samples were aliquoted into 
RNAse-free Eppendorf tubes and stored at -20ºC for no more than 2 weeks 
before use. 
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Protocol 3.5:  RT-PCR of cell lines using Qiagen One-Step RT-PCR kit 
1. Taq mix, buffer, dNTPs, RNAse-free water (from kit), primer stocks and 
template RNA were thawed on ice and vortexed to mix. 
2. Skirted 96-well ThermoFast low profile PCR plates (Thermo Scientific) were 
labelled with primer and template details and sterile, RNAse-free microfuge 
tubes for each sample plus blanks labelled using a permanent marker.  Blank 
wells were situated well away from sample wells to prevent cross-
contamination. 
3. Mastermixes minus Taq were made up according to the manufacturer’s 
recommendations (see Table 3.5 below) and vortexed to mix. 
4. 0.1-1µg of RNA template diluted in UV-irradiated Milli-Q filtered water was 
added to the appropriate PCR plate wells.  An appropriate volume of water 
was added to each blank well. 
5. Appropriate volumes of Taq mix were added to each mastermix and vortexed. 
6. Mastermix was added to each PCR reaction well and pipetted to mix. 
7. Plates were covered with self-adhesive heat-seal film (Thermo Scientific) and 
sealed well to prevent evaporation of reagents, then centrifuged at 1000rpm 
for 1 minute. 
8. The thermal cycler (Bio-Rad DNA Engine Tetrad2 Peltier Thermocycler) was 
pre-heated to 50ºC before adding the PCR plates, the lid locked in place and 
the PCR program shown in Table 3.6 below initiated. 
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Table 3.5: Mastermix formula for RT-PCR 
To give 50µl sample/well of PCR plate: 
Component Volume/reaction Final concentration 
RNAse-free water Variable (make up 
to 50µl) 
- 
5X Qiagen One-Step RT-PCR 
buffer (contains 12.5mM MgCl2) 
10.0µl 1X 
dNTP mix (10mM of each dNTP) 2.0µl 400µM of each dNTP 
Primer A (L) Variable 0.6µM 
Primer B (R) Variable 0.6µM 
Qiagen One-Step RT-PCR 
enzyme mix (Taq) 
2.0µl - 
Template RNA  
(added to plate, not into 
mastermix) 
Variable 0.1-1µg/reaction 
Total volume 50.0µl  
 
 
Table 3.6:  PCR program 
Step Temperature 
(ºC) 
Time 
(minutes) 
Details Number of 
cycles 
Pre-heat 50 As required  1 
Reverse 
transcription 
50 30  1 
PCR start 95 15  1 
Cycle A 94 1 Denaturation 39 
Cycle B 60 1 Annealing 39 
Cycle C 72 1 Extension 39 
Final 72 10 Final extension 1 
Infinite 12    
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Protocol 3.6:  Gel electrophoresis of RT-PCR products 
1. Agarose gels were cast as follows:  1.5g of ultra-pure agarose powder 
(Invitrogen as before) was added to 150ml of Tris-buffered EDTA (Gibco 
Ultrapure TBE buffer 10X diluted to 1X in Milli-Q filtered water) and 
microwaved on high power for 4 minutes to dissolve. 
2. 2µl of 0.5mg/ml ethidium bromide (Invitrogen) was added and the agarose 
mixed well. 
3. Gels were cast directly into Mupid Exu Submarine Electrophoresis System 
tanks according to manufacturer’s instructions, allowed to set for 30 minutes, 
trimmed, combs removed and TBE running buffer (Qiagen as above) added to 
cover. 
4. 5µl volumes of 100-1500bp DNA ladder (Qiagen Gel Pilot 100bp Plus 
Ladder) and PCR products were admixed with equal volumes of Qiagen Gel 
Pilot DNA loading dye on ParaFilm then 5µl aliquots added per well of the 
agarose gel. 
5. Gels were then run at 100V for 36 minutes, checked, and run for a further ~10 
minutes as required. 
6. Gels were then removed, visualized and photographed under UV light using a 
BioDoc-It Ultra Violet trans-illumination and imaging system (UVP LLC). 
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Table 3.7:  RT-PCR experiment design 
Expt. 
# 
Purpose Cell lines Reps Primer 
pairs 
Template 
concentration 
(per reaction) 
1 Determine primer suitability 
Titrate RNA concentration 
CaCo-2 3 + 
blank 
#1 
#2 
#3 
#4 
#5 
1µg 
2 Assess CD133-1 mRNA in 
hPDAC lines 
Titrate template quantity 
CaCo-2 
Capan-2 
COLO357 
Panc-1 
Psn1 
3 + 
blank 
#2 0.1µg 
1µg 
3 Assess CD133-1 mRNA in 
hPDAC lines 
Titrate template quantity 
CaCo-2 
Capan-2 
COLO357 
Panc-1 
Psn1 
1 + 
blank 
#2 1ng 
10ng 
 
 
3.2.3 CD44 in pancreatic cell lines 
Four human PDAC cell lines, Capan-2, COLO357, Panc-1 and Psn1, were 
maintained in routine monolayer culture in 75cm2 tissue culture flasks as before.  The 
expression of CD44 was evaluated by immunocytochemistry and flow cytometry, and 
correlated to the expression of CD133 and colony forming ability by flow cytometry, 
FACS and colony-forming assay as described below.  All antibodies were pan-CD44 
specific. 
 
Immunocytochemistry 
Cells from all four lines were harvested from flask bases with T/V as normal, then 
seeded at clonal density into 6-well culture plates in triplicate and allowed to grow 
under routine culture conditions for 14 days with one change of medium at 7 days, 
and into glass chamber slides (LabTek as before) at a density of 1×105 cells/ml and 
grown under routine conditions until sub-confluent.  Cultures were then fixed with 
4% PFA and stored as described in Chapter 2 before immunocytochemistry was 
performed.  Indirect avidin/biotin/peroxidase labeling was carried out according to 
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Protocol 2.2 (Chapter 2) using the reagents detailed in Table 3.8 below.  For negative 
controls primary antibody was substituted for PBS during the primary antibody 
incubation stage, and as pancreatic ductal cells are reported to express CD44 [471], 
no further positive control was employed.  Cultures were then examined using bright 
field microscopy and photographed as detailed in Chapter 2. 
 
Table 3.8:  Reagents used for CD44 IHC of hPDAC cultures 
Reagent Details Source 
Tween 20 H5152 Molecular Biology Grade 
Used as 0.05% Tween 20 in 0.01M 
phosphate-buffered  
0.9% NaCl pH 7.4 
Promega 
PBS 0.01M phosphate-buffered 0.9% NaCl 
pH 7.4 
Prepared in-house 
at CRUK 
Triton X-100 H5142 Molecular Biology Grade 
Used as 0.1% Triton X-100 in PBS 
Promega 
Normal rabbit serum X0902 
Used at a dilution of 1:25 in PBS 
DAKO 
Mouse monoclonal 
anti-CD44 
NCL-CD44-2 
Used at a dilution of 1:80 in PBS 
IgG1 
Novocastra 
Biotinylated rabbit 
anti-mouse IgG1 
E0354 
Used at a dilution of 1:300 in PBS 
DAKO 
Streptavidin/HRP P0397 
Used at a dilution of 1:500 in PBS 
DAKO 
Hydrogen peroxide 30% w/v (216763) 
Used as 300µl 30% H2O2 in 50ml 
PBS 
Sigma-Aldrich 
DAB 3,3’-Diaminobenzidine 
tetrahydrochloride hydrate (D5637) 
Used as 5mg DAB powder in 10ml 
PBS;  
20µl 30% H2O2 added immediately 
before use 
Sigma-Aldrich 
 
 
Correlation of CD44 expression with CD133 expression and colony formation 
Cells from all four lines were cultured as monolayers under routine conditions in 
75cm2 flasks until sub-confluent, and prepared for immuno-labelling and FACS 
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analysis as described for CD133 and in Protocol 3.3 above, with the following 
modifications.   
 
Following harvesting and suspension in MACS buffer, two 1ml aliquots were 
removed from one 5ml sample per line to act as negative and single colour controls.  
Forty microlitres of FcR blocking agent (Table 3.3) was added to all tests and 
controls, then 1µg per 1×106 cells of FITC-labelled anti-CD44 antibody (AbCam. 
ab19622, monoclonal FITC-labelled rat anti-human pan-CD44) added to each test 
and to CD44 single colour controls and mixed well.  Samples were then incubated for 
20 minutes in the dark at 4ºC, then 20µl per 1×106 cells of PE-labelled anti-CD133-1 
antibody (Miltenyi, see Table 3.2) added to each test and mixed well.  All samples 
were incubated for a further 10 minutes in the dark at 4ºC then spin washed, filtered 
to remove clumps and placed on ice as in Protocol 3 above.  Five microlitres of sterile 
DAPI (Table 3.2) was added immediately before analysis to enable live/dead 
discrimination.   
 
Analysis was performed using a BD LSRII FACS analyzer as described for CD133 
above, with the addition of a compensation step using single-colour controls to 
correct for bleed-through of fluorescence between the FITC and PE channels.  The 
percentage of live single cells staining positively for CD133, CD44 and for both 
antigens was  assessed on FITC  (530/30 blue) versus PE (575/26 blue) plots and 
recorded for 3 samples of each line.  Where present, CD133+/CD44+, CD133+/CD44-, 
CD133-/CD44+, CD133-/CD44- sub-populations and all live cells ± antibody controls 
were sorted at clonal density in triplicate into 24-well plates using a MoFlo cell 
sorter.  Cells were then cultured for 14 days under routine conditions with one change 
of medium at 7 days, then colonies fixed, stained, scanned and counted as before. 
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3.2.4    ALDH activity in hPDAC cell lines 
The presence and growth properties of subsets of cells with high ALDH activity was 
investigated via FACS using Aldefluor (StemCell Technologies, Inc.); a commercial 
reagent that undergoes a stoichiometric fluorescent reaction under the action of 
ALDH: a reaction that is inhibited by diethylaminobenzaldehyde (DEAB) [431].  
Capan-2, COLO357, Panc-1 and Psn1 cells were seeded into 75cm² or 175cm² Falcon 
brand polystyrene tissue culture flasks and cultured under routine conditions for 7 
days until 70%-95% confluent, in order to avoid contact inhibition of the cultures.  
The entire cell population for each line was then removed from the flask base with 
T/V, quenched in serum-containing medium, re-suspended in Aldefluor buffer (Stem 
Cell Technologies, Inc.), triturated and filtered using a 40µm cell-safe strainer to 
obtain a single cell suspension, one sample comprising the contents of one tissue 
culture flask.   
 
The cell suspension was adjusted to a density of 1×106 cells/ml in Aldefluor buffer 
and incubated with 5, 10 or 15µl/ml Aldefluor substrate ±10µl/ml DEAB inhibitor as 
per the manufacturer’s instructions in order to determine optimal staining. 100µl of 
sterile-filtered 50µg/ml propidium iodide (PI; Sigma) was added to each sample 
immediately before analysis.  Optimal staining, giving the best separation between 
ALDHdim and ALDHbright cells without inducing non-specific staining in the DEAB 
control, was seen with 10µl/ml Aldefluor, and this concentration was used for 
subsequent experiments (data not shown for brevity).  Aldefluor fluorescence was 
assayed in the 530/30nm channel using a BD FACS Calibur or BD LSRII flow 
cytometer for evaluation of the size and distribution of the ALDH+ cell population.  
Cell suspensions were gated to include only a live, single cell population on PI vs. 
SSC and SSC vs. FSC plots, then a gate for the ALDH- cell population constructed 
using the DEAB control.  Arbitrary gates delineating ALDH+ and ALDH++ 
populations for FACS sorting were established using Dako Cytomation MoFlo, based 
on the overall range of ALDH activity shown.  Data were collected and analyzed 
using CellQuest or Facs Diva and FlowJo software as before.   
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In order to visually assess the range of fluorescence intensity exhibited by stained 
cells, 100µl samples of Aldefluor-treated cells were run under glass coverslips placed 
onto microscope slides and examined and photographed in the FITC channel using an 
Olympus fluorescence microscope equipped with a digital camera as described for 
immunofluorescence above. 
 
Correlation of ALDH activity with CFA 
Using a DAKO Cytomation MoFlo FACS machine, cells of each line from the 
ALDH-, ALDH+, ALDH++ and Aldefluor or vehicle-treated cells from the “all live” 
populations were sorted at clonal density into 6-well tissue culture plates for 
assessment of CFA.  Cells were cultured under routine conditions for 14 days, with 
one change of medium at 7 days, and then colonies were fixed, stained, scanned and 
counted as before.  Three replicates for each of 3 samples were evaluated for each 
cell line. 
 
Panc-1 cells were also assayed to investigate the relationship between ALDH activity 
and anchorage-independent growth.  A small sub-set of Panc-1 cells is known to form 
non-adherent spheroids in serum-free culture [320] and a serum-free spheroid culture 
system was devised as described in section 2.2.2 of Chapter 2.  ALDH-, ALDH+, 
ALDH++ and vehicle-treated or Aldefluor-treated cells from the whole live population 
were sorted at clonal density (50 cells/ml) into defined serum-free medium in 24-well 
plates in quadruplicate and allowed to form spheroids for 7 days.  The number of 
spheroids per well was recorded, medium topped up and spheroids allowed to grow 
for a further 7 days then counted again.  The experiment was repeated 3 times and 
results plotted as the average percentage of plated cells forming spheroids.  Results 
were analyzed using Student’s two tailed t test as before. 
 
Correlation of ALDH activity and CD133 expression via flow cytometry 
COLO357, Panc-1 and Psn1 cells were grown to sub-confluence in 75cm2 tissue 
culture flasks under routine culture conditions in triplicate.  Cells were then harvested 
as before, re-suspended at a density of approximately 3×106 cells/ml in 4ml Aldefluor 
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buffer (AB) and filtered through a 40µm cell-strainer to remove clumps as described 
for CD133 FACS analysis above.  Cells were double-stained with Aldefluor and anti-
CD133/1 antibodies according to Protocol 3.7 below.  APC-labelled anti-CD133/1 
and APC-labelled murine IgG1 (isotype control) antibodies were purchased from 
Miltenyi Bioscience (catalogue numbers 130-090-826 and 130-092-214). 
 
Aldefluor, APC and DAPI were excited as described previously, and Aldefluor 
fluorescence collected with a 530/30 blue filter, CD133-APC with 660/20 red, and 
DAPI with 440/40 UV.  SSC-area, SSC-width and FSC-area signals were used to 
include a cellular population and non-viable DAPIbright cells removed from the 
analysis using FSC-area and 440/40 UV signals.  ALDH- populations were identified 
using DEAB-treated controls and CD133- populations using isotype controls, whilst 
bleed-through from APC fluorescence in the Aldefluor channel and vice-versa were 
compensated for using single-stained CD133 and Aldefluor compensation controls.  
ALDH+ and ALDH++ populations were identified using gates set up relative to the 
entire spectrum of Aldefluor fluorescence exhibited.  Data was captured using Facs 
Diva software and subsequently analyzed using Flow Jo software as described 
previously. 
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Protocol 3.7: Aldefluor/CD133-1 double-staining for FACS analysis 
1. 1.5ml was removed from each sample to a sterile FACS tube for 
Aldefluor-free controls.   
2. To the remaining 2.5ml of each sample was added 10µl/ml of Aldefluor 
substrate, followed by trituration to mix well.   
3. 0.5ml of suspension was immediately removed from each Aldefluor-
containing sample to corresponding labelled, sterile FACS tubes each 
containing 10µl DEAB and mixed well (Aldefluor-negative controls).   
4. All samples (including Aldefluor-negative and Aldefluor-free controls) 
were incubated for 30 minutes at 37ºC in the dark in a thermostatically-
controlled water bath. 
5. 0.5ml of suspension was removed from each Aldefluor-treated sample and 
placed into labelled FACS tubes to act as Aldefluor-only compensation 
controls. 
6. From each Aldefluor-free control sample, 0.5ml was set aside for CD133-
only compensation controls and 0.5ml was set aside for isotype controls. 
7. All samples were then spun down at 200× g and re-suspended in fresh 
Aldefluor buffer (AB; 40µl of buffer per 0.5ml of suspension). 
8. The following reagents were added for the second incubation: 
  CD133/Aldefluor stained: 20µl FCR block, 10µl anti-CD133/1- 
  APC 
  Aldefluor compensation: 15µl AB 
  CD133 compensation: 10µl FCR block, 5µl anti-CD133/1-APC 
  Unstained control:  15µl AB 
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  Aldefluor DEAB control: 15µl AB 
  Isotype control:  10µl FCR block, 5µl IgG1-APC 
9. All samples were incubated for a further 10 minutes at 4ºC in the dark. 
10. Samples were spin-washed twice in AB then re-suspended in twice their 
original volume of AB to give a density of approx 1.5×106 cells/ml. 
11. All samples were placed on ice in the dark until analysis using a BD 
LSRII flow cytometer as before. 
12. To each tube, 5µl of 200µg/ml DAPI was added per ml of sample 
immediately before analysis. 
 
 
3.2.5 ABC-transporter activity in cell lines: the Side Population (SP) 
The presence of a side population (SP) of cells with high Hoechst 33342 (Ho33342)-
efflux capacity was evaluated in Panc-1 and Capan-2 cell lines via flow cytometric 
analysis.  Ho33342, propidium iodide (PI) and reserpine were purchased from Sigma-
Aldrich (Poole, UK) and dissolved as 1000X stock solutions.  Panc-1 and Capan-2 
were cultured under routine conditions as outlined in Chapter 2.  At confluence or 
just before, cells were removed from the flasks as before, re-suspended at high 
density in serum-free medium, filtered using a 40µm cell strainer to ensure a single 
cell suspension and the suspension adjusted to a density of 1x106 cells/ml in serum-
free medium for FACS analysis.   
 
Evaluation of the SP fraction 
Evaluation of the presence of a side population (SP) was performed as follows: 
aliquots of cell suspensions were incubated at 37°C with Ho33342 at concentrations 
ranging from 2.5µg/ml to 10µg/ml with or without 10µg/ml reserpine (an inhibitor of 
ABC-transporter function).  Fifty microlitres of 50mg/ml membrane-impermeable 
propidium iodide (PI) was added to each 4ml cell sample immediately prior to FACS 
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to enable exclusion of non-viable cells from the analysis.  The Ho33342 fluorescence 
profile was analyzed at 20-minute intervals using a BD LSRII flow cytometer.  
Scatter signals were generated by a 488nm laser and used to gate a cellular 
population.  Hoechst 33342 and PI were excited by a 355nm laser, Hoechst blue 
emission was detected using a 450/50 bandpass filter and Hoechst red and PI 
emission were detected with a 620nm long pass filter.  Signals were separated with a 
485nm dichroic longpass filter and the Ho33342 fluorescence profile then plotted as 
Ho red fluorescence versus Ho blue fluorescence (620LP versus 450/50).  Doublets 
and clumps of cells were electronically gated out on height versus area signals in the 
450/50 channel, whereas debris was gated out on forward scatter (FSC) versus side 
scatter (SSC) plots.  The SP was defined as a distinct population of 
HoReddim/HoBluedim cells visible below the main G1 population at an incubation time 
and concentration adequate to clearly reveal DNA content and resolve the cell cycle 
profile, and which could be ablated by the addition of the ABC transporter inhibitor 
reserpine.  Optimal conditions for resolution of the SP thus ascertained are shown in 
Table 3.9.  Cells from within the SP and non-SP gates and from within the entire live 
(PI-negative) cell population were sorted for clonogenicity assay as outlined below. 
 
 
Table 3.9:  Optimal conditions for SP evaluation in hPDAC cell lines 
Cell line Incubation time Ho33342 concentration 
Capan-2 110 minutes 5µg/ml 
Panc-1 120 minutes 7.5µg/ml 
Reserpine was added to controls at a concentration of 10µg/ml. 
 
 
Comparative Colony-forming Assays of SP vs. Non-SP Cells 
For evaluation of colony-forming potential, following incubation, cells were sorted 
using MoFlo fluorescence activated cell sorter as before.  Scatter signals were 
generated from a 488nm laser, and Hoechst and PI were excited using a 337.5-
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356.4nm multi-line UV laser (50mW, Innova 90-C5, Coherent).  Detection of 
fluorescence signals was performed using the same filter set up as per the LSRII as 
outlined above.  Cells from within the SP or non-SP gate on the HoRed vs. HoBlue 
plot or from within the entire live, PI-negative population were sorted at clonal 
density into 6-well plates containing 2ml fresh routine culture medium per well.   
 
Prior to sorting, cells were electronically gated to exclude debris, doublets and non-
viable cells as described above.  Three replicates were included per treatment or 
population and each experiment carried out three times.  Colonies were grown for 14 
days with one change of media at 7 days.  Plates were then washed with PBS, fixed 
for 20 minutes with 4% PFA at room temperature, rinsed in PBS and stained for 1 
minute with 0.1% toluidine blue or 2% crystal violet and rinsed in tap water to 
remove excess stain.   
 
Stained plates were then scanned at 600dpi using an Epson 1680 flatbed scanner and 
colonies counted directly on the magnified jpg image.  Colony-forming ability (CFA) 
was calculated as the percentage of visible colonies formed per number of cells plated 
as described in Chapter 2.  The experiment was carried out three times in triplicate. 
 
Analysis of the Effects of Ho33342 Exposure on Growth and CFA 
To evaluate the possible effects of Hoechst exposure on each line, aliquots of single 
cell suspension were placed into sterile polystyrene FACS tubes and Ho33342, 
reserpine, both or their vehicles were added at concentrations and incubations 
previously found necessary for routine separation of the SP for each line, as shown in 
Table 3.10.  All incubations were carried out at 37°C in a thermostatically controlled 
water bath, then cells were held in suspension on ice until analysis, sorting or plating.   
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Table 3.10:  Treatments for determining the effects of Ho33342 on growth and 
colony formation 
 
Treatment Panc-1 Capan-2 
Reagent 
concentration 
Incubation 
times 
Reagent 
concentration 
Incubation 
times 
Control n/a 120 min n/a 110 min 
Hoechst 33342 7.5µg/ml 120 min 5µg/ml 110 min 
Reserpine 10µl/ml 120 min 10µl/ml 110 min 
Hoechst 33342 + 
reserpine 
7.5µg/ml + 
10µl/ml 
120 min 5µg/ml + 
10µl/ml 
110 min 
 
 
For evaluation of proliferation, subsequent to incubation, treated cells were spin-
washed twice at 200× g for 4 minutes, re-suspended in 10ml fresh routine culture 
medium to remove the Hoechst/reserpine, and plated at a density of 1×104 cells/ml 
into 24-well plates.  The proliferation rate was determined for each cell line by 
counting trypsinized cells daily for 11 days in each of three wells per treatment group 
using a haemocytometer and constructing growth curves. The experiment was carried 
out in triplicate and media were changed daily from the third day of the experiment 
onwards. 
 
For assessment of colony-forming potential, following Ho33342 incubation, cells 
were spin washed as above, re-suspended at a density of 1×106 cells/ml in serum-free 
medium and 40µm filtered for MoFlo FACS sorting as described above.  Briefly, 
cells were electronically gated to exclude non-viable cells by excluding PI-positive 
cells on forward scatter (FSC) versus PI fluorescence plots, and to exclude debris and 
doublets on SSC versus FSC and pulse width versus FSC plots.  Live, PI-negative 
cells were sorted, plated at clonal density and cultured, fixed and counted as 
described above for SP versus Non-SP CFA evaluation.  The experiment was carried 
out three times in triplicate.  To overcome errors in colony counting resulting from 
differences in cell size that might be induced by exposure to Ho33342, this 
experiment was repeated, but colonies counted manually using a phase-contrast 
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microscope equipped with a plate reader and 10× objective in place of scanning 
stained plates. 
 
Analysis of the effects of Ho33342 on viability and cell cycle profile 
Cell viability was measured during SP analysis by examining PI fluorescence vs. 
forward scatter plots; PI was used to gate non-viable cells by virtue of their inability 
to exclude this membrane-impermeable DNA intercalating dye [520].   The 
percentage of PI-positive (non-viable) cells was compared between cell suspensions 
exposed to Ho33342, Ho33342 and reserpine, reserpine or vehicle alone for each line.  
This experiment was repeated in triplicate. 
 
DNA content and the proportion of cells of each line in G0/G1, S-phase and G2/M 
stages of the cell cycle were estimated during SP analysis by staining with Ho33342.  
Histograms plotting number of cells versus Ho33342 fluorescence at identical 
cytometer voltages and Ho33342 incubations (5µg/ml for 110 minutes at 37ºC for 
both lines) were used to calculate the percentage of cells of each line in G1, as well as 
to compare the location of the G1 peaks on the Ho33342 axis as an indication of 
DNA content. 
 
Cell cycle analysis was carried out subsequent to SP analysis to evaluate the medium-
term effects of Ho33342 on cell cycle kinetics for each line.  Aliquots of Capan-2 and 
Panc-1 cell suspensions were treated with Ho33342, Ho33342 and reserpine, 
reserpine or vehicle alone in triplicate under the conditions used to identify the SP as 
described above, then spin washed twice in serum-containing routine medium to 
remove dye.  Cells from samples of each treatment group were then plated in 
duplicate into 25cm2 flasks at a density of 3×105 cells/ml in routine media.  One flask 
per sample was allowed to grow for 2 days under routine culture conditions and one 
for 6 days, with media changes every other day.  Flasks were then trypsinized in their 
entirety and contents removed to routine serum-containing medium and pelleted at 
200× g for 4 minutes.  Pellets were triturated and rinsed in ice-cold PBS then 40µm -
filtered into FACS tubes, then pelleted as before.  Pellets were fixed for 30 minutes at 
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4ºC in ice-cold 70% ethanol (added drop-wise whilst vortexing) and kept refrigerated 
until analysis.  Immediately prior to analysis, samples were carefully spin-washed 
twice in PBS pH 7.6 then treated with 50µl of 100µg/ml ribonuclease per ml of 
sample, to ensure staining of DNA only.  Finally, 200µl of 50µg/ml PI was added to 
each sample and mixed well.  Samples were then analyzed using BD LSRII FACS 
analyzer as follows. 
 
Single cell populations were identified on FSC versus SSC plots, and pulse processed 
to exclude doublets on pulse area versus pulse height signals.  PI fluorescence was 
measured with 610/20 blue filter at around 300V and displayed versus FSC.  Debris 
was gated out on scatter plots and cell cycle data displayed as a histogram (number of 
cells versus PI fluorescence intensity).  Facs Diva software tools were used to 
estimate the size of G0/G1, S-phase and G2/M populations, or calculated using Cell 
Cycle or FlowJo software platforms by deconvolution using the Watson Pragmatic 
logarithm Gaussian curve fitting function. 
 
 
3.2.6 Other stem cell markers in human pancreatic cell lines and tissues 
The presence of the proposed gastrointestinal stem cell marker Lgr5 in human 
pancreatic tissues was investigated by ISH and the presence of Msi-1 and Oct-4 in 
hPDAC cell lines investigated by IHC. 
  
Evaluation of Lgr5 mRNA expression in human pancreatic tissues via ISH 
Isotopic in situ hybridization to detect Lgr5 mRNA was performed on FFPE sections 
of 5 normal human pancreata and 6 cases of hPDAC, as described [521] with 
modifications (outlined in detail in Chapter 4).  Riboprobe templates were generated 
from ~500bp exon-spanning cDNA PCR products cloned into a pGEM3Z vector, 
following validation by sequencing [522].  The ISH probe region spanned 5’-UTR to 
exon 5 of the Lgr5 gene; forward primer ctgctctctgctcccagtct, reverse primer 
agggacgtctgtgagagcat, as previously published [522].  Some tissue blocks contained 
duodenal mucosa and these were used as a positive control.  Four slides were cut 
 180
from each block, one for β-actin control to assess mRNA presence, two for different 
exposures of Lgr5, and one negative.  Two exposure times, one of 7 and one of 14 
days were employed for Lgr5 test sections and negative controls.  Sections were 
examined with both transmitted light (bright field) and epi-illumination (dark field) 
using a Nikon Eclipse ME600 microscope equipped with Nikon E plan lenses 5x/0.1 
Numerical Aperture [NA], 10x/0.25, 20x/0.40)  and a digital camera (Q Imaging 
MicroPublisher 5.0 RTV). 
 
Immunohistochemical evaluation of Oct-4 and Msi-1 expression in hPDAC lines 
Primary rabbit polyclonal antibodies to Oct-4 were purchased from Santa Cruz (SC-
8629), rabbit polyclonal antibodies to Msi-1 from AbCam (ab33251 and ab21628) 
and Chemicon (AB5977), and secondary biotinylated swine anti-rabbit 
immunoglobulins were purchased from Dako (E353).  Frozen sections of human 
seminoma, normal small intestine and murine foetal brain were obtained from the 
CRUK tissue bank and used as positive controls [130, 523] in accordance with HTA 
guidelines.  Antibodies were titrated on 4% PFA or acetone-fixed positive control 
sections: Oct-4 at dilutions ranging from 1:25-1:200 and Msi-1 at dilutions ranging 
from 1:25-1:400 using the indirect avidin/biotin/peroxidase/DAB chromogen 
methodology outlined in Protocol 2.2 (Chapter 2) in accordance with manufacturer’s 
recommendations.  Secondary antibodies were applied at a dilution of 1:300 and all 
incubations were carried out at room temperature.  Cells of all four hPDAC cell lines 
were grown as monolayers in glass chamber slides (LabTek as before) under routine 
conditions until sub-confluent, then fixed in 4% PFA as described above before 
immunohistochemistry was performed. 
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3.3 RESULTS 
 
3.3.1 CD133 in human pancreatic cell lines and tissues  
Immunofluorescence 
CaCo-2 monolayers showed strong membranous and punctuate staining with anti-
CD133-1 (Figure 3.2) in a subset of cells.  In monolayers, occasional, scattered 
medium-sized COLO357 cells exhibited stippled apical staining (Figure 3.3), whilst 
Panc-1 cells were largely negative.   However, rare, isolated positive Panc-1 cells 
were seen in sub-confluent areas and exhibited stippled apical or peri-nuclear staining 
(Figure 3.4).  Psn1 monolayers showed a subset of cells exhibiting a CD133+ peri-
nuclear dot (Figure 3.5 A).  These CD133+ Psn1 cells were small in size and more 
common in confluent areas.  Cells of all three PDAC lines undergoing cytokinesis 
showed symmetrical staining for CD133.  Negative controls showed no positive 
staining for CD133 (Figure 3.5 B). 
 
Cell blocks stained for CD133 revealed an apical membranous distribution for 
CD133 in CaCo-2 cells, and a cytoplasmic or membranous distribution in Psn-1 cells 
(Figure 3.6). 
 
Double-staining for CD133 and CK19 showed that CD133+ Psn1 cells did not 
express CK19 (Figure 3.7) in contrast to Panc-1, where CD133+ cells were mostly 
positive for CK19 (Figure 3.8).  CD133+ COLO357 cells showed variable staining 
with CK19, with double and single positive cells seen with approximately equal 
frequency (Figure 3.9). However, due to the rarity of CD133+ cells, formal 
quantification was not possible.  Negative controls showed no positive staining for 
CD133 or CK19. 
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Key to Figures 3.2-3.6: 
 
GREEN  CD133 (FITC channel) 
PINK/WHITE  auto-fluorescence (Aqua channel) 
BLUE   DAPI-stained nuclei 
 
 
 
Figure 3.2:  CD133 expression in CaCo-2 cells as shown by immunofluorescence. 
 
 
 
 
Strong punctate apical and membranous staining for CD133 (green) is seen in a sub-
set of cells.  CD133 was localised by indirect immunofluorescence using polyclonal 
anti-CD133 stem cell antigen antibody (AbCam ab19898, raised to a region of the 
CD133 C-terminus that specifically identified stem cells in neural tissue), nuclei were 
stained blue with DAPI and auto-fluorescence indicated by pink or white coloration.  
Original magnification 200×. 
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Figure 3.3:  CD133 expression in COLO357 cells as shown by immunofluorescence. 
 
 
 
Rare small clusters of cells (shown here) showed stippled staining for CD133 (green) 
using the antibody described previously, whilst the majority of cells showed no 
staining for this marker.  Original magnification 200×.
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Figure 3.4:  CD133 expression in Panc-1 cells as revealed by immunofluorescence. 
 
 
 
 
CD133 expression (green) was present as membranous (above; large arrows) stippled 
staining (below) or peri-nuclear staining (above; double arrows) in sub-confluent 
Panc-1 monolayers.  Indirect immunofluorescence, anti-CD133 AbCam ab19898 as 
before.  Above: main photo 200×, insets 400×; below: 400×. 
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Figure 3.5:  CD133 expression in Psn1 cells as revealed by immunofluorescence. 
 
 
 
 
 
Small clusters of cells showed a peri-nuclear dot pattern of CD133 positivity (green), 
whilst the majority of cells showed no staining (top).  Negative controls (bottom) 
showed no positive staining.  Indirect immunofluorescence, CD133 labelled with 
anti-CD133 stem cell antigen AbCam ab19898 as before, original magnification 
400×.
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Figure 3.6: Immunofluorescence of cell blocks 
 
 
 
Cells were grown as monolayers then harvested, fixed in suspension, spun into pellets 
then FFPE blocks prepared and stained using anti-CD133 stem cell antigen (AbCam 
ab19898 polyclonal) using an indirect immunofluorescence technique as before.  
CaCo-2 cells (A) show membranous staining for CD133 (green), which extends only 
part-way around each cell, consistent with a polar distribution (thin arrows).  Psn1 
cells (B) show cytoplasmic staining for CD133, which may include all or part of the 
cytoplasm (arrowheads).  
 
 
200x 400x 
A 
B 
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Key to Figures 3.7-3.9: 
 
GREEN*  CD133      (FITC channel) 
RED   CK19    (Cy3 channel) 
YELLOW  CD133 & CK19  (merged) 
PINK/WHITE  auto-fluorescence  (Aqua channel) 
BLUE   DAPI-stained nuclei 
* AbCam ab19898, rabbit polyclonal anti-CD133 stem cell antigen as before 
 
 
Figure 3.7:  Expression of CD133 and CK19 in Psn1 cells 
 
 
 
 
CK19 (red) expression was seen in a fibrous pattern in a sub-set of cells 
(arrowheads), whilst peri-nuclear CD133 expression (green) was seen in a separate 
CK19- sub-set of cells (thin arrow).  CD133 labelled with polyclonal anti-CD133 
stem cell antigen (AbCam ab19898, as before); original magnification 400×. 
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Figure 3.8: Expression of CK19 and CD133 in Panc-1 cells. 
 
 
 
 
CK19 (red) and CD133 expression (green) were seen in a subset of cells.  CK19 and 
CD133 were present together (yellow; double arrows) or singly (single arrows).  
Original magnification 400×.
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Figure 3.9:  CK19 and CD133 expression in COLO357 cells. 
 
 
 
 
Cells doubly positive (double arrows) for CD133 (green) and CK19 (red) and singly 
positive (single arrows) were present in COLO357 cultures.  Original magnification: 
top 200×, bottom 400×. 
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In all 5 specimens of normal human pancreas, CK19+ cells of small intra-lobular 
ductules and centroacinar cells showed speckled apical staining for CD133 (Figures 
3.10, 3.11), whilst CK19+ cells of inter-lobular ducts showed weaker, speckled 
cytoplasmic staining for this marker (Figure 3.11) and larger ducts were negative.  In 
3 of 6 cases of PDAC, small clusters of invading cancer cells, variably positive for 
CK19, showed membranous and cytoplasmic staining for CD133 (Figure 3.12).   
 
Key to Figures 3.10-3.12: 
GREEN  CD133*   (FITC channel) 
RED   CK19   (Cy3 channel) 
YELLOW  CK19 & CD133 (merged) 
BLUE   nuclei stained with DAPI 
PINK/WHITE  auto-fluorescence  (Aqua channel false colored) 
* AbCam ab19898, rabbit polyclonal anti-CD133 stem cell antigen as before. 
 
 
Figure 3.10:  CD133 expression in normal human pancreas as revealed by IF 
 
Small CK19+ ductules (red) exhibited apical membranous staining for CD133 (green; 
arrows).  Original magnification 200×.  NB This micrograph exhibits considerable 
background staining with the anti-CD133 antibody. 
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Figure 3.11:  CD133 expression in normal human pancreas as revealed by IF   
 
 
Apical membranous CD133 staining (green) was seen in CK19+ cells (red) of intra-
lobular ducts (yellow arrowheads) and centroacinar cells (double arrows).  Inter-
lobular ducts showed diffuse staining for CD133 (white arrows). Original 
magnification 400×.
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Figures 3.12:  CD133 expression in PDAC as revealed by IF 
 
 
 
Small clusters of invading CK19± tumour cells (red) show positive staining for 
CD133 (green).  Cells positive for both CK19 and CD133 appear yellow.  Original 
magnification 400×. 
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Flow cytometric analysis 
Three of four of the cell lines studied (Panc-1, Psn1, COLO357) showed distinct, 
small sub-populations of cells staining positively for CD133-1 (Figure 3.13a & b and 
Table 3.11).  Capan-2 cells showed pronounced background staining when stained 
with anti-CD133-1 antibody and were not sorted or subjected to further analysis.   
 
 
Figure 3.13a: Identification of CD133+ cells in Panc-1 and Capan-2 hPDAC cell 
lines by FACS analysis 
 
 
 
A small sub-population of Panc-1 cells (0.3%; inside pink gate) showed positive 
staining for CD133 (Miltenyi PE-labelled anti-AC133/CD133-1) (top).  Capan-2 cells 
treated with anti-CD133/1 antibody showed an abnormal staining pattern, 
characterized by a diffuse broadening of the fluorescence profile in both directions 
along the Y axis (bottom).  Representative LSRII data, analyzed using FlowJo; ~100k 
events. 
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Figure 3.13b: Identification of CD133+ cells in COLO357 and Psn1 hPDAC cell 
lines by FACS analysis 
 
 
 
A small sub-population of COLO357 and Psn1 cells showed positive staining for 
CD133 (inside upper pink gates), whilst the great majority of cells were negative.  
Representative LSRII plots, analyzed by Flow Jo: ~100k events shown for 
COLO357, ~10k events for Psn1. 
 
 
 
CD133+ COLO357, Panc-1 and Psn-1 cells were distributed across the entire FSC 
range for each line. 
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Table 3.11:  Percentage of hPDAC cells expressing membranous CD133-1 as 
revealed by flow cytometry. 
 
Cell Line CD133+ fraction (% live, single cell population) 
On analysis* On sorting† 
Panc-1 
(n=12) 
0.80% 
(0.2-3.2%) 
0.54%  
(0.2-1.25%) 
Psn1 
(n=14) 
1.10% 
(0.5-1.7%) 
0.52% 
(0.03-2.02%) 
COLO357 
(n=12) 
0.29% 
(0.04-1.1%) 
0.22% 
(0.03-0.55%) 
 
* BD FACS Calibur or LSRII; † DAKO Cytomation MoFlo; average values shown in 
bold, range given in brackets.   
 
 
The CD133+ fraction of the Psn1 cell line demonstrated high colony forming ability 
(CFA) compared to the entire unsorted live cell population, with an average of 76% 
of CD133+ cells forming macroscopically visible colonies at 14 days, versus 23% of 
the whole live population (Figures 3.14, 3.15).  Conversely, CD133- Psn1 cells 
showed reduced CFA compared to controls, but this did not reach statistical 
significance (Figures 3.14, 3.15).   In the Panc-1 line, the CD133+ population showed 
poor colony formation, with an average 24% CFA versus 49% for the unsorted live 
population (Figure 3.15).  No differences in CFA were seen between CD133+ 
COLO357 cells and the whole live population.  Furthermore, CD133-1-PE stained 
cells of this line showed small but significant decreases in CFA compared with 
unstained cells (Figure 3.15).   
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Figure 3.14: Colony formation of Psn1 sub-fractions sorted for CD133 expression. 
 
Cells were sorted on the basis of membranous CD133-1 expression as evaluated by 
FACS analysis using fluorescently labeled anti-CD133-1 antibody (Miltenyi 
monoclonal anti-CD133-1-PE), then subjected to routine colony forming assay as 
described previously.  Cells were plated at clonal density of 100 cells/well (50 
cells/ml). Representative plate scan after 14 days in routine culture, colonies stained 
with toluidine blue. 
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Figure 3.15:  Correlation of colony forming ability with CD133 expression in human 
pancreatic cell lines. 
              
Cells were gated for viability using DAPI and sorted at clonal density using MoFlo FACS machine.  
CD133 expression was determined on the basis of membranous labeling with monoclonal PE-labelled 
anti-CD133-1/AC133 antibody (Miltenyi).  Average CFA at 14 days shown ± SD; Student’s two-tailed 
t test assuming equal variances, * p<0.05, ** p<0.01; *** p<0.001:  comparisons with the “all live 
(stained)” group. 
 
*** 
 
*** 
* 
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Behavior of CD133+ versus CD133- COLO357 cells in monolayer culture 
Between 4 and 12 days, CD133+ COLO357 cells sorted into 6 well plates at low 
density had formed heterogeneous colonies, and colonies exhibiting holoclone, 
meroclone and rarely paraclone morphologies were seen.  In contrast, colonies 
formed from CD133- cells were heterogeneous but holoclone-type colonies were 
largely absent, and meroclone-type colonies predominated.  At 18 days, CD133+ -
derived colonies continued to display high morphological heterogeneity, with a high 
proportion of holoclone-type colonies (Table 3.12).  However, CD133- -derived 
colonies predominantly exhibited meroclone-type morphology (Table 3.12).  After 
approximately one month in culture, CD133+-derived colonies continued to expand 
and to exhibit a smooth outline, and were generally comprised of very small uniform 
cells, whilst CD133--derived colonies had become very ragged in outline, composed 
of larger, less cohesive cells and in some cases begun to shrink (Figure 3.16).   
 
Table 3.12:  Frequencies of morphological colony types of CD133± COLO357 cells 
at 18 days 
 
 
Parent fraction 
Colony morphologies (%) 
Holoclone Meroclone Paraclone 
CD133+ 60 32 8 
CD133- 2 63 35 
All live control 18 57 25 
 
Data obtained by scoring 90 consecutive colonies over 3 replicates per fraction 
following 18 days routine culture.   
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Figure 3.16:  Colonies derived from CD133± COLO357 cells after 30 days growth 
 
Colonies derived from CD133+ cells typically showed a smooth outline and were 
composed of small, uniform cells (holoclone-like), whereas colonies derived from 
CD133- cells showed a ragged outline and were composed of heterogeneous cells 
(meroclone-like).  Cells sorted on the basis of membranous staining with anti-CD133-
1/AC133 antibody and plated at clonal density.  Original magnification 100×, phase 
contrast.  Representative examples shown. 
 
 
This pattern was partly repeated in colonies derived from cells plated at clonal density 
following trypsinization (Figure 3.17).  Approximately 31% of clonal colonies 
derived from the offspring of CD133+ cells after passaging exhibited holoclone 
morphology, compared to approximately 6% of those derived from CD133- cells and 
24% of those derived from the entire, unsorted live population.  On ICC, almost all 
cells of colonies derived from CD133- COLO357 cells stained positively for CK19, 
whilst a much smaller proportion of CD133+ derived colonies showed positive 
staining with this marker, although this was not quantifiable due to the close-packed 
nature of the cells (Figure 3.17).  The percentage of CK19+ cells was lowest in 
colonies exhibiting holoclone morphology (Figure 3.17). 
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Figure 3.17:  Morphology and CK19 status of colonies derived from CD133± cells 
 
 
After 18 days in routine culture, clonal colonies of second passage cultures derived 
from CD133+ COLO357 cells commonly showed a holoclone-type morphology (top 
left), whilst those derived from CD133- cells did not (bottom left).  Colonies derived 
from CD133+ cells showed heterogeneous staining for CK19, with many CK19- cells 
(top right), whilst CK19- cells were rare in CD133- -derived colonies (bottom right).  
Representative examples shown.  Original magnifications: left side 200×, right side 
100×.  CK19; counterstain. 
 
Following trypsinization and re-plating, CD133+ COLO357 cells seeded at high 
density into 25cm2 tissue culture flasks showed a heterogeneous morphology after 12 
days.  Areas composed of very small, uniform cells were present, adjacent to areas 
composed of more heterogeneous, larger cells (Figure 3.18).  In contrast, CD133--
derived cultures did not show these clusters of very small cells, but were composed of 
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larger, pleomorphic cells throughout (Figure 3.18).  Of these two cultures, the 
CD133+-derived monolayers more closely recapitulated the spectrum of cell 
morphologies seen in the parent line at a similar degree of confluence (See Chapter 2 
Figure 2.1b), whilst only a subset of these were seen in the CD133- -derived cultures. 
 
After 18 days expansion, flow cytometric analysis of the sub-confluent offspring of 
CD133- and unsorted COLO357 cells revealed positive staining for CD133 in 
approximately 0.05% of live single cells.  In contrast, an average of 11% of the 
offspring of CD133+ cells showed positive staining for this marker (Table 3.13, 
Figure 3.19).   
 
 
Figure 3.18: Morphologies of third passage COLO357 monolayer cultures derived 
from CD133± cells 
 
 
Viable COLO357 cells were sorted using a MoFlo FACS machine on the basis of 
membranous labeling with Miltenyi monoclonal APC-labeled anti-CD133-1/AC133 
antibody and subject to routine monolayer culture for three passages.  At the third 
passage, the progeny of CD133+ and CD133- cells exhibited markedly different 
morphology.  Phase contrast, original magnification 100×.
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Figure 3.19: FACS analysis of CD133+ and CD133- derived COLO357 cultures 
 
 
 
 
After one passage, sub-confluent cultures derived from CD133+ and CD133- cells 
were re-analyzed for the presence of CD133+ cells and compared to the parent line.  
Upper pink gates include CD133+ cells, figures in gates denote the percentage of live 
singlets contained therein.  Data captured using BD LSRII FACS analyzer and Facs 
Diva software with subsequent re-analysis using Flow Jo.  Representative data, ~100k 
events shown, each dot representing one cell. 
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Table 3.13:  Percentage of CD133+ cells in COLO357 cultures derived from CD133± 
cells 
 
Fraction CD133+  
(% of live) 
Parent line 
(all live cells) 
0.05 
(0.03-0.07) 
CD133+ derived 11.3 
(10.4-11.9) 
CD133- derived 0.05 
(0.02-0.07) 
 
Sub-confluent second passage cultures were immunostained for CD133 and analyzed 
using a BD LSRII flow cytometer (see Figure 3.19) in triplicate (n=3).  Average 
shown in bold, range in brackets. 
 
 
Correlation of CD133 expression and anchorage-independent growth 
Panc-1 cells sorted 20 cells/well into poly-HEMA coated 96-well plates on the basis 
of CD133 fluorescence and maintained under routine culture conditions showed no 
differences in spheroid formation between any sub-populations.  In contrast, CD133+ 
Psn1 cells showed an approximate doubling of spheroid formation versus the 
unsorted live population (Figure 3.20).   CD133- Psn1 cells and unsorted live cells 
that were not exposed to antibody showed no significant differences in spheroid 
forming abilities versus the unsorted antibody-exposed live cell population (Figure 
3.20). 
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Figure 3.20:  Anchorage-independent colony-formation of Panc-1 and Psn1 cells 
sorted on the basis of membranous CD133 expression 
 
 
 
Cells were FACS sorted 20 cells/well into 96-well plates that had been coated with 
poly-HEMA to prevent adherence, and grown in routine culture for 14 days.  Average 
data shown +SD and analyzed using Student’s 2-tailed t test; *** p<0.001.  
Comparisons versus antibody-treated unsorted parent line (Control +Ab). 
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Evaluation of CD133 mRNA expression in hPDAC cell lines via RT-PCR 
Preliminary experiments using CaCo-2 (positive control) cells produced PCR 
products of the expected size, showing strong bands with all 5 primer pairs (Figure 
3.21).  However, faint extra bands were seen with primer pairs #1, #4 and #5, and 
further experiments were carried out using primer pair #2 only.  There was 
considerable smearing present, therefore the template concentration was 
incrementally titrated downwards in subsequent experiments, from 0.5µg/reaction to 
1ng/reaction.  Using primer pair #2 and 10ng/reaction of RNA template, PCR 
products of the expected size (approximately 542bp) were seen in all cell lines 
(Figure 3.22), which manifest as clear, discrete bands with no smearing or extra 
bands seen.  No signal was seen for any blank. 
 
 
Figure 3.21:  RT-PCR of CaCo-2 cells using CD133-specific primers 
 
Initial experiment, using all AC133 primer pairs (numbered 1-5 as per Table 3.6): 
CaCo2 mRNA template added at 1µg and 0.5µg per reaction.  Bl = blank, water 
replacing mRNA template.  Left hand scale indicates product size in base pairs (bp). 
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Figure 3.22:  RT-PCR of hPDAC cell lines using CD133-specific primers 
 
 
Representative samples using primer pair #2, 10ng/well RNA template.  Left hand 
scale indicates product size (bp). 
A CaCo2 (positive control) 
B Panc-1 
C Psn-1 
D Capan-2 
E COLO357 
F blank (water in place of template) 
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3.3.2 CD44 in human pancreatic cell lines 
On IHC, Panc-1, Psn1 and Capan-2 cells showed heterogeneous staining for CD44 
(Figure 3.23).  Capan-2 cells showed moderate-strong membranous and weaker 
cytoplasmic staining, with smaller cells tending to show stronger membranous 
staining than larger cells.  Panc-1 cells showed ubiquitous moderate-strong 
cytoplasmic staining and moderate-strong staining of smaller cells.  Psn1 cells 
showed near-ubiquitous weak cytoplasmic staining, but membrane staining was hard 
to detect, perhaps due to the poorly adherent nature of these cells in monolayer 
culture. 
 
Evaluation of membranous CD44 expression via flow cytometry showed that the 
majority of Panc-1 and Psn1 cells could be labelled with antibodies specific for this 
marker, whilst a minority of Capan-2 cells showed positive staining (Figure 3.24 and 
Table 3.14).  A small sub-set of Panc-1 and Psn1 cells showed positive staining with 
antibodies to both CD44 and CD133, but CD44-/CD133+ cells were absent in Psn1 
and exceptionally rare in Panc-1 (Figure 3.24 and Table 3.14).  Diffuse, possibly non-
specific staining for CD133 made evaluation of double or singly positive fractions 
difficult for Capan-2 (Figure 3.24).  When stained for CD44, the entire COLO357 
live cell population shifted upward on the CD44-FITC axis, suggesting weak positive 
staining in most, if not all cells (Figure 3.25).  Therefore, quantitative identification 
and evaluation of a true CD44+ population versus a CD44- population was not 
possible.  However a minority of cells fell into the CD44++ gate, set using unstained 
controls to exclude all auto-fluorescence (Figure 3.25).  The remainder of the 
COLO357 cells were designated CD44+.  No COLO357 cells staining with CD133 
and unequivocally with CD44 (i.e. CD44++) were present (data not shown). 
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Figure 3.23:  CD44 expression in hPDAC cell lines as revealed by immunohistochemistry 
 
  
 
 
In routine monolayer culture, the three cell lines studied showed heterogeneous membranous and cytoplasmic staining with anti-CD44 
antibodies (brown), both in colonies (top) and at confluence (bottom).  Nuclei counterstained blue with haematoxylin, indirect 
avidin/biotin method with DAB chromogen. 
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Table 3.14:  Percentages of hPDAC cells showing CD44 and CD133 expression 
 
 
Cell line 
Average percentage of live cells in gate  
(n=3) 
CD44+ CD44+/CD133+ CD44+/CD133- CD44-
/CD133+ 
CD44-
/CD133- 
Capan-2 
 
nd 4.1 12.1 5.8 38.9 
Panc-1 
 
nd 1.2 93.6 0.06 3.8 
Psn-1 
 
nd 0.58 70.2 0 3.6 
COLO357 
 
2.8* nd nd nd nd 
 
* CD44++ (see Figure 3.24); nd = not done.  Flow cytometric data. 
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Figure 3.24:  Co-expression of CD44 and CD133 in hPDAC cell lines as revealed by 
flow cytometry 
 
Representative FACS plots of live single cells.  CD133+/CD44+ cells fall within the 
upper right pink gate of each plot.  Numbers indicate percentage of live single cells 
falling into the adjacent gate.  Data captured using BD LSRII with post hoc FlowJo 
analysis. ~100k events per plot. 
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Figure 3.25:  CD44 expression in COLO357 cells as evaluated by flow cytometry 
A small percentage of live single COLO357 cells fell into the CD44++ gate (pink 
box), whilst the entire population moved upward on the CD44-FITC axis, indicating 
weak FITC fluorescence.  FL2 indicates autofluorescence signals.  Representative 
data; BD LSRII and FlowJo as before; ~100 events shown per plot. 
 
When sorted at clonal density into 24 or 6 well plates and allowed to form colonies 
for 14 days, CD44-/CD133+ Panc-1 cells and CD44+/CD133+ Psn1 cells showed 
enhanced colony formation over unsorted controls (Figure 3.26).  However, CD44+ 
sub-populations did not show CFAs differing significantly from controls, although 
CD44-/CD133- cells of Capan-2, Panc-1 and Psn1 showed relatively poor CFA, 
which only reached statistical significance for Psn-1 (Figure 3.26).  Antibody-treated 
Psn-1 cells also showed slightly reduced CFA in comparison with untreated cells.  As 
no CD44- or CD133+/CD44++ COLO357 cells could be identified, cells from the 
CD44+ and CD44++ populations were sorted as above, in parallel with live cells from 
antibody and vehicle-treated aliquots (Figure 3.27).  CD44+ COLO357 cells were 
poorly clonogenic compared to controls, whilst there were no significant differences 
between any other groups (Figure 3.27).  
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Figure 3.26:  CFA of hPDAC sub-populations sorted on the basis of CD44 and 
CD133 expression (see following page for legend) 
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Figure 3.27:  CFA of COLO357 cells sorted on the basis of CD44 expression 
 
 
 
Legend to Figures 3.25 and 3.26:  Colony formation in 24-well plates after 14 days, 
significance assessed by Student’s two-tailed t test, *** p<0.001, ** p<0.01, * 
p<0.05.  All statistical comparisons versus the unfractionated antibody-treated parent 
line (control +Ab).  Data shown ±SD. 
 
 
 
Similarly, when Capan-2, Panc-1 and Psn1 cells were stained solely for CD44 and 
sorted at clonal density, CD44+ sub-populations showed no significant differences in 
CFA relative to the unsorted parent population (Figure 3.28). 
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Figure 3.28: CFA of hPDAC cells sorted on the basis of membranous CD44 
expression 
 
 
Cells were sorted at clonal density into 6 well plates in triplicate using a MoFlo cell 
sorter and allowed to grow for 14 days.  Data shown +SD and analyzed using 
Student’s two-tailed t test as before; (n=6). 
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3.3.3 ALDH activity in human pancreatic cell lines 
The activity of ALDH was assessed in all four cell lines using Aldefluor, and 
ALDH++, ALDH+ and ALDH- populations identified in each (Figures 3.29a, 3.29b).  
Due to the necessarily rather arbitrary nature of gating for ALDH activity, the size of 
these sub-populations was largely estimated.  The estimated average percentage of 
ALDHpositive (ALDH+ and ALDH++) cells was highest for Capan-2 and lowest for 
COLO357, and the percentage of live cells falling into each category is shown in 
Table 3.15.  Differences in Aldefluor fluorescence could be readily appreciated by 
eye using fluorescence microscopy, with dim cells barely visible and ALDH++ cells 
brightly fluorescing in the FITC channel (Figure 3.30).  ALDH+ and ALDH++ cells of 
Capan-2 and COLO357 were generally distributed at the lower range of SSC and 
FSC plots (Figures 3.29a, 3.29b), but no cell line showed a discrete 
SSClow/ALDHpositive sub-population. 
 
Standard colony formation assays revealed high CFA of ALDH++ and ALDH+ Panc-1 
cells versus vehicle-treated controls, whilst ALDH- cells showed relatively low CFA, 
and these trends were highly significant for ALDH++ and weakly significant for 
ALDH+ cells (Figure 3.31).  Conversely, ALDH++ and ALDH+ Capan-2 cells showed 
a weakly significant, slight decrease in CFA relative to controls.  ALDH++ and 
ALDH+ COLO357 cells showed a slight increase in CFA relative to controls but this 
did not reach statistical significance, and no significant differences in colony 
formation were seen for any sub-population of Psn-1 (Figure 3.31). 
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Figure 3.29a:  ALDH activity in hPDAC cell lines as assessed by flow cytometry 
 
 
 
ALDH- (area to the far left of each plot), ALDH+ (middle pink gates) and ALDH++ 
cells (far right pink gates) were detected in Capan-2 and Panc-1 cell lines using 
Aldefluor.  Percentage of live single cell population contained in each gate shown.  
Data captured with BD LSRII with subsequent FlowJo analysis as before, ~100k 
events shown per plot, representative data.  
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Figure 3.29b: ALDH activity in hPDAC cell lines as assessed by flow cytometry 
 
 
 
ALDH- (left hand gates), ALDH+ (middle gates) and ALDH++ cells (right hand gates) 
were detected in Psn-1 and COLO357 lines using Aldefluor.  Percentage of plotted 
cells in each gate shown.  BD LSRII/FlowJo as before, representative data, ~10k 
events shown per plot. 
 
 
Table 3.15:  ALDH activity in hPDAC cell lines 
 
Cell line Average percentage of live single cells, gated on Aldefluor 
fluorescence (range in brackets) 
ALDH- ALDH+ ALDH++ 
Capan-2 
(n=5) 
65.9 
(52.1-82.5) 
27.9 
(12.7-39.2) 
3.3 
(0.4-6.4) 
COLO357 
(n=5) 
90.2 
(59.2-99) 
3.92 
(0.28-15.1) 
0.34 
(0.04-1.5) 
Panc-1 
(n=13) 
88.8 
(74.5-96.5) 
6.9 
(1.3-12.6) 
1.4 
(0.3-3.4) 
Psn1 
(n=8) 
88.2 
(61.1-98.2) 
11.0 
(1.5-35.9) 
0.3 
(0.13-0.6) 
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Figure 3.30:  Aldefluor-treated Panc-1 cells seen by fluorescence microscopy 
 
                        
 
Composite fluorescence image showing cells from images captured with identical exposure times. 
Original magnification 600×. 
 
 
Figure 3.31:  Comparative CFA of sub-populations of hPDAC cell lines sorted on 
the basis of ALDH activity 
 
 
ALDH++ and ALDH+ sub-populations of Panc-1 showed a higher percentage of colony-forming cells 
than ALDH- cells or the unsorted line, whilst ALDH++ and ALDH+ Capan-2 sub-populations showed 
the opposite pattern.  Data shown +SD, Student’s two-tailed t test, *** p<0.001, * p<0.05; (n=9).  All 
statistical comparisons performed versus unfractionated controls for each line. 
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However, ALDH++ and ALDH+ Panc-1 cells did not show enhanced spheroid 
formation over unsorted controls when colony forming assay in serum-free culture 
was performed: no significant differences in spheroid formation were seen between 
any sub-population when plated at clonal density in 24-well plates or one cell/well 
into 96-well plates (Figure 3.32).  The number of spheroids persisting at 14 days was 
lower than that seen at 7 days for every sub-population (Figure 3.32).  There were no 
significant differences in spheroid survival between any sub-population (Figure 3.33). 
 
CD133+ and ALDHpositive fractions did not significantly overlap for any cell line 
studied (Figure 3.33).  Small percentages of CD133+ cells fell into the ALDHpositive 
region comprising ALDH+ and ALDH++ cells for COLO357 and Panc-1, and Panc-1 
whilst no CD133+ Psn1 cells were ALDH++ (Figure 3.34, Table 3.16).  No line 
exhibited a discrete CD133+/ALDHpositive sub-population on FACS analysis. 
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Figure 3.32:  Comparative adhesion-free CFA of Panc-1 sub-populations sorted on 
the basis of ALDH activity 
 
 
 
Spheroid formation of cells plated at clonal density into serum-free medium in 24-
well plates  or one cell/well in 96-well plates using a MoFlo cell sorter.  Average data 
shown ±SD and analyzed using Student’s two-tailed t test as before.  
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Figure 3.33:  Comparison of mortality of spheroids formed from cells sorted on the 
basis of ALDH activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Percentage of spheroid colonies failing between 7 and 14 days.  Panc-1 sub-
populations sorted at clonal density into serum-free medium in 24-well plates.  
Average data shown ±SD, Students two-tailed t test as before.(n=16). 
 
 
 
 
Spheroid mortality at 14 days
0
10
20
30
40
50
60
70
ALDH++ ALDH+ ALDH- Live Live no sub
sub-population
Sp
he
ro
id
 
m
o
rt
a
lit
y 
(%
)
 222
Figure 3.34:  Correlation between ALDH activity and membranous CD133 
expression as evaluated by flow cytometry 
 
 
 
Data captured using BD LSRII and Facs Diva, with subsequent analysis in FlowJo.  
Representative data; ~50k events/plot.  Single cell population included (red) on Psn1 
SSC-A vs. ALDH plots for clarity.  
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Table 3.16:  Overlap between CD133+ and ALDHpositive subpopulations in hPDAC 
cell lines 
 
Cell line CD133+ cells falling into gate (average %) 
ALDH+ ALDH++ 
COLO357 
(n=3) 
4.0 
 
0.8 
Panc-1 
(n=3) 
5.6 
 
1.4 
Psn1 
(n=3) 
5.4 
 
0 
 
Cells were gated using a BD LRSII flow cytometer to include only a live, single cell 
population, and CD133+ cells plotted onto Aldefluor fluorescence plots as shown in 
the top portion of Figure 3.32.  The percentage of CD133+ cells falling into each gate 
was evaluated using FlowJo. 
 
 
 
3.3.4 ABC transporters and the SP phenotype in human pancreatic cell lines 
The SP was revealed as a discrete sub-population of cells showing enhanced 
Ho33342 efflux compared to the main G1 population at optimal cell cycle profile 
resolution, and verified by comparison of the test with the reserpine control (Figure 
3.35a).  Optimal side population resolution was seen after 90-110mins incubation 
with 5µg/ml Ho33342 (Capan-2), and after 120-135mins incubation with 7.5µg/ml 
Ho33342 (Panc-1).  A small, well defined SP of Hored/Hoblue dim cells was seen in 
both Panc-1 and Capan-2 cell lines and was variable in size; comprising 1.5% of all 
live single cells of the Capan-2 line and 11.6% of the Panc-1 line on average (Figure 
3.35a, Table 3.17).    
 
The SP was difficult to measure for Panc-1, as even after more than 3 hours 
incubation with Ho33342, no reduction in the size of the SP was seen, suggesting an 
unusually high dye efflux capacity in this line.  Therefore, a “low SP” gate (as seen in 
Figure 3.35) was set for Panc-1 cells, to limit the SP to the cells with the highest dye 
efflux capabilities.   The wide variation in SP size seen for both cell lines was largely 
due to differences between the numbers of cells that could be detected by each FACS 
machine: the LSRII had previously proven to be more sensitive than the MoFlo 
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(Table 3.11), and these differences were more pronounced during SP analysis and 
sorting (Table 3.17).  Panc-1 cells with the SP phenotype exhibited side scatter 
properties reflecting those of the whole live cell population, with no clustering in the 
low side scatter range, whilst Capan-2 SP cells clustered loosely in the lower whole 
live cell population side scatter range (Figure 3.35b).   
 
At sorting, the percentage of non-viable cells as revealed by PI staining did not vary 
significantly between Panc-1 and Capan-2 cells or between cells exposed to Ho33342 
or vehicle alone for either group (Figure 3.36).  Furthermore, there were no gross 
differences in DNA content or the fraction of cycling cells (S-M fraction) between the 
two lines at SP analysis (Figure 3.37). 
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Figure 3.35a:  Side Population analysis of Panc-1 and Capan-2 hPDAC cell 
lines
 
A small SP (lower pink gates) was seen in both lines (left), which was inhibited by 
addition of reserpine (right).  Upper pink gates delineate the G1 population of each 
line, to enable correct placement of the SP gate on control plots.  Numbers indicate 
the percentage of the live singlet population contained by each gate.  Representative 
data; captured using MoFlo FACS machine and CellQuest software, with subsequent 
analysis using Flow Jo.  
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Figure 3.35b:  Side scatter and forward scatter profiles of Capan-2 and Panc-1 SP 
cells 
 
 
 
 
 
SP cells were identified on Ho red vs. Ho blue plots (pink gates; left) then plotted 
onto FSC vs. SSC distribution plots (right).  Scatter plots include debris and doublets 
(easily identified by location at the extreme bottom and top of plots) but not dead 
cells.  Representative data; LSRII/Facs Diva with subsequent FlowJo analysis as 
before. 
 
 
 
 
Table 3.17:  SP populations of Panc-1 and Capan-2 cells 
 
Cell line Average SP (% live cells) SP range (% live cells) 
 
 Analysis Sort Analysis Sort 
Capan-2 
(n=5) 
1.5 0.5 0.02-4.7 0.02-1.8 
Panc-1 
(n=5) 
11.6 9.6  6.7-15.3 3.3-14.2 
 
NB: values cited for Panc-1 refer to the “low SP” fraction.  Analysis was performed 
using an LSRII and sorting using a MoFlo. 
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Figure 3.36:  Viability of Capan-2 and Panc-1 cells exposed to Ho33342 or vehicle 
alone at sorting 
 
 
 
 
 
 
The percentage of non-viable cells at SP sorting as evaluated by flow cytometric 
analysis of PI staining (A; representative data, percentage of viable Ho-exposed cells 
within pink gates indicated bottom right of each plot) did not differ significantly 
between cell lines or between populations treated with Ho33342 or vehicle alone (B; 
n=6, Student’s two tailed t test, data shown ±SD). 
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Figure 3.37:  DNA content and cell cycle profiles of Capan-2 and Panc-1 cells at SP 
sorting 
 
 
 
 
 
The G0/G1 peaks (A, denoted by horizontal bars) for both cell lines showed similar 
DNA content at identical cytometer voltages (two different voltages shown for 
clarity, one in top and one in bottom panel) and staining conditions.  The estimated 
percentages of cycling cells (B; S-M phases indicated by horizontal bars) at SP 
sorting were also similar for both cell lines. Data captured using a BD LSRII and 
Facs Diva with subsequent FlowJo analysis. 
 
 
 
 
Following sorting at clonal density and 14 days in routine culture, SP cells of both 
Capan-2 and Panc-1 cell lines showed moderately enhanced colony formation over 
unsorted controls, with non-SP cells exhibiting somewhat reduced CFA (Figure 
3.38).  However, this trend only reached statistical significance for Capan-2. 
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Figure 3.38:  CFA of SP versus non-SP cells of hPDAC cell lines 
 
 
 
Colony formation at 14 days shown +SD, Student’s two-tailed t test, comparisons 
versus vehicle-exposed controls: ** p<0.01, * p<0.05, (n=6).  Plate scan 
methodology. 
 
 
 
Growth analysis revealed severe suppression of proliferation of Capan-2 cells 
exposed to Ho33342 under conditions necessary to reveal the SP, which persisted for 
the 11 day duration of the experiment.  This growth suppression was exacerbated by 
the addition of reserpine (Figure 3.39).  In contrast, a slight delay in the onset of 
proliferation was seen in Panc-1 cells exposed to Ho33342, with or without the 
addition of reserpine, after which proliferation rates matched those of vehicle-
exposed controls (Figure 3.39).  Exposure to reserpine alone did not affect 
proliferation rates in either line. 
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Figure 3.39: Growth curves of Panc-1 and Capan-2 cells exposed to Ho33342, with 
or without reserpine 
 
 
 
Ho33342 exposure increased the doubling time of Capan-2 (right) but not Panc-1 
cells (left), and this was exacerbated by reserpine. In the Capan-2 line, cell number 
slowly increased over time following exposure to Ho33342 alone, whilst the 
population of the group exposed to Ho33342 and reserpine remained static. Panc-1 
cells exposed to Ho and Ho and reserpine grew at a slightly slower rate than those not 
exposed to the dye, but all treatment groups attained the same population size by day 
11.  Gross reduction in cell number was not seen following plating for either line. 
Pooled data from 3 experiments, error bars omitted for clarity. 
 
 
 
Paradoxically, the CFA of Capan-2 cells exposed to Ho33342 appeared only 
modestly reduced (Figure 3.40), despite an obvious macroscopic reduction in the size 
and number of colonies (Figure 3.41).  This reduction in colony formation was 
exacerbated by the addition of reserpine, which did not affect colony formation when 
administered without the addition of Ho33342.  The CFA of Panc-1 cells exposed to 
Ho33342, reserpine or both did not significantly vary from that of vehicle-exposed 
controls, although reserpine-exposed cells showed a slight increase which did not 
reach statistical significance (Figure 3.40). 
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Figure 3.40:  Colony formation of Ho33342-exposed Panc-1 and Capan-2 cells:  
plate scan methodology 
 
 
 
Data shown +SD, Student’s two-tailed t test, comparisons versus vehicle-exposed 
controls: *** p<0.001; ** p<0.01, (n=9). 
 
 
Figure 3.41:  Colonies formed from Capan-2 cells exposed to Ho33345 with or 
without reserpine under conditions necessary to reveal the SP 
 
  
Colonies formed from Ho-exposed Capan-2 cells were smaller and less frequent than 
those formed from unexposed cells. Representative plate scan at 14 days, colonies 
stained with toluidine blue. 
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However, on microscopic examination, Capan-2 cells exposed to Ho33342 were seen 
to be enlarged, irregular in outline and vacuolated in comparison with unexposed 
cells (Figure 3.42).  Therefore assessment of colony formation was repeated, 
identifying and scoring colonies of ≥10 cells at 7 days and ≥20 cells at 14 days using 
phase contrast microscopy, as colonies comprising less than these numbers of cells 
were liable to be scored erroneously using the plate scanning method.  Using this 
method, CFA of Capan-2 cells exposed to Ho33342 was seen to be dramatically 
reduced in comparison with vehicle-exposed controls, with a further reduction in 
CFA in cells exposed to Ho33342 and reserpine (Figure 3.43).  The number of 
colonies formed by cells of all treatment groups rose slightly between 7 and 14 days, 
except for cells exposed to Ho33342 and reserpine, which showed no increase (Figure 
3.43). 
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Figure 3.42:  Morphological appearances of Ho33342-exposed and vehicle-exposed 
Capan-2 cells 
 
 
 
Capan-2 cells exposed to Ho33342, Ho33342 and reserpine, reserpine or vehicle 
alone under conditions necessary to reveal the SP, seeded at identical densities and 
allowed to grow for 7 days.  Phase contrast, original magnification 100×.  
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Figure 3.43:  Colony formation of Ho33342-exposed Capan-2 cells: plate reader 
method 
 
 
 
Data shown ±SD, Student’s two tailed t test. Comparisons shown versus vehicle-
exposed controls unless indicated; *** p<0.001, ** p<0.01, (n=9). 
 
 
 
Cell cycle analysis of Capan-2 and Panc-1 cells exposed to Ho33342 under 
conditions necessary to reveal the SP revealed a complete loss of G2/M cells in 
Capan-2 at 2 days (Figure 3.44a), with recovery at 6 days.  The G0/G1 population 
size was moderately reduced and the size of the S-phase and G2/M populations 
enlarged accordingly for Ho33342-exposed Panc-1 cells after 2 days in culture 
(Figure 3.44b). 
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Figure 3.44a: Cell cycle profiles of Capan-2 cells following exposure to Ho33342 
under conditions necessary to reveal the SP 
 
 
 
Cells were exposed to Ho33342 under conditions necessary to reveal the SP then 
grown under routine conditions for 2 or 6 days and cell cycle profile measured using 
propidium iodide staining.  Representative data shown; data acquired using BD 
LSRII and Facs Diva with Watson Pragmatic curve fitting performed with FlowJo 
shown as thick black lines.  Curve fitting was not possible where G2/M populations 
were absent.  
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Figure 3.44b:  Cell cycle profiles of Panc-1 cells 2 days following exposure to 
Ho33342 under conditions necessary to reveal the SP 
 
 
 
Cells were exposed to Ho33342 under conditions necessary to reveal the SP then 
cultured for 2 days.  DNA content was measured by PI staining; representative data 
shown; data acquired with BD LSRII and FacsDiva with automated cell cycle 
analysis. Percentages of cells in phase are shown above each bracket. 
 237
3.3.5 Other stem cell markers in human pancreatic cell lines and tissues 
 
Immunohistochemistry for Msi-1 and Oct 4 was performed on both cell lines and 
pancreatic tissues.  However, despite positive staining for Oct4 being seen in the 
nuclei of positive controls (frozen sections of seminoma), no positive staining was 
seen either in pancreatic cell lines or in FFPE tissue (data not shown).  Despite 
extensive antibody titration and antigenic retrieval experiments, no staining for Msi-1 
could be detected by any antibody in cell lines, or in the intestinal positive control 
(data not shown). 
 
Positive control tissues (human small intestine) showed mRNA expression of Lgr5 
localized to crypt bases (Figure 3.45).  However, no obvious Lgr5 mRNA was 
detected in either normal pancreata or PDAC specimens (Figure 3.45).   
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Figure 3.45:  Lgr5 mRNA expression in human duodenum and pancreas as shown by 
isotopic ISH 
 
 
Silver grains localizing Lgr5 mRNA appear black on bright-field (left) and white on 
dark-field (right).  Lgr5 mRNA localized to duodenal crypt bases (top) but no mRNA 
expression was seen in normal pancreas (bottom): islet of Langerhans outlined in 
orange, interlobular ducts in yellow.  Giemsa counterstain; original magnification 
100×.  
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3.4 DISCUSSION 
 
CD133 
All cell lines except Capan-2 showed unequivocal evidence of CD133 expression in a 
small subset of cells on IHC and FACS analysis.  Some Panc-1 and COLO357, as 
well as CaCo2 cells showed apical membranous expression on IF, with a punctuate 
staining pattern consistent with the reported distribution of CD133 on apical cell 
membrane protrusions [109-111, 122, 470].  However, IF revealed a largely peri-
nuclear distribution in some Panc-1 and most CD133+ Psn-1 cells, which may suggest 
a location within the Golgi network where association of the CD133 protein with 
lipid rafts prior to transit to the cell membrane is thought to occur [111, 461, 463].  
Nevertheless, the observation that a small number of Psn1 cells showed CD133 
positivity at FACS analysis indicates that a proportion of this cell line also expresses 
CD133 on the external surface of the cell membrane, and the small size of this 
fraction may account for its non-appearance in IF experiments.  It should be noted, 
however, that the antibodies employed for FACS analysis were monoclonal 
antibodies raised to the specific glycosylation-dependent CD133-1/AC133 epitope of 
CD133, whilst the antibody employed for IF was a polyclonal antibody raised to 
“CD133 stem cell antigen”, using a synthetic immunizing peptide corresponding to a 
region within 800 residues from the C-terminus of the CD133 molecule.  This 
antibody may therefore be considered not to be as reliable for detection of the stem 
cell-specific AC133 epitope, although the manufacturer’s data sheet states that it may 
be used for the isolation of neural and haemopoietic stem cells (AbCam, personal 
communication).  CD133 expression was confirmed at the mRNA level in all four 
lines by RT-PCR, which showed a product of the correct size with no non-specific 
products in tests or blank lanes.  However, the RT-PCR technique employed was 
unable to give any information of the relative levels of CD133 mRNA expression, 
and quantitative RT-PCR should be employed to assess this parameter.   
 
CD133+ cells were also seen with low frequency in human tumour sections.  Where 
detected, these CD133+ epithelial cells were seen mainly in clusters at the outer edges 
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of hPDAC tumours and in areas of invasion, and were seen in tumours of all 
differentiation grades.  Interestingly, CD133 expression was seen ubiquitously on the 
apical membranes of CK19+ epithelium lining small interlobular ducts throughout 
normal pancreata, but in a more general distribution within cells lining the larger 
ducts, a distribution that has been subsequently reported by other authors [202, 203].  
This widespread distribution throughout normal ducts tends to suggest that, at least in 
normal tissues, CD133 is not a specific pancreatic stem cell marker, unless the normal 
stem cell is itself widespread, at odds with the prevailing adult stem cell model.  A 
similar scenario is seen in the colon, where CD133, once thought to delineate rare 
stem cells, has now been shown to be present throughout the mature colonic 
epithelium [120]. 
 
CD133 expression correlated with expression of the ductal differentiation marker 
cytokeratin CK19 [193, 381, 383] in Panc-1 and some COLO357 cells, normal 
pancreatic ductal epithelium and some hPDAC cells, but CD133+/CK19- cells were 
seen in Psn1 and COLO357 and in hPDAC specimens.  This may indicate that these 
CD133+ cells are less differentiated (and more progenitor-like), however, CK19 
expression does not always correlate with the degree of cellular differentiation seen 
ultrastructurally in these cell lines in culture [380].  Furthermore, a wealth of 
evidence from rodent and human studies indicate that embryonic pancreatic 
progenitors and the adult pancreatic stem cell itself may express ductal differentiation 
markers including CK19 [175, 176, 196, 226, 524-526].  In addition, doubts as to the 
precise nature of the epitope detected by the anti-CD133 antibody used for these 
experiments mean that the possibility that confounding non-stem associated CD133 
epitopes were also being detected (see above). 
 
In contrast to my findings, recent reports failed to find evidence of CD133 expression 
in a number of different hPDAC cell lines [527] and extremely low expression in 
hPDAC in vivo [528], however, the bulk of further recent reports are in agreement 
and confirm the presence of CD133 in a sub-set of cells in most, but not all human 
primary PDAC tumours [202, 272, 321], normal adult pancreas  [201, 202, 206, 529] 
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and other hPDAC cell lines [183, 530].  Admittedly, CD133 expression was low and 
variable in all of the cell lines examined in the present study, and difficult to detect by 
immunohistochemistry and by FACS analysis.  However, low levels of protein were 
consistently detected by IHC and FACS analysis and supported by detection of 
CD133 mRNA by RT-PCR; their presence in my study and absence from others may 
reflect variable expression between cell lines and tumours and the low numbers of 
tumours evaluated in these studies.   
 
When sorting was carried out solely on the basis of membranous CD133 expression, 
adhesion-dependent colony formation was not elevated for any CD133+ fraction for 
any line except Psn-1.  CD133+ Psn1 cells consistently showed an almost three-fold 
increase in their colony-forming potential over controls in this assay.  In further 
experiments examining sub-populations sorted on the basis of both membranous 
CD133 and CD44 expression, the minority of CD133+ Panc-1 cells that were negative 
for CD44 also showed enhanced CFA over controls, albeit to a lesser degree.  A 
similar CD133+/CD44- fraction was not seen for Psn1, and high colony-formation 
was associated with the CD133+/CD44+ fraction.  COLO357 cells sorted on the basis 
of membranous CD133 expression showed no significant differences in colony 
formation.  However, CD133 antibody treatment was seen to affect the colony-
forming capabilities of the unsorted COLO357 line, and the possibility of antibody 
binding to membrane-bound molecules exerting an influence of cell growth and 
behaviour is well-known from the literature [531-534].  Therefore, the colony-
forming potential of CD133+ COLO357 cells may be artefactually reduced by the 
binding of the CD133 antibody, although the potential mechanism is unknown.   
 
Although CD133+ COLO357 cells were no more clonogenic than unsorted cells, they 
produced three times the proportion of colonies with stem-associated morphologies 
[17, 353, 359] compared to controls and a low degree of differentiation when 
compared to their CD133- counterparts, as evidenced by a lowered percentage of cells 
expressing CK19.  In addition, CD133+ COLO357 cells gave rise to heterogeneous 
offspring; after passaging: cultures derived from CD133+ cells were composed of 
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mostly CD133- cells, whilst retaining a higher percentage of CD133+ cells than the 
unsorted parent population control.  The numbers of cells showing CD133 expression 
in these cultures exceeded the original CD133+ founder population by several orders 
of magnitude, indicating that CD133+ and CD133- progeny must both have been 
produced during culture expansion.  The ability to give rise to phenotypically 
heterogeneous offspring, recapitulating the original spectrum of morphologies present 
in the tumour (or cell line) is one of the defining features of cancer stem cells [244, 
245].  However, it should be noted that CD133+ offspring were also seen to arise in 
cultures derived from CD133- cells, regaining the frequency of CD133+ cells seen in 
the parent population after just one passage.  As the number of CD133+ cells isolated 
in the first experiment was too small to re-analyze for purity, the number of 
erroneously sorted cells is not known, and it is possible that CD133+ cells were 
present in CD133- fractions and vice versa.  Nevertheless, it is unlikely that 
contaminating cells were responsible for the presence of the large majority of CD133- 
cells seen in cultures derived from CD133+ cells, as this would imply a greater 
proliferation rate for these rare cells, which would quickly result in the extermination 
of CD133+ cells from the parent culture under normal conditions. 
 
As stated, CD133+ Psn1 cells were highly clonogenic in adhesion-dependent assays 
compared to unsorted and CD133- cells.  Notably, CFA of Psn1 CD133+ cells was in 
some cases greater than 100%, and rose from between day 7 and day 14, implying 
that some cells were able to detach from nascent colonies and subsequently form 
daughter colonies.  Psn1 cells are motile and do not form tessellated monolayers with 
high cell-cell contacts as do Capan-2 and Panc-1 cells, and this phenomenon of 
seeding of daughter colonies by poorly adherent cells from extant colonies is known 
from other poorly-attached cell lines such as HeLa-S3 and CHO [535].  Further 
colony formation experiments utilizing an immobilizing matrix such as methocel or 
agar could be performed to investigate whether this increased colony formation is a 
result of a higher fraction of clonogenic cells in this sub-population or merely an 
increase in the fraction of cells moving from parent colonies to form daughter 
colonies.  This issue was partially addressed by assessing anchorage-independent 
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colony formation in vitro using plates treated to prevent adhesion, which also 
prevents anchorage-dependent cell migration.  In these assays, CD133+ Psn1 cells 
continued to be significantly more clonogenic than unsorted controls, but to a lesser 
degree, suggesting that anchorage-dependent migration of cells may account for 
some, but not all of the increased colony-formation exhibited by CD133+ Psn1 cells 
in anchorage-dependent assays. 
 
Macroscopically, colonies derived from CD133- COLO357 cells were markedly less 
adherent and cohesive than those derived from CD133+ cells, showing a lower 
tendency to form close contacts between cells, than those derived from their CD133+ 
counterparts; a morphology associated with differentiation and replicative senescence 
([17, 359] also see Chapter 2 for evidence that Panc-1 clones with this morphology 
exhibit attenuated proliferative capacities).  The formation of short-lived daughter 
colonies by detached cells from these colonies could also explain why CFA was 
similar for both groups, despite their otherwise dissimilar behaviour.  Correlation of 
colony morphology with replicative capabilities was not investigated for this line, but 
studies conducted in other cell lines and primary cultures suggest that colonies of 
small, adherent cells (holoclones) possess greater replicative potential than those of 
larger, non-adherent cells as seen here [17, 353, 359].  However, as this line had 
previously not been cloned, this raises the possibility that these divergent colony 
morphologies are reflecting the presence of multiple clones.  Nonetheless, the 
observed change in the CD133+ fraction in these clonal cultures over time lends 
credence to the hierarchy model. 
 
Interestingly, it has also been suggested that a subset of specialized motile cells with 
enhanced colony-forming abilities is present within CSC fractions, which may also 
account for the high number of colonies [341].  This transformation from a sessile 
epithelial to a peripatetic mesenchymal habitus is accompanied by the de novo 
expression of specific markers such as Snail, Slug and vimentin alongside down-
regulation of E-cadherin and is termed epithelial-mesenchymal-transition (EMT) 
[144, 323, 536-538].  The phenomenon of EMT is important developmentally and has 
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also been suggested as a hallmark of cancer stem cells, associated with the ability to 
detach from the main tumour mass, invade and colonize distant tissues [144, 271, 
530, 536, 537, 539].  However, “true” EMT, associated with activation of Notch and 
Wnt signaling cascades in vivo may not be the same as the migratory phenotype 
associated with the expression of vimentin that is seen in cultured cells, which may 
be a consequence of two-dimensional tissue culture [540-542]. 
 
The enhanced ability of CD133+ Psn1 cells to survive and proliferate in the absence 
of adhesion raises the likelihood of enhanced tumorigenic potential, as correlation 
between these two factors has long been known [249, 543-545].   Nevertheless, 
confirmation of tumour initiation in vivo, histological analysis of xenografted 
tumours and serial transplantation to confirm self-renewal and the ability to 
recapitulate the original tumour are necessary.  The majority of Psn1 colonies were 
seen to be serially passageable in early experiments (see Chapter 2), but the gold 
standard for CSC identification remains serial tumour transplantation in xenograft 
models.  It should be noted however, that recent experiments investigating cancer 
stem cells in syngeneic animal models have cast doubt on whether results from 
studies prospectively identifying cancer stem cells using xenograft models accurately 
reflect the true scenario [264, 265, 546, 547].  
 
Further in vitro characterization showed that CD133+ Psn1 cells were not 
ALDHpositive, but expressed CD44, another putative cancer stem cell marker.  
However, CD44 expression was ubiquitous in this line and no CD133+/CD44- cells 
were detected.  Correlation of CD133 with other proposed stem cell markers such as 
Bmi1, Nanog [132, 133, 138, 329, 548-550], proposed markers of adult pancreatic 
precursors such as Pdx-1, Notch1 and nestin [226, 285, 307, 551-554] and CSC-
associated molecules such as CXCR4 [205, 292, 294, 555, 556] could shed light on 
its possible utility as a CSC marker in this line, and remains to be performed.  
CXCR4 in particular shows promise as a pancreatic CSC marker, with especial 
relevance to metastatic potential [207, 208, 272, 292, 293, 297], and is reportedly co-
expressed in CD133+ pancreatic CSCs isolated from human tumours [272].  
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However, Msi1 and Oct-4 could not be detected in this cell line by IHC, and SP 
analysis was not performed due to the deleterious effects exerted by Ho33342 on the 
cell lines studied (see below).  Affymetrix or other gene chip arrays could also be 
employed to study differential expression of a broad range of stem-associated genes 
in CD133+ versus CD133- cells for this line. 
 
Since this study was performed, further evidence has arisen to suggest that CD133 
may have utility, not only in identifying CSCs in hPDAC, but also multi-potential 
adult pancreatic stem cells.  In vitro studies of CD133+ cells isolated from normal 
human pancreata have reported the existence of a sub-population of cells in this 
fraction which are enriched for a host of stem cell markers (including the ABC-
transporter ABCG2, Oct4 and Nanog), which could be trans-differentiated to 
functional β-cells in vitro [201, 206].  Moreover, clinicopathological research has 
suggested CD133 expression to be an independent prognostic factor correlating with 
poor prognosis in PDAC, due to an association with enhanced metastatic potential 
[321], although this is disputed [202].  Cells from hPDAC positive for CD133 and 
CXCR4 also exhibit enhanced tumour initiating capabilities in a xenograft model 
[272] and targeted ablation of this population in vivo abrogated metastasis, reduced 
tumour mass and enhanced long-term survival [331].  Additionally, it has been 
reported that CD133+ cells from other hPDAC cell lines (MiaPaCa) show enhanced 
spheroid formation in vitro and tumorigenicity in vivo [327].  In light of these data, it 
seems likely that, in common with other identified normal and neoplastic stem cell 
populations, a combination of markers which includes CD133 may more specifically 
delineate a pancreatic stem cell population. 
 
Similarly, outside of the pancreatic literature, the utility of CD133 as an adult stem 
cell and CSC marker continues to gain support.  In two widely-cited studies of human 
colorectal cancer, CD133+ cells were uniquely responsible for tumour formation in 
xenografts [115, 273] and similar cells isolated from breast tumours and 
hepatocellular carcinoma were also shown to be highly tumorigenic in comparison 
with CD133- counterparts [119, 338].  Moreover, in mice, experiments employing an 
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inducible Cre, nuclear LacZ reporter allele knocked into the Prom1 (murine AC133) 
locus revealed that CD133+/Lgr5+ intestinal stem cells were susceptible to malignant 
transformation upon activation of aberrant Wnt signaling, giving rise to the typical 
tumours seen in this model [251], although a further population of CD133+/Lgr5- 
cells may constitute a transit amplifying compartment [557].  It was also shown that 
CD133+ fractions of glioma and non-small cell lung cancer are radio and 
chemoresistant and able to maintain tumour growth following therapy [339, 469].  
However, CD133 expression is not a universal trait of CSCs, as both CD133+ and 
CD133- colorectal carcinoma cells have been shown to have tumour-initiating 
properties, with CD133- tumour-initiating cells giving rise to more highly metastatic 
tumours [120].  Likewise, CD133- glioblastoma cells were shown to be capable of 
tumour initiation, whilst CD133+ cells were responsible for tumour progression [558].  
These varying data illustrate the possibility of the presence of multiple populations 
with CSC properties within a single tumour type: some responsible for tumour 
initiation, some for tumour recurrence following ablative therapy, and some for 
metastasis. 
 
CD44 
The majority of cells in each line studied were seen to express membranous and 
cytoplasmic CD44 on immunohistochemistry, and indeed pan-CD44 is known to be 
ubiquitously expressed the normal pancreas in vivo with CD44v7, 8 and 9 
prominently so [471], as well as reportedly expressed in at least some hPDAC in vivo 
and in vitro [559].  Pan-CD44+ hPDAC cells isolated on the basis of membranous 
expression were no more clonogenic than CD44- cells for any line studied.  Since the 
cancer stem cell properties of enhanced invasion, metastasis and chemoresistance 
afforded by CD44 expression result from its interactions with and degradation of 
extracellular matrix proteins [400, 471, 486, 487], the potential lack of such in these 
experiments may partly account for this.  As mentioned above for CD133, not only 
adult but also cancer stem cell properties often depend not only cell-matrix but on 
heterotypic cell-cell interactions: i.e. “the niche matters” [335, 560].  Furthermore, 
antibody binding to CD44 may alter cell behaviour in vitro [475, 482], and Psn1 cells 
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treated with anti-CD44 during flow cytometry showed reduced colony formation in 
comparison with unstained controls, suggesting that colony formation of CD44+ cells 
in this line may be similarly affected by antibody binding.  This may account for the 
slight decrease in colony-formation relative to controls exhibited by CD133+ cells, 
which were also CD44+, when stained for both CD133 and CD44 rather than just for 
CD133. 
 
However, hyaluronan and other matrix components that interact with CD44 are 
known to be produced by pancreatic cell lines in vitro [561-563] and by pancreatic 
tumours in vivo [564], inferring that autocrine stimulation of the CD44-mediated 
pathways responsible for CSC characteristics may occur in both scenarios [400, 563].  
The observation that several of the cell lines studied exhibited cytoplasmic CD44 
expression may be indicative of hyaluronan degradation, as this pattern of distribution 
correlates with this phenomenon in vivo, as CD44 bound to hyaluronan is 
internalized, eventually translocating to the nucleus [472, 476, 565].     
 
Moreover, interactions of CD44 with specific ECM proteins and correlation with 
metastatic potential may also be contingent upon the spectrum of expression of 
particular variant isoforms [471, 480, 485, 486, 566-568], and the expression pattern 
of CD44 isoforms was not investigated.  Therefore, the expression of pan-CD44 may 
not necessarily be expected to correlate with stem cell characteristics.   
 
Pan-CD44 expression was not seen to correlate with CD133 expression on flow 
cytometric analysis; a small minority of CD133+ COLO357 and Panc-1 cells co-
expressed CD44, and CD133+ Psn1 cells formed a small percentage of the CD44+ 
population.  In colony-forming assays of cells separated on the expression of both 
markers, only CD133+ Panc-1 cells that did not co-express CD44 showed enhanced 
CFA.  Therefore, if CD133 is a CSC candidate for pancreas, this rules out CD44 as a 
specific CSC marker, as in these lines at least it is expressed either in a different, or 
much larger sub-set of cells, although this statement is subject to the caveats related 
to CD44v expression described above. 
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Nevertheless, recently, CD44+/CD24+/ESA+ cells isolated from pancreatic tumours 
have been reported to be highly tumorigenic and express the stem cell marker Bmi1 
[319]. This observation is supported by a report that CD44 expression in pancreatic 
cells is regulated by CXCR4, itself a strong candidate pancreatic CSC marker [295] 
and adds to earlier reports that CD44 expression correlates with metastasis of both 
human and rodent pancreatic cancer cells [474, 480], and studies that have 
successfully reduced PDAC metastasis by anti-CD44 treatments such as CD44v7 
knockdown and anti-CD44v antibodies [482, 567].  
 
ALDH 
A high proportion of ALDHpositive and a sub-population of ALDHbright cells were seen 
in all four pancreatic cell lines studied.  ALDHbright cells did not tend to be SSClow 
(often a hallmark of undifferentiated cells), except in COLO357 and Capan-2, where 
this broadly tended to be the case, although this distribution may reflect the general 
distribution of scatter characteristics of the lines.  However, a discrete 
ALDHbright/SSClow sub-population as seen in haematopoietic cells [80] was not seen 
in any line, with the pattern of Aldefluor fluorescence seen in our cell lines similar to 
that shown subsequently in other cancer cell lines [569].  High ALDH activity did not 
correlate with enhanced colony formation in adhesion-dependent assays for any line 
studied except for Panc-1, however this elevated CFA did not persist when cells were 
subjected to a non-adherent colony forming assay under serum-free conditions.  This 
technique is thought to be superior to adhesion-dependent assays in determining CSC 
status and has been used to investigate CSC characteristics in this and other cell lines 
and tissues [78, 271, 320, 338, 394, 399, 468].  High ALDH activity did not correlate 
with CD133 expression for any line, with the great majority of CD133+ cells showing 
low ALDH activity for all lines studied.   Correlation of ALDH activity with SP 
phenotype was not possible, as evaluation using Aldefluor depends on inhibition of 
ABC-transporters responsible for the SP phenotype, to prevent efflux of the 
fluorescent product from cells.  
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The highest proportion of ALDHpositive cells was seen in the well-differentiated 
Capan-2 line and was lower in poorly differentiated lines.  The presence and activity 
of ALDHs (particularly ALDH1) has recently been demonstrated in order of 
decreasing intensity, in ducts, islet cells, acinar cells and peri-acinar stellate cells in 
normal human pancreata and at high levels in the parenchyma of hPDAC by IHC and 
enzyme histochemistry [495, 497].  Furthermore, the fraction of ALDHpositive cells 
was highly variable for each line, which may be a consequence of the subjective 
nature of flow cytometric gating, or of inevitable variability in the degree of 
confluence exhibited by each culture examined.  These data raise the possibility that 
ALDH activity in vitro might merely reflect the degree of ductal differentiation 
attained, and correlation with the expression of CK19 or other measures of ductal 
differentiation such as CAII or MUC-1 might be informative on this front.   
 
Another factor to take into consideration is that ALDH expression confers resistance 
to cytotoxic compounds, including those used in chemotherapy, and has been shown 
to increase in tumours and tumour cell lines following chemotherapy or experimental 
exposure to xenobiotics [87-89, 492]. Therefore high ALDH activity in cell lines may 
be a result of negative selection of ALDHnegative tumour cells in vivo by previous 
therapy, the history of which is unknown for these lines.  It should also be noted that 
the levels of ALDH activity seen in the monoculture scenario may not represent the 
in vivo scenario, as ADH levels in stellate cells have been suggested to influence 
ALDH levels in the pancreas [495].   
 
High levels of ALDH activity continue to show utility in isolating stem cell 
populations.  Recently, ALDH activity has been used to isolate convincing CSC 
populations from colonic carcinomas [277, 279] and head and neck squamous cell 
carcinomas (where knockdown of ALDH down-regulated Snail, suppressed EMT and 
tumorigenicity)[570], and high levels of ALDH1 have been demonstrated in CSCs of 
human mammary carcinoma and in a Brca1-deficient murine breast cancer model 
[86, 338].  However, recent work claiming to identify slowly-cycling stem-like cells 
within pancreatic cell lines reports only a partial overlap with an ALDHbright 
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population [530], whilst ALDH+ cells were responsible for tumour recurrence in vivo 
[324].  In the adult stem cell field, ALDH activity still forms the main basis for 
isolation of multipotential haematopoietic stem cells [84], and has recently been 
shown to identify murine prostatic SCs [79], whilst ALDH1++ cells resident in the 
crypt base stem cell zone in the human colon have been shown to contribute to the 
development of cancer, giving rise to ALDHbright CSCs [277]. 
 
SP  
Panc-1 and Capan-2 cell lines both showed a small SP on flow cytometric analysis.  
In both cell lines, this SP was reserpine-sensitive, implying both the presence and 
activity of ABC transporter pump expression in their cell membranes.  In normal 
pancreatic tissues, the ABC transporter ABCG2 (BCRP), was reported to be absent 
by one study [437], although weak cytoplasmic expression in islets and acinar cells 
was subsequently reported by immunohistochemistry and very low mRNA levels by 
Northern analysis [106].  In contrast, strong ABCG2 expression was seen in a small 
sample of hPDAC specimens [436], in accordance with the appearance of an SP in 
our cell lines.  A side-population has also been shown to exist in human pancreatic 
progenitor cells, both foetal and adult [185, 187]. 
 
Both cell lines showed a small increase in CFA of SP cells over unsorted and non-SP 
cells, but this only reached statistical significance for Capan-2 cells.  However, 
Capan-2 cells exposed to Ho33342 under conditions necessary to reveal the SP 
subsequently became enlarged, vacuolated and showed reduced proliferation and 
colony formation. Our group has also found various epithelial gastrointestinal cell 
lines to have a well-defined and reproducible SP, which may be isolated by FACS 
[571], and isolation of the SP has become a popular tool for prospective stem cell 
isolation [104, 105].  Naturally, we wished to know whether the method of isolation 
may compromise the proliferative potential of the sorted populations.  Despite recent 
suggestions that caution should be exercised when investigating the stem cell 
properties of Ho33342-exposed cells [98, 101, 572] and numerous reports of 
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Hoechst-induced proliferation changes (discussed below), this possibility is largely 
overlooked in studies of SP cells.    
 
This may be partly due to the technical difficulties encountered when undertaking 
studies of SP vs. non-SP populations: since the separation of the SP, by definition, 
relies on the differential efflux of the Ho33342 or other dye from cells, this becomes 
a difficult parameter to control adequately.  Firstly, it is not possible to achieve a 
useful number of “extreme” SP cells that totally exclude the Ho33342 dye to test, 
since some residual dye is needed to gate them in the flow cytometer.  We gated the 
SP at a consistent, low fluorescent signal to maximize SP cell yield and minimize dye 
exposure: an imperfect compromise.  Furthermore, the SP population is also defined 
by the duration of exposure to Ho33342, in our lines around two hours, which yields 
a large enough population to electronically gate and sort for experimentation.  This 
time may itself be adequate to account for the sensitivities of Capan-2 cells to the 
dye, as indicated by reductions in CFA and growth.  This exposure enabled us to 
isolate SP cells with higher CFA than non-SP cells in this line, however, we could not 
resolve a large enough SP at lower incubation times or dye concentrations to sort for 
further experiments.   
 
Sadly, this rules out studies to calculate the relationship between dye dosage, 
incorporation and exposure time and the relative clonogenicity, growth rates and 
doubling times of the SP versus non-SP cell populations.  However, clear alterations 
in growth behaviour in whole populations of the cell lines were seen when these were 
exposed to either Ho33342 or reserpine, or both, and a major difference in the 
sensitivity of the lines to Ho33342 was also observed.  Capan-2 cells were 
consistently impaired in their growth and colony-forming capacity by Ho33342, and 
this was exacerbated by reserpine, whereas Panc-1 cells were almost immune to these 
effects.  This could not be attributed to less dye loading in the non-SP fraction in this 
line compared to that of Capan-2 cells, as the DNA content of the two lines was seen 
to be broadly similar, with significant overlap of the DNA profiles.  
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Although the possible adverse effects of Hoechst exposure have long been known, 
these are rarely addressed in recent SP literature.  While some cell lines such as HeLa 
remain relatively unaffected by even long exposures to Ho33342, exposure is known 
to reduce proliferation of CHO, murine tumour and human glioma cells in a cell cycle 
status-dependent manner, with cells in S-phase being particularly sensitive [515, 573, 
574].  Ho33342 is a potent topoisomerase I poison, and may repress DNA synthesis, 
induce apoptosis and be mutagenic and cytotoxic even at low doses similar to those 
used for SP isolations [516, 517, 575, 576].  Artefactual differences in SP and non-SP 
kinetics may also result from intrinsically different sensitivities to apoptosis [577].  
Ho33342 has also been shown to suppress proliferation and colony-formation 
secondary to use in cell cycle profiling, resulting in alterations in cell kinetics of 
HSCs, cell lines and human leukaemic cells even at concentrations lower than those 
necessary to resolve DNA content and cell cycle profiles [506, 573, 578, 579].  Cell 
survival is further reduced on exposure to stressors such as low temperature and UV 
irradiation [515], both typically encountered during the flow cytometric isolation of 
SP cells.  Ho33342 exposure has also been reported to instigate terminal 
differentiation in several pluripotent embryonal carcinoma cell lines in vitro, which 
may mask stem-cell behaviour in non-SP cells [580].  Potential masking of stem-cell 
behaviour in non-SP cells is also seen in a study of C6 glioma cells [581].  Whilst all 
cells of this line were similarly tumorigenic and clonogenic, the authors demonstrated 
that these properties in CD133- cells were reduced upon Ho33342 exposure, 
suggesting that non-SP cells may be deprived of stem cell features during Ho33342 
staining to separate out SP.  Furthermore, Ho33342 is able to leak into cells in early 
apoptosis [582], which may account for some of the less or non-clonogenic but 
apparently viable non-SP cells which are sorted after dye exposure which we have 
observed.   However, the lack of a significant number of red-shifted cells during SP 
sorting indicates that the percentage of apoptotic cells was likely to be negligible in 
our experiments [583]. 
 
Thus, apparent enhanced proliferation, tumorigenicity and other stem cell properties 
of SP cells over non-SP cells may be sequelae of lower dye retention and 
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concomitantly lower DNA incorporation of this potentially toxic substance.  Some 
studies have suggested that the absence of a high proportion of non-viable cells at 
sorting is an adequate control for Ho33342-related proliferation artefacts [435].  
However, in our study no difference in the size of the viable cell population was seen, 
either as reduced viability in the affected line versus the unaffected one, nor between 
exposed and non-exposed samples, suggesting that Ho33342 can alter proliferation 
and the clonogenic capacity of hPDAC cells without inducing a significant increase 
in the non-viable PI+ fraction seen at sorting.  During evaluation of proliferation, only 
a small decrease in cell number was seen, following soon after plating, similar to that 
seen in the unsorted line in preliminary experiments (see Chapter 2), indicating that 
loss of cell viability following FACS probably does not account by itself for reduced 
CFA.  Therefore the absence of acute toxic effects during FACS sorting may not 
preclude chronic Ho33342-associated suppression of cell cycle activity in non-SP 
cells following separation, in agreement with published data [517, 576].  However, 
the lack of a defined G2/M population in Ho33342-exposed Capan-2 cells at 2 days 
following plating, with a subsequent return to the control cell cycle profile at 6 days 
suggests that Hoechst-induced alterations of proliferation are only present in a sub-set 
of cells, which then die, leaving a relatively unaffected subset that then proliferates to 
rescue the culture, causing the slow increase in cell number observed in Ho-treated 
Capan-2 cultures.  Alternatively, these effects may be temporary in the majority of 
the cell population, which then regains the ability to cycle. 
 
As mentioned above, it has been shown that Ho33342 exerts a more severe anti-
proliferative effect on dividing cells, especially those involved in DNA synthesis 
[574, 584].  Our data suggest that the increased sensitivity of Capan-2 over Panc-1 
cells to Hoechst-associated perturbations in proliferation and clonogenicity are 
probably not attributable to differences in cell-cycle properties, as both lines were 
examined in the relatively steady state of confluence and showed broadly similar 
percentages of cells in the S-M phases of the cell cycle at sorting.  However, the 
reason for the dye sensitivity exhibited by Capan-2 cells remains unknown. 
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In further SP studies, it may be practical to substitute the fluorescent ABC-transporter 
substrate rhodamine 123 (R123) for Ho33342, and this has very recently been 
suggested [585].  R123 may be excluded from cells in a similar fashion, and 
Hodim/R123dim/CD34+ haematopoietic cells have been shown to be enriched for long-
term haematopoietic stem cells in human bone marrow [511, 586], whilst murine 
spermatogonial stem cells and highly clonogenic leukaemic cells are reportedly 
isolated more successfully by virtue of differential R123 efflux rather than by 
Ho33342 efflux [587, 588].  However, use of R123 to measure ABC-transporter 
function is not without caveats, as this dye is preferentially retained by mitochondria 
of metabolically active cells, and thus may be retained even where ABC-transporter 
activity is high, depending on metabolic status [589, 590].  Additionally, R123 has 
been shown to inhibit growth of and exert toxic effects on several cell types, 
particularly human epithelial cancer cells both in vitro and in vivo [591, 592].  
Furthermore, these effects are dose-dependent and exacerbated by exposure to visible 
light [593-595].  Studies of ABC transporter expression in cell lines and tissues have 
been carried out using immuno-labelling of specific molecules such as MDR1 and 
ABCG2 [106, 339, 436, 438].  Using antibodies to extracellular epitopes, it should be 
possible to isolate cell populations based upon expression levels of these specific 
transporters.  However, as for ALDH, the SP phenotype itself, rather than the 
expression level of any specific transporter, may prove to correlate with SC fractions 
[596].  Although MDR1 and ABCG2 have been shown to be responsible for the SP 
phenotype in several systems [91-94], manifestation of the SP phenotype may not 
depend solely on the expression of these two ABC transporters [571, 596]. 
 
Nevertheless, despite these criticisms, a survey of recent literature reveals that 
exclusion of Ho33342 continues to be reported as a hallmark of an ever-growing 
number of normal and cancer stem cell populations.  In addition to the tissues in 
which SP is already known to correlate with a stem cell population, side populations 
isolated from normal murine mammary epithelium [447] and pituitary gland [597], 
human endometrium and conjunctiva [512, 598], and rabbit corneal limbus [433] 
have now also been variously shown to possess stem cell traits such as 
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multipotentiality and enhanced spheroid formation in vitro.  In urological 
malignancies, human tumours have been shown to possess a small SP, which has 
been tentatively suggested to possess CSC properties on the basis of in vitro growth 
characteristics [599].  SP cells have also been proposed as CSCs in several lung, 
gastric, oral carcinoma and neural cancer cell lines [513, 600-605] due to associations 
of the SP variously with increased metastatic potential in vivo, chemoresistance in 
vitro and other stem cell properties; although in the latter study of oral carcinoma, SP 
veracity is somewhat contentious, as it was not always sensitive to verapamil [605].  
Nonetheless, the evidence from lung cancer cell lines is particularly compelling, 
where SP cells exhibited enhanced tumorigenicity, enhanced in vitro metastatic 
potential and the ability to recapitulate the properties of the entire cell line as well as 
elevated expression of stem cell markers [513].  Panc-1 SP cells have also recently 
been shown to have high tumorigenicity in vivo [606] and to exhibit high 
chemoresistance and highly invasive properties that correlated with EMT in vitro 
[184, 322] and may represent a CSC population for this line, underscoring the 
necessity for in vivo CSC assays, and the potential inability of adhesion-dependent 
colony formation assays to reveal anything more than growth characteristics in vitro.  
However, the latter study also suggests stem cell traits for Capan-2 SP cells, but 
failed to detect the deleterious effects that Ho33342 was seen to have on this line in 
my experiments, casting doubts on its stringency [322].  
 
Moreover, it should be noted that the SP may not identify CSCs in all tumour types, 
however, as comprehensive analysis of human colorectal cell lines showed that there 
were no differences between the abilities of SP and non-SP cells to form tumours in 
vivo, form colonies in vitro or give rise to heterogeneous offspring, nor any 
differences in the expression of other stem cell markers such as Oct4, CD133, CD44 
and Msi-1 between the two populations [571].  Additionally, a recent report suggests 
that SP cells do not to correlate with a normal human mammary stem cell population 
[336].  
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Other stem cell markers 
Lgr5 
No Lgr5 mRNA could be localized in sections of human pancreas on ISH, despite 
localization to the region of a putative stem cell population at the base of small 
intestinal crypts where duodenal mucosa was included in pancreatic resection blocks 
and in positive controls [18].  However, recent unpublished experiments isolating 
Lgr5+ cells from murine pancreas via tamoxifen-inducible Lgr5 promoter-driven GFP 
expression suggest that Lgr5+ cells are not only present, but also uniquely able to give 
rise to organoid structures in vitro (Nick Barker, personal communication).  However, 
given the paucity of well-characterized, commercially available specific antibodies to 
Lgr5, the presence of Lgr5+ cells in human tissues has been sparsely reported [607] 
and distribution in human pancreata remains to be shown.  Lgr5 (also known as 
GPR49)  continues to gain prominence as a gastrointestinal stem cell candidate, and a 
mass of robust evidence including long-term lineage tracing using inducible Cre-
recombinase systems has made its likelihood as a specific stem cell marker for small 
and large intestine extremely high [62, 63, 126].  Some uncertainty still exists as to 
the exact location of stem cells in the small intestine, however, due to disparity in the 
results of Lgr5 Cre-recombinase and mitochondrial mutation lineage tracing studies 
[19].  Furthermore, lineage tracing experiments in murine epidermis pinpoint Lgr5 as 
a defining trait of multipotent stem cells in this system too [62, 454].  These Lgr5+ 
stem cells have also been convincingly shown to be the cell of origin of intestinal 
malignancy in in vivo murine models [250, 251].  In the human colon, OLFM4, 
which identifies Lgr5+ stem cells, has been proposed as an easily detectable surrogate 
marker in this system [608], and this may also prove useful for future investigations 
of human pancreas. 
  
Msi1 
Despite numerous attempts with multiple antibodies, Msi1 expression could not be 
demonstrated in any cell line or tissue, including positive controls.  Based on 
numerous personal communications, this experience appears to be common amongst 
stem cell researchers using commercially available antibodies.  The rat monoclonal 
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anti-Msi1 14H1 antibody developed by Okano Hideyuki [609] seems to give robust 
staining in human tissues [441, 610], however, and this clone may be of use, as may 
be other more recently developed Msi1 antibodies.  Msi1 expression in normal and 
neoplastic human pancreas is not ruled out.  In addition to previous reports of utility 
as a stem cell marker for breast and gastrointestinal tract (see Introduction), 
knockdown of Msi1 has recently been reported to cause growth arrest and induction 
of apoptosis in tumour xenografts of colonic cancer cell lines [611], and further 
studies are worthwhile. 
 
Oct-4 
Although nuclear Oct-4 expression was detected in positive control sections of 
human seminoma, a germ cell tumour known to over-express this marker [523], no 
expression was detected in any pancreatic cell line or tissue using IHC.  Nevertheless, 
a report of Capan-2 exhibiting Oct-4 immunoreactivity exists in the literature [141].  
As Oct4 expression can be low and difficult to detect immunohistochemically, the 
more sensitive technique of IF may be of more value than indirect ICC with a DAB 
chromogen as employed here.  Oct-4 continues to receive prominence in stem cell 
studies, especially since discovery of its utility in the induction of pluripotency in 
more differentiated human and murine cells [3, 4, 139, 140] and regulation of 
differentiation in combination with Sox2 and other factors [612].  This demonstrated 
role for Oct-4 as a regulator of stemness, and reports that expression is up-regulated 
in many, but not all human cancers, where it often correlates with poor prognosis 
[613-615], suggest that further investigation as a cancer stem cell marker is 
warranted.  Furthermore, over-expression has been reported to localize to cancer stem 
cell populations in some systems [338, 616]. However, previous reports that Oct-4 is 
a universal stem cell marker [451] may need revising, as confusion of expression with 
that of other closely-related transcription factors and the presence of multiple 
pseudogenes may account for the discrepancies in reports of Oct-4 expression in 
certain cell lines and tissues [617-619].  Furthermore, knockdown of Oct-4 in murine 
models suggests that expression is not necessary for the maintenance of stem cell 
phenotype in all adult mammalian tissues [142].  
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General considerations 
A major criticism of any study of cancer stem cells performed in vitro is that 
manifestation of cancer stem cell characteristics such as enhanced invasion and 
metastasis, lymph node homing, induction of angiogenesis and avoidance of immune 
surveillance and apoptosis may be at least partly dependent on tumour 
microenvironment [287, 290, 620, 621].  Specifically, expression of many stem cell 
markers is dependent on interactions between several signaling pathways such as Hh, 
Wnt and Notch [329, 622], which may require heterotypic cell interactions not 
present in monoculture systems [291, 623](Bamba S, Otto WR, Brittan M and Wright 
NAW unpublished work).  Ergo, the presence of tumour stroma (consisting of both 
extracellular matrix and stromal cells) and interactions with immune cells may all be 
necessary in order to detect CSC behaviour in vitro, and in vivo serial transplantation 
remains the gold standard for confirming CSC properties during prospective 
isolation.  To illustrate the importance of this, SP cells of Panc-1, though showing no 
significant enhancement of colony forming abilities in vitro in my studies, have 
subsequently been shown to possess high tumorigenicity in vivo and are suggested to 
represent a CSC population in this line [606].  
 
This lack of a potential CSC “niche” in vitro may have implications for CSC 
identification in hPDAC cell lines.  For example Type I collagen has been shown to 
modulate the malignant phenotype of hPDAC in vitro, promoting proliferation and 
resistance to apoptosis [81].  Likewise, the collagen-rich desmoplastic reaction 
mediated by pancreatic stellate cells (PSCs) in PDAC in vivo [288, 624] is also 
important for tumour progression.  PSCs interact with tumour parenchymal cells, 
producing matrix metalloproteinases (MMPs), platelet-derived growth factor 
(PDGF), and vascular endothelial growth factor (VEGF) which enhance invasion, 
proliferation and angiogenesis in vitro, and increase tumorigenicity and metastasis in 
vivo [289, 291, 300, 332, 333].  Hypoxia has also been implicated in tumour 
progression modulated by interactions between PDAC parenchymal and stromal cells 
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[298, 299], and is known to interact with the Notch signaling pathway via HIF-1α 
(reviewed in [625]).   
 
Also, the pancreatic progenitor marker Pdx-1 was seen commonly in hPDAC 
specimens, where presence correlated with poor prognosis, but absent from all of the 
hPDAC cell lines examined in vitro [552].  It has been reported that active Wnt 
signaling is rare in hPDAC cell lines in vitro [626], a feature reflected by the cell 
lines employed in this study, which showed either no immunoreactive β-catenin, or 
solely membranous expression.  However, the lack of APC mutations and very low 
frequency of nuclear β-catenin seen in hPDAC indicates that canonical Wnt signaling 
(via APC at least) may not play a large role in pancreatic cancer in vivo either [389, 
627].  Partial reconstruction of the tumour microenvironment is also possible in vitro: 
some pancreatic cell lines secrete ECM proteins in vitro [561-563], Matrigel [395] 
and other matrix components that support differentiation in these lines can be added 
to culture plates, and in addition, hPDAC/hPSC co-culture may prove useful in this 
context.  Although stromal-parenchymal interactions may be facilitated more readily 
in vivo, xenograft CSC assays have also recently been criticized as giving inaccurate 
data due to the imperfectly immunocompromised status of commonly used 
NOD/SCID or athymic nude murine models, and as such may vastly underestimate 
the proportion of tumour cells with CSC properties [546, 547].  It has been shown 
that in some cell lines and tumours, as many as 99% of all tumour cells have the 
ability to initiate tumours and metastasize [264, 265, 581].   
 
Importantly, there is evidence to suggest that differentiation hierarchies are 
maintained in vitro [341, 359, 628], manifest by the fact that cell lines contain cells 
capable of forming tumours that exhibit the differentiation patterns of the parent 
tumour, even following many years of culture [374, 377, 378, 381], and show 
evidence of multi-lineage differentiation in vitro [343, 344].  Sub-populations with 
cancer stem cell properties have also been successfully isolated from several cancer 
cell lines [340, 341, 499, 513, 629].  The cell lines used in this study were all capable 
of forming a spectrum of colony morphologies, which proved to be broadly 
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associated with proliferative potential for Panc-1 at least (see Chapter 2).  
Conversely, there is evidence that stem cell traits can be lost in vitro, especially for 
adult stem cells isolated from normal tissues, leading some authors to question the 
validity of stem cell research carried out on cell lines [245, 336, 338].  However, 
changes in marker expression in cultured stem cells do not always correlate with a 
loss of stem cell functions [630].   
 
It is often proposed that normal and cancer stem cells must have the ability to give 
rise to multiple lineages, and this has been demonstrated for many systems both in 
vitro and in vivo, such as the gastrointestinal tract, epidermis and haematopoietic 
system [18, 248, 344, 454, 631], but this largely depends on the tissue type and is not 
true for all.  For example, unipotent stem cells exist in the interfollicular epidermis 
(see Chapter 1).  In the context of cancer, the ability of a cancer stem cell to give rise 
to a differentiating hierarchy of offspring to recapitulate the spectrum of 
differentiation seen within tumours typical of that organ system would appear to offer 
a reasonable comparison to the adult stem cell scenario.  However, in tumours this 
hierarchy may also be extremely small: in the pancreas, mixed phenotype tumours are 
extremely rare and where reported are often later shown to be the result of 
misidentification of distorted normal structures within the tumour as part of the 
neoplastic lesion [301, 302]; and pancreatic tumours broadly exhibit either ductal, 
endocrine, or rarely, acinar phenotypes with greater or lesser degrees of 
differentiation.  Therefore, hierarchy is to be inferred by degree of differentiation, and 
differentiation may be lost as a feature of high-grade tumours as well as retained by a 
CSC derived from a potentially undifferentiated normal SC.  Furthermore, 
differentiated pancreatic cells exhibit a high degree of phenotypic plasticity: fully 
differentiated murine and human pancreatic cells can transdifferentiate in vitro from 
acinar to ductal, exocrine to endocrine and even from exocrine pancreatic to 
hepatocytic phenotypes [227, 228, 233, 235, 236, 241].  Moreover, this 
transdifferentiation may occur in vivo under certain conditions [175, 230, 231, 241, 
281, 632].  Proof-of-concept rodent studies, including in vivo lineage tracing and in 
vitro transdifferentiation of exocrine cells into functioning islet cells, further indicate 
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a possibility that this feature may eventually be harnessed to treat diabetes [175, 229].  
Taken together, these data cast doubt on the relevance of the ability to produce cells 
of different phenotypes as a unique stem cell determinant in this organ. 
 
There has historically been an assumption that CSCs should resemble normal SCs: 
however, the hierarchical stage at which CSCs are formed may affect the phenotype 
of the resulting tumour:  data from leukaemia shows that derivation of CSCs from 
either HSCs or more committed progenitors (granulocyte or myeloid lineages) 
determines phenotype of leukaemia ([260] Huntly in press).  It is also not clear if 
stem cell properties may be retained or acquired by CSCs during tumour progression.  
In the field of Drosophila stem cell biology at least, it has been shown that germline 
stem cell properties may be induced in more committed progenitor cells if these are 
allowed to enter an experimentally emptied niche capable of maintaining Hh 
signaling [56], indicating the possibility that pathologically emptied or simulated 
niches may support development of stem cell characteristics in non-stem cells.  
Theoretically, stem cell properties of some CSCs might not match those of adult SCs 
beyond the ability to self-renew and to give rise to a hierarchy of offspring.  The 
terminology describing CSCs is accordingly confused: CSCs are variously referred to 
as tumour initiating cells, cells which give rise to metastases and cells which drive 
tumour recurrence following chemotherapy, when these cells may not necessarily be 
one and the same [558](see Chapter 1).  Furthermore, cell lines with very different 
metastatic and other properties in vivo may be isolated from within the same tumour 
or even from within the same cell line [272, 633].  However, these cloned lines may 
be both immortal in vitro and tumorigenic, therefore it follows that the cells 
responsible for tumour initiation and maintenance are not always those responsible 
for metastasis formation.  In this manner, the clonal expansion and CSC models 
might overlap, as multiple, distinct CSCs within one tumour may give rise to the 
original tumour, and metastases or recurrences with a different phenotype.  
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3.5 CONCLUSIONS 
 
Sub-populations of cells expressing CD133, CD44, or demonstrating the SP 
phenotype or high activity of ALDH were seen in most of the cell lines studied, 
demonstrating that markers associated with CSCs in vivo persist in long-term culture 
of human pancreatic cancer cell lines.  However, the sub-populations prospectively 
isolated on the basis of these characteristics did not consistently show correlations 
between any single marker or combination thereof and enhanced colony formation.  
CD133+ cells of Psn1 were highly clonogenic in both adhesion-dependent and 
adhesion-independent assays, and expressed CD44 but did not show high ALDH 
activity.  CD133+ COLO357 cells were largely undifferentiated but able to give rise 
to differentiated and undifferentiated progeny, as well as to CD133+ and CD133- 
offspring.    CD133 therefore presented the candidate CSC marker most deserving of 
further investigation.  The SP fraction of Capan-2 cells was more clonogenic than the 
non-SP fraction, probably a result of artefactual suppression of cell cycle in non-SP 
cells by the dye used to isolate them.  Cell lines may not present the best platform for 
CSC identification, as they lack tumour-stroma and other interactions that may 
determine CSC behaviour in vivo.  In addition, the strategy of using markers of 
normal stem cells to identify CSCs may be flawed, as recent evidence suggests that 
tumour stem cells may arise from a variety of cell types, including committed and 
intermediate progenitors, and that stem cell behaviour may be acquired during 
tumorigenesis.  
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Chapter 4: Trefoil Factor Peptides in Normal and Diseased Human Pancreas 
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4.1 INTRODUCTION 
 
Trefoil factor family (TFF) peptides are small molecules secreted by mucinous 
epithelia, notably in the gastrointestinal (GI) tract, where they are known for their role 
in restitution following ulceration [634-636].  In humans, three TFFs are known: 
TFF1, TFF2 and TFF3 (formerly known as pS2, SP and ITF respectively), all 
possessing at least one shared common sequence motif which forms a tri-lobed trefoil 
or P-domain.  This clover-like structure is maintained by 3 disulphide bonds between 
6 conserved cysteine residues and probably confers resistance to proteolysis in the 
harsh environment of the GI tract [637].  Each TFF member possesses a different 
conformation: TFF1 and TFF3 dimerize in solution via an additional cysteine-rich 
domain, forming homo- or heterodimers, whilst TFF2 is secreted as a dimer with 
variable glycosylated epitopes [637].  Despite indirect evidence of their existence 
from label-displacement studies [638], currently no major cell-surface receptors for 
TFFs are known, although a secreted TFF-binding protein, GKN-2/TFIZ1/blottin has 
recently been discovered [639-641]. 
 
Each TFF shows a characteristic cell- and tissue-specific pattern of expression, often 
paired with that of a secreted mucin glycoprotein, as shown in Table 4.1 [642, 643].  
Outside of the gut, TFF expression has been demonstrated in a wide range of 
mucinous epithelia, including corneal, endocervical, respiratory and salivary, as well 
as in biliary and pancreatic ductal epithelium [644-647].  Within the human gut, 
TFF1 and 2 show complimentary expression in the stomach: TFF1 is expressed in the 
superficial foveolar epithelium [642, 648, 649] and TFF2 in the mucous neck cells of 
antral and pyloric glands as well as Brunner’s glands of the duodenum [642, 650].  
TFF3 expression is absent in the stomach, but is seen in the mucin-secreting goblet 
cells of the small and large intestine [642, 645, 651, 652].   
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Table 4.1:  A summary of major expression patterns of TFFs and mucin 
glycoproteins in normal human and rodent tissues  
 
Trefoil Expression site Co-expressed mucin 
TFF1 Stomach (foveolae) [642, 645, 648] MUC-5AC [642, 653] 
TFF2 Stomach (mucous neck cells)[654] 
Duodenum (Brunner’s glands)[642] 
MUC-6 [642, 655] 
TFF3 Small intestine and colon (goblet 
cells)[642, 656, 657] 
Respiratory tract, salivary gland, conjunctiva 
[644] 
 
MUC-2 [642, 658] 
 
 
Bold text indicates major expression site. 
 
 
Rapid up-regulation of TFF expression and secretion is seen during ulcer healing and 
inflammation in the GI tract [659], both at the site of mucosal injury and by the EGF-
secreting ulcer-associated cell lineage (UACL) [642, 660, 661] which arises locally in 
response to the injury.  EGF, an epithelial motogen and mitogen, induces expression 
of TFFs in adjacent epithelia, acting in synergy with them to promote rapid re-
epithelialization (restitution) of damaged mucosa by enhancing coordinated migration 
of epithelial cells across the mucosal defect [635, 662, 663].  TFF3 at least is essential 
for restitution, as experimentally-induced colitis proves rapidly fatal in TFF3 -/- mice 
whilst wild-type animals show mild symptoms from which they rapidly recover 
[664].  The enhanced restitution seen in response to TFFs is primarily due to 
motogenic effects exerted by these peptides on epithelial cells: numerous studies 
show that TFFs act as motogens on both normal and transformed epithelia in vitro, 
including gastrointestinal, respiratory and corneal [644, 665-669], as well as on non-
transformed fibroblasts [670].  Luminal or systemic delivery of TFFs in experimental 
animals also variously affects ulcer healing in vivo [671-676] and much research has 
been undertaken to investigate their therapeutic potential in inflammatory intestinal 
diseases such as ulcerative colitis [677, 678].  TFF peptides probably also enhance 
restitution in mucinous epithelia outside of the GI tract in a similar fashion, for 
example in the biliary tract [679]. 
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As well as promoting epithelial migration, TFF peptides have a cytoprotective barrier 
function.  TFFs interact directly with specific mucin glycoproteins to alter their 
rheological properties in vitro [680]; in vivo, secreted TFFs likely similarly interact 
with mucin glycoproteins present in the mucus layer lining the luminal surface of the 
gut, where they alter its viscosity to minimize contact of irritant gut contents with the 
epithelium [681, 682].  The interplay with mucins goes beyond a physical barrier 
function, however; application of appropriate mucin glycoproteins also enhances the 
motogenic effects of TFFs in vitro [683].   
 
However, TFF peptides are not thought to act as mitogens: systematic and repeated in 
vitro experiments utilizing tritiated thymidine (3H-T) or bromodeoxyuridine (BrdU) 
have failed to demonstrate mitogenic effect [216, 644, 667, 669, 683-685], with only 
occasional reports of weak mitogenic effects under certain conditions [215, 669, 686].  
TFFs also appear to modulate apoptosis, with pro-apoptotic [687] and anti-apoptotic 
effects reported in vitro [633, 688-691].  Interestingly, observations that TFF2 is 
expressed in lymphoid tissues, reduces inflammation in experimentally-induced 
colitis and that TFF2 -/- mice suffer from exacerbated immune responses to acute 
injury have led to speculation that this peptide (and possibly TFF3) may also serve a 
role within the immune system, perhaps influencing lymphocyte homing [678, 692-
694].  
 
Unsurprisingly for peptides associated with cell migration and modulation of cell 
survival, TFFs have additional importance in neoplasia.  TFF expression is ectopic or 
aberrant in several malignancies (see Table 4.2 for a selection), where dysregulated 
TFF-mucin co-expression is also frequent [655, 695].  There is strong evidence to 
suggest a tumour suppressor function for TFF1 in the stomach, possibly linked to 
defects in the mucous layer secondary to expression of mutant forms of the peptide or 
to dysregulated co-expression with GKN2/TFIZ1/blottin [639, 640].  The pro-
invasive and pro-migratory effects of TFFs are also well known from experiments on 
cancer cell lines in vitro [633, 666, 671, 684, 687, 696, 697], and these peptides have 
been suggested to influence patterns of metastasis in tumours in vivo, perhaps via 
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chemotactic effects [698].  Furthermore, transfection of a non-aggressive colorectal 
cell line with TFF3 in vitro resulted in acquisition of an aggressive metastatic 
phenotype in vitro and in vivo [633], with the reverse effect upon knockdown of 
expression using siRNA [699], suggesting that TFFs may directly modulate tumour 
invasion.  Pro-angiogenic effects have been reported for TFF3, via up-regulation of 
VEGF expression secondary to Stat3 activation [700, 701], which may also play a 
role in metastasis and tumour growth. 
 
So, what relevance do TFFs have to pancreatic physiology and pathology?  The 
normal human pancreatic ductal tree is lined with mucinous epithelium which 
produces MUC-1 throughout [384, 723, 724], and focally low levels of TFF1 and 
TFF3, whereas TFF2 is generally reported to be absent [645, 725].  In chronic 
pancreatitis, where ductal ulceration secondary to obstruction or stone formation is 
often seen, ductal TFF1 expression is greatly up-regulated, both in humans and in 
experimental models [662, 725, 726].  TFF1 expression is reportedly elevated in 
PanIN [243] and hPDAC, where hypomethylation of the TFF2 gene and concomitant 
over-expression is also reported [711, 712, 726-729].  Mucinous and intraductal 
papillary mucinous-cystic tumours (IPMT) of the pancreas in particular show 
elevated levels of TFF secretion [710, 730].  These data suggest potential roles for 
TFFs in ductal restitution and carcinogenesis.  
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Table 4.2:  Trefoil factors and their roles in cancer 
Tumour 
site 
Trefoil 
peptide 
Role or expression status 
Stomach TFF1 
 
 
 
 
 
 
 
 
Under-expressed in human tumours [649] 
Dysregulated co-expression with TFIZ1/GKN2/blottin 
[639] 
Tumour suppressor in mice in vivo [702] 
High expression in metastases [703] 
Co-expression with MUC-5AC dysregulated in ~30% 
[704] 
Mutated in human tumours; tumour suppressor function 
[705] 
Mutant forms lose tumour suppressor function and 
enhance invasion over wild type in vitro [706] 
TFF2 Down-regulated in human tumours [707] 
Colon TFF1 
 
 
 
Induced expression induces invasive phenotype in vitro; 
ectopic expression in tumours [666] 
Transfection induces malignant transformation in vitro 
and potentiates xenograft growth in vivo [708] 
TFF3 Knockdown ameliorates invasive phenotype in vitro; 
expression in liver metastases [699] 
Transfection induces aggressive phenotype in vitro: 
enhanced migration and resistance to apoptosis [633] 
Facilitates invasion by activating Stat3 oncogene in vitro 
[701] 
Anti-apoptotic in vitro [689] 
Biliary tract TFF1 Over-expressed with MUC-5AC in biliary dysplasia and 
early cholangiocarcinoma; declining in invasive tumour 
due to promoter methylation [695] 
Pancreas TFF1 Highly expressed in PDAC [709] and IPMT* [710]  
TFF2 
 
 
Ectopic, highly expressed in PDAC [711] 
Hypomethylated in PDAC [712] 
Activates MAPKs in vitro, dependent on CXCR4 [694] 
TFF3 Ectopic expression in IPMT [710] 
Breast TFF1 Regulated by oestrogen; linked to prognosis [713, 714] 
Uterus TFF3 High expression in endometrioid endometrial carcinoma 
[715] 
Skin TFF1 
TFF3 
Expressed in cutaneous mucinous carcinoma along with 
oestrogen receptor [716]  
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Table 4.2: Trefoil factors and their roles in cancer (contd.) 
 
Tumour 
site 
Trefoil 
peptide 
Role or expression status 
Prostate TFF1 Over-expressed in cancer, absent in benign hyperplasia 
[717] 
TFF3 Over-expressed in cancer [718, 719] with high serum levels 
[720] 
Ovary TFF1 Expression specific to mucinous tumours [709] 
Lymphoma TFF2 Activates CXCR4 receptor implicated in chemotaxis [694] 
Oral 
mucosa 
TFF3 Enhances migration of malignant oral keratinocytes in vitro 
[684] 
 
For reviews of the roles and expression of trefoils in cancer see Wong, et al. 1999, 
May & Westley 1997 and Perry, et al. 2008 [698, 721, 722].  *IPMT = Intraductal 
papillary-mucinous tumour 
 
 
Most interestingly, expression of TFF3 has recently been reported in human 
pancreatic islets using the reverse transcriptase-polymerase chain reaction (RT-PCR) 
technique and immunohistochemistry [216].  A subsequent report suggests that TFF3 
can act as a mitogen for human β-cells in vitro [215].  In vitro production of 
functional β-cells for islet replacement has up to now been difficult, as induction of 
proliferation usually leads to a loss of glucose-stimulated insulin secretion (GSIS) 
[731].  However, Fueger et al. report that adenoviral transfection of human β-cells 
with TFF3 in vitro led to replication without loss of GSIS under certain conditions 
[215].  These two studies differ in methodology and have conflicting results: one 
detecting TFF3 expression in human islets ex vivo [216] and the other unable to 
confirm this [215].  TFF3 was also reported to be absent in the endocrine pancreas in 
an independent immunohistochemical study, which detected the peptide solely in the 
ductal compartment of the human pancreas [645], so these reports remain 
controversial.    
 
Using local in situ hybridization and trefoil factor biology expertise, a study re-
examining the expression of all TFFs in the human pancreas in health and disease 
was undertaken, primarily to assess the mRNA and protein expression status of TFF3 
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in human islets.  It would seem logical that if TFF3 is implicated in islet cell 
proliferation in vivo, then levels of TFF3 mRNA expression or protein would increase 
in pathological scenarios where islet hyperplasia is seen, such as chronic pancreatitis 
[732] or islet cell tumours.  Furthermore, as trefoils are known motogens for other 
epithelial tissues, the effect of TFF2 and TFF3 on wound healing and directional 
migration of human pancreatic carcinoma and fibrocytic stellate cell lines was 
assessed in vitro in order to determine a possible role for these peptides in pancreatic 
ductal restitution, desmoplasia and tumour invasion in vivo.  
 
A major reason for the poor prognosis of PDAC is late diagnosis, partly due to late 
presentation with non-specific symptoms, and partly due to a paucity of specific 
diagnostic tests.  However, an increased understanding of early lesions may greatly 
assist the development of tools for early diagnosis.  PDAC often arises within a 
setting of CP and can be difficult to distinguish histologically from the reactive 
ductular changes thereof [732].  The metaplasia-dysplasia-neoplasia sequence is also 
controversial for the pancreas, with all forms of mucinous metaplasia and hyperplasia 
(e.g. pyloric gland, mucinous gland and goblet cell metaplasia) seen incidentally in 
normal organs and in inflammation, now generally classified as early pancreatic intra-
epithelial neoplasia (PanIN-1) [242, 281, 733], where PanIN probably represents a 
pre-malignant state with a characteristic sequence of alterations in the activation of 
genes such as K-ras, p16, DPC4 and p53 accompanying progression towards PDAC 
[280, 281, 308].  However, whilst the later stages of PanIN are widely accepted as a 
pre-malignant state for PDAC, it is not uniformly accepted that the common, early 
non-dysplastic grades of PanIN progress through this sequence to malignancy [281, 
283, 308, 734-736].  Characteristic changes in mucin gene expression, notably MUC-
5AC, are seen in pancreatic metaplasia and neoplasia [737-742] and form the basis of 
several diagnostic tests [743, 744].  In several well-known metaplasia-dysplasia-
neoplasia sequences of the gastrointestinal tract and elsewhere, changes in mucin 
expression are also of prognostic and diagnostic relevance and are typically 
associated with changes in TFF expression [652, 655-657, 695, 745-748] .  In vitro, 
paired alterations in TFF and mucin expression in gastrointestinal epithelial cells are 
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associated with changes in cellular differentiation and concomitant changes in 
resistance to apoptotic agents [749-751], and co-expression of TFFs and their 
associated mucin glycoproteins are often dysregulated as an early event in 
gastrointestinal malignancies [657, 752].  With these data in mind, an 
immunohistochemical study of TFF and mucin expression patterns was undertaken to 
investigate changes in ductal differentiation in chronically inflamed and neoplastic 
human pancreatic tissues, with the possibility of shedding light on the nature of the 
reactive changes seen in CP, as well as on metaplastic processes and carcinogenesis. 
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4.2 MATERIALS AND METHODS 
4.2.1 Assessment of TFF mRNA distribution in normal and diseased human 
pancreas using isotopic in-situ hybridization 
 
Tissues 
Formalin-fixed, paraffin-embedded human archival tissue from 5 normal pancreata, 5 
cases of chronic pancreatitis (CP), 6 PDAC and 6 pancreatic neuroendocrine tumours 
were obtained from Dr ME El-Bahrawy, Histopathology Department and Division of 
Investigative Medicine, Hammersmith Hospital, Du Cane Road, London under the 
conditions of COREC license number 06/Q0601/33 approved by the local ethics 
committee.  Normal pancreatic tissues were incidentally resected during surgery to 
excise extra-pancreatic primary or metastatic neoplasms (three colonic 
adenocarcinomas, one ocular melanoma metastatic to spleen and one 
cholangiocarcinoma of the lower common bile duct).  Chronic pancreatitis specimens 
comprised 3 alcoholic and 2 idiopathic CP.  PDAC specimens included 4 moderate-
poorly differentiated tumours, one well-differentiated invasive mucinous tumour and 
one poorly differentiated tumour.  The neuro-endocrine malignancies consisted of one 
insulinoma, one glucagonoma, one VIPoma and three further unclassified tumours.  
Human tissue blocks and sections were handled and stored in the Histopathology Unit 
at Cancer Research UK in accordance with the Human Tissue Act (HTA license 
12271).  Sections were labeled with probes for human (h) TFF1, hTFF2, hTFF3, 
hBlottin (GKN-2) and compared to positive control sections and technical controls 
labeled with probe to β-actin. 
 
Probe preparation 
35S-labelled riboprobes to hTFF1, 2 and 3, hBlottin (GKN-2) and β-actin were 
prepared as follows: for each riboprobe required, 2.4µl of DNA template was added 
to 9.7µl mastermix containing 35S-UTP and 0.4µl of appropriate RNA polymerase 
(see Table 4.3), mixed well, centrifuged briefly and allowed to polymerise for 60 
minutes at 37ºC.  The DNA template was then destroyed by addition of 1µl of 1U/µl 
RNAse-free DNAse I (Boehringer or Promega Quality Grade) to each probe mix and 
incubating at 37ºC for 15 minutes.  DNA/RNA fragments smaller than 40bp were 
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removed by eluting the sample on a Chromaspin-30 column (Clontech).  First, the 
column was prepared and spun at 700× g for 3 minutes at 15ºC and the eluate and 
collection tube discarded.  Subsequently, 4µl RNAsin and 6µl DTT were added to a 
new collection tube and each reaction mixture diluted with 25µl of carrier (7.5µl of 
10mg/ml rRNA, 25µl 10mM DTT plus 150µl Q H2O).  The bulk of the reaction mix 
was added to the column and 1µl retained for scintigraphy (see below).  The column 
was then spun as before and the eluate containing the probe collected.  Riboprobes 
were stored at -20ºC for no more than 48 hours or used immediately. 
 
Scintigraphy was used to assess 35S-UTP incorporation into the riboprobe: prior to 
elution, 1µl of probe mix was removed to 50µl Q H2O and 4ml scintillant (Ultima 
Gold, Perkin Elmer 6013329).  Using a Beckman LS6500 scintillation counter, the 
count for this pre-elution sample was compared to that for 1µl of eluted probe mix in 
50µl Q H2O and 4ml scintillant.  Incorporation of 35S was deemed acceptable if 
counts for the eluted sample were between 40-80% of counts recorded for pre-elution 
controls and sufficient to give approximately 1x106 counts/slide following 
hybridization.  
 
Probe quality was evaluated by electrophoresis:  prepared riboprobe samples were 
diluted in sample buffer (Invitrogen #6876) diluted 1:1 with distilled water to give 
approximately 1x106 cpm/well and loaded 10µl/well into 6% TBE/urea pre-cast gels 
(Invitrogen #EC 6855) alongside a nucleic acid standard ladder (Novagen Perfect 
RNA Marker Template Mix, 0.1-1Kb).  Gels were run at 250V/75mA/30W for 55 
minutes in an X-Cell SureLok gel electrophoresis tank filled with Tris-buffered 
EDTA (0.05M Tris/HCl buffer/0.005M EDTA pH 7.6) until the migration front was 
seen to reach the gel base. 
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Table 4.3: Reagents used for riboprobe production 
 
Reagent Details Polymerase 
hPS2/hTFF1 
template 
PS2 8B: Anti-sense from T7, BAMH1 
plasmid, probe is 17 bases before sequence 
start +412 (429nt), sub-cloned to remove 
polyA tail. 
Ref: Wright NA, et al. 1990 [662] 
Obtained from Prof R Poulsom, CRUK 
T7-specific 
bacterial RNA 
polymerase 
(Promega 
P207B) 
hSP/hTFF2 
template 
Anti-sense from T7, BAMH1 using 
approximately 300bp of hSP sequence 
Refs: Wright NA, et al. 1990 [662];  
Tomasetto C, et al. 1990 [654] 
Obtained from Prof R Poulsom, CRUK 
T7 polymerase 
(as above) 
hITF/hTFF3 
template 
Long insert, anti-sense from T3; Xh01 plasmid 
ligated into JM109, 500-550nt length hP1.B. 
Ref: Hauser F, Poulsom R, et al. 1993 [753] 
Obtained from Prof R Poulsom, CRUK 
T3-specific 
bacterial RNA 
polymerase 
(Promega 
P208C) 
hBlottin/GKN-
2 template 
Anti-sense from T3, ECoR1 IMAGE Clone 
#1693411 
Refs: Otto WR, et al. 2006 [641]  
Lennon G, et al. 1996 [754]  
Obtained from Dr WR Otto, CRUK 
T3 (as above) 
hβ-actin 
template 
Dra1-linearized phβA-10 plasmid containing 
~450bp fragment of clone pHFβA3´ut 
Ref: Zandvliet DW, et al. 1996 [755] 
Obtained from Mrs R Jeffery, CRUK 
SP6-specific 
bacterial RNA 
polymerase 
(Promega 
P108B) 
Mastermix 1X Promega Transcription Buffer 
1.5 U/µl Promega 20U/µl RNAsin  
11.2mM DTT (Sigma D9779) 
1mM @ ATP, GTP, CTP 
14µM 35S-UTP + 5.6mM DTT (SJ 40383) 
 
 
 
The gel plate was then removed, opened and the gel fixed in 10% acetic acid for 10 
minutes at room temperature, then rinsed in dH2O for a further 15 minutes.  The gel 
was then picked up onto and blotted with filter paper (3M) to remove excess water 
and covered with cellulose film (Saran Wrap), leaving the edges open.  Gel and paper 
were then dried at 80ºC on a vacuum slab gel dryer (Hoefer GD2000, Amersham 
Biosciences) for 30-60 minutes and the cellulose film removed.  Under an X-ray safe 
light in a darkroom, the dried gel and adherent paper were taped to the bottom of an 
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X-ray film cassette (Hypercassette TM, Amersham Life Sciences) and exposed to X-
ray film (Hyperfilm MP, Amersham Life Sciences 28906844) for 20 minutes, then 
the film processed using an automatic X-ray film processor (Jungwon Precision 
Industrial Co. Korea JP-33).  Good probe quality was defined as a strong, single band 
of the expected size. 
 
Isotopic in-situ hybridization 
Five micron thick serial sections were cut under RNAse-free conditions onto DEPC-
treated water, collected onto clean SuperFrost slides and stored for a maximum of 24 
hours before labeling was performed.  Isotopic in-situ hybridization was performed 
using a protocol adapted from Poulsom R, Longcroft JM, et al. [521] as follows.  All 
incubations were carried out at room temperature unless stated and aqueous solutions 
treated with the RNAse inhibitor diethylpyrocarbonate (DEPC).  Reagents are 
detailed in Table 4.4.  
 
Briefly, sections were de-waxed in xylene, hydrated through DEPC-treated graded 
alcohols and washed in DEPC-treated phosphate-buffered saline (PBS+).  Sections 
were then permeabilised in 20µg/ml proteinase K in PBSA for 10 minutes at 37ºC, 
stopped in PBS/0.2% w/v glycine for 5 minutes then rinsed in PBSA for 5 minutes.  
Post-fixation was performed using freshly- prepared 4% PFA in PBSA for 10 minutes 
then sections rinsed three times in PBS+.  Sections were then acetylated for 10 
minutes in 500ml 0.1M triethanolamine + 1.2ml acetic anhydride mixed immediately 
before use then rinsed three times in PBS+, dehydrated to absolute ethanol/0.1% 
DEPC and air dried. 
 
The following day, hybridization buffer and probes for β-actin, hTFF1, hTFF2 and 
hTFF3 were prepared.  Hybridization buffer containing the 35S-labelled probe was 
denatured to 80ºC for 1 minute then 20µl added to each tissue section and covered 
with an RNAse-free glass cover-slip.  Slides were then placed in slide racks in 
humidified boxes containing blotting paper saturated with 1X salts mix/50% 
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formamide and sealed in with tape.  The probe was then allowed to hybridize 
overnight at 55ºC. 
 
Coverslips were removed and slides rinsed in 50% formamide buffer at 55ºC.  Slides 
were again placed into new racks and three more rinses in 50% formamide buffer at 
55ºC performed over 3 hours on an orbital shaker.  Formamide was then removed by 
rinsing 9 times in TNE buffer at 37ºC on an orbital shaker.  RNAse A solution was 
then prepared, boiled for 2 minutes and added to TNE buffer, then slides incubated in 
this mixture for 60 minutes at 37ºC to remove all unbound probe.  Slides were then 
washed in 2X and then 0.5X SSC for 30 minutes each at 65ºC.  Finally, slides were 
dehydrated through graded alcohols containing 0.3M ammonium acetate (to enhance 
RNA-RNA hybrid permanence) and air dried overnight.   
 
Table 4.4:  Reagents used for isotopic in-situ hybridization 
 
Reagent Recipe/stock Details Source 
Acetic 
anhydride 
  Sigma 
A6404 
Acetate 
buffer 
200mM stock: 
442µl glacial acetic acid 
359mg sodium acetate 
trihydride 
Made to 100ml with dH2O 
pH 4.2 
Stored at 4ºC 
 
Ammonium 
acetate 
5M stock: 
96.25g in 1l distilled H2O 
Autoclaved before use Sigma 
A1542 
Denhardt’s 
solution 
BSA/Ficoll/ 
polyvinylpyrollidine 
Stored at 0-5ºC Sigma 
D9905 
DEPC  Stored at 4ºC Sigma 
D9779 
Dextran 
sulphate 
50g in 10ml autoclaved Q 
H2O 
Dissolved at 80ºC and 
stored at -20ºC 
Sigma 
D8906 
Formamide De-ionised stock solution:  
400ml formamide 
20g resin 
 
 
Stirred overnight in fume 
hood, filtered to remove 
resin and stored at  
-20ºC 
 
BDH 
BioRad 
AG501-x8 
Formamide 
buffer 
Stock solution: 
250ml 10X salt sol. 
1250ml non de-ionised 
formamide 
Made to 2.5l with 
autoclaved DEPC-treated 
Q H2O 
 
As above 
BDH 
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Table 4.4:  Reagents used for isotopic in-situ hybridization (contd.) 
 
Reagent Recipe/stock Details Source 
Glycine 0.2% in 2X PBS Autoclaved Sigma G5516 
Hybridization 
buffer 
10% 10X salts in 
Denhardt’s solution 
50% formamide 
3% rRNA 
20% dextran sulphate 
1% 1M DTT 
16% DEPC Q H2O plus 
1x106 counts/section 
volume of riboprobe 
Buffers pH and 
osmolarity 
Increases 
stringency 
Probe carrier 
Wetting agent 
Reducing agent 
 
See below for 
reagent sources 
Proteinase K Stock: 10mg/ml in TE 
buffer stored at -20ºC 
Working solution: 
20µg/ml in PBS 
 
Stock stored at -
20ºC 
Gibco 25530-
015 
RNAse A 500mg RNAse A 
1ml Q H2O (no DEPC) 
Stored at -20ºC Sigma R5503 
rRNA 283µl DEPC-treated Q 
H2O added per 50U vial 
to give 10mg/ml 
 Sigma R5502 
Salts mix 10X stock solution: 
3M NaCl 
100mM Na2HPO4 
100mM Tris/HCL 
50mM EDTA 
 
Not autoclaved, 
stored at room 
temp 
 
 
 
Sigma T3253 
Sigma E5134 
SSC Standard saline citrate 
20X stock 
Diluted in DEPC-
treated Q H2O for 
use 
 
TNE buffer 146g NaCl in Q H2O 
50ml 1M Tris/HCl pH 7.6 
25ml 0.2M EDTA pH 7.5 
Made to 5l with 
non-DEPC treated 
Q H2O and pH 
adjusted to 7.2-7.6.  
Stored overnight at 
37ºC before use. 
 
Triethanolamine 0.1M in 0.1% Q H2O Autoclaved and 
stored at room 
temp 
Sigma T1502 
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Autoradiography 
Photographic emulsion was prepared and applied to slides in a darkroom under a 902 
(orange) filtered light as follows.  No metal implements were used in the procedure.  
A glass measuring cylinder containing 25ml of Milli-Q filtered H2O was warmed to 
37ºC in a water bath, then Ilford K5 scientific emulsion (Size A in gel form) added to 
give a volume of 40ml, allowed to melt for 5-10 minutes then mixed with a warmed 
glass rod.  Emulsion was transferred to a dipping vessel and allowed to rest for 10-20 
minutes to de-bubble.  Emulsion quality was ascertained by immersion of a test slide.   
 
Slides were dipped so that emulsion completely covered the tissue section, wiped on 
reverse, then placed onto pre-cooled metal plates to dry for 60 minutes in the dark, 
until emulsion was set enough to resist scratching with a fingernail.  Slides were 
placed into plastic slide racks and then into light-proofed containers.   Two exposures 
were performed at 4ºC for 7 days (initial exposure) and up to 14 days depending on 
the strength of the first exposure signals compared to controls.  Following exposure, 
slides were developed by dipping into plastic receptacles containing developer then 
stop, rinsed in tap water, fixed and finally washed in running water as detailed in 
Table 4.5.  Sections were then counterstained with Giemsa (stock diluted 1:100 in 
distilled water), dehydrated then mounted in DePeX for microscopy. 
 
Table 4.5:  Autoradiography protocol 
 
Step Reagent details Time Source 
Develop Kodak D19 developer 4 minutes Kodak 
Stop 1% acetic acid 30 seconds  
Rinse Tap water 30 seconds  
Fix 30% sodium thiosulphate 8 minutes  
Wash Running water 60 minutes  
Giemsa 
counterstain 
Stock: 
10ml Giemsa 
20ml acetate buffer* 
50ml acetone 
320ml dH2O 
4 minutes  
BDH #35086 
* See Table 4.4 
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Scoring and assessment of TFF mRNA expression 
Sections were examined with both transmitted light (bright field) and epi-illumination 
(dark field) using a Nikon Eclipse ME600 microscope equipped with Nikon E plan 
lenses 5x/0.1 Numerical Aperture [NA], 10x/0.25, 20x/0.40)  and a digital camera (Q 
Imaging MicroPublisher 5.0 RTV), by two observers.  The distribution pattern, 
intensity and frequency of labeling was assessed relative to that of positive and 
negative controls and recorded semi-quantitatively and qualitatively.  The scoring 
system employed was adapted from several histopathology scoring systems and was 
as follows: slides were accorded a score for intensity and a score for frequency of 
signal.  These two values were then added together to give a derived score value of 
between 0 and 6.  Average scores for each group were rounded to the nearest whole 
number and graded as shown below. 
 
Frequency Score (F)  Intensity Score (I)  Derived Score (F+I) 
Negative 0  Negative 0  0 - 
Focal  1  Weak  1  1-3 + 
Patchy  2  Moderate 2  4 ++ 
Diffuse 3  Strong  3  5-6 +++ 
 
Where: 
Focal    = < 25% showing expression 
Patchy    = 25-75% showing expression  
Diffuse   = > 75% showing expression  
 
 
Images were captured using QCapture Pro 6 software (QImaging) running under Mac 
OS X and processed to remove shadows using Photoshop (Adobe, CS3), utilizing the 
method described by Marty and co-authors [387]. 
 
 
4.2.2  Assessment of TFF and mucin expression in human pancreatic tissue and 
cell lines using immunohistochemistry 
 
Immunofluorescence of cell lines: 
Cultures of human PDAC lines Panc-1, COLO357, Psn-1 and human colonic 
adenocarcinoma line HT29 (as before) between passages 10 and 23 were routinely 
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cultured until just confluent in glass LabTek chamber slides (BD Falcon).  
Monolayers were then fixed in 4% PFA for 15 minutes, rinsed twice in PBS, slides 
covered, sealed with Parafilm and stored at 4ºC for no more than 7 days.  Slides were 
then stained with anti-TFF3 antibody (see Table 4.6) using the indirect 
immunofluorescence protocol previously outlined in Chapter 3.  Primary antibody 
was replaced with PBS for negative controls. 
 
Briefly, de-waxed and hydrated sections were blocked in normal goat serum (Dako 
X0907, diluted 1:25 with PBS) for 15 minutes, rinsed, then primary antibody diluted 
to a concentration of 3µg/ml in PBS and applied for 60 minutes, as recommended by 
Okada H, et al.[756].  Sections were rinsed, then incubated in AlexaFluor 488-
labelled secondary antibody (goat anti-mouse IgG AF-488, Invitrogen SKU# A-
11001) diluted 1:200 in PBSA for 30 minutes in the dark, rinsed and mounted in 
DAPI-containing aqueous mounting medium (VectaShield Hard Set +DAPI, Vector 
Laboratories).  Sections were kept at 4ºC in the dark until examination to avoid 
photo-bleaching.  Microscopy and image capture were performed as outlined in 
Chapter 3 for CD133. 
 
Immunohistochemistry and immunofluorescence of archival tissue: 
Formalin-fixed, paraffin embedded sections were obtained from 15 normal human 
pancreata, 15 cases of CP, 16 PDACs and 16 neuro-endocrine tumours from the 
archives of Hammersmith Hospital as before. These cases included the 22 used in the 
ISH study and additional “normal” pancreata consisted of marginal tissue distant to 
primary tumour from PDAC resection specimens and showed no morphological 
abnormalities.  Sections were stained with antibodies to the ductal cytokeratin CK19, 
MUC-1, MUC-2, MUC-5AC, MUC-6, TFF1, TFF2, and TFF3 as detailed in Table 
4.6 using the indirect avidin/biotin/HRP immunohistochemistry method outlined in 
Chapter 2.  The series of 22 cases employed for the ISH study was concurrently 
stained using antibodies to TFF3 and GKN-2; subsequently, this series and the 
additional cases were subjected to staining using the entire antibody panel.  Formalin 
fixed, paraffin embedded human archival tissues were used as positive controls as 
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detailed in Table 4.6: salivary gland showing intestinal metaplasia was also used as 
positive control material for TFF3 during preliminary antibody titration experiments.  
Immunostaining using a range of dilutions (1:10-1:500 in PBSA), with or without 
heat-induced epitope retrieval (HIER) for each primary antibody was performed on 
positive control tissues to establish optimal concentrations.  Primary antibody was 
replaced with PBSA for negative controls.  Where antigenic retrieval was required, 
HIER was performed by microwaving de-waxed sections in boiling 0.01M sodium 
citrate buffer at pH 6.0 or 1mM EDTA buffer at pH 8.0 for 11 minutes on high power 
as appropriate, then quenching in cold running tap water prior to carrying out the 
standard IHC protocol. 
 
Co-localization of TFF3 with insulin and glucagon was investigated by indirect 
double immunofluorescence carried out according to the protocol detailed in Chapter 
3 for CD133/CK19 dual labeling.  
 
To assess the specificity of TFF3 staining, paired positive control sections and 
sections of human pancreas containing islets of Langerhans were stained with the 
TFF3 mAb as before, or with the TFF3 primary antibody pre-absorbed with 10× by 
weight recombinant hTFF3 monomer (Novo Nordisk, a gift of Lars Thim).  Pre-
absorbed antibody was prepared by adding 2.25µl of 1mM hTFF3 in PBSA to 500µl 
TFF3 antibody (primary antibody diluted to ~3µg/ml in normal goat serum working 
solution) to give ~30µg/ml hTFF3 monomer and ~3µg/ml TFF3 antibody and 
incubated for 30 minutes at room temperature before use.  Sections were then stained 
using the routine indirect avidin/biotin/peroxidase method as before, substituting pre-
absorbed antibody for primary antibody as required. 
 
Antibodies: 
Indirect immunohistochemistry: Monoclonal antibodies to MUC-1, MUC-2, MUC-
5AC, MUC-6, cytokeratin 19 (CK19), TFF1, TFF2, TFF3 and polyclonal antibody to 
GKN-2 were obtained as shown in Table 4.6.  Additional antibodies and reagents 
were obtained as shown in Table 4.7.  Indirect immunofluorescence: Primary 
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antibodies to insulin and glucagon and species-specific, fluorophore-conjugated 
secondary antibodies were obtained as shown in Table 4.8. 
 
Scoring system 
Sections subjected to immunohistochemistry were examined by bright-field 
microscopy (Nikon Eclipse E600 microscope equipped with Nikon plan lenses and Q 
Imaging MicroPublisher 5.0 RTV digital camera) and all staining compared to that 
for positive control sections for each run.  Staining was assessed using a system 
modified from scales routinely used in diagnostic histopathology [757].  Two 
parameters were assessed for each section: staining intensity and staining distribution.  
Staining intensity was semi-quantitatively graded negative, weakly, moderately or 
strongly positive and staining distribution was semi-quantitatively graded as absent, 
rare (<25% of a given structure showing positive staining), patchy (25-75% of a 
given structure showing positive staining) or widespread (>75% showing positive 
staining).  These grades were given number codes as for TFF mRNA assessment 
described for ISH above, and scores for both parameters added together to give an 
overall staining score.  Slides were examined and scored by at least two independent 
observers and average staining scores were calculated for each group, rounded to the 
nearest whole number and assigned a final grade as before. 
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Table 4.6:  Primary antibodies used to investigate the co-localization of TFFs and 
mucins in FFPE human pancreatic tissues by indirect avidin/biotin/HRP IHC 
 
Antibody Details Source Dilution Positive 
control 
TFF1 pS2, 28aa immunizing 
peptide; Clone GE2 
MM IgG1. Ref: [758] 
George Elia, 
CRUK 
1:400 C Stomach 
TFF2 SP, clone GE16C 
ab49536 
Specific to C-terminal 
epitope 
MM, IgM lyophilized 
1.4mg/ml or 
culture supernatant 
Ref: [759] 
George Elia, 
CRUK/ 
AbCam 
1:10 E/1:50 C Stomach 
TFF3 H00007033-MO1 
Clone 3D9 
Immunizing peptide 
aa15-74; MM IgG1 
AbNova 1:300 C small intestine 
colon 
GKN-2 RP anti-human blottin 
0.45mg/ml.  
Ref: [641] 
Bill Otto, 
CRUK 
1:200 C Stomach 
MUC-1 NCL-MUC-1 
Clone Ma695 
Specific to human 
carbohydrate epitope 
MM IgG1 
Novocastra 1:100 C normal 
pancreas 
MUC-2 NCL-MUC-2 
Clone Ccp58 
Specific to human 
MM IgG1 
Novocastra 1:100 C small intestine 
colon 
MUC-5AC NCL-MUC-5AC 
Clone CLH2 
Specific to human 
MM IgG1 
Novocastra 1:50 Stomach 
MUC-6 NCL-MUC-6 
Clone CLH5; IgG1 
Specific to human 
Novocastra 1:50 Stomach 
CK19 M0888 
Clone RCK108 
MM IgG1 kappa 
Dako 1:200 C normal 
pancreas 
 
All controls consisted of human FFPE material. (MM mouse monoclonal; RP rabbit 
polyclonal; C HIER with sodium citrate pH6.0; E = HIER with 1mM EDTA pH 8.0) 
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Table 4.7:  Secondary antibodies and other reagents used in avidin/biotin/HRP 
immunohistochemistry 
 
Reagent/antibody Details Source Dilution 
Normal rabbit serum Cat. #10510 Invitrogen 1:25 
Normal swine serum X0901 119g/L DAKO 1:25 
Rabbit anti-mouse 
biotinylated IgG 
E0354 DAKO 1:300 
Swine anti-rabbit 
biotinylated IgG 
E0353 DAKO 1:300 
Streptavidin/horseradish 
peroxidase (HRP) 
P0397 DAKO 1:500 
DAB Vector IMMPACT 
DAB substrate 
Vector According to 
manufacturer’s 
instructions 
PBS/Tween 20 0.05% Tween 20 in 
0.01M phosphate-
buffered 0.9% NaCl 
pH 7.4 
Prepared by 
CRUK 
laboratories 
n/a 
 
 
Table 4.8:  Reagents used in indirect immunofluorescence.   
 
Reagent/antibody Details Source Dilution Positive 
control 
Insulin Anti-human RP 
ab65454 
AbCam 1:10 C Normal 
pancreas 
Glucagon Anti-human RP 
ab9379 
AbCam 1:50 C Normal 
pancreas 
TFF3 H00007033-MO1 
Clone 3D9, MM 
AbNova 1:300 C Colon 
Insulin/glucagon 
secondary 
Goat anti-rabbit 
AF647/FITC 
Molecular 
Probes 
1:100 n/a 
TFF3 secondary Goat anti-mouse 
AF555/Cy3 
Molecular 
Probes 
1:100 n/a 
Aqueous 
mountant and 
counterstain 
VectaShield Hard 
Set with DAPI 
Vector n/a n/a 
 
MM mouse monoclonal; RP rabbit polyclonal; C HIER with sodium citrate pH6.0; 
n/a not applicable.
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4.2.3 Assessment of the effect of TFF peptides on wound healing 
 
A scratch assay technique was devised to evaluate the effect of TFF2 and TFF3 on 
wound healing rates of hPDAC cell line monolayers in vitro.  Responses of these 
lines to EGF were also assessed, as the motogenic activity of TFFs may be linked to 
the ability of cells to respond to this motogenic growth factor [688].  The human 
colonic carcinoma cell line HT29 is known exhibit enhanced wound-healing in 
response to TFFs and EGF in vitro [671] and was used as a positive control. 
 
Cells 
Four hPDAC cell lines: Capan-2, COLO357, Panc-1 and Psn1 (as detailed in Chapter 
2), and one human colonic carcinoma cell line, HT29, were obtained from the CRUK 
Histopathology Laboratory Cell Bank.  Cells were maintained in routine monolayer 
culture as described in Chapter 2; HT29 cells were maintained in DMEM/10% FCS.  
As RPMI-1640 culture medium contains the reducing agent glutathione, which may 
potentially affect the disulphide bonds crucial to maintaining conformation of the 
trefoil domain [686], Capan-2 cells were adapted from routine culture in RPMI/15% 
FCS (A) to DMEM/10% FCS (B) over a period of 10 days by incrementally reducing 
the fraction of medium A and increasing the fraction of medium B until transition to 
100% medium B was achieved.  Growth was observed for a further 4 days to ensure 
that growth characteristics were unchanged.   
 
For optimization experiments, PDAC cell lines were used up to passage 39 and HT29 
up to passage 20.  Cultures with low passage numbers (Capan-2 and COLO357 up to 
passage 20 and HT29 up to passage 6) were used for final time-lapse experiments. 
 
Scratch assay 
Confluent cultures were removed from the flask base with trypsin/versene as 
described in Chapter 2 and seeded at high density in DMEM/10% FCS to give 
confluent monolayers in 24-well tissue culture plates (Falcon) within 24 hours using 
routine incubation.  Cultures were then serum-starved in migration medium 
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(DMEM/0.2% FCS for time-lapse, DMEM/1% FCS or DMEM/0.2% FCS for 
optimization experiments) for a further 18-24 hours. 
 
Preliminary optimization studies (Table 4.9) were performed to assess migration in 
response to wounding in these cell lines in the presence of low concentrations of 
FCS.  Cultures were washed in serum-free DMEM and a sterile 200µl pipette tip and 
a ruler used to make uniform, straight-edged wounds across the centre of each well.  
Each well was then rinsed twice in serum-free DMEM to remove floating cells and 
debris and 500µl of sterile-filtered migration medium added.  Cells were then allowed 
to migrate under routine incubation conditions for the times shown in Table 4.9.  
Plates were examined using an Olympus IMT-2 inverted phase contrast microscope 
equipped with a calibrated stage-mounted plate reader and Optronics digital camera 
(SNBG6024254-H).  A segment of wound was selected and photographed for each 
well immediately following scratching and the stage position noted.  The plate was 
returned to routine incubation until the next time point, then re-fitted to the plate 
reader and returned to the position recorded for the previous time point and re-
photographed.  Image capture was performed using MagnaFire 2.0 (Karl Storz 
Imaging) running on a Mac G4 PowerPC (OS X 10.2.8) and images stored as 
monochrome .tif files.  
 
Table 4.9:   Preliminary optimization experiments to titrate the effect of FCS on 
migration of human pancreatic cell lines 
 
Experiment Cell Lines Treatments Time Points Replicates 
Opt. 1 COLO357 
Panc-1  
Psn1 
1% FCS 0, 22, 72h 3 
Opt. 2 COLO357 
Psn1 
1% FCS 0, 4, 72, 96h 3 
Opt. 3 Capan-2 
Panc-1 
0.2% FCS 
1% FCS 
0, 4, 24, 48h 3 
Opt. 4 Capan-2 
COLO357 
hPSCs 
Panc-1 
Psn1 
0.2% FCS 
1% FCS 
0, 24, 48, 72h 3 
 287
Once base-line migration speeds and an optimal FCS concentration for evaluating 
migration were established, time-lapse experiments were performed to assess the 
effect of EGF, TFF2 and TFF3 on wound-healing rates on selected cell lines.  
Confluent cultures were serum-starved, scratched and rinsed as before, and 500µl of 
sterile-filtered migration medium supplemented with human recombinant EGF, non-
glycosylated human recombinant TFF2, human recombinant TFF3 monomer or 
vehicle added (Tables 4.10 and 4.11).  Sections of syringe driver were placed at the 
plate margins to raise the plate lid slightly and the lid sealed with autoclave tape.  A 
small vent was made in the lid above an empty well using a red-hot needle, to allow 
fitting of a CO2 supply nozzle which was attached and sealed using electrical tape. 
 
Migration was recorded using a Zeiss Axiovert 135TV microscope fitted with 
motorized stage controls (Marzhauser Motorized XY stage and Prior ProScan 
Motorized Z), and with a thermostatically regulated cabinet set to 37ºC with 10% 
CO2 in air directly injected into the plate, replicating routine incubation conditions.   
Using a 5× phase contrast objective with an NA of 0.15, 1× optivar and a phase 
contrast ring (Sutter Lambda10-2 filter wheel), up to 10 positions were captured for 
each well using MetaMorph (Universal Imaging Corp, USA) Version 6.3r6 imaging 
software and Hamamatsu Orca ER CCD camera (model C4742-95-12ER) and 
recorded as coded files to enable blind assessment during analysis.  Exposures of 
100ms were taken for each position at 30 minute intervals for 48 hours, with 
transmitted light only switched on for the duration of the exposure.   
 
Table 4.10:  Peptides assessed for motogenic activity in wound-healing and transwell 
migration assays 
 
Compound Details Formulation Source 
EGF Human recombinant 
 
0.76 µg/ml in 
PBSA 
Cuba Biotech 
 
TFF2 Human recombinant, non-
glycosylated  
1mM in PBSA Lars Thim, Novo 
Nordisk 
TFF3 Human recombinant, monomer 1mM in PBSA Lars Thim, Novo 
Nordisk 
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Table 4.11:  Design of time-lapse wound-healing experiments to assess motogenic 
activity of EGF, TFF2 and TFF3 on human pancreatic cell lines 
 
Expt. Treatment 
(final concentration in DMEM/0.2% 
FCS) 
Cell lines Replicates/ 
treatment 
(wells) 
Segments/ 
replicate 
recorded 
EGF  TFF2 TFF3 control 
Opt.1 
(TL1) 
ND ND ND MM Capan-2 
COLO357 
hPSCs 
HT29 
Panc-1 
3 2 
Opt .2 
(TL2) 
1ng/ml 
10ng/ml 
100ng/ml 
600ng/ml 
0.1µM 
1µM 
5µM 
10µM 
ND vehicle HT29 1 2 
Opt .3 
(TL3) 
1ng/ml 
10ng/ml 
100ng/ml 
600ng/ml 
0.1µM 
1µM 
5µM 
10µM 
ND vehicle Capan-2 
HT29 
1 2 
Opt .4 
(TL4) 
1ng/ml 
10ng/ml 
100ng/ml 
0.1µM 
1µM 
10µM 
ND vehicle Capan-2 
COLO357 
HT29 
1 4 
Final (TL5) 10ng/ml 1µM 
10µM 
2µM vehicle Capan-2 
COLO357 
HT29 
3 
3 
1 
2 
2 
4 
 
ND = not done, MM = DMEM/0.2% FCS migration medium alone. 
 
 
Time-lapse image analysis and data collection 
MetaMorph image analysis software (Universal Imaging, USA; V6.1) was used to 
collate and convert stacks of .tif files for each saved stage position into video files.  
Microsoft1 compression was applied at the highest quality and 16 second .avi files 
with a frame rate of 5× second/300 produced.  These videos were used to assess 
which wound segments were appropriate for data collection (i.e. straight, horizontal, 
un-obscured) and to decide the time frame to be analyzed based on wound closure 
times. 
 
TIF image files were selected at 3 hour intervals for each position selected and loaded 
into the open-source image analysis program ImageJ (obtained from the National 
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Institute of Health website at http://rsbweb.nih.gov/ij/).  A standardized field 
measuring 506×332 pixels was cropped from an identical area of each original image 
for each position and the cell free area measured using the polygon select tool.  The 
cell-free area calculated for subsequent frames was subtracted from the cell-free area 
of the initial frame of a series (T0) to give a “wound closure” value in pixels (cell-
free area at T0 minus cell-free area at Tx) in a protocol adapted from Oertel et al. 
2001 [668].  The average wound closure values for each treatment were plotted 
against time using MS Excel 2003 (Microsoft) and shown ± standard deviation.  
Student’s two-tailed t tests for paired samples were performed to assess the 
significance of the findings. 
 
4.2.4 Assessment of the effects of TFFs on invasion and directional migration 
Cells 
Cultures of 2 human PDAC lines; Panc-1 and COLO357 were maintained as 
monolayers as described previously.  Human pancreatic stellate cells were isolated by 
Drs Osamu Inatomi and Wey-Ran Lin from macroscopically normal human 
pancreatic tissue obtained from therapeutic hPDAC resections.  Pancreatic tissue was 
supplied by Mr Hemant Kocher (The Royal London Hospital, Whitechapel) under the 
conditions of REC reference number 2006/Q0601/33, with ethical approval granted 
by the Redbridge and Waltham Forest Local REC.  Stellate cells were isolated using 
a modification of the protocol detailed by Saotome and co-authors [760] as outlined 
briefly below, and stellate cell identity confirmed by immunophenotyping.  Briefly, 
resected pancreatic tissue was minced using sterile razor blades in Hank’s Balanced 
Salt Solution (HBSS; prepared in-house at CRUK), then 10ml HBSS containing 5mg 
dispase (Roche; Cat. No. 11 284 908 001), 5mg collagenase (Sigma C5138; type 4 
collagenase) and 0.1mg DNAse (Roche; Cat. No. 11 284 932 001) was injected into 
the fragments using a sterile 27G needle and syringe.  Specimens were then shaken 
for 30 minutes at 37ºC, centrifuged for 5 minutes at 400rpm and the supernatant 
removed.  The supernatant was then spin-washed twice for 5 minutes at 2000rpm in 
DMEM/10% FCS (see Chapter 3 for details) and seeded into 25cm2 tissue culture 
flasks.  The remaining undigested tissue was then further incubated with 10ml HBSS 
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containing 5mg dispase and 0.1mg DNAse (as before) for 30 minutes at 37ºC then 
filtered through a 150µm sterile nylon mesh and centrifuged at 400rpm and the 
supernatant collected, spin-washed twice as before and seeded into separate 25cm2 
tissue culture flasks.  hPSCs were then cultured in DMEM/10% FCS for no more 
than 6 passages before being discarded.  Immunophenotyping was carried out to 
confirm stellate cell identity using antibodies to α-smooth muscle actin, desmin, 
vimentin and glial fibrillary acidic protein (GFAP) according to Protocols 2.1 and 2.2 
in Chapter 2.  Cultures were grown to confluence then serum-starved in DMEM/0.2% 
FCS for 24 hours prior to use.  Panc-1 and HT29 cells were used up to passage 25, 
COLO357 to passage 9 and hPSCs to passage 6. 
 
Collagen coating of transwell inserts 
Costar transwell inserts (24-well plate format track-etched polycarbonate, 8µm pore 
size) were purchased from Corning.  Inserts were treated on the underside with type I 
collagen (5mg/ml rat tail collagen in 10mM acetic acid stock diluted as necessary 
with sterile-filtered 10mM acetic acid) or acetic acid alone as shown in Table 4.10 for 
120 minutes at 37ºC, rinsed in sterile PBSA, dried in a laminar flow cabinet and kept 
sealed and refrigerated at 4ºC until use.  The appropriate collagen treatment was 
marked on each insert using a permanent marker (Sharpie). 
 
Migration assay 
500µl of DMEM/0.2% FCS supplemented with EGF, TFF2, TFF3 or vehicle as 
shown in Tables 4.11 and 4.12 was added to each well of a sterile 24-well plate 
(Falcon) in duplicate and plates pre-warmed in tissue culture incubators until use.  
Appropriately labelled transwell inserts were placed into wells containing migration 
medium, then tilted slightly to ensure that no bubbles remained trapped underneath.  
Plates were covered and placed in tissue culture incubators at 37ºC until use. 
 
Cells were removed from flasks as usual, substituting 1:1 T/V diluted 1:10 in EDTA 
for 1:1 T/V and quenching in DMEM/0.2%FCS to prevent damage and minimize 
serum exposure.  Single cell suspensions were adjusted to give the cell densities 
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shown in Table 4.12 and 100µl aliquots added to the upper compartment of each 
transwell insert.  Plates were replaced into routine incubators and cells allowed to 
migrate for the times shown in Table 4.12. 
 
Plates were then removed from the incubator, medium aspirated, inserts washed 
gently with PBSA to remove non-adherent cells and a swab used to remove non-
migrated cells from the upper side of the membrane.  Membranes were then fixed in 
4% PFA for 15 minutes at room temperature, rinsed in distilled water and stained in 
filtered 10% Mayer’s haematoxylin for 10 minutes.  Membranes were then blued in 
tap water, rinsed in distilled water, then placed into 24-well plates containing distilled 
water for photography. 
 
Table 4.12:  Design of transwell experiments to assess directional motogenic activity 
of EGF, TFF2 and TFF3 on human pancreatic cell lines  
 
Ex. Treatment 
 
Cell line Replicates 
 
Duration 
(hours) 
EGF TFF2 TFF3 control  cells  
seeded 
* 
  
1 ND ND ND MiM Panc-1 
hPSCs 
1×104, 
5×104, 
1×105 
A, C 
A, C 
4, 24 
4, 24 
2 ND ND ND MiM Panc-1 
HT29 
hPSCs 
5×104, 
1×105 
A, C 
A, C 
A, C 
6, 12, 24 
6, 12, 24 
6, 12, 24 
3 ND ND ND MiM Panc-1 
hPSCs 
HT29 
5×104 A, B, C 
A, B, C 
A, B, C 
6, 12 
12, 24 
12, 24 
4 1ng/ml 
10ng/ml 
2µM 
10µM 
ND vehicle Panc-1 
hPSCs 
5×104 2 A, B, C 
2 A, C 
4 
8 
5 10ng/ml 2µM 
10µM 
2µM vehicle Panc-1 5×104 4 A, B 4 
10ng/ml 2µM 
10µM 
ND vehicle COLO357 5×104 4 A, B 4 
1ng/ml 2µM 
10µM 
2µM vehicle hPSCs 5×104 4 A, C 
 
8 
 
Key:  
A no collagen (acetic acid only)  * number of cells in 100µl MiM 
B 5µg/ml collagen coating  MiM migration medium  
C 10µg/ml collagen coating  ND not done 
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Data collection and analysis 
Membranes were photographed in situ using bright-field illumination on an inverted 
Olympus IMT-2 phase contrast microscope equipped with S plan (4×/0.13, 10×/0.30) 
and LWD CD Plan objectives (20×/0.40 20PL, 40×/0.60 40PL), phase contrast unit 
(ULWCD 0.30) and Optronics camera (as before).  Ten randomly selected fields were 
photographed at 200× magnification (20× objective, 1× optivar) in colour and stored 
as .tif files using MagnaFire running on a Macintosh G4 PowerPC (as before).  
Photographs were then loaded into MS Paint (Microsoft) and cell nuclei manually 
marked and counted on each image.  The average numbers of migrated cells present 
per 10 fields were plotted for each treatment using MS Excel as before and errors 
presented as ± standard deviation.   Student’s two-tailed t tests were performed to 
assess the significance of the results obtained. 
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4.3 RESULTS 
4.3.1 Isotopic in situ hybridization 
In control tissues, intense expression of TFF1 and GKN-2 mRNAs was seen in 
superficial and foveolar stomach epithelium, whilst high expression of TFF2 was 
seen extending further into the gastric glands and in Brunner’s glands of the 
duodenum, as expected.  TFF3 expression was not detected in the stomach, but was 
seen in a gastric ulcer bed containing UACL (Figures 4.1a, 4.1b). 
 
In general, normal pancreata showed weak-moderate expression of TFF1 and 2 
mRNAs in the ductal compartment (Figures 4.2a, 4.2b), whilst TFF3 expression was 
seen rarely and at low levels in both ducts and islets (Figures 4.2a, 4.2b, 4.2c).  In CP, 
frequent moderate-strong expression of TFF1, 2 and 3 mRNAs was seen in inflamed 
ducts, with rare weak TFF3 expression in islets (Figures 4.3a, 4.3b, 4.3d, 4.4d).  
Expression of all three TFF mRNAs remained high in PDAC, with expression highest 
in well-differentiated areas and lowest in poorly differentiated areas of tumour 
(Figures 4.4a, 4.4b, 4.4c).  Glucagonoma (Figure 4.5) and insulinoma showed weak 
peripheral expression of TFF1 and TFF3 mRNAs but neuroendocrine tumours were 
generally negative for all peptides.  Incidental PanIN-1 (mucinous metaplasia and 
hyperplasia without dysplasia) showed variable expression of TFF1 and TFF2 
mRNAs but were largely negative for TFF3 (Figure 4.3c).  GKN2 mRNA expression 
was extremely rare and therefore differences between pathological conditions were 
unable to be assessed.  These data are summarized in Table 4.13 below. 
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Figure 4.1a:  Expression of TFF1, 2 and 3 and GKN-2 mRNA in normal human 
stomach  
 
 
 
 
Isotopic in-situ hybridization of formalin-fixed, paraffin embedded human stomach.  
Labelled probe is revealed by autoradiographic silver which shows black using 
transmitted light.  Original magnification 100×. 
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Figure 4.1b:  Expression of TFF1, 2 and 3 and GKN-2 mRNA in human gut   
 
 
 
Isotopic in-situ hybridization of formalin-fixed, paraffin embedded human tissues.  
TFF1 is shown in normal stomach, TFF2 in Brunner’s glands of the duodenum, TFF3 
in UACL (outlined in orange) adjacent to a gastric ulcer and GKN-2 in normal 
stomach.  Labelled probe is revealed by autoradiographic silver which shows black 
on bright-field (left hand side) and white on dark-field (right hand side) microscopy.  
Original magnifications: TFF1, GKN-2 = 100×, TFF2 = 50×, TFF3 = 200×. 
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Table 4.13:   Summary of expression of TFF1, 2 and 3 and GKN-2 in human 
pancreatic tissue 
 
Ductal Compartment (including tumour) 
Group ISH IHC 
TFF1 TFF2 TFF3 GKN2 TFF3 
Normal  
(n=5) 
+     (2.3) 
* 
+       (2.6) 
* 
+      (0.8) 
** 
- + 
Apical 
Chronic 
pancreatitis 
(n=5) 
++   (4.5) 
*** 
++     (3.7) 
*** 
++    (4.0) 
*** 
- ++ 
Cytoplasmic 
Ductal 
adenocarcinoma 
(n=6) 
+++ (5.5) 
**** 
+++   (4.7) 
**** 
++    (4.2) 
**** 
- +++ 
Cytoplasmic 
Neuroendocrine 
tumours 
(n=6) 
n/a n/a n/a n/a n/a 
Islet Compartment (including tumour) 
Group ISH IHC 
TFF1 TFF2 TFF3 GKN2 
 
TFF3 
Normal  
(n=5) 
- - + (0.8) - +++ 
Cytoplasmic 
Chronic 
pancreatitis 
(n=5) 
- - + (1.0) - +++ 
Cytoplasmic 
Ductal 
adenocarcinoma 
(n=6) 
n/a n/a n/a n/a n/a 
Neuroendocrine 
tumours 
(n=6) 
- - + (1.0) 
**** 
- +/++ 
Cytoplasmic 
 
Symbol scores were allocated according to mean derived numeric scores (bracketed) 
for each group using the scoring schemes detailed in sections 4.2.1 and 4.2.2 above. * 
= interlobular and large ducts; ** = larger ducts, especially branches; *** = ductular 
complexes and larger ducts; **** = tumour. 
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In normal pancreata, TFF1 mRNA expression was seen in 5 of 5 cases.  This 
expression was seen in large and medium sized ducts (main, interlobular and largest 
intralobular) comprised of cuboidal or low columnar epithelium, but absent from 
smaller intralobular and intercalated ducts (Figures 4.2a, 4.2b).  TFF2 mRNA 
expression was seen in 4 of 5 cases, with a distribution similar to that of TFF1 
(Figures 4.2a, 4.2b).  TFF3 mRNA expression was seen at low levels in 3 of 5 cases, 
mostly at what appeared to be branch points of large ducts, with expression in 
interlobular ducts seen in only one case (Figures 4.2a, 4.2b).  In 2 of 5 cases, weak 
TFF3 mRNA expression was also detected in occasional islets (Figure 4.2c).  No TFF 
expression was seen in acinar cells and GKN-2 mRNA was not detected in any 
section.  In contrast to the pattern of mRNA expression revealed by ISH, IHC for 
TFF3 showed a large fraction of cells within almost all islets in 5 of 5 cases 
exhibiting moderate-strong staining, with a subset of cells showing no 
immunoreactivity.  These TFF3-positive cells were typically scattered throughout the 
islet (Figures 4.2c, 4.2d).  Superficial apical TFF3 immunostaining was seen in a 
small number of ducts, largely reflecting the distribution of mRNA expression 
(Figures 4.2b, 4.2c, 4.2d).  However, some ducts exhibiting papillary, columnar 
epithelia showed strong apical cytoplasmic immunostaining with TFF3 (Figure 4.2d).  
 
In CP, 5 of 5 cases showed high expression of all TFF mRNAs in reactive ductular 
complexes, most prominently in ducts showing low or tall columnar epithelial 
morphology and/or budding from large interlobular ducts (Figures 4.3a and 4.3b).  
Ducts showing papillary, tall columnar epithelium (probably mucinous metaplasia 
analogous to PanIN-1) showed increased TFF1 mRNA expression in these papillary 
regions (Figure 4.3c).  Numerous large, cribriform, hyperplastic islets were seen in 
several sections: however, islet TFF3 mRNA expression was rarely detected, at low 
levels similar to those seen in normal islets (Figure 4.3d).  Acinar tissue was largely 
absent or atrophic, but where present showed no expression of any trefoil peptide 
mRNA.  No GKN-2 mRNA expression was seen in any section.  Apical and 
cytoplasmic TFF3 immunostaining was seen in the ductal compartment, reflecting the 
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pattern of mRNA expression.  TFF3 immunostaining of hyperplastic islets exhibited 
similar intensity and distribution to that of normal islets. 
   
In 6 of 6 PDAC cases, variable but generally high expression of all TFF mRNAs was 
seen in both primary and metastatic areas of tumour (Figures 4.4a, 4.4b, 4.4c) 
including areas of peri-neural and lymph node invasion (Figure 4.4c).  TFF1 and 2 
expression was higher than TFF3 in all cases, with expression of all TFF mRNAs 
highest in well-differentiated areas of tumour with well-organized lumen formation; 
in poorly differentiated areas demonstrating high pleomorphism or anaplasia 
expression was often low or absent.  Highest TFF3 expression was seen in areas of 
goblet cell differentiation (Figure 4.4b).  Areas of CP adjacent to tumour showed very 
high expression of all three TFF mRNAs in the 2 of 6 cases where present (Figure 
4.4d).  TFF3 IHC showed variable apical and cytoplasmic staining of tumour tissue, 
largely reflecting mRNA expression patterns.  This staining was especially intense in 
areas of goblet cell differentiation (Figure 4.4b).  GKN-2 mRNA was rarely detected 
in scattered, possibly inflammatory cells (Figures 4.4b, 4.4c).  
 
The neuroendocrine tumours were a mixed bag of islet cell tumours.  Weak 
expression of TFF1 mRNA was seen at the tumour periphery in sections of 
glucagonoma (Figure 4.5a) and insulinoma.  Expression of TFF1 and 2 was 
occasionally seen in regular, duct-like structures within the main tumour masses for 
all cases; thought to correspond to entrapped residual interlobular ducts.  Individual 
cells exhibiting strong cytoplasmic TFF3 immunostaining were seen in scattered 
clumps within the main tumour mass and at the periphery of the insulinoma and 
glucagonoma (Figure 4.5b).  
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Figure 4.2a:  Expression of TFF 1, 2 and 3 in normal human pancreatic ducts   
 
 
 
Patchy moderate expression of TFF1 mRNA is seen in this large duct, with diffuse 
strong expression in its branches.  Focal moderate TFF2 and very focal, very weak 
expression of TFF3 mRNA expression are seen in some branches (arrows).  TFF3 
IHC is negative apart from a small islet of Langerhans, seen centre left.  Original 
magnification 100×. 
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Figure 4.2b: Expression of TFF1, 2 and 3 and GKN-2 in normal human pancreatic 
ducts.  
 
 
Patchy moderate expression of TFF1 mRNA and focal weak expression of TFF3 
mRNA and protein is seen in this large duct, most prominently where smaller 
branches bud from it.  Unusually, strong diffuse TFF2 expression is seen throughout 
this duct.  No GKN-2 is seen.  TFF3 immunostaining is seen apically in the 
epithelium of the large duct and its branches.  Original magnification 100×. 
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Figure 4.2c:  Expression of TFF1, 2 and 3 in normal human islets of Langerhans 
 
 
 
Moderate TFF1 and weak expression of TFF2 and 3 can be seen in a small 
interlobular duct (outlined in yellow).  Weak expression of TFF3 but not TFF1 and 2 
mRNA can be seen in an islet of Langerhans (outlined in orange).  TFF3 IHC shows 
moderate-strong staining in a subset of cells in all islets, but no staining in ducts.  
Original magnification 200×. 
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Figure 4.2d: Distribution of TFF3 immunostaining in normal pancreas   
 
 
Interlobular ducts showing cuboidal epithelium were negative or occasionally showed 
apical staining (arrows; A, B, C).  Ducts showing low columnar or tall columnar 
epithelia occasionally showed cytoplasmic staining (A, B).  Islets typically showed 
heterogeneous staining for TFF3 (C; outline in orange).  Original magnification 
200×. 
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Figure 4.3a:  Expression of TFF1, 2 and 3 and GKN-2 in chronic pancreatitis 
 
 
Widespread moderate-strong expression of all three TFFs is seen throughout an 
inflamed patch of ducts, particularly in regions of possible mucinous metaplasia 
(insert and arrows).  TFF3 IHC shows strong diffuse cytoplasmic staining throughout 
the ductal epithelium.  GKN-2 expression is absent.  Original magnification 100×. 
GKN-2 
TFF3 
TFF2 
TFF3 IHC 
TFF1 
H&E 
GKN-2 
TFF3 
TFF2 
TFF1 
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Figure 4.3b: Expression of TFF1, 2 and 3 and GKN-2 in chronic pancreatitis   
 
 
 
In this inflamed large duct, smaller reactive branching ducts show widespread 
moderate-strong expression of all TFF mRNAs but no GKN-2.  TFF3 IHC shows 
strong diffuse cytoplasmic staining of all of the branching ducts.  Original 
magnification100×. 
GKN-2 GKN-2 
TFF3 
TFF2 
TFF1 
H&E 
TFF3 
TFF2 
TFF1 
TFF3 IHC 
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Figure 4.3c:  Expression of TFF 1, 2 and 3 in PanIN-1   
 
 
 
Strong diffuse TFF1 and focal weak TFF2 mRNA expression are seen in this 
papillary ductal lesion, whilst no TFF3 mRNA is seen.  TFF3 IHC shows patchy 
positivity.  Original magnification 100×. 
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Figure 4.3d:  Expression of TFF3 mRNA in islets of normal pancreas and CP   
 
 
 
Rare islets in normal and inflamed pancreata showed weak TFF3 expression.  Top 
row normal; bottom row CP; A, D H&E; B, E bright field (mRNA black); C, F dark 
field (mRNA white); islets outlined in orange. Original magnifications: A-C 200×, D-
F 100×. 
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Figure 4.4a:  Expression of TFF1, 2 and 3 and GKN-2 in invasive PDAC 
 
 
 
Moderate-strong diffuse expression of TFF1 and 2 mRNA and patchy weak 
expression of TFF3 mRNA is seen within infiltrating tumour.  Patchy moderate-
strong cytoplasmic TFF3 immunostaining is also seen.  Original magnification 100×. 
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Figure 4.4b:  Expression of TFF1, 2 and 3 and GKN-2 (blottin) in invasive PDAC 
showing goblet cell differentiation   
 
 
 
Patchy moderate TFF1, focal moderate TFF2 and focal strong TFF3 expression are 
seen in this section.  TFF3 immunostaining correlates with areas of goblet cell 
differentiation (arrowed).  Scattered non-epithelial cells show GKN-2 expression.  
Original magnification 100×. 
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Figure 4.4c:  Expression of TFF1, 2 and 3 and GKN-2 in metastatic PDAC  
 
 
 
Strong diffuse expression of TFF1 and focal-patchy weak-moderate expression of 
TFF2 and 3 mRNA is seen in tumour deposits within a lymph node.  Scattered non-
epithelial cells show GKN-2 expression.  TFF3 ISH shows patchy strong staining of 
the tumour deposit.  Original magnification 100×. 
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Figure 4.4d: Expression of TFF1, 2 and 3 in CP adjacent to PDAC   
 
 
 
Diffuse strong expression of TFF1, 2 and 3 mRNAs is seen in ductular complexes of 
CP seen adjacent to tumour (not seen).  Original magnification = 100×. 
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Figure 4.5a: Expression of TFF1, 2 and 3 and GKN-2 mRNA in glucagonoma 
 
 
 
Chronically inflamed ducts (double arrows) show moderate-strong diffuse expression 
of TFF1 and 2 and focal moderate expression of TFF3 mRNA.  An area of invasive 
tumour (single arrow) shows diffuse weak expression of TFF1 and scattered non-
epithelial cells show expression of GKN-2.  Moderate cytoplasmic TFF3 
immunostaining is seen in inflamed ductal epithelium (double arrows).  Original 
magnification = 200×. 
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Figure 4.5b:  TFF3 immunostaining of neuroendocrine tumours   
 
 
 
Scattered cells with strongly staining cytoplasm are seen in glucagonoma (A, B) and 
insulinoma (C, D), resembling the positively staining cells seen in normal islets. 
Original magnification:  A, C 200×, B, D 400×.
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4.3.2 Immunohistochemistry 
 
The potential expression of TFF3 in monolayer cultures of hPDAC cells and the 
colonic cell line HT29, which is known to be capable of expressing TFF3 in vitro 
{Gouyer, 2001 #48}, was investigated by indirect immunohistochemistry.  No 
positive staining for TFF3 was seen in any cell culture, including the HT29 control.  
 
In the series performed concurrently with ISH, strong staining for TFF3 was seen in 
human salivary gland and colon control sections (Figures 4.6 and 4.7).  The 
distribution of immunostaining for TFF3 in human pancreatic tissues largely mirrored 
the patterns of mRNA expression seen in the ductal compartment using ISH (Figures 
4.2-4.5).  Cuboidal or low columnar ductal epithelia in normal pancreata showed 
superficial apical staining with TFF3, whilst more papillary areas additionally 
showed staining of the apical cytoplasm (Figures 4.2a-d).  However, in contrast to 
ISH, strong staining of a large subset of cells was seen in all islets in 5 of 5 normal 
and 5 of 5 CP specimens (Figures 4.2c, 4.2d, 4.3d).  Frequent moderate-strong 
cytoplasmic staining of ducts was seen in CP, with similar widespread staining in 
islets to that seen in normal tissue (Figure 4.3a, 4.3b).  Widespread moderate-strong 
cytoplasmic staining of well-differentiated areas of PDAC was seen (Figures 4.4a-c), 
with staining particularly prominent in areas of goblet cell differentiation (Figure 
4.4b).  Poorly differentiated areas of tumour showed weak or negative 
immunoreactivity.  Scattered strongly positive cells were seen in insulinoma and 
glucagonoma (Figure 4.5b).  Pre-absorption of the primary antibody with hTFF3 
peptide ablated staining in salivary gland controls and in sections of human pancreas 
(Figure 4.6). 
 
In the further, broader series, control tissues all exhibited clear positive 
immunostaining with antibodies to TFF1, 2 and 3, MUC-1, 2, 5AC and 6, as well as 
to CK19 (Figure 4.7).  In the “normal” pancreatic series, immunohistochemistry for 
mucins and TFFs on serial sections revealed widespread moderate-strong staining for 
MUC-1 throughout the ductal tree but no staining for MUC-2, MUC-5AC or MUC-6 
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(Figures 4.8a, 4.8b).  TFF1 and TFF3 staining was occasionally seen at low to 
moderate levels in intermediate and large ducts,  particularly at the branch points, but 
in general no positive ductal staining was seen (Figures 4.8a-d).  TFF1 staining was 
not present in islets and no significant TFF2 staining was seen in either ducts or islets.  
A large proportion of islet cells stained strongly for TFF3, and these were scattered 
throughout the islets as before.  No staining was seen with GKN-2. 
 
In CP sections, cytoplasmic staining for TFF1 and TFF3 increased in frequency and 
intensity in the ductal compartment, where moderate cytoplasmic TFF2 staining was 
additionally seen, in contrast to normal tissues (Figures 4.9a-d).  Moderate to strong 
cytoplasmic TFF3 staining continued to be seen in a subset of islet cells.  In ducts, 
MUC-1 staining decreased in frequency and intensity whilst, in contrast to normal 
tissues, weak-moderate MUC-6 staining was commonly present.  No staining was 
seen with MUC-2 or GKN-2 and MUC-5AC positivity was rarely seen (Figure 4.9b).  
 
Incidental PanIN-1, often in the form of Alcian Blue/diastase-Periodic Acid-Schiff’s 
(AB/dPAS)-positive mucinous metaplasia (Figures 4.3c, 4.10a-c, 4.11a; AB/PAS 
data not shown) was seen in sections of 6 “normal”, 3 CP, 4 PDAC cases and one 
neuroendocrine tumour case.  Strong staining with TFF1, and moderate staining with 
TFF2, TFF3 and MUC-5AC was commonly seen (Figures 4.10a, 4.11a), with 
occasional weak staining with MUC-1.  MUC-2, MUC-6, GKN-2 were uniformly 
negative, and 4 cases showed no staining with TFF2 (Figures 4.10b, 4.10c).   
 
Moderate staining with all TFFs was commonly seen in PDAC, with highest intensity 
seen in well-differentiated areas and poorly differentiated areas showing weaker or an 
absence of staining.  Moderate TFF1 and 3 staining was commonly seen in both 
primary tumours (Figure 4.11a, 4.11d) and metastases (Figures 4.11b, 4.11c).  About 
half of all cases showed weak-moderate staining with TFF2, with the rest negative.  
TFF1 largely exhibited a cytoplasmic staining pattern, but nuclear staining was 
occasionally seen (Figure 4.11b), whereas TFF2 and TFF3 showed solely 
cytoplasmic staining patterns.  Around 50% of cases also showed at least moderate 
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cytoplasmic staining with MUC-6, and all cases showed moderate-strong cytoplasmic 
staining with MUC-5 (Figures 4.11a-d).  Rarely, membranous staining with GKN-2 
was seen at the invading border of primary tumours (Figure 4.11d). 
 
Neuroendocrine tumours were negative for all antibodies except TFF3.  Scattered, 
polygonal cells with strong cytoplasmic TFF3 positivity were seen in glucagonoma, 
insulinoma (Figure 4.5b, 4.12), VIPoma and PNETs of unknown subtype.  Two 
neuroendocrine tumours of extra-pancreatic origin included erroneously (a lung 
carcinoid and a neuroendocrine tumour of intestinal origin) also showed a similar 
staining pattern.  One neuroendocrine tumour additionally showed focal staining with 
TFF1 at the periphery (Figure 4.12). 
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Figure 4.6: Pre-absorption of TFF3 mAb with hTFF3 monomer ablated positive 
immunostaining   
 
 
 
Sections of human pancreata and TFF3-expressing salivary glands were 
immunostained for TFF3 with or without the addition of hTFF3 peptide. 
Islets of Langerhans in normal human pancreas (left) and intestinal metaplasia of 
human sub-mandibular salivary gland (right) outlined in orange. Original 
magnification = 200×
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Figure 4.7: TFF1-3, MUC-1, 2, 5AC, 6 and CK19 immunostaining in normal human 
control tissues   
 
 
 
TFF1, TFF2, MUC-5AC, MUC-6 = stomach; TFF3, MUC-2 = colon; MUC-1 = lung; 
CK19 = pancreas.  The expression patterns of TFF1 and MUC-5AC were alike, as 
were those of TFF2/MUC-6, and TFF3/MUC-2.  Original magnification 200× 
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Figure 4.8a:  Immunostaining of normal human pancreas   
 
 
Smaller ducts 
were typically 
negative for 
TFFs1-3, MUC-
2, 5AC and 6, but 
showed strong 
positivity with 
MUC-1 and 
CK19.  Islets of 
Langerhans 
(arrowed) 
showed positive 
staining with 
TFF3 but no 
other antibody.  
Original 
magnification 
200× 
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Figure 4.8b:  Immunostaining of normal human pancreas   
 
 
 
Large interlobular and main ducts frequently showed weak-moderate staining with 
CK19, TFF1 and TFF3, mostly at branch points.  Staining with TFF2, MUC-1, 2, 
5AC and 6 was not seen.  Original magnification 200×
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Figure 4.8c:  Immunostaining of normal human pancreas   
 
 
 
This large duct shows a common staining pattern.  Moderate apical and cytoplasmic 
immunostaining is seen with TFF3, but not with TFF1, 2, MUC-2, 5AC or MUC-6.   
Islets of Langerhans are outlined in orange and show focal moderate staining with 
TFF3.  Original magnification 200×
 321
Figure 4.8d:  Immunostaining of normal human pancreas  
 
 
 
A large, interlobular duct showing very focal staining of goblet-type cells with TFF3 
(insert).   Equivocal/weak staining was seen with TFF1 but no staining is seen with 
any other antibody.  Original magnification 200× 
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Figure 4.9a:  Immunostaining of chronic pancreatitis   
 
 
A common 
pattern of focal 
staining with 
MUC-1, MUC-
6, TFF2 and 
TFF3 
(arrowed), and 
moderate-
strong staining 
with TFF1 can 
be seen in this 
region of 
inflamed ducts. 
 
 323
Figure 4.9b:  Immunostaining of chronic pancreatitis.   
 
 
 
This inflamed duct with numerous branch points exhibits typical moderate-strong 
staining with all three TFFs and MUC-6.  Unusually, MUC-5AC staining is also seen.  
Original magnification 100×
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Figure 4.9c:   Immunostaining of chronic pancreatitis.   
 
 
 
This cluster of reactive ducts shows a typical pattern of positive staining with all three 
TFFs and largely absent MUC-6 staining.  Original magnification 200×
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Figure 4.9d:  Immunostaining of chronic pancreatitis.   
 
 
 
This extensive ductular complex shows moderate staining with TFF1, 2, CK19 and 
MUC-6 and strong staining with TFF3.  MUC-1 positivity is focally seen in residual 
intralobular ducts (arrowed).  Original magnification 100× (x10 objective).
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Figure 4.10a:  Immunostaining of PanIN  
 
 
 
This region of low-grade, mucinous metaplasia-type PanIN in CP shows typically 
strong TFF1, weak-moderate TFF2 and 3 and focal MUC-5AC immunostaining.  
MUC-2 and MUC-6 were typically negative.  Original magnification 100× (x10 
objective).
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Figure 4.10b:  Immunostaining of PanIN 
 
 
 
This low-grade PanIN of a medium-sized duct in CP shows typically strong TFF1 
and moderate TFF3and MUC-5AC staining.  Original magnification 200× unless 
otherwise stated.
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Figure 4.10c:  Immunostaining of PanIN  
 
 
 
This PanIN in an otherwise normal pancreas is the same as that showing mRNA 
expression in Figure 4.3c and shows strong staining with TFF1, TFF3 and MUC-
5AC.  GKN-2, MUC-2, MUC-6 and TFF2 were not detected.  Original magnification 
200×
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Figure 4.11a:  Immunostaining of invasive PDAC  
 
 
 
This region of infiltrating ductal adenocarcinoma adjacent to an area of PanIN 
(arrowed) shows strong staining with TFF1, focal moderate staining with MUC-5AC, 
MUC-6 and TFF3, whilst MUC-1, MUC-2 and TFF2 are largely negative.  In 
contrast, diffuse moderate staining with TFF1, 2, 3 and MUC-6 are seen in the area of 
PanIN.  Original magnification 200× (×20 objective) unless indicated.
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Figure 4.11b:  Immunostaining of PDAC tracking along a nerve   
 
 
 
This CK19-positive tumour deposit surrounding an intra-pancreatic nerve (at the left 
of each panel) also stains strongly for TFF1 as well as focally for TFF3, MUC-5AC, 
MUC-1 and unusually, very focally for MUC-2.  MUC-6 and TFF2 are negative.  
Two islets of Langerhans showing typical strong patchy staining with TFF3 can be 
seen right and centre.  Original magnification 200× (×20 objective).
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Figure 4.11c:  Immunostaining of metastatic PDAC deposit in a lymph node   
 
 
 
This area of tumour invading a lymph node is the same as that showing mRNA 
expression in Figure 4c and shows a common pattern of TFF1, TFF3 and MUC-5AC 
positivity whilst showing no staining for TFF2 and MUC-6.  Unusually, focal strong 
staining with MUC-2 is seen in cells with a goblet phenotype (MUC-2; inset).  
Original magnification = 200× (×20 objective), except MUC-2 = 400× (×40 
objective). 
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Figure 4.11d:  Immunostaining of invasive PDAC 
 
 
 
This infiltrating tumour shows an unusual pattern of moderate TFF3 and GKN-2 
immunostaining but negativity with all other antibodies in the panel.  Original 
magnification 200× (×20 objective). 
 333
Figure 4.12:  Immunostaining of islet cell tumour of unknown subtype   
 
 
 
In this unusual example, scattered cells showing moderate staining with TFF1 and 
TFF3 can be seen at the invading edge.  This tumour was negative for MUC-1, 2, 
5AC, 6, TFF2 and GKN-2.  Original magnification 200× (×20 objective). 
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In summary, immunohistochemistry frequently detected low levels of TFF1 and 
TFF3 in normal pancreatic ducts, predominantly at the branch points of larger ducts, 
but TFF2 was very rarely detected (Figure 4.13).  This was in partial agreement with 
ISH, which occasionally detected low levels of all three TFFs in the ductal 
compartment of normal pancreata (Table 4.14).  In most normal islets, a majority of 
cells stained strongly with TFF3 (Figure 4.14), in contrast with ISH, where only 
occasional islets showed weak mRNA expression (Figure 4.2c, Table 4.14).  Smaller 
interlobular, intralobular and intercalated ducts of normal pancreata exhibited strong 
staining with MUC-1 but the ductal compartment showed no immunostaining with 
MUC-2, 5AC or 6 (Figure 4.13).  Ergo, MUC-5AC did not co-localize with TFF1 
staining and MUC-2 did not co-localize with TFF3 in any normal pancreata.  GKN-2 
was not detected in any of the 5 cases examined and therefore did not co-localize with 
TFF1 or TFF2.  These data are summarized in Figure 4.14. 
 
Ductal staining with TFF1, 2 and 3 was frequent and intense in CP, PanIN and PDAC 
and strikingly increased over levels seen in normal pancreata (Figures 4.13, 4.14), in 
agreement with the ISH data (Table 4.14).  TFF3 staining of the endocrine 
component in CP remained similar to that seen in normal islets, with a slight 
reduction in frequency and intensity in PET (Figures 4.15a, b).  Equivocal weak 
staining with GKN-2 was seen at the periphery of 2 of 6 PDAC cases examined and 
moderate membranous staining in one (Figure 4.11d), but no staining was seen in any 
of the 5 CP or 5 PanIN cases examined.  MUC-1 immunostaining declined slightly in 
CP and dramatically in PanIN, but remained high in PDAC (Figures 4.13, 4.14), 
while MUC-2 was never seen, except very focally in two metastatic cases of PDAC 
(Figures 4.11b, 4.11c).  Consequently, MUC-2 and TFF3 staining did not co-localize 
in CP, PanIN or PDAC.  MUC-5AC staining was entirely absent from normal 
pancreata and rare in CP, whereas most PanIN and all PDACs exhibited moderate 
positive staining (Figures 4.13, 4.14).  MUC-5AC staining was accompanied by 
TFF1 in a minority of CP cases (2 of 12), however, the majority of CP (10 of 12) 
expressed TFF1 alone.  In contrast, MUC-5AC and TFF1 co-localized in the majority 
of PanIN (9 of 12) and PDAC (15 of 16) cases (Figure 4.13). MUC-6 staining was 
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commonly seen in CP and PDAC, where co-localization with TFF2 was often 
present.  However, MUC-6 staining was never seen in PanIN, where TFF2 staining 
was also occasionally seen (Figure 4.13).   
 
Indirect double immunofluorescence of islets of normal pancreata for TFF3 and either 
insulin or glucagon revealed occasional cells showing double positivity with TFF3 
and either hormone (Figure 4.16).  No islets showed complete overlap of TFF3 with 
either hormone-expressing cell subset, and most insulin- and glucagon-positive cells 
did not stain with TFF3. 
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Figure 4.13:  Expression of TFFs and mucin glycoproteins in ducts of normal and 
diseased human pancreata as assessed by immunohistochemistry   
 
 
 
Each square represents the score for one case and each bold horizontal line represents 
the average score per condition. As MUC-2 was uniformly negative, no chart is given 
for this antibody. 
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Table 4.14: Comparison of mRNA expression of TFFs and protein expression of 
TFFs and mucins in normal and diseased human pancreas 
 
Ductal Compartment (including tumour) 
Group ISH IHC 
TFF1 
 
TFF2 
 
TFF3 
 
GKN-2 ‡TFF1 
‡MUC-
5AC 
‡TFF2 
‡MUC-6 
‡TFF3 
‡MUC-
2 
GKN-2 
Normal  
(n=5; 
‡
n=15) 
+     
(2.3) 
* 
+       
(2.6) 
* 
+/-      
(0.8) 
** 
- +/-, - 
(0.9, 0) 
* 
-, - 
(0.3, 0) 
* 
+, - 
(2.3, 0) 
 
- 
(0) 
CP 
(n=5; 
‡n=16) 
++   
(4.5) 
*** 
++     
(3.7) 
*** 
++    
(4.0) 
*** 
- +, - 
(2.6, 
0.3) 
*** 
+, + 
(2.5, 1.5) 
*** 
++, - 
(4.3, 0) 
*** 
- 
(0) 
PanIN 
(n=2; 
‡n=12) 
n/a n/a n/a - +++, ++ 
(4.6, 
3.7) 
† 
+, - 
(2.3, 0) 
† 
++, - 
(3.9, 0) 
† 
- 
(0) 
PDAC 
(n=6; 
‡n=16) 
+++ 
(5.5) 
**** 
+++   
(4.7) 
**** 
++    
(4.2) 
**** 
- ++, ++ 
(3.8, 4) 
**** 
+, + 
(1.8, 1.8) 
**** 
++, - 
(3.7, 
0.3) 
**** 
+/- 
(1.3) 
**** 
Islet/Endocrine Compartment (including tumour) 
Group ISH IHC 
TFF1 TFF2 TFF3 GKN-2 
 
‡TFF1 
‡MUC-
5AC 
‡TFF2 
‡MUC-6 
‡TFF3 
‡MUC-2 
GKN-2 
Normal  
(n=5; 
‡n=15) 
- - +/- 
(0.8) 
- -, - 
 
-, - 
 
+++, - 
(4.6, 0) 
- 
 
CP 
(n=5; 
‡n=16) 
- - + 
(1.0) 
- -, - -, - ++, - 
(4.3, 0) 
- 
PET 
(n=6; 
‡n=12) 
- - + 
(1.0) 
**** 
- +/-, - 
(0.7, 0) 
-, - +, - 
(3.3, 0) 
- 
Data obtained from ISH and IHC. 
 
Key: 
*  = interlobular and large ducts  
** = larger ducts, especially branches 
***  = ductular complexes and larger ducts  
****  = tumour  
† = PanIN-1 and above (including “mucinous metaplasia”)
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Figure 4.14:  Summarized expression patterns of TFFs and mucin glycoproteins in normal and diseased human pancreata 
 
 
Low levels of TFF1 and TFF3 immunostaining were seen in normal ducts, which increased in CP, PanIN and PDAC (indicated by 
coloured polygons).  Co-expression of TFF1/MUC-5AC and TFF3/MUC-2 was only seen in neoplasia.  TFF2 and MUC-6 were co-
expressed at low levels in CP, PanIN and PDAC.  GKN-2 expression was rarely seen in PDAC, and did not co-localize with TFF1.  
Data obtained by IHC. 
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Figure 4.15a:  Expression of TFF3 in islet cells in normal and diseased human 
pancreata   
 
 
Each square represents one case and each bold horizontal line represents the average 
score per condition.  Data from IHC analysis. 
 
 
Figure 4.15b:  Summarized expression patterns of TFF3 and MUC-2 in islet cells of 
normal and diseased human pancreata 
 
 
 
TFF3 immunostaining was prominent in normal islets, declining in malignant islet 
cell tumours.  TFF3 and MUC-2 staining were never seen together in islets.  TFF3 
expression occasionally co-localized with insulin expression, and more rarely with 
glucagon expression, in both normal and malignant islet cells. 
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Figure 4.16:  Co-expression of TFF3, insulin and glucagon in normal human pancreatic islets as assessed by immunofluorescence   
 
 
 
Green: FITC channel; Red: Cy3 channel; Yellow: co-localization of green and red-labelled antibodies; Blue: DAPI counterstain.  
TFF3 and insulin (left) and TFF3 and glucagon (right: arrows) are both occasionally, but not ubiquitously seen to co-localize in 
individual islet cells.  Original magnification 200× 
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4.3.3 Wound healing 
 
Preliminary optimization experiments using a plate reader showed that wound-edge 
cells of all cell line monolayers migrated for at least 4 days following wounding, and 
that this migration occurred faster in 1% than in 0.2% serum-containing medium.  
However, the plate reader methodology was revealed to be unreliable and inadequate 
for quantification and further optimization experiments were carried out using the 
time-lapse methodology. 
 
Time-lapse experiment Opt. 1 confirmed migration of wounded Capan-2, COLO357, 
Panc-1, hPSCs and HT29 monolayers in DMEM/0.2% FCS migration medium over a 
period of 48 hours (Figure 4.17).  Capan-2, COLO357 and HT29 cells were seen to 
migrate en masse as a confluent sheet, whereas Panc-1 and hPSCs migrated as 
scattered single cells.  Consequently, Panc-1 and hPSCs were discounted from time-
lapse experiments due to difficulties measuring cell-free area accurately.  Migration 
in all lines was seen to slow after 24 hours. 
 
Enhanced wound closure of HT29 monolayers in response to EGF and TFF2 [671, 
685] was confirmed in the second optimization experiment (Figure 4.18).  The dose-
response curve was bell-shaped for TFF2 with maximal migration seen between 
concentrations of 1 and 5µM.  The dose-response curve for EGF was bimodal with 
maxima at 10 and 600ng/ml (1.6nM and 100nM).  No statistical analyses were 
performed due to the small number of samples.   
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Figure 4.17:  Migration of cell lines in low serum over 48 hours   
 
 
 
In time-lapse studies, all wounded cell lines showed continued migration in 
DMEM/0.2% FCS over a 48 hour period.  HT29, Capan-2 and COLO357 migrated as 
confluent sheets, whilst hPSCs and Panc-1 migrated as single cells.  Yellow line: 
original wound border.  Phase contrast, original magnification 50×. 
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Opt.2: Migration of wounded HT29 monolayers in response to EGF 
(n=2) 
0
5000
10000
15000
20000
25000
30000
0 5 10 15 20
Time since wounding (hours)
W
o
u
n
d 
ar
ea
 
co
v
er
ed
 
(pi
x
el
s)
control
1ng/ml
10ng/ml
100ng/ml
600ng/ml
Opt.2: Migration of wounded HT29 monolayers in response to TFF2 
(n=2)
0
5000
10000
15000
20000
25000
30000
control 0.1µM 1µM 5µM 10µM
Treatment
W
o
u
n
d 
ar
ea
 
c
o
v
er
ed
 
(pi
x
el
s)
6 hours
12 hours
18 hours
Opt.2: Migration of wounded HT29 monolayers in response to TFF2 
(n=2)
0
5000
10000
15000
20000
25000
30000
0 5 10 15 20
Time since wounding (hours)
W
o
u
n
d 
ar
ea
 
co
ve
re
d 
(p
ix
el
s)
control
0.1µM
1µM
5µM
10µM
Opt.2: Migration of wounded HT29 monolayers in response to EGF 
(n=2)
0
5000
10000
15000
20000
25000
30000
control 1ng/ml 10ng/ml 100ng/ml 600ng/ml
Treatment
W
o
u
n
d 
ar
ea
 
co
v
er
ed
 
(pi
x
el
s)
6 hours
12 hours
18 hours
Figure 4.18: Opt.2:  Migration of 
wounded HT29 monolayers in 
response to EGF and TFF2  
 
 
Monolayers treated with EGF 
showed increased wound coverage 
over vehicle-treated controls 
between 6 and 18 hours following 
wounding for all concentrations, 
maximal at 10ng/ml (1.6nM).  
Wound coverage was also 
increased between 6 and 18 hours 
in wounds treated with 1-10µM 
TFF2, maximal at 1µM.  Error 
bars = SD.      
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In the third experiment (Opt.3), Capan-2 monolayers treated with EGF at 
concentrations between 1 and 600ng/ml (0.16-100nM) showed increased wound 
coverage over 18 hours following wounding, maximal at 1ng/ml.  HT29 cells 
continued to exhibit modestly enhanced migration in response to EGF (max. 10-
100ng/ml) and TFF2 (max. 10µM).  These data are shown in Figure 4.19.  Statistical 
analyses were not performed due to the small sample size. 
 
HT29 cells continued to show significantly enhanced wound coverage in response to 
EGF at 10ng/ml and TFF2 at 10ng/ml in the final optimization experiment (Opt.4), 
while wound coverage was significantly enhanced in Capan-2 cells treated with 
10ng/ml EGF (Figure 4.20a).  Capan-2 cells treated with 1ng/ml TFF2 showed 
moderately enhanced migration, which only reached statistical significance at 3 hours 
following wounding.  Additionally, wounded COLO357 monolayers showed 
significantly enhanced wound coverage in response to EGF, (max. 10ng/ml) but did 
not respond significantly to TFF2 at any dose studied (Figure 4.20b).   
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Figure 4.19:  Opt.3:  Wounded 
Capan-2 and HT29 monolayers show 
increased wound coverage when 
treated with EGF or TFF2  
 
Capan-2 shows maximal responses 
at 1-10ng/ml EGF and 1µM TFF2.  
HT29 shows maximal responses at 
10-100ng/ml EGF and 10µM TFF2.  
Average data shown ± SD.    
 346
Figure 4.20a:  Opt.4:  Increased migration of Capan-2 and HT29 cells in response to 
EGF and TFF2 is moderate but statistically significant  
 
 
 
Student’s two-tailed t test: * p<0.05, ** p< 0.01, *** p< 0.001.  Error bars = SD. 
Comparisons are versus control for each time point. 
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Opt.4: Migration of Wounded COLO357 
Monolayers in Response to EGF (n=4)
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Figure 4.20b:  Opt.4:  Wounded 
COLO357 monolayers showed 
significantly enhanced migration in 
response to EGF but not TFF2 
 
 
10ng/ml EGF treatment was 
associated with a significant 
increase in wound coverage at 12 
hours following wounding.  
Student’s two-tailed t test versus 
controls for each time point: * 
p<0.05, ** p<0.01, *** p<0.001.  
Error bars = SD. 
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Enhanced wound healing responses exhibited by Capan-2 and HT29 cells treated with 
EGF and TFF2 in previous optimization experiments were seen more clearly in the 
larger final experiment (where n=6 and n=4 respectively).  Wound healing rates of 
vehicle-treated and 10ng/ml EGF-treated monolayers of all three cell lines were seen 
to diverge significantly from 9 hours post-wounding onwards (Figure 4.21a).  Further 
analysis revealed that wound coverage of 10ng/ml EGF-treated monolayers was 
significantly increased over controls from 3, 6 and 12 hours following wounding in 
Capan-2, COLO357 and HT29 cell lines respectively (Figure 4.21b).  Wound healing 
rates of vehicle and TFF2-treated monolayers were also divergent for all three lines 
(Figure 4.21a).  Wound coverage was significantly enhanced over controls in Capan-
2 monolayers treated with 1µM and 10µM TFF2 from 3 hours post-wounding, 
whereas only the higher concentration induced a similar effect in HT29 cells (Figure 
4.21b).  Migration of TFF2-treated COLO357 monolayers over controls did not 
generally reach statistical significance (Figure 4.21b).  Migration of cells treated with 
2µM TFF3 was not significantly elevated over controls for any line (Figure 4.21b). 
 
When significant effects were seen, the degree to which EGF and TFF2 enhanced 
migration was similar.  When wound coverage at 12 hours was compared across all 
experiments, 10ng/ml EGF induced an average 1.7-fold increase in wound coverage 
in HT29 and 2.1-fold increases in both Capan-2 and COLO357 (Figure 4.22).  10µM 
TFF2 treatment was associated with 1.5-fold and 2.2-fold migration increases in 
HT29 and Capan-2 respectively, with 1µM inducing 1.3 and 2.2-fold increases.   
 
In contrast, in 2 of 3 cell lines the patterns of migration induced by EGF and TFF2 
were dissimilar.  HT29 (Figure 4.23a) and COLO357 (Figure 4.23b) cells migrating 
in response to EGF showed a non-cohesive morphology with scattered single cells or 
prominent cell protrusions at the wound edge, whereas those exposed to TFF2 or 
vehicle alone retained a confluent, more epithelioid morphology with a smooth 
wound edge.  This morphological change was especially pronounced at 48 hours 
following wounding but could be seen at 24 hours (Figures 4.23a, b).  Capan-2 
monolayers showed no morphological differences between treatments (Figure 4.23c) 
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Figure 4.21a:  Migration rates of wounded Capan-2, COLO357 and HT29 
monolayers in response to EGF, TFF2 and TFF3   
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Migration of Wounded HT29 Monolayers (n=4)
0
2000
4000
6000
8000
10000
12000
14000
16000
control EGF 10ng/ml TFF2 1µM TFF2 10µM
Treatment
W
o
u
n
d 
ar
ea
 
co
v
er
ed
 
(pi
x
el
s)
3 hours
6 hours
12 hours
18 hours
*** 
** 
* 
** 
*** 
Migration of Wounded Capan-2 Monolayers (n=6)
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
control EGF 10ng/ml TFF2 1µM TFF2 10µM TFF3 2µM
Treatment
W
o
u
n
d 
ar
ea
 
co
v
er
ed
 
(pi
x
el
s)
3 hours
6 hours
12 hours
18 hours
*** *** 
*** *** 
*** *** *** 
*** 
*** 
** 
** 
** 
Migration of Wounded COLO357 Monolayers (n=6)
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
control EGF 10ng/ml TFF2 1µM TFF2 10µM TFF3 2µM
Treatment
W
o
u
n
d 
a
re
a
 
co
v
e
re
d 
(pi
x
e
ls
)
3 hours
6 hours
12 hours
18 hours
* 
*** 
*** 
* 
 
Figure 4.21b:  
Migration of 
wounded Capan-
2, COLO357 and 
HT29 
monolayers in 
response to EGF, 
TFF2 and TFF3   
 
 
All cell lines 
showed 
significantly 
enhanced wound 
coverage in 
response to 
10ng/ml EGF.  
Capan-2 and 
HT29 cells also 
showed 
enhanced 
healing in 
response to 
10µM TFF2.  
Average values 
shown ± SD.  
Student’s two-
tailed t test:  
* p<0.05, ** 
p<0.01,  *** 
p<0.001. 
All comparisons 
vs control for 
each time point. 
 
 
 
 
 
 
 
 
 
 
 
 351
Figure 4.22:  Relative wound healing responses of Capan-2, COLO357 and HT29 
cells to EGF and TFF2   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results of 3 experiments pooled.  Average migration rates for each treatment divided 
by average control migration rate.  Results shown ± SD. 
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Figure 4.23a:  Wound healing of HT29 cells over 24 hours   
 
 
 
Wounded monolayers exposed to EGF (10ng/ml) showed a ragged border with numerous cell protrusions (arrows) at 24 hours, whilst 
those exposed to TFF2 (10µM) or vehicle alone did not.  Enhanced wound coverage by EGF and TFF2-exposed monolayers over 
control is not discernable by eye in this series.  Original magnification 50×; phase contrast.  Black bar indicates initial scratch position.
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Figure 4.23b:  Wound healing of COLO357 cells over 48 hours  
 
 
 
Wounded monolayers exposed to EGF (10ng/ml) showed a ragged border with non-
cohesive, single cells at the wound edge (arrows), whilst those exposed to vehicle 
(control) showed a smooth, continuous edge.  Monolayers exposed to TFF2 (10µM), 
and to a lesser extent, TFF3 (2µM) showed confluent tongues of advancing cells (*). 
EGF and TFF2-exposed monolayers both show enhanced wound coverage over 
controls in this series of micrographs.  Original magnification 50×; phase contrast.  
Black bar indicates initial scratch position.
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Figure 4.23c:  Wound healing of Capan-2 cells over 24 hours   
 
 
 
Cells exposed to EGF (B; 10ng/ml), TFFs (C TFF2 1µM; D TFF2 10µM; E TFF3 
2µM) or vehicle alone (A) migrated as a confluent monolayer.  Monolayers exposed 
to EGF, TFF2 and TFF3 all showed enhanced wound coverage over vehicle exposed 
control in this series.  Original magnification 50×; phase contrast.  Black bar indicates 
initial scratch position.
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4.3.4  Directional migration 
 
The first three preliminary experiments determined optimal cell seeding densities and 
migration times, which were then employed in subsequent experiments.  Collagen 
coating of the underside of the transwell membrane enhanced migration of Panc-1 
cells, maximal at 5µg/ml, but did not enhance migration of hPSCs (Figures 4.24a, b).  
HT29 cells migrated too slowly to produce usable data and were not used in 
subsequent experiments (Figure 4.24b). 
 
In the final two experiments, Panc-1 cells showed enhanced migration in response to 
EGF, maximal at 10ng/ml (1.6nM) and to 10µM TFF2, in both collagen-treated and 
untreated groups (Figures 4.25, 4.26).  COLO357 cells showed enhanced migration in 
response to 10ng/ml EGF and two concentrations of TFF2 when collagen-treated 
membranes were employed, however this only reached statistical significance for 
cells treated with EGF (Figure 4.25a).  COLO357 cells did not migrate through 
collagen-free membranes in sufficient numbers for analysis.  hPSCs showed a 2.5 to 
4-fold increase in migration in response to 1ng/ml EGF and a small but consistent 
increase in migration in response to 2µM TFF2 when collagen-coated membranes 
were employed (Figure 4.25a, b).  No cell line studied showed significantly enhanced 
migration in response to 2µM TFF3.   
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Figure 4.24a:  Migration of PDAC and primary human pancreatic stellate cells through 8µm pore size transwell membranes treated 
with collagen or vehicle alone   
 
 
 
 
Panc-1 cells were allowed to migrate for 6 hours and hPSCs for 8 hours prior to fixation and staining.  Panc-1 but not hPSCs exhibited 
enhanced migration in response to collagen.  Cells are shown in-situ, original magnification = 200× 
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Figure 4.24b:  Migration of PDAC and primary human pancreatic stellate cells 
through 8µm pore size transwell membranes treated with collagen or vehicle alone   
 
 
 
Panc-1 cells exhibited enhanced migration in response to collagen, maximal at 
5µg/ml, whilst hPSCs did not.  HT29 cells also showed measurable migration in 
response to collagen but migrated too slowly to be detected in vehicle-treated 
controls. Pooled results of transwell experiments 1-3, shown ± SD. 
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Figure 4.25:  Migration of hPDAC cell lines and hPSCs through 8µm transwell 
membranes in response to EGF and TFFs   
 
 
 
When compared to controls, PDAC cell lines and hPSCs showed enhanced migration 
in response to EGF, whilst only Panc-1 and hPSCs responded positively to TFF2. 
Pooled data from experiments 4 and 5, mean values shown ± SD.  Migration was 
measured by counting cells per 10 high power fields (HPF) on the underside of the 
membrane. Student’s two-tailed t-test, * = p<0.05; ** = p<0.01; *** = p<0.001
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Figure 4.26:  Migration of Panc-1 cells through 8µm transwell membranes in 
response to EGF and TFF2   
 
 
Cells were allowed to migrate for 4 hours prior to fixation and staining, and 
representative fields are shown in situ, original magnification 200×.  Cell nuclei are 
indicated by orange dots and cell count shown numerically in orange. Enhanced 
migration was seen on exposure to EGF (10ng/ml) and to TFF2 (10µM).
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Figure 4.27:  Migration of hPSCs through 8µm transwell membranes in response to 
EGF and TFF2   
 
Cells were allowed to migrate for 8 hours prior to fixation and staining.  
Representative fields are shown as before, with cell nuclei indicated in orange; 
original magnification 200×.  Enhanced migration was seen in response to EGF 
(1ng/ml) and TFF2 (2µM).
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4.4 DISCUSSION 
 
 
From our ISH data, we conclude that TFF3 mRNA is present at low levels in 
occasional islets in both normal and chronically inflamed pancreata.  Low levels of 
TFF3 mRNA continued to be detected in neoplastic islet tissue (glucagonoma, 
insulinoma and other neuroendocrine tumours).  TFF3 expression in islets is 
somewhat unusual as TFF expression is primarily confined to mucinous epithelia, and 
TFF3 more specifically to goblet cells [634, 635, 651, 761-764], although TFF1 
expression in gut neuroendocrine cells has been noted [762, 765] and one report of 
TFF3 expression in human islets of Langerhans does exist in the literature [216].  Our 
observation that TFF3 mRNA expression was only present in rare islets may go some 
way to explaining why this group reported TFF3 expression using PCR on isolated 
islets whereas Fueger et al. could not detect it [215, 216]:  the number of islets used 
in each experiment was low, and rare TFF3-expressing islets would have had a low 
chance of inclusion.  In contrast to our ISH data, our IHC data suggests high levels of 
TFF3 peptide in almost all islets in normal pancreas, as well as in scattered cells of 
diverse islet cell tumours.  However, expression of neither TFF3 mRNA nor peptide 
increased in hyperplastic islets of CP or in PET, where islet cell proliferation would 
be expected to be higher than in normal islets [732, 766].  Proliferation in these 
tissues was not directly evaluated, however, and correlation of TFF expression and 
assessment of proliferation, perhaps via IHC for Ki67/MIB-1 would be desirable.  
Nesidoblastosis would also present an informative pathology in which to evaluate the 
expression of TFF3. 
 
A previously published immunohistochemical study failed to note TFF3 peptide in 
the pancreas, except for ubiquitous expression in medium sized ducts [645].  
However, the TFF3-positive ducts illustrated in this study appear to exhibit an 
epithelial morphology akin to that seen in mucinous metaplasia or PanIN, and it is 
unclear as to whether these truly represent “normal” ducts.  Other 
immunohistochemical investigations of TFF3 in the pancreas agree with our data, 
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however, reporting a similar distribution of TFF3 in islets [216].  These differences 
may reflect differences in antibody specificity, as differing methods of antibody 
production were used in each study and each antibody may detect differing epitopes.  
However, in our study, pre-absorption of the antibody with TFF3 peptide resulted in 
complete abolition of staining in both positive control and pancreatic tissues, 
indicating high affinity of this antibody for TFF3.  Furthermore, this antibody 
detected TFF3 peptide expression in colonic goblet cells and in intestinal metaplasia 
of the salivary gland, which are known to produce and secrete this peptide [634, 651, 
660, 761, 764, 767].  Nevertheless, this does not rule out a cross-reaction of the 
antibody with a similar epitope of an otherwise dissimilar protein.  Other proteins 
with homology to TFF3 exist, such as lysosomal α-glucosidase, which possesses a 
similar P-domain and is expressed in the endocrine pancreas [654, 768].  However, 
TFF1 and TFF2 also possess P-domains (a.k.a. trefoil domains), which might be 
expected to bind antibodies to TFF3 if the cross-reaction involved this region.  TFF3 
staining did not correlate consistently with any one sub-type of hormone-producing 
cell in islets, further suggesting that not only individual islets but also individual α 
and β cells therein are heterogeneous with respect to TFF3 expression [216].  This 
puzzle might be solved by comparison of multiple antibodies raised to different 
epitopes of the TFF3 molecule as well as antibodies to other proteins with significant 
structural homology; unfortunately, at this time a wide range of antibodies to TFF3 is 
not available. 
 
In further support of our data, expression of TFFs in neuroendocrine cells is known 
from other tissues.  TFF1 peptide is ectopically expressed in prostatic carcinoma, 
where it correlates with neuroendocrine differentiation as evidenced by chromogranin 
A immunoreactivity [769], as well as in neuroendocrine cells of the UACL present in 
Crohn’s disease [765]. 
 
If TFF3 mRNA expression is generally low in occasional islets, and the ubiquitous 
high levels of TFF3 peptide in islets implied by IHC are authentic, then why might 
there such a discrepancy?  One possibility is that TFF3 is not generally produced by 
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islets but is taken up and stored by islet cells.  Islets may be continuous with the 
ductal tree, particularly during regeneration, and consequently exposed to TFFs 
secreted by ductal epithelium either lumenally or basolaterally, and are endowed with 
a large capillary network and thus also exposed to circulating TFFs.  Systemic 
administration of TFFs has been shown to lead to uptake in distant cells, however, 
this uptake is generally by cells known to be major producers of TFFs, or at least 
mucinous epithelia [638, 681].  Whether uptake of TFF3 occurs in islet cells, and if 
so, why this should be the case remain to be elucidated.  Furthermore, it should be 
borne in mind that mRNA and protein expression need not correlate.  ISH reveals a 
snapshot in time, as mRNA is not stored and may be unstable, whereas proteins may 
be stored until required, which can lead to negative ISH but positive IHC.  High 
translation efficiency may also give rise to similar discrepancies.  In addition, mRNA 
is subject to epigenetic regulation by small, non-coding (nc) RNAs which may pose a 
barrier to translation [770], and proteins may be aberrant and undetectable by 
antibodies raised to normal epitopes or secreted at a faster rate than they are 
produced, leading to negative IHC and positive ISH.   
 
Overall, it seems likely that TFF3 gene transcription occurs at low levels in 
occasional normal and diseased islets.  The presence of TFF3 peptide in α and β cells 
would also seem likely, but further IHC investigations and perhaps Western blotting 
experiments on islet tissue should be performed to confirm this.  Furthermore, as islet 
cell proliferation was not directly investigated and the sample sizes were small, it is 
not possible to comment on how likely it is that TFF3 drives islet cell proliferation in 
vivo, other than to say that increased mRNA levels were not seen in pathologies that 
can be associated with islet-cell proliferation.     
   
In the exocrine pancreas, we conclude that TFF1, 3 and very rarely, TFF2 mRNA is 
present at low levels in normal ducts, mostly at the branch points of larger ducts.  
These ISH observations were supported by our IHC data and agree with previous 
published immunohistochemical and ISH studies [216, 662, 725, 728, 730].  No 
evidence of GKN-2 expression was seen at mRNA or protein level in normal ducts, 
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regardless of whether TFF1 was present or absent, and we conclude that TFF1/GKN-
2 are probably not co-expressed in normal pancreatic ducts.  TFF1 and 3 mRNA and 
protein expression were seen to increase in CP, PanIN and well-differentiated PDAC 
specimens, whereas ectopic TFF2 expression was commonly detected in CP and 
PDAC, but often absent in PanIN.  These data agree with previously published 
studies of pancreatic TFF expression; TFF1 has been reported to increase in PDAC 
and CP [725, 726, 728], with TFF2 also reportedly over-expressed in PDAC [728, 
730].  Our data add to these reports by finding, for the first time, increased expression 
of TFF2 in CP and TFF3 over-expression in both chronic pancreatic inflammation 
and neoplasia.  Ectopic or over-expression of TFF3 is observed in and implicated in 
the progression of several other cancers, notably colonic and prostatic [689, 718, 771] 
and down-regulation of expression is seen in gastric carcinoma [707], therefore a link 
with PDAC deserves closer scrutiny.  Interestingly, a very similar pattern is also seen 
in the liver, where TFF3 is expressed at relatively low levels in normal biliary ductal 
epithelium, becoming over-expressed in response to ductal damage via graft-versus-
host disease or hepatolithiasis, and continuing to be over-expressed in biliary intra-
epithelial neoplasia and cholangiocarcinoma [695, 772-775].   Quantification of TFF 
expression in normal and diseased human pancreata via quantitative reverse 
transcriptase-PCR would be desirable to further confirm these results.   In addition, 
not only the levels of TFFs but their sub-cellular immunostaining pattern varied 
between normal and diseased pancreata.  Whilst TFF staining was largely 
membranous and apical in normal ducts, cytoplasmic staining with TFF1, 2 and 3 and 
nuclear staining with TFF1 were frequently seen in inflammation and neoplasia.  We 
did not investigate the significance of this finding, and further study should be 
undertaken to ascertain whether this reflects hyper-production, a possible change 
from apical to basal secretion, or the presence of mutant isoforms with compromised 
secretion.  Nuclear TFF1 immunostaining may correlate with oestrogen responsivity 
in breast and prostatic cancer [713, 776, 777], although this relationship is far from 
simple.  
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Our IHC data indicate high levels of MUC-1 in normal pancreata, CP and PDAC, 
with a pronounced reduction in PanIN, an almost total absence of MUC-2 in normal 
and diseased pancreata, ectopic MUC-5AC expression in PanIN and PDAC, but not 
CP, and ectopic expression of MUC-6 in CP and PDAC but not PanIN.  These 
observations broadly agree with previous immunohistochemical studies, which report 
very rare MUC-2 expression in PDAC and common MUC-5AC expression in 
pancreatic neoplasia from PanIN onwards, but no expression of either mucin in 
normal pancreata [384, 739, 742, 778].  However, variable, low expression of MUC-6 
has been reported via ISH and IHC in occasional ducts of normal human pancreatic 
[742, 779, 780], whereas we failed to detect this mucin by IHC outside of inflamed or 
neoplastic ducts.  The presence of multiple glycosylated mucin isoforms in normal 
tissues and mutant variants of these isoforms in disease confounds comparisons of 
mucin expression in the literature, however, and the sensitivity and specificity of anti-
mucin antibodies may vary considerably [742, 744].  Fixation may also affect the 
results of mucin IHC, as whilst alcoholic fixation is preferable to aldehyde fixation 
for carbohydrate moieties [781], studies on archival material almost always employ 
FFPE material. 
   
With regards to the co-expression of mucins, TFFs and GKN-2; although TFF1 and 
TFF3 were noted in normal pancreatic ducts, TFF1/GKN-2/MUC-5AC and 
TFF3/MUC-2 were not seen to be co-expressed, in contrast to the normal human 
stomach and colon [653].  Co-expression of TFF1 with MUC-5AC and occasionally 
GKN-2 was seen in PanIN and PDAC, but was not observed in CP cases.  TFF2 
peptide expression was not seen in normal pancreata on IHC, and in PanIN co-
expression with MUC-6 was not detected in areas of TFF2 expression. This mucin 
was also rarely co-expressed in TFF2-expressing regions of CP, in contrast to the 
normal stomach, where overlapping TFF2/MUC-6 expression is typical [726, 745].  
However, in contrast, TFF2/MUC-6 co-expression was commonly seen in PDAC.  
TFF3/MUC-2 co-expression was not seen in any of the pancreatic pathologies 
examined, despite the large increases in TFF3 expression detected at mRNA and 
protein level.   
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The patterns of mucin and TFF expression here described present further evidence 
suggesting a complex series of phenotypic changes in pancreatic ductal epithelium 
spanning reactive to frankly neoplastic conditions.  In CP and PanIN, the presence of 
TFF1 and TFF2 suggests metaplasia of a gastric phenotype, but co-expression of 
TFF3 suggests that this also has intestinal features.  Co-expression of mucins and 
their trefoil partners varied considerably between and within pathologies, further 
highlighting the mixed gastric and intestinal nature of pancreatic metaplasia.  This 
mixed gastro-intestinal pattern of TFF and mucin expression is reminiscent of that 
seen in the UACL, the specialized metaplastic cell lineage that arises in response to 
mucosal injury in intestinal inflammatory conditions such as Crohn’s disease, with 
counterparts in Barrett’s oesophagus and ileal pouchitis [762, 782-785].  This 
organized, ramifying structure, which in the intestine resembles gastric glands, 
produces TFF1, TFF2, TFF3, EGF, MUC-6, focally MUC-5AC but not MUC-2 and 
presents an incomplete gastric metaplastic phenotype associated with neuroendocrine 
cell hyperplasia [642, 661, 753, 762, 786].  TFFs, mucins and EGF are rapidly 
secreted from the UACL in response to injury and promote mucosal restitution.  
Depending on its location, the UACL is thought to arise from the base of nearby 
crypts, Brunner’s glands or oesophageal glands, and form a branched structure close 
to the damaged epithelium [785, 787, 788].  Interestingly, in CP, particularly high 
levels of TFFs were seen in numerous, branching, small mucinous ducts adjacent to 
areas of larger ducts denuded of epithelium, however, whether these mucosal injuries 
were always pathological or artefactual due to probing of ducts during histological 
examination ex-vivo is debatable.  Duct ectasia and ulceration secondary to lithiasis 
were commonly seen in CP specimens, however, as were branching complexes of 
TFF-rich mucinous ducts.  Perhaps pertinently, both EGF and its receptor also show 
up-regulated expression in CP and PDAC [620, 789-792], and strong evidence 
implicating this over-expression in fibrosis, repair, invasion and cancer progression is 
present in the literature [518, 620, 793-796].  Although EGF/EGFR expression was 
not investigated in this study, the coincident over-expression of EGF, EGFR and 
 367
TFFs in CP and PDAC may implicate interactions between these peptides in these 
pathological processes.  
 
Perhaps of additional relevance, incomplete gastric metaplasia indicated by 
discordant expression of TFFs and their mucin partners in the bowel is implicated in 
carcinogenesis: complete gastric metaplasia is generally benign, whereas incomplete 
gastric metaplasia is associated with the development of malignancy [797].  Intestinal 
metaplasia is also a suggested forerunner of gastric malignancy [726, 786].  However, 
it is possible that pancreatic TFF3 expression fulfils a different function to that of the 
colon, as co-expression with MUC-2 was not seen in normal or diseased pancreata.  
The changing pattern of TFF and mucin co-expression from chronic inflammation, 
through pre-malignancy to pancreatic cancer also suggests increasing suppression of 
the pancreatic differentiation program.  The disappearance of a pancreatic pattern 
(TFF1/TFF3/MUC-1+, GKN-2/MUC-5AC/TFF2/MUC-6-) and subsequent 
emergence of a more gastro-intestinal pattern (TFF1/TFF2/TFF3/MUC-5AC/MUC-
6/GKN-2+) may reflect a re-emergence of the “default” gastro-intestinal 
differentiation program seen embryologically, and which is modulated by hedgehog 
signaling during pancreatogenesis from duodenal tissue [729].  Hedgehog signaling is 
also strongly implicated in pancreatic and colonic tumour progression [798-800], and 
Pdx-1 is also re-expressed in PDAC, where it is associated with poor prognosis [552, 
798].  Clearly, much further study is required to elucidate the potential roles of TFFs 
and mucins as correlative or causative factors in pancreatic carcinogenesis. 
 
 
Interestingly, the highest levels of TFF1 were seen in regions of PanIN 
morphologically resembling gastric metaplasia and probably analogous to PanIN-1.   
Expression of TFFs was variable in PanIN, possibly due to variations in grade and the 
fact that PanIN comprises a broad spectrum of pancreatic metaplasias and dysplasias 
rather than representing a single pathological entity [736].  It was not possible to 
study PanIN in detail due to the paucity of material available and inter-observer 
disagreement on grades.  A larger, defined series covering all grades would be 
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required in order to reliably investigate the co-expression of mucins and TFFs in 
PanIN.  The overall pattern of mucin and TFF expression that we observed in PanIN 
(MUC-1/MUC-6-, TFF1++, TFF2+/-) was distinct from that seen in CP and PDAC 
(both MUC-1/TFF1+, TFF2/MUC-6+/-), however, which were broadly more similar to 
each other.  Published data on TFF and mucin expression in IPMN (low MUC-1, very 
high TFF1) compares more closely to the pattern of expression in PanIN [384, 710, 
741, 742, 778, 801].  This may present indirect evidence to support the hypothesis of 
twin pathways of carcinogenesis: one leading to PDAC via progression through 
PanIN-2 and 3 and one leading to IPMN via PanIN-1 without progression through 
further PanIN grades [734, 778] . 
 
 
This study also investigated the potential effects of TFFs on human pancreatic cells in 
vitro.  TFF2 and TFF3 were both seen to be markedly over-expressed in CP and 
PDAC, therefore their biological activity on a range of human pancreatic cell lines 
was assessed.  In vitro, TFF2 but not TFF3 was seen to significantly enhance 
migration of some hPDAC cell lines in both wound healing and directional assays.  
Non-transformed hPSCs also exhibited a weak response to TFF2, indicating that this 
peptide is capable of acting as a motogenic stimulus for both pancreatic epithelial and 
fibrocytic cells.  The well-differentiated PDAC cell line Capan-2 [374, 380], which 
produces mucins when over-confluent or exposed to extracellular matrix (see Chapter 
2) and non-transformed hPSCs showed the strongest responses to both EGF and 
TFF2.  Capan-2 showed the largest increase in restitution speed in response to these 
peptides and hPSCs responded at lower concentrations than other cell lines in 
directional migration assays, whereas more poorly differentiated cell lines Panc-1 
[377, 380] and COLO357 [380] showed weaker responses.   
 
The motogenic effects of TFF2 and 3 observed in these experiments (typically 1.5-2 
fold and not reaching statistical significance respectively) were relatively modest 
compared to some reports in the literature [633, 665, 669, 671]; typically indicating 
2-4 fold increases in migration for cells treated with TFF2 or TFF3 in either wound-
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healing or transwell type assays.  This may be due in part to differences in peptide 
formulations and in part to the lower concentrations employed in our experiments due 
to the limited quantities of peptide available.  The glycosylated variant of TFF2 and 
the dimerized form of TFF3 have also frequently been shown to possess higher 
biological activity than the non-glycosylated and monomeric forms as employed in 
our study, both in vitro and in vivo [637, 667, 668, 684, 802], although this is not 
always the case [668].  It should be noted, however, that responses of the cell lines 
examined to EGF were also lower than those reported for other cell lines in the 
literature, and this could reflect differing abilities of cell lines of different tumour 
types to respond to motogenic stimuli.  The motogenic effect of TFFs on non-
epithelial cells (hPSCs) may seem far-fetched, however, it is not without precedent, 
as non-transformed rat fibroblasts transfected with TFF3 also showed enhanced 
invasion in vitro [670].  Moreover, TFFs have also been shown to enhance fibrosis 
and angiogenesis [670, 700, 803], therefore the possibility exists that over-expression 
of TFFs in pancreatic malignancy may affect invasion and tumour progression via 
effects on stromal cells.  Fibroblasts may also come into contact with TFFs during 
exposure to pancreatic ductal contents during ulceration, and basolateral secretion of 
TFFs is known to occur [683].   
 
The differentiation status of epithelial cells is also known to impact on their responses 
to TFFs [749, 751, 804], and the enhanced responses seen in more well-differentiated 
cells may also reflect the higher levels of TFF expression seen in well-differentiated 
tumours.   Assessment of TFF expression in PDAC cell lines via IHC was attempted 
in order to evaluate the potential contribution of endogenous peptide to their wound-
healing responses, but no positive staining was seen in any cell line including the 
HT29 positive control.  Although technical failure has not been ruled out, this may 
have been due to the differentiation status of these cells at the time of staining:  
Capan-2 cells do not show the mucin secretion associated with the well-differentiated 
phenotype until over-confluent or cultured on Matrigel and HT29 cells may not show 
the enterocytic differentiation required for TFF expression unless over-confluent or 
treated with methotrexate [749, 750], and furthermore this ability may be lost at 
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passage numbers greater than 5 (T. Marchbank and W. Otto, personal 
communication).  Further experiments are required to rule out TFF expression in 
pancreatic cell lines. 
 
It is also known that the ability of a given cell to respond to TFFs may depend upon 
epidermal growth factor receptor status.  Various TFFs have been shown to interact 
with the EGFR in vitro and to promote migration in a synergistic fashion with EGF, 
the stereotypical EGFR ligand [665, 668].  Although k-Ras is typically mutated in 
PDAC, and EGFR activation requires intact Ras machinery, Panc-1 cells at least are 
able to respond to EGFR-modulated signals via n-Ras [401], and enhanced migration 
in response to EGF as well as to TFF2 was demonstrated by our migration 
experiments.  The EGFR status of COLO357 cells is not documented; however, 
enhanced migration in response to EGF was seen.  Interestingly, the pattern of 
migration observed in wounded PDAC monolayers varied between EGF-treated, 
TFF-treated and vehicle-treated groups.  The ragged border observed in EGF-treated 
PDAC cell lines was also reported in a study of wounded intestinal cell monolayers, 
in contrast to those treated with TFFs, which migrated as a confluent sheet [669], 
which may imply that TFF-induced migration involves different signaling pathways 
to that induced by EGF.  Recently, TFF2 has been reported to interact with CXCR4 
[694], a chemokine receptor expressed in pancreatic ducts and islets that has also 
been implicated as PDAC CSC marker [205, 272] and known to modulate invasion of 
PDAC [295], and this provides an exciting avenue for further investigation. 
 
Further titration of TFF peptide concentrations may be required in order to fully 
assess their effects on migration in vitro: some PDAC cell lines showed significant 
responses only at the highest doses used and hPSCs only at the lowest.  These 
experiments could further have been improved by employing a bovine serum albumin 
control to rule out non-specific effects of media protein concentration on cell 
migration.  However, the differing responses of cell lines to the various peptides 
studied makes this unlikely.  Experiments comparing the effects of TFFs and EGF in 
the presence or absence of mitomycin C are also planned, in order to rule out 
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proliferation as a cause of apparently enhanced wound-healing and migration, 
although this is unlikely given the short time spans covered by previous experiments. 
 
 
4.5 CONCLUSIONS 
These albeit limited data, support the hypothesis that TFFs may play a similar role in 
pancreatic ductal epithelia as they do in the gut, becoming locally over-expressed and 
enhancing wound healing (specifically restitution) in response to epithelial damage 
such as that seen in obstructive pancreatitis where ductal ulceration is common.  In 
this manner, the TFF-rich ductal complexes seen in CP and the metaplastic mucin-
producing epithelium of PanIN may act in a similar fashion to the UACL in the gut, 
producing EGF and TFFs to promote restoration of epithelial integrity, thereby 
protecting the pancreatic parenchyma from enzyme-rich duct contents.  Likewise, the 
desmoplastic reaction surrounding and containing damaged ducts in CP may also be 
enhanced by the action of luminal TFFs on the exposed stroma.  However, the 
enhanced directional migration properties conferred on PDAC cell lines by TFF2 in 
vitro may also indicate a role in tumour progression and invasion in vivo, perhaps via 
the potential PDAC CSC marker CXCR4.  The role of TFFs and especially that of 
TFF2 and 3 in pancreatic repair and carcinogenesis is a subject deserving of further 
study. 
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CONCLUDING REMARKS 
 
The aims of this study were two-fold: firstly, to investigate whether pancreatic cell 
lines could be used to prospectively identify a potential CSC population, which could, 
in turn, cast light on the characteristics of potential adult pancreatic precursors.  
Identification of pancreatic stem cells is important, not only because of potential 
value for the generation of functional β-cells to treat diabetes, but also to better 
understand the relevance of the cancer stem cell hypothesis to pancreatic tumour 
progression and treatment.  Secondly, the trefoil factor family peptide TFF3 had been 
suggested as a potential β-cell mitogen, although even its expression status in human 
pancreatic islets was disputed.  As other members of this protein family had been 
implicated in pancreatic cancer progression [709, 710] and had not otherwise been 
comprehensively surveyed in the human pancreas in health and disease, we undertook 
to investigate the expression of all TFFs in endocrine and exocrine pancreas in a 
range of conditions.  We hypothesized that the role of TFFs in gut repair might also 
hold true for the pancreas and, in response to expression data, evaluated the 
motogenic properties of TFF members on pancreatic epithelial and stellate cells in 
vitro. 
 
Cells of one hPDAC cell line (Panc-1) were shown to possess heterogeneous 
clonogenicity and proliferative capacities, which manifested as a spectrum of colony 
morphologies that broadly correlated with those previously shown to reflect the 
repopulating capacities of various epithelial tissues and cell lines [17, 359].  Cells of 
holoclones showed the greatest proliferative potential and gave rise to decreasing 
numbers of holoclones and increasing numbers of paraclones over time, additionally 
exhibiting cytological changes consistent with increasing terminal differentiation.  A 
similar spectrum of colony morphologies was seen in further PDAC lines and these 
data were taken as evidence supporting the hypothesis that a hierarchy of potential as 
described by the cancer stem cell hypothesis persists in these cell lines in vitro.  
Irregularities in the data could be partly explained by misidentification of holoclones, 
meroclones and paraclones by relying solely on morphological criteria, perhaps due 
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to presence of multiple clones within the parent line or the high degree of genetic 
instability exhibited by PDAC. 
 
Markers of stem cells reported for other normal and malignant tissues were selected 
from the literature and used to isolate sub-populations from hPDAC cell lines.  Sub-
populations of cells could be isolated from most hPDAC lines on the basis of 
membranous CD133 and CD44 expression, and by the high activity of ALDH or 
ABC-transporters (i.e. SP cells).  No single marker or combination of markers was 
associated with increased clonogenicity across all cell lines, but CD133+ cells of one 
line (Psn1) showed especially high colony-forming abilities in both anchorage-
dependent and independent assays.  CD133+ fractions of other lines isolated on the 
basis of this marker alone or in conjunction with other markers showed enhanced 
colony or holoclone formation or the ability to produce phenotypically heterogeneous 
offspring.  Correlation of CD133 expression with stem cell properties (i.e. high 
clonogenicity and the production of differentiating offspring) in several hPDAC cell 
lines thus singles this molecule out for further investigation as a potential pancreatic 
CSC marker [272].   
 
Conversely, membranous CD44 expression alone did not identify a highly clonogenic 
fraction in any line, and the same was true for high levels of ALDH activity.  Side 
population cells of Capan-2 showed slightly enhanced clonogenicity, but this was 
shown to probably be an artefact of effects exerted by the dye used to identify them 
(Ho33342) on the non-side population.  Further investigations of the effects of this 
dye on hPDAC lines revealed that growth kinetics were negatively affected by 
Ho33342 exposure during SP analysis.  In particular, Capan-2 cells exposed to 
Ho33342 showed severe, temporary cell cycle arrest, reduced CFA and a terminally 
differentiated, senescent appearance but did not show viability changes during 
sorting.  The sub-lethal but nevertheless dramatic effects of Ho33342 on this cell line 
suggested that some studies of SP vs. non-SP cells might be adversely influenced by 
this phenomenon.  
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A small in situ hybridization study of TFF expression in normal and diseased human 
pancreas showed the presence of TFF3 mRNA in a rare subset of islets of both 
normal and chronically inflamed pancreata, thus perhaps explaining the different 
conclusions drawn as to TFF3 expression in studies performed on small numbers of 
islets.  However, immunostaining for TFF3 peptide suggested a widespread 
distribution for TFF3 in normal, inflamed and neoplastic islets at odds with the ISH 
data.  Furthermore, dual immunofluorescence suggested that TFF3 was co-expressed 
in some insulin+ and rare glucagon+ cells of normal islets, therefore representing a 
sub-population of islet cells with both β and α-cell traits.  The expression of TFF3 in 
islet cells deserves further investigation in a larger sample of pancreatic tissues where 
correlation with islet cell proliferation can be assessed.   
 
Expression of TFF1, TFF2 and rarely TFF3 mRNA was seen focally in ducts of 
normal pancreata on ISH, but only expression of TFF1 and TFF3 was detectable by 
IHC.   TFF expression was predominantly detected at branch or bud-points of larger 
ducts, although expression was sometimes seen in small intralobular ducts of normal 
pancreata.  Expression of TFF1 in normal pancreata did not pair with that MUC-5AC, 
nor TFF3 with MUC-2, as is the case elsewhere in the gut.  This expression pattern at 
least partly synchronizes with the distribution of a recently described novel pancreatic 
duct gland (PDG): a blind-ended gland-like structure observed budding from larger 
normal murine pancreatic ducts [309] and which expresses gastric mucins.  This 
study also proposed these structures as the site of potential intraductal pancreatic 
precursor cells, and further confirmation and expansion of these data are required. 
 
In the present study, both ISH and IHC data showed that expression of all TFFs 
increased at both the mRNA and peptide level in chronically inflamed pancreatic 
ducts and was further increased in PDAC.  As TFFs are known for their motogenic 
effects, it was hypothesized that ectopic or over-expression of TFFs in inflamed 
pancreatic ducts and PDAC may serve to enhance migration of pancreatic ductal 
epithelia to accomplish restitution or invasion.  Wound-healing studies confirmed that 
TFF2 can act as a motogen for at least some pancreatic ductal cells, and directional 
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migration was also enhanced by this peptide for some hPDAC cells and primary 
pancreatic stellate cells, suggesting that this peptide may act in an autocrine or 
paracrine manner to enhance migration of tumour parenchymal or stromal cells in 
PDAC.  Since interactions between PSCs and ductal cells up-regulate proliferation in 
a reciprocal manner [289, 291], recruitment of hPSCs via TFF release from ductal 
cells may also act to enhance healing of ductal lesions in CP.  A potential mechanism 
for the mitogenic effects exerted on PDAC cells by TFF2 reported by this project 
may be found in the recent observation that this peptide may activate CXCR2 [694].  
Expression of this chemokine receptor has been correlated PDAC progression and 
concomitantly poor prognosis in vivo, and has been also been used to identify 
putative PDAC CSCs with high metastatic potential [272, 293, 295, 296], and the 
effect of TFFs on the CXCR4 signaling system presents a significant area for further 
study.   
 
Intriguingly, the recent study by Strobel et al. [309], which proposes ‘pancreatic 
ductal glands’ to house a pancreatic progenitor population reported expansion of 
these gastrointestinal-like cell aggregates during chronic inflammation, a scenario 
where metaplasia of ducts and consequently PanIN is often seen, in a manner that 
calls to mind the appearance of the UACL following intestinal ulceration [661].  As 
PanIN is suggested to represent the pre-malignant state for PDAC, if this model is 
proven correct it may further consolidate the validity of the assertion that cancer 
arises in stem cells for the pancreas. 
 
All-in-all, the data presented in this study, taken together with the literature, suggest 
that pancreatic regeneration and homeostasis is probably achieved via two routes: 
primarily by duplication or transdifferentiation of mature exocrine, ductal or 
endocrine cells, but with activation, expansion and differentiation of a multipotent 
progenitors resident in the ductal tree under special circumstances.  Repair of ductal 
lesions may progress in a similar fashion to that seen following gut ulceration, via 
restitution of ductal epithelium at least partly regulated by enhanced expression of 
TFFs.  TFF expression by injured and regenerating ducts may also have a sinister 
 376
side, with a potential role promoting invasion and migration of PDAC.  TFF3 was 
also shown to be produced by at least some pancreatic islets, where its function 
remains to be elucidated.  In addition, pancreatic cell lines have been shown to 
contain a differentiation hierarchy resembling that proposed by the CSC model, and 
highly clonogenic cells that can be prospectively isolated on the basis of expression 
of CD133 alone or in conjunction with other markers, thus presenting a potential 
model system for further studies of human PDAC TPCs.
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